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TARGETING AUTOPHAGY TO IMPROVE EFFICACY OF CDK4/6 INHIBITION IN 
BREAST CANCER 
 
Smruthi Vijayaraghavan, B.S 
Advisory Professor: Khandan Keyomarsi, Ph.D. 
 
Deregulation of the cell cycle machinery is a hallmark of cancer, leading to aberrant 
proliferation and tumorigenesis. The crucial role of the CDK4/6-Cyclin D pathway has led to the 
development and FDA approval (palbociclib, ribociclib) of CDK4/6 inhibitors for the treatment of 
advanced estrogen receptor positive breast cancer. However, three major clinical challenges 
remain: i) adverse events leading to discontinuation of therapy and ii) lack of reliable 
biomarkers to identify responsive patients and iii) acquired resistance to CDK4/6 inhibitors. 
Previous in vitro studies have shown that palbociclib mediated CDK4/6 inhibition induces G1 
arrest and senescence in ER+ breast cancer cells, and a recent study in fibroblasts implicated 
a role for palbociclib in inducing autophagy, a catabolic process that facilitates survival of the 
cells under stress. Thus, we hypothesize that in the presence of an intact G1/S checkpoint, 
autophagy protects ER positive breast cancer cells from palbociclib induced 
senescence. Further, based on our preliminary results, we hypothesize that cancer stem cells 
and EMT mediates acquired resistance to palbociclib. Results from this study show that breast 
cancer cells activate autophagy in response to palbociclib, and that the combination of 
autophagy and CDK4/6 inhibitors induces irreversible growth inhibition and senescence in vitro, 
and diminishes growth of cell line and patient-derived xenograft tumors in vivo. Furthermore, 
intact G1/S transition is necessary and predictive of preclinical sensitivity to this drug 
combination, and Rb positive and low-molecular-weight isoform of cyclin E negative status are 
reliable prognostic biomarkers in advanced estrogen receptor positive breast cancer patients. 
Inhibition of CDK4/6 and autophagy was also synergistic in other solid cancers with an intact 
	 vii 
G1/S checkpoint, providing a novel and promising biomarker-driven combination therapeutic 
strategy to treat breast and other solid tumors. Lastly, combined targeting with STAT-3 and 
PARP inhibitors can effectively target acquired resistant to palbociclib. Collectively, results from 
this study can help improve the efficacy, selectivity and treat acquired resistance to CDK4/6 
inhibition in breast and other solid tumors. 
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CHAPTER 1: INTRODUCTION 
  
1.1. BREAST CANCER 
1.1.1. EPIDEMIOLOGY OF BREAST CANCER 
 Breast cancer is the most commonly diagnosed cancer in women worldwide, with an 
estimated 252,710 new patients expected to be diagnosed with the disease in 2017 (Siegel, 
Miller et al. 2016). It is also the second most common cause of cancer death in women, 
accounting for about 15% of all cancer related deaths and an estimated 40,610 deaths in 2017 
(Siegel, Miller et al. 2016). While there has been a decrease in breast cancer deaths over the 
years, the continued increase in cancer incidence emphasizes the need for more reliable and 
efficacious treatment strategies to combat the disease. 
 
1.1.2. BREAST CANCER SUBTYPING 
 Like most cancers, breast cancer is highly heterogeneous. Breast cancers can be 
classified based on numerous features such as histopathology, grade, stage, receptor status 
and genomic / DNA based classification (Sotiriou, Neo et al. 2003, Onitilo, Engel et al. 2009). 
Historically, breast cancer was classified based on staining for the hormone receptors such as 
estrogen receptor (ER), progesterone receptor (PR), and Her-2 (Onitilo, Engel et al. 2009). 
Based on the presence or absence of these receptors, breast cancer can be divided into four 
subtypes: i) hormone receptor positive (ER+/PR+/HER2-), ii) hormone receptor and Her-2 
positive (ER+/PR+/HER2+), iii) Her-2 amplified (ER-/PR-/HER2+) and iv) triple negative (ER-
/PR-/HER2-) (Figure 1) (Sorlie, Perou et al. 2001, Sorlie, Tibshirani et al. 2003). The hormone 
receptor positive is the most prevalent subtype, comprising about 66% of all breast tumors 
(Figure 1) (Sorlie, Perou et al. 2001, Sorlie, Tibshirani et al. 2003).  They can also be classified 
based on histopathological features of the tumor biopsy specimens such as ducts and lobules  
 
	 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subtype
ER PR
HER2 
expression
Frequency Characteristics Prognosis Current treatments
Luminal A ER+, PR+, HER2- 50-60% 
low Ki67 Good Endocrine therapy 
Luminal B ER+, PR+, HER2 10-18% high Ki67 
Intermediate
/ Poor 
Endocrine therapy 
plus chemotherapy 
HER2 
positive 
ER-, PR-, 
HER2+ 10-15%
Her2
amplification Poor 
Trastuzumab, 
lapatinib (plus 
chemotherapy) 
Basal-like ER-,PR-, HER2- 10-20% CK 5/6, EGFR Very poor 
Chemotherapy, 
surgery 
Normal-
like 
ER-/+, 
HER2- 3-10%
Low PARP1,
Chk1, high 
ALDH 
Good Undetermined 
Claudin-
low 
ER-,PR-, 
HER2- 12-14%
Low claudin
3,4,7, E-
cadherin, high 
CSC
Poor 
Chemotherapy 
(dependent upon 
HR/HER2 status) 
Table 1: Breast cancer subtypes: Table showing the subtypes of breast cancer and their characteristics 
when classified based on gene expression profiles
Figure 1: Breast cancer subtypes: Pie chart showing the subtypes of 
breast cancer based on the receptor status
Breast Cancer
TNBC
(18.9%)
HER2+ (5.9%)
ER+/PR+/HER2+
(8.5%)
ER+/PR+/HER2-
(66.5%)
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into i) Invasive ductal carcinoma, ii) Invasive lobular carcinoma and iii) Ductal carcinoma in situ 
(DCIS) (Eheman, Shaw et al. 2009)  
A more recent classification of breast tumors was carried out based on gene expression 
profile of normal and tumor tissues using cDNA microarray (Perou, Sorlie et al. 2000). 
Classification of 42 patient tumors identified four distinct molecular subtypes within breast 
cancer namely, ER positive / luminal, Her2 / ErbB2 positive, basal-like and normal subtypes 
(Perou, Sorlie et al. 2000). Further classification was performed using microarray based gene 
expression profiles from 99 breast tumors to yield six intrinsic subtypes namely Luminal A, 
Luminal B, Her2 positive, basal-like, normal breast and claudin-like subtypes (Table 1) 
(Sotiriou, Neo et al. 2003, Eroles, Bosch et al. 2012). Luminal A breast cancer, which is the 
most common type is characterized by the expression of ER, PR, absence of expression of 
Her2 and low expression of Ki67. This subtype is currently being treated using aromatase 
inhibitors, selective ER modifiers or selective regulators of ER, depending on the menopausal 
status of the patient and the source of estrogen (Baum, Budzar et al. 2002). In pre-menopausal 
women, ovaries are the primary source of estrogen, making anti-estrogens such as tamoxifen 
or fulvestrant as the mainstay treatment (Baum, Budzar et al. 2002). In post-menopausal 
women, however, since estrogen is produced by the conversion of androgens (from the 
adipose tissue) by the aromatase enzyme, the aromatase inhibitors such as letrozole and 
anastrazole are more commonly used (Baum, Budzar et al. 2002). Luminal B tumors have a 
more aggressive phenotype and exhibit expression of ER, presence or absence of Her2 and 
high levels of Ki67 (Sotiriou, Neo et al. 2003). Her2 positive breast cancers are characterized 
by high levels of expression of Her2 and have poor prognosis. Basal-like or triple negative 
breast cancers have the absence of the key receptors of ER, PR and Her2. They have very 
poor prognosis and high relapse rates and frequently harbor mutations in critical tumor 
suppressor genes like p53 and BRCA1 (Liedtke, Mazouni et al. 2008, Hernandez-Aya, Chavez-
Macgregor et al. 2011). The normal breast subtype is very poorly classified and comprise of 
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fibroadenomas and some normal breast samples. They have characteristics intermediate 
between the luminal and basal subtypes, and they do not respond to neoadjuvant 
chemotherapy (Sotiriou, Neo et al. 2003). Finally, the claudin-like, subtype which was a newly 
identified subtype has low expression of cell adhesion and tight junction genes. These tumors 
also have a high expression of genes involved in EMT and exhibit a cancer stem cell 
phenotype, which makes them resistant to standard chemotherapy (Sotiriou, Neo et al. 2003). 
Hence, genomic analysis of these tumors might help to understand their mutation profile, and in 
turn utilize targeted therapy options such as PARP, EGFR inhibitors to treat this subtype 
(Sotiriou, Neo et al. 2003). 
  
1.1.3. HORMONE RECEPTOR POSITIVE BREAST CANCER – CURRENT TREATMENTS 
 The hormone receptor (HR) positive subtype is the most common subtype of breast 
cancer comprising of over 65% of all breast cancer patients (Figure 1)  (Eroles, Bosch et al. 
2012). Due the presence of the hormone receptors, the mainstay treatment for these tumors 
are hormonal therapy (Goldhirsch, Wood et al. 2011). Typically, early stage HR positive 
cancers are treated with anti-estrogens, which includes tamoxifen in the case of 
premenopausal women and aromatase inhibitors in the case of post-menopausal women 
(Baum, Budzar et al. 2002). The biology of these treatments and the modes of resistance will 
be discussed in detail later in this chapter. While anti-estrogens are currently administered for a 
period of 5 years, studies propose longer treatment regiments, which have been shown to 
improve the disease free survival by 48% when patients were treated with letrozole following 5 
year tamoxifen (Jin, Tu et al. 2012). However, this prolonged treatment with tamoxifen or 
aromatase inhibitors might give rise to side-effects including enhanced risk of endometrial 
cancer and joint pain or fracture respectively (Jin, Tu et al. 2012, Davies, Pan et al. 2013).  
 Unlike early HR positive breast cancer, patients presented with metastatic disease are 
often inherently resistance to the anti-hormonal therapy or acquire resistance within few 
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months (Piccart, Hortobagyi et al. 2014). Hence, fulvestrant, a drug that directly inhibits and 
downregulates ER protein is used in the metastatic setting to treat these patients (Agrawal, 
Robertson et al. 2016). The last few years has seen the advent of targeted therapies, 
specifically the CDK4/6 inhibitors, which showed great results in clinical trials, by prolonging 
progression free survival by 12 months, and are currently approved for the treatment of 
advanced ER positive breast cancers (Clark, Karasic et al. 2016, Sherr, Beach et al. 2016). 
Finally, several pre-clinical and clinical studies have shown promising results for the use of 
PI3K and mTOR inhibitors as single or combination treatments in HR positive breast cancer 
(Paplomata and O'Regan 2014). These targeted therapies and their application has been 
explained in detail later in this chapter.  
 
1.1.4. HER2 POSITIVE BREAST CANCER – CURRENT TREATMENTS 
About 15 to 20% of all breast cancers express Her-2 receptor (Figure 1) (Yaziji, 
Goldstein et al. 2004). Her-2 belongs to the EGFR family and is a trans-membrane receptor 
that is amplified or overexpressed in breast cancer patients (Owens, Horten et al. 2004). Thus, 
targeted therapy directly blocking the pathway, such as herceptin, lapatinib, pertuzumab and T-
DM1 are currently used to treat early and advanced Her-2 positive breast cancer patients 
(Romond, Perez et al. 2005, Lewis Phillips, Li et al. 2008, Piccart-Gebhart, Holmes et al. 2016).  
Trastuzumab (herceptin) is a monoclonal antibody that binds to and inhibits the 
extracellular domain of Her-2 receptor. Results from a phase II study conducted on 235 
metastatic Her-2 positive breast cancer patients who received chemotherapy vs herceptin + 
chemotherapy, revealed that herceptin significantly prolonged time to progression and 
improved objective response rate (~50%) compared to chemotherapy alone (32%) (Slamon, 
Leyland-Jones et al. 2001). However, over time patients develop resistance to herceptin 
treatment as well (Oliveras-Ferraros, Vazquez-Martin et al. 2010). This resistance occurs either 
by loss of the receptor’s extracellular domain (which prevents recognition by herceptin) or 
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formation of a heterodimer complex between the Her-2 sand Her-3 receptors (which mediates 
tyrosine kinase activity despite herceptin treatment) (Hellyer, Kim et al. 2001, Scaltriti, Rojo et 
al. 2007, Junttila, Akita et al. 2009).  
Lapatinib is a tyrosine kinase inhibitor, which binds to the intracellular domain of Her-2 
and inhibits its kinase activity. Since lapatinib functions by targeting the receptor’s intracellular 
domain, it can be effective even in tumors that have acquired resistance to herceptin by 
acquiring modifications in the extracellular domain (Scaltriti, Chandarlapaty et al. 2010). Hence, 
studies have shown that the combination of lapatinib and trastuzumab in Her-2 positive 
xenograft model results in enhanced tumor growth inhibition (Scaltriti, Verma et al. 2009).  
Pertuzumab, is a monoclonal antibody, similar to herceptin and to bind to the 
extracellular domain of Her-2 at a site different from that of herceptin, which prevents the 
hetero-dimerization between Her-2 and Her-3, one of the resistance mechanisms to herceptin 
(Agus, Akita et al. 2002). Thus, preclinical studies have shown enhanced antitumor activity 
upon combination treatment with pertuzumab and herceptin (Scheuer, Friess et al. 2009), 
which was further confirmed in phase III clinical trial show, where the addition of pertuzumab to 
herceptin in Her-2 positive breast cancer patients proved to be an effective combination 
strategy (Baselga, Cortes et al. 2012)  
TDM-1 is a conjugate of an antibody (herceptin) with a microtubule inhibitor emtasine 
(T-DM1). Upon binding of the antibody to Her-2 receptor, the chemotherapy agent is 
internalized and released resulting in cytotoxicity exclusively in the cancer cells. Phillips at al 
examined the combination of T-DM1 with pertuzumab in a xenograft model of breast cancer 
using Her-2 expressing cell lines. The results revealed that the combination synergistically 
inhibited cell proliferation and induced cell death in vitro and induced tumor regression in vivo 
(Phillips, Fields et al. 2014).   
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1.1.5. TRIPLE NEGATIVE BREAST CANCER – CURRENT TREATMENTS 
About 15% of all cancers is characterized by the absence of ER, PR and Her2 and 
termed as Triple Negative or basal tumors (Figure 1). They show increased expression of 
cytokeratin, c-kit and epidermal growth factor receptor and frequently harbor mutations in tumor 
suppressors like p53 and BRCA (Foulkes, Stefansson et al. 2003). Several critical signaling 
pathways including MAPK, PI3K-Akt, NF-Kb, Wnt are seen to be deregulated in these cancers 
(Miki, Swensen et al. 1994. Genetic aberrations like copy number variation, gene amplification 
is also common in this cancer subtype (Foulkes, Stefansson et al. 2003). Further, epigenetic 
modifications, mainly DNA methylation has a distinct signature of basal or TNBC tumors 
(Wooster, Bignell et al. 1995). Given this diversity within the TNBC tumors, a recent study 
classified them further based on gene expression profile from 386 triple negative tumors 
(Lehmann, Bauer et al. 2011). This clustering resulted into 6 new TNBC subtypes namely 
basal, mesenchymal, mesenchymal stem-like (MSL), immunomodulatory (IM), luminal 
androgen receptor (LAR), basal like 1 (BL1), and basal like 2 (BL2), each having their own 
characteristic enrichment of genes and pathways (Lehmann, Bauer et al. 2011). For example, 
the LAR subtype showed enrichment in the androgen receptor signaling and metabolism 
pathways, while the BL1 subtype showed enrichment of the cell cycle and DNA replication 
pathways (Lehmann, Bauer et al. 2011). Further, the currently used TNBC cell lines can also 
be classified into these subtypes based on the gene expression profiles, and will facilitate 
better pre-clinical investigation (Lehmann, Bauer et al. 2011). Another recent study, which 
analyzed the RNA and DNA profiles of 198 TNBC tumors, classified them into four distinct 
molecular subtypes, each having their own characteristic gene amplification or target molecule: 
i) Luminal androgen receptor (LAR) subtype which overexpresses the cell surface mucin 
MUC1, ii) Mesenchymal (MES) subtype overexpressing the growth factor receptors, PDGF 
receptor A and c-kit, iii) Basal-like immune suppressed (BLIS) which expresses the immune 
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suppressing molecule VTCN1 and iv) Basal-like immune activated (BLIS) expresses STAT3 
molecules and cytokines (Hartkopf, Taran et al. 2016).   
By definition, the triple negative breast cancer (TNBC) tumors are negative for ER, PR 
and HER-2, and hence these patients will not benefit from hormonal therapy or Her-2 targeting 
therapies, leaving cytotoxic chemotherapy as the current standard of care for these patients 
(Rocca, Bravaccini et al. 2014). Overall, among all the breast cancer subtypes, patients with 
TNBC tumors have the worst prognosis (Carey, Perou et al. 2006, Liedtke, Mazouni et al. 
2008). While there is no standard of care drug for TNBC, patients are usually treated with a 
variety of chemotherapy drugs including anthracyclines, fluropyrimidines, taxanes and 
platinum-based drugs (Levine, Pritchard et al. 2005, Zeichner, Terawaki et al. 2016). 
Anthracyclines, such as doxorubicin, epirubicin and etoposide, which are one of the most 
commonly used class of chemo drugs in TNBC, work by intercalating the DNA or inhibiting the 
topoisomerase II activity (Zeichner, Terawaki et al. 2016). In many cases, the chemotherapy 
drugs are also given in combination to increase therapeutic benefit (Zeichner, Terawaki et al. 
2016). TNBC patients are often given anthracyclines as adjuvant chemotherapy combination 
with taxanes, such as docetaxel and paclitaxel, which work by binding to ß-tubulin and 
stabilizing the microtubules (Zeichner, Terawaki et al. 2016). Further, TNBC patients can also 
receive platinum-based chemotherapy, such as cisplatin or carboplatin both as a single agent 
and in combination therapy, with TNBC patients responding better to the platinum based drugs 
compared to other subtypes of breast cancer (Levine, Pritchard et al. 2005).  
While TNBC tumors are highly prone to genetic mutations compared to the other 
subtypes, the lack of complete knowledge about the deregulated genes has made it difficult to 
develop targeted therapies for TNBC (Zeichner, Terawaki et al. 2016). Basal like or TNBC 
breast tumors frequently have mutations (commonly germline mutations) in the BRCA family of 
DNA repair genes, which are involved in repairing double strand DNA breaks via the efficient 
and homologues recombination (HR) pathway (Moynahan, Chiu et al. 1999). About 10-15% of 
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TNBC patients harbor BRCA-1 mutation and is associated with high-grade tumor (Foulkes, 
Stefansson et al. 2003). Interestingly, over 75% of the breast cancers that develop BRCA1 
mutation belong to the TNBC subtype (Bayraktar, Gutierrez-Barrera et al. 2011). Cells deficient 
in BRCA1 are unable to repair the double strand breaks efficiently, forcing them to activate the 
alternate repair pathway, base excision repair (BER), which is regulated by the PARP (poly 
ADP ribose polymerase) family of proteins and are typically used to repair single strand DNA 
breaks (Ashworth 2008). PARP is a family of DNA binding proteins that are recruited to the site 
of single strand DNA breaks and repair them via the BER mechanism (Eustermann, Videler et 
al. 2011, Langelier, Planck et al. 2011). This results in synthetic lethality and increased 
genomic instability and apoptosis observed with PARP inhibitor treatment in BRCA1/2 deficient 
cell lines and Brca1−/−, p53−/− mouse model (Farmer, McCabe et al. 2005, Ashworth 2008). 
Tumors developed in the BRCA1−/− p53−/− mouse model were treated with the PARP inhibitor 
(olaparib - AZD2281) and cisplatin as single agents or in combination and results revealed that 
PARP inhibitor treated tumors had improved survival compared to vehicle treatment, and the 
combination treatment further improved mouse survival, demonstrating synthetic lethality of 
PARP inhibition with BRCA mutation (Rottenberg, Jaspers et al. 2008).  
The PARP inhibitors, olaparib, rucaparib and more recently niraparib have been FDA 
approved for the treatment of advanced ovarian cancers harboring BRCA1/2 mutation (2017, 
Lin and Kraus 2017). These drugs are under phase II/III clinical trials in TNBC tumors and are 
the one of the most promising results targeted therapies currently under investigation for TNBC 
(2017, Lin and Kraus 2017). A phase II clinical trial in which 54 breast cancer patients 
harboring BRCA1 or BRCA2 mutation, received two different doses of olaparib, 400 mg twice 
daily or 100 mg twice daily showed that 41% of the patients who received the higher dose 
displayed objective response while 22% of those who received the lower dose responded (Tutt, 
Robson et al. 2010). Olaparib treatment was largely well tolerated with the fatigue, nausea, and 
anemia being the most common side effects (Tutt, Robson et al. 2010). Another study showed 
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that the combination of PARP inhibitor (velaparib) with platinum based chemotherapy 
(carboplatin) in TNBC patients doubled the rate of pathologic complete response 52% 
compared to 26% with carboplatin alone (2014).  
Apart from PARP inhibitors, other targeted treatment strategies that are currently under 
investigation in TNBC patients include angiogenesis inhibitors, EGFR inhibitors and 
immunotherapy (Baselga, Gomez et al. 2013, Stagg and Allard 2013, Makhoul, Klimberg et al. 
2015). TNBC patients exhibit higher expression of EGFR compared to non-TNBC tumors, 
which led to a phase II study with the addition of the EGFR inhibitor, cetuximab to cisplatin in 
metastatic TNBC patients, which showed an increase in the response rate from 10% to 20% 
and prolonged progression free survival time (Baselga, Gomez et al. 2013). Similarly, TNBC 
tumor specimens also express higher levels of the angiogenesis factor VEGF, leading to a 
phase III clinical study combining bevacizumab, the monoclonal antibody against VEGF, along 
with docetaxel in metastatic Her2 negative breast cancer patients, and showed that addition of 
bevacizumab delayed tumor progression with no additional toxicity (Senger, Galli et al. 1983, 
Presta, Chen et al. 1997). (Miles, Chan et al. 2010). Finally, while breast cancer is considered 
non-immunogenic, they can induce an adaptive immune response and this has led to recent 
studies aimed at making the breast cancer tumors sensitive to immunotherapy and checkpoint 
blockade (Stagg and Allard 2013). Studies have shown that the TNBC subtype of breast 
tumors are particularly attractive for cancer immunotherapy since they have the presence of 
PD-1+ve TILs (tumor infiltrating lymphocytes) and higher rates of PD-L1 expression by the 
tumor and the immune cells (Cimino-Mathews, Thompson et al. 2016). This led to a phase I 
clinical study with the PD-1 inhibitor atezolizumab as a monotherapy in 112 heavily pretreated 
metastatic TNBC, which showed pathological complete response in 11 patients and partial 
response in 15 patients (2017). While only 10% of the patients responded to the anti–PD-L1 
therapy, those who did had a median duration of response of 21 months (2017), Further, a 
combination treatment of atezolizumab with paclitaxel in metastatic TNBC patients exhibited an 
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overall response rate of 41.7% (Sylvia Adams 2016). These studies provide evidence to 
develop immunotherapy as a promising treatment strategy for TNBC in the future.  
   
1.2. ER POSITIVE BREAST CANCER 
1.2.1 ROLE OF ESTROGEN AND ER IN BREAST CANCER 
 Estrogen, which is the primary female sex hormone is primarily secreted by the ovaries 
in premenopausal women (Ryan 1959). In post-menopausal women, estrogen is obtained by 
the enzyme aromatase via the conversion of androgens (testosterone) produced from the 
adipose tissues (Ryan 1959, Thompson and Siiteri 1974). Estrogen mediated its function and 
biologic activity by binding to and activating its hormone receptor, estrogen receptor (ER) 
(Deroo and Korach 2006). There are two estrogen receptors, ERα and ERβ, encoded by ESR1 
and ESR2, respectively (Deroo and Korach 2006). The binding of estrogen to the receptor 
facilitates dimerization of ER  and translocation into the nucleus, where it binds to ER 
responsive elements (ERE element) on the promoter region of the target genes (Yi, Driscoll et 
al. 2002). This is the classical and canonical pathway by which ER functions as a transcription 
factor in response to estrogen (Deroo and Korach 2006). The transcriptional function of the 
estrogen receptor is regulated by several coactivator and corepressor proteins, which interact 
with ER at the DNA and regulate gene transcription (Deroo and Korach 2006). Some of the 
crucial co-activators and co-repressors in breast cancer include, TRAP-220 (a link between ER 
alpha and RNA polymerase II), CARM1 (which is overexpressed in breast cancer), nuclear 
receptor co-repressor NCoR (represses ER gene transcription), RTA (repressor of tamoxifen 
activity, interacts with and represses ER) (Deroo and Korach 2006). Additionally, ER signaling 
can be directly activated in a ligand (estrogen) independent manner through MAPK and cAMP 
induced protein kinase A (PKA) (Arnold, Obourn et al. 1995, Chen, Washbrook et al. 2002, 
Carascossa, Dudek et al. 2010).  
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Data from clinical and animal studies show that estrogen and ER play a crucial role in 
mammary development and breast cancer (Deroo and Korach 2006). Two current hypothesis 
have been proposed to functionally explain this relationship: i) Increased estrogen activates ER 
and ER signaling, which increases cell division and DNA synthesis and the risk for replication 
errors, resulting in the acquisition of detrimental mutations, which lead to mammary tumor 
formation (Henderson and Feigelson 2000); ii) estrogen metabolism produces genotoxic 
products which directly induce DNA damage leading to mutations and cancer formation. 
Further, epidemiologic studies also show a strong link between estrogen and breast cancer 
formation (Trichopoulos, MacMahon et al. 1972), with greater duration of exposure to estrogen 
increasing the risk for breast cancer (Clavel-Chapelon and Group 2002, Press and Pharoah 
2010).  
 
1.2.2. CURRENT TREATMENTS FOR ER POSITIVE BREAST CANCER 
Due to significant role of estrogen pathway in breast cancer and given that 65% of 
breast cancers being estrogen receptor (ER) positive, drugs targeting the hormone receptor 
have been developed and are currently used (Table 2). The estrogen pathway can be targeted 
by three different strategies: i) selective estrogen receptor modulator (SERM), such as 
tamoxifen, which inhibits binding of estrogen to ER (Sini, Cinieri et al. 2016); ii) selective 
estrogen receptor down regulator (SERD) such as fulvestrant, which competitively inhibits ER, 
by binding to it and degrading it (Dauvois, White et al. 1993, Nicholson, Gee et al. 1995); and 
iii) aromatase inhibitors (AI), which are primarily used in post-menopausal women and target 
aromatase, the enzyme required for the conversion of androgens to estrogen (Furet, Batzl et al. 
1993). Recent years have witnessed the development of more specific and targeted agents 
such as CDK4/6 inhibitors, PI3K and mTOR inhibitors (Paplomata and O'Regan 2014, Sherr, 
Beach et al. 2016). The development and current clinical use of these drugs have been 
discussed in detail in sections below.  
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1.2.3. SERM - TAMOXIFEN 
 The rationale for developing an anti-estrogen to treat breast cancer arises to from the 
principle block hormone production, which was achieved in the 1970s by irradiate ovaries of 
newly diagnosed ER positive breast cancer patients (Lees, Giuffre et al. 1980). The first trial 
Class of drug Drug Structure
Selective estrogen 
receptor modulator
(SERM)
Tamoxifen
Selective estrogen 
receptor downregulator
(SERD)
Fulvestrant
Aromatase inhibitors
Letrozole
Anastrozole
Exemestane
Table 2: Anti-estrogens:Table listing the anti-estrogens used for the treatment of 
ER positive breast cancer and their chemical structures.
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with tamoxifen (originally known as IC146474) in 1971 reported response in 10 out of 46 breast 
cancer patients (Cole, Jones et al. 1971), and the drug has revolutionized the field of breast 
cancer treatment since then. The primary mechanism of action of tamoxifen as a selective 
estrogen receptor modulator (SERM) involves binding of the drug to the estrogen receptor (ER) 
and preventing the binding of estrogen to ER, thus turning off the ER signaling pathways. The 
ability of tamoxifen to block the binding of estrogen to ER and prevent the induction and growth 
of ER dependent tumors was first tested in ER positive carcinogen-induced rat mammary 
carcinomas (Jordan 1976, Jordan and Dowse 1976). The anti-tumor effects of tamoxifen were 
further confirmed in a nude mouse model with subcutaneously implanted (in the presence of 
estrogen pellets) ER positive breast tumor (generated by injecting ER positive breast cancer 
cells lines, MCF7 or T47D) treated with daily dose of tamoxifen, exhibiting significant anti-tumor 
activity (Long, Jelovac et al. 2004). This led to about 28 clinical studies conducted in over 
16,000 breast cancer patients, the consensus of which demonstrated that tamoxifen treatment 
provides significant advantage with reduction in mortality, leading to the recommendation that 
tamoxifen should be also be used as an adjuvant therapy for postmenopausal ER positive 
breast cancer patients with breast cancer (1985, Early Breast Cancer Trialists' Collaborative 
1988).  
Further, animal studies in mice with low burden or early mammary tumors showed that 
long term tamoxifen treatment in animals is better than shorter term adjuvant therapy in 
providing better efficacy and a longer tumor free state (Jordan and Brodie 2007). These studies 
combined with results from pilot clinical studies showed that long term tamoxifen treatment 
would prove to be more effective in treating women with ER positive breast cancer, and led to 
the current treatment regimen of 5-year anti-estrogen treatment. (Jordan and Brodie 2007). 
However, one of the concerns with long terms anti-estrogens is the non ER associated and 
side effects with this treatment (Love, Mazess et al. 1992, Zidan, Keidar et al. 2004). For 
example, tamoxifen has been shown to have oncogenic effect on uterus, results in higher 
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incidence (rate of 1.2% annually) of endometrial cancer in patients receiving long-term 
tamoxifen (Fisher, Costantino et al. 1994). Patients receiving long term estrogen treatment also 
suffered from higher rate of hot flashes, vaginal discharge and menstrual irregularities (Powles, 
Jones et al. 1994). On the other hand, tamoxifen treatment has beneficial effects such as 
reduction in cholesterol levels and decreased death from myocardial infarction (Bagdade, 
Wolter et al. 1990, Love, Newcomb et al. 1990, Love, Wiebe et al. 1991).  
 While tamoxifen has proven to be highly effective over the years in treating ER positive 
breast cancer, one concern is the development of resistance over time (Toy, Shen et al. 2013). 
Hence, several studies over the years have focused on understanding the molecular 
mechanism of resistance to tamoxifen, which include mutation of the estrogen receptor, loss of 
ER expression and non-canonical ER signaling pathways (Encarnacion, Ciocca et al. 1993, 
Fuqua, Wiltschke et al. 2000). Mutations in ER are more commonly detected in the resistant 
tumors compared to treatment naïve tumors (Toy, Shen et al. 2013). These mutations in the 
receptor allow ER to dimerize even in the absence of the ligand (estrogen) (Toy, Shen et al. 
2013). This would result in activation of the downstream ER signaling pathway, even in the 
presence of anti-estrogens such as tamoxifen (Toy, Shen et al. 2013). Specifically, a study in 
59 tissues with hyperplasia observed a Lys to Arg mutation (K303R) in the estrogen receptor in 
20 tissues (Fuqua, Wiltschke et al. 2000). While mutations in ER are not common, they are 
frequently found in metastatic patients who have progressed on anti-estrogen therapy (Toy, 
Shen et al. 2013). These mutations are frequently located in the ligand-binding domain of the 
receptor and facilitates estrogen independent activity of the mutants (Toy, Shen et al. 2013). 
Further, loss of expression of the hormone receptor ERα is another established mechanism of 
resistance to tamoxifen (Encarnacion, Ciocca et al. 1993, Ellis, Tao et al. 2008). Given that 
tamoxifen functions by binding direct ER, loss of the receptor makes the cells / tumors become 
unresponsive to the drug (Ellis, Tao et al. 2008). Finally, another known mechanism of 
resistance to tamoxifen is the non-canonical crosstalk between ER and other major growth 
	 16 
factor signaling pathways such as Her-2, PI3K and MAPK pathways (Campbell, Bhat-Nakshatri 
et al. 2001, Riggio, Polo et al. 2012). ER can activate growth factor receptors such as Her-2 
and EGFR (Lee, Cui et al. 2001), while PI3K and MAPK pathways can phosphorylate and 
activate ER in a ligand independent manner (Campbell, Bhat-Nakshatri et al. 2001, Riggio, 
Polo et al. 2012), ultimately resulting in cellular proliferation even in the absence of estrogen 
and resistant to tamoxifen treatment (Shou, Massarweh et al. 2004, Britton, Hutcheson et al. 
2006). This suggests combination treatment strategies with the inhibitors targeting these 
signaling pathways to combat tamoxifen resistance. This has led to pre-clinical studies with the 
combination of tamoxifen and trastuzumab or lapatinib or the EGFR inhibitor, gefitinib, which 
significantly prolonged response to tamoxifen and delayed the acquired resistance (Benz, Scott 
et al. 1992, Massarweh, Osborne et al. 2008). Further, results from a phase II clinical study 
showed the efficacy of trastuzumab in breast cancer patients who have become resistant to 
tamoxifen (Kaufman, Mackey et al. 2009).  
 
1.2.4. SERD - FULVESTRANT 
Fulvestrant, an analogue of 17β-estradiol, acts as an anti-estrogen by selectively 
binding to the estrogen receptor (ER) preventing its dimerization and nuclear localization 
(Fawell, White et al. 1990, Dauvois, White et al. 1993). The drug also mediates degradation of 
ER, resulting in complete shutdown of the ER signaling pathway (Nicholson, Gee et al. 1995). 
Given that its mechanism of action is different from that of tamoxifen, early clinical studies 
focused on utilizing fulvestrant to treat patients who have acquired resistance to prior tamoxifen 
or aromatase inhibitor therapy (Freedman, Amir et al. 2009). A study in 19 patients who 
progressed on tamoxifen treatment showed that fulvestrant can successfully extend the 
duration of response of breast tumors to anti-estrogens (Howell, DeFriend et al. 1995). More 
recently, clinical studies have also been conducted to test the efficacy of fulvestrant in 
treatment naïve patients (Robertson, Llombart-Cussac et al. 2009). For example, on 
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comparison with the aromatase inhibitor, anastrazole in a phase II study in advanced post-
menopausal breast cancer patients, patients on the fulvestrant arm had a longer time to 
progression compared to the anastrozole arm (Robertson, Llombart-Cussac et al. 2009). 
Further, a recently published phase III study confirmed that fulvestrant treatment improved 
progression free survival by 2.8 months compared to anastrazole treatment arm (Robertson, 
Bondarenko et al. 2016). Moreover, unlike tamoxifen, fulvestrant does not have an oncogenic 
effect and hence does not increase the risk of endometrial cancer (Bergman, Beelen et al. 
2000). Thus, these studies show that fulvestrant can serve as an effective anti-estrogen 
treatment in early and advanced (resistant to other anti-estrogen treatment) stage ER+ breast 
cancer patients. 
 
1.2.5. AROMATASE INHIBITORS 
 Aromatase inhibitors (AI) are a class of antiestrogens, primarily used to treat post-
menopausal women with ER positive breast cancer, and functions by inhibiting the activity of 
aromatase, the enzyme required for the generation of estrogen in post-menopausal women  
(Yue, Wang et al. 2005). They are typically divided into two classes based on their structure: i) 
non-steroidal AIs such as letrozole and anastrozole and ii) steroidal AI such as exemestane 
(Yue, Wang et al. 2005). The non-steroidal AIs, letrozole and anastrozole, competitively inhibit 
aromatase in a reversible manner by binding to the enzyme non-covalently (Soudon 2000). 
They are FDA approved are currently the standard of care drugs for post-menopausal ER 
positive breast cancer patients (Howell, Cuzick et al. 2005). The steroidal class of AI, 
exemestane, resembles in structure to androstenedione and inhibit aromatase in an irreversible 
manner by binding to the enzyme covalently (Oliveras-Ferraros, Vazquez-Martin et al. 2010). 
Exemestane has also been FDA approved for use in postmenopausal ER positive breast 
cancer patients (Coombes, Goss et al. 1984).  
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Numerous clinical studies have been performed to compare the efficacy of aromatase 
inhibitors against tamoxifen in post-menopausal breast cancer patients (Mouridsen, 
Gershanovich et al. 2001, Breast International Group 1-98 Collaborative, Thurlimann et al. 
2005, Howell, Cuzick et al. 2005). Treatment of anastrozole in combination with tamoxifen a 
phase III randomized clinical trial in the adjuvant setting showed that anastrazole treated 
patients had significantly higher disease-free survival, time to recurrence and time to distant 
metastasis compared to treatment with tamoxifen alone (Howell, Cuzick et al. 2005). Further, to 
test the effectiveness of AI in the adjuvant setting, a phase III clinical trial was performed in 
8010 postmenopausal ER+ non-metastatic patients by comparing long term letrozole treatment 
to tamoxifen (Breast International Group 1-98 Collaborative, Thurlimann et al. 2005). Results 
showed that the letrozole arm had greater disease-free survival with lower rates of distant 
metastasis compared to tamoxifen treatment arm (Breast International Group 1-98 
Collaborative, Thurlimann et al. 2005). A similar phase III clinical study in advanced (stage IIIb 
with recurrent tumors) postmenopausal ER positive breast cancer where patients received 
letrozole or tamoxifen as first line therapy revealed that a significantly higher (increased by 15 
weeks) time to progression and higher rate of objective response in the letrozole treated 
patients compared to tamoxifen treatment arm, indicating that AI treatment with letrozole is also 
beneficial in the advanced disease stage (Mouridsen, Gershanovich et al. 2001).  
 While aromatase inhibitors have been successful in the treating advanced and 
treatment naïve ER positive post-menopausal breast cancer patients, these tumors tend to 
eventually acquire resistance via numerous mechanisms (Jordan and Brodie 2007, Ma, Reinert 
et al. 2015). Research in the recent years have hence focused on elucidating these 
mechanisms, including androgen receptor (AR) expression, signaling through growth receptor 
pathways such as Her-2, PI3K and MAPK pathways, epithelial mesenchymal transition (EMT) 
and cancer stem cells (Ma, Reinert et al. 2015). Androgen receptor (AR) is a nuclear hormone 
receptor, similar to AR that gets activated when bound to androgen regulates downstream 
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effector genes (Schoenmakers, Alen et al. 1999), Since AR can activate the ER pathway 
independent of estrogen, it has been shown to mediate de novo resistance of AIs (Rechoum, 
Rovito et al. 2014). Hence, treatment with an AR antagonist (abiraterone) or an ER degrading 
drug (fulvestrant) can restore sensitivity to the aromatase inhibitors even in the AR 
overexpressing resistant cell (Rechoum, Rovito et al. 2014). Similar to tamoxifen resistance, 
the activation of the parallel growth signaling pathways is a common mechanism by which 
tumors acquire resistance to AIs (Ma, Reinert et al. 2015). This involves upregulation and 
activation of the growth factor receptors such as PI3K, MAPK, Her-2 and their downstream 
pathway proteins, thus enabling the AI resistant cells to adapt to and survive in low estrogen 
conditions (Sabnis, Schayowitz et al. 2009, Ma, Reinert et al. 2015). Hence, the AI resistant 
cells are significantly sensitive to the MAPK inhibitor (PD98059) or a MEK inhibitor (UO126) 
resulting in decreased proliferation (Jelovac, Sabnis et al. 2005). Moreover, drugs targeting the 
PI3K downstream protein, mTOR (everolimus) have been tested clinically (phase III study) in 
combination with exemestane in ER+ patients who have progressed on aromatase inhibitors 
(anastrozole or letrozole) and showed that addition of everolimus significantly improved 
progression-free survival in these patients (Baselga, Campone et al. 2012). Thus, these studies 
show that combined targeting of these growth signaling pathways might help re-sensitize the 
cells to AI treatment. Further, studies have shown a link between mutations in ER and other 
genes, and resistance (intrinsic and acquired resistance) to aromatase inhibitors (Ma, Reinert 
et al. 2015). A study using whole genome sequencing of 77 ER positive tumor biopsies before 
and after treatment with aromatase inhibitors, showed a correlation between ESR1 mutations 
and response to treatment (Ellis, Ding et al. 2012). This study also examined mutations in other 
genes such as Pi3K, p53, Rb and p27, and showed that mutations in PI3K (41.3%) and p53 
(16.1%) correlated with resistance (measured by change in Ki67) to aromatase inhibitor 
therapy (Ellis, Ding et al. 2012). A more recent study examined the ESR1 mutations in the 
plasma and correlated it with response to aromatase inhibitors (exemestane) or fulvestrant 
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(Fribbens, O'Leary et al. 2016). Results showed that while ESR1 mutations did not affect 
response to fulvestrant, a correlate between mutations and resistance to exemestane was 
observed (Fribbens, O'Leary et al. 2016). Finally, a link between EMT, cancer stem cells and 
resistance to AIs has also been shown by in vitro studies (Creighton, Li et al. 2009).  
 Further, ER alpha has been shown to promote progression through the cell cycle by 
binding to p27, which is one of the mechanisms by which ER alpha regulates cell proliferation 
(Moghadam, Hanks et al. 2011). A recent study shows a novel mechanism by which anti-
estrogens control the cell cycle, where the stabilization of ER alpha delays cell cycle 
progression leading cell cycle arrest (Moghadam, Hanks et al. 2011). Results from this study 
also showed that ER alpha is cell cycle regulated, and the presence or absence of the estrogen 
ligand on the receptor (ER alpha) determines the duration of the cell cycle in both ER positive 
(MCF7) and TNBC cell lines (MDA-MB-231) (JavanMoghadam, Weihua et al. 2016). Thus, 
deregulation of the cell cycle is a mechanism of resistance to anti-estrogens, making it an 
attractive drug target in ER positive breast cancer.    
 
1.3. CELL CYCLE 
1.3.1. CELL CYCLE REGULATION  
 Cell cycle is the complex and highly regulated process by which a cell divides to form 
two daughter cells (Vermeulen, Van Bockstaele et al. 2003). The normal mammalian cell cycle 
typically lasts for 24 hours and comprises of two major phases, the interphase, which is the 
period during which the cells grow, undergo DNA replication and prepare for cell division and 
the mitotic phase, when the DNA, nuclear material and cytoplasm is separated into two 
daughter cells (Harper and Brooks 2005). The interphase in turn comprises of 3 phases, i) G1 
phase, which is the longest phase of the cell cycle and the phase when the cells prepare for 
DNA synthesis, ii) S phase, the phase when the replication of the DNA content occurs, and iii)  
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G2 phase, the phase when the cells increase their protein and other content to prepare for 
mitosis or cellular division (Figure 2) (Harper and Brooks 2005, Malumbres and Barbacid 
2009). The mitotic phase or the M phase in turn comprises of four phases called prophase, 
metaphase, anaphase and telophase (Harper and Brooks 2005). The M phase is characterized 
by the condensation of the chromosomes, formation of the spindle fibers which enables 
separation of the sister chromatid and finally leading to cytokinesis, which gives rise to two 
identical daughter cells (Harper and Brooks 2005). 
 Tight regulation of the cell cycle is necessary for controlled cell division in a normal cell 
(Vermeulen, Van Bockstaele et al. 2003). This is achieved by regulatory checkpoints at 
different points in the cell cycle and through regulatory proteins – the CDKs and cyclins (Harper 
and Brooks 2005). There are three cell cycle checkpoints, namely i) G1/S, which ensures that 
there is no DNA damage and that the cell has accumulated sufficient materials for DNA 
synthesis, ii) G2/M, which ensures that the replicated DNA is intact and the proteins required 
for cell division are present and iii) M phase checkpoint, which is present at the end of the 
metaphase to ensure the proper attachment of the spindle fibers to the sister chromatids 
Figure 2: Mammalian cell cycle: Model depicting the mammalian cell cycle 
with its different phases, checkpoints and regulatory proteins, CDKs and cyclins
CELL CYCLE
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(Figure 2) (Harper and Brooks 2005, Malumbres and Barbacid 2009). These checkpoints help 
regulate which cells can move forward and complete the cell division process (Malumbres and 
Barbacid 2009). The presence of any defect in the normal cell cycle process will halt the cells 
at checkpoint until the defect is repaired (Vermeulen, Van Bockstaele et al. 2003). The G1/S 
checkpoint is the most crucial transition checkpoint, since cells that have passed this 
checkpoint no longer rely on external stimuli are committed to divide (Bertoli, Skotheim et al. 
2013). 
 Progression through the cell cycle is further regulated by the cyclin dependent kinases 
(CDKs) and their activating subunit, the cyclins (Figure 2) (Satyanarayana and Kaldis 2009) 
While CDKs are expressed at constant levels throughout the cell cycle, the expression levels of 
the cyclins oscillate through the different phases and regulate the kinase activity of the cyclin-
CDK complex (Malumbres and Barbacid 2009). The activity of CDKs are inhibited by the cyclin 
dependent kinase inhibitors (CKIs), which belong to two families of CKIs, INK family proteins 
that inhibit CDK4/6 such as p15, p16, p18 and p19 and the Cip/Kip family proteins that inhibit 
CDK1 and CDK2 such as p21 and p27 (Hirai, Roussel et al. 1995) (Ball, Lain et al. 1997). Rb 
protein, a well-known tumor suppressor regulates the G1/S checkpoint (Malumbres and 
Barbacid 2009). While the hypophosphorylated state of Rb keeps the transcription factor E2F in 
its inactive state, the sequential phosphorylation of Rb by cyclin D-CDK4/6 and cyclin E-CDK2 
complexes inactivates the protein, releasing E2F, which in turn transcriptionally activates genes 
needed for DNA synthesis (Ikeda, Jakoi et al. 1996, Connell-Crowley, Harper et al. 1997). 
Since the expression of cyclin E and cyclin A are also regulated by E2F, cyclin E protein levels 
increase through the G1 phase, reaching its peak at the of G1/S transition, where its activity is 
required for entry into the S phase (Duronio, Brook et al. 1996). Further, the expression of 
cyclin A increases through G2 phase and is replaced by cyclin B during mitosis to form a 
complex with CDK1 and enable cells to cross the G2/M checkpoint and enter mitosis (Lindqvist, 
van Zon et al. 2007). Finally, the degradation of cyclin B is required for the cells to exit mitosis 
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Gene 
deleted Phenotypes Lethality Fertility
Cdk1 None E2.5
Cdk2 Reduced body size, impaired neural progenitor cell proliferation Viable
Both males and 
females are sterile
Cdk4 Reduced body size, insulin deficient diabetes Viable
Male and female 
infertility
Cdk6 Hypoplasia of thymus and spleen and defects in hematopoiesis Viable Fertile
Cdk2/4 Heart defects E15.5
Cdk2/6 Reduced body size, hematopoietic defects Viable Both male and female are sterile
Cdk4/6 Severe anemia E14.5-E18.5
Cdk2/4/6 Heart defects, hematopoietic defects E13.5
Cdk5 Severe neurological defects
Died 
immediately 
after birth
Not known
Cdk11 Mitotic defects E3.5 Not known
Cyclin A1 No abnormalities Viable Only males are sterile
Cyclin A2 Not-known E5.5 Not-known
Cyclin B1 Not-known E10.5 Not-known
Cyclin B2 No abnormalities Viable Fertile
Cyclin D1 Reduced body size, neurological abnormalities, mammary gland defects Viable Fertile
Cyclin D2
Defects in B-lymphocyteand pancreatic -
cell proliferation, adult neurogenesis and 
hypoplastic thymus
Viable
Females sterile; 
males fertile with 
hypoplastic testes
Cyclin D3 Defects in T-lymphocyte development Viable Fertile
Cyclin 
D1/D2 Reduced body size, hypoplastic cerebella
Viable but die 
within 3 weeks
Cyclin 
D1/D3 Neurological abnormalities
Die soon after 
birth
Cyclin 
D1/D2/D3
Proliferative defects in hematopoietic cells 
and cardiac myocytes E16.5
Cyclin E1 No abnormalities Viable Fertile
Cyclin E2 No abnormalities Viable Reduced male fertility
Cyclin 
E1/E2 Severe defects in extraembryonic tissues E11.5 Not known
Table 3: Defects in CDK and cyclin knockout mice: Table summarizing the defects and 
survival of mice without knockout in the different cyclins and CDKs
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(Malumbres and Barbacid 2009). The expression of the different cyclins and the activity of the 
CDKs tightly regulate the cell cycle and progression through the cell cycle checkpoints. To 
understand in detail the function of the different cyclins and the CDKs, knockout mice have 
been made over the years for the cyclin or the CDK proteins alone or multiple cyclins and 
CDKs in combination (Table 3).   
 
1.3.2. CELL CYCLE IN CANCER 
Deregulation of cell cycle is a common hallmark in cancers, causing uncontrolled proliferation 
and cell division (Figure 3), resulting in tumorigenesis (Malumbres and Barbacid 2009). This 
occurs due to the numerous alterations present in the components of cell cycle (CDKs, cyclins 
and CKIs) seen in cancers (Vermeulen, Van Bockstaele et al. 2003). For example, cyclin D1 is 
amplified in about 15% and overexpressed in about 50% of all breast cancers (Bartkova, Lukas 
et al. 1995). While cyclin E is rarely amplified, it is overexpressed in about 40% of all breast 
cancer, contributing to poor prognosis in breast cancer and hyper activation of CDK2 
(Keyomarsi, Conte et al. 1995, Hunt, Karakas et al. 2016). Further, high cyclin B1 expression 
correlated with poor overall survival in breast cancer (Vermeulen, Van Bockstaele et al. 2003). 
Apart from aberrant expression of the cyclins, CKIs are also deregulated in cancer. p27 has 
lower expression and is seen to be mislocalized (localized in the cytoplasm instead of the 
nucleus) in breast cancer, thus correlating with high tumor grade, absence of ER and 
decreased disease free survival (Wu, Shen et al. 1999). Further, hypermethylation is seen 
about 20 to 30% of breast cancer, which can inactivate the CKIs by methylation at the promoter 
region, as seen with silencing of p16 (Merlo, Herman et al. 1995). p21, while is rarely mutated 
in breast cancer, p53, which is transcription factor of p21 is mutated in 54-82% of TNBC tumors 
(Vermeulen, Van Bockstaele et al. 2003). Thus, these alterations and the deregulated cell cycle 
make it an attractive target for drug development.  
	 25 
 
1.3.3. CDK INHIBITORS IN BREAST CANCER 
Given the importance of the cell cycle and CDKs in cancer, several drugs have been 
developed over the years. Typically, CDK inhibitors are small molecule inhibitors that inhibit the 
CDK kinase activity by competitively binding to the ATP pocket of the CDK proteins (De 
Azevedo, Leclerc et al. 1997). The first generation CDK inhibitors that were developed lacked 
specificity to a particular CDK and underwent clinical trials without a biomarker, resulting in 
increased toxicity and early termination of the clinical trials (Asghar, Witkiewicz et al. 2015). 
Hence these drugs cannot be used effectively as monotherapy (Asghar, Witkiewicz et al. 
2015). Recent studies have given rise to a new class of more specific and potent CDK4/6 
inhibitors, namely palbociclib, ribociclib and abemaciclib (Fry, Harvey et al. 2004). Given their 
promising results in clinical studies, they were FDA approved and are currently used to treat 
advanced ER positive breast cancer (O'Leary, Finn et al. 2016).   
Flavopiridol (alvocidib) is one of the first generation of CDK inhibitors that was tested 
clinically. While flavopiridol can target CDK2, it is a pan-CDK inhibitor as it inhibits multiple 
other CDKs such as CDK1, CDK4, CDK6, CDK7 and CDK9 (Carlson, Dubay et al. 1996). 
Treatment with flavopiridol results in cell cycle arrest and apoptosis as measured by Annexin V 
Figure 3: Cell cycle in normal and cancer cells: Models showing the regulation of the 
cell cycle in normal vs cancer cells. Normal cell cycle depicts the growth and division of the 
cells (green cartoon) along the difference phases. The cancer cell cycle depicts the 
uncontrolled division of the cancer cells (red cartoon).  
CANCER CELL
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(Wirger, Perabo et al. 2005). A phase I study examined flavopiridol in two breast cancer patient 
among a cohort of 34 patients with advanced solid tumors, and showed no response in both 
the two breast cancer patients (Ramaswamy, Phelps et al. 2012). Another phase I trial which 
tested the combination of flavopiridol with docetaxel in breast cancer did not yield satisfactory 
results and had high toxicity (neutropenia) in most patients (Tan, Yang et al. 2004). Given their 
high levels of toxicity and lack of efficacy, flavopiridol was not pursued clinically beyond phase 
II in advanced colorectal cancer patients and malignant melanoma (Aklilu, Kindler et al. 2003, 
Burdette-Radoux, Tozer et al. 2004). 
Roscovitine (seliciclib), is another first generation CDK2 inhibitor that can inhibit CDK1, 
CDK5, CDK7, and CDK9 in addition to CDK2 (IC50 0.7μM) (Meijer, Borgne et al. 1997). Pre-
clinical analysis of roscovitine in vitro using ER positive breast cancer cell lines showed that 
degu treatment resulted in cell cycle arrest (G2 arrest) and cell death via apoptosis and 
enhanced anti-proliferative activity when combined with tamoxifen (Gritsch, Maurer et al. 2011). 
The effect of roscovitine of breast tumorigenesis was interrogated in an MCF7 xenograft mouse 
model, where treatment of tumors with roscovitine or doxorubicin resulted in decreased tumor 
volume in almost 50% of mice, with combination of roscovitine and doxorubicin resulting in a 
70% tumor shrinkage.  (Appleyard, O'Neill et al. 2009). Clinically, in a phase I study of 21 
patients bearing solid tumors, treatment with roscovitine at a range of doses resulted in stable 
disease in about 8 out of the 21 patients (Benson, White et al. 2007).  
Dinaciclib (SCH 727965), is another small pan-CDK inhibitor that targets multiple CDKs 
including CDK2 (IC50=1nM), CDK5 (IC50=1nM), CDK1 (IC50=3nM) and CDK9 (IC50=4nM) 
(Parry, Guzi et al. 2010). Pre-clinical studies have primarily tested the use of dinaciclib in triple 
negative cell lines, where it showed significant anti-proliferative effects in vitro and tumor 
regression in xenograft tumors in vivo (Horiuchi, Kusdra et al. 2012). Further, studies in ovarian 
cancer cell line A2780 showed that dinaciclib treatment decreased Rb phosphorylation and 
induced apoptosis (measured by PARP cleavage) (Chen, Xie et al. 2015). This led to clinical 
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studies in breast cancer patients, with a randomized phase II trial in patients with advanced 
breast cancer (patients who failed previous chemotherapy), who received either dinaciclib 
(50mg/m2 once every three weeks) or capecitabine (Mita, Joy et al. 2014). While the study had 
to be stopped due to increased toxicity (neutropenia in 47% of patients and leukopenia in 21% 
of patients) and lower progression free survival in the dinaciclib arm, significant antitumor 
activity was seen in 2 out of 7 breast cancer (Mita, Joy et al. 2014). Further, a phase I clinical 
trial conducted at MD Anderson Cancer Center, which tested the combination of dinaciclib and 
epirubicin in advanced metastatic triple negative breast cancer patients also showed severe 
side effects (febrile neutropenia), resulting in early termination of the study (Mitri, Karakas et al. 
2015). This suggests that while dinaciclib has shown promise in pre-clinical studies in breast 
cancer, the dosage and treatment regimen has to be optimized for efficacious clinical studies.  
 
1.4. CDK4/6 INHIBITORS IN BREAST CANCER 
1.4.1. DISCOVERY AND DEVELOPMENT OF CDK4/6 INHIBITORS 
While pan-CDK inhibitors have been available since the early 1990's, they were mostly 
non-specific and toxic, limiting their clinical applicability (Asghar, Witkiewicz et al. 2015). The 
emerging significance of the G1/S checkpoint and the deregulation of the CDK4/6-cyclin D 
pathway in cancers fueled efforts for the discovery a selective and potent drug targeting 
CDK4/6 (Sherr, Beach et al. 2016). These drugs target the kinase activity of CDK4 and CDK6, 
resulting in decreased phosphorylation of Rb, which keeps the Rb protein bound to the E2F 
transcription factor (Figure 4) (Bertoli, Skotheim et al. 2013). This prevents E2F mediated 
transcription of the cell cycle proteins, resulting in the arrest of the cells at the G1 phase of the 
cell cycle (Bertoli, Skotheim et al. 2013). Thus, chemists at Parke-Davis developed the specific 
CDK4/6 inhibitor, PD0332991, which eventually became Pfizer's Palbociclib (Ibrance™) (Sherr, 
Beach et al. 2016). Palbociclib is now FDA approved for clinical use in advanced ER positive 
breast cancer (O'Leary, Finn et al. 2016). The other two CDK4/6 inhibitors, ribociclib and  
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abemaciclib were subsequently developed by Novartis and Eli Lilly respectively (O'Leary, Finn 
et al. 2016). Of these, ribociclib was recently approved for clinical use in advanced ER positive 
breast cancer and abemaciclib has obtained breakthrough FDA approval in the same group of 
cancers (Sherr, Beach et al. 2016). Table 4 summarizes the basic characteristics of the three 
CDK4/6 inhibitors, with the stage of approval and clinical characteristics. The pre-clinical and 
clinical development of the individual CDK4/6 inhibitors along with their future utility has been 
described in detail in the sections below.  
 
1.4.2. PALBOCICLIB  
Palbociclib (PD-0332991) is an oral specific and potent inhibitor of the CDK4/6 
developed by Pfizer (O'Leary, Finn et al. 2016). A study in 2009 examined the sensitivity (IC50   
Figure 4: CDK4/6 inhibitors in cancer cells: Models how treatment with the 
CDK4/6 inhibitors molecular affects the G1/S transition and the cell cycle
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value) of a panel of breast cancer cell lines to palbociclib treatment, which showed that most of 
the sensitive cell lines belonged to the ER positive subtype of breast cancer (Finn, Dering et al. 
2009). Further, analysis of the gene expression profile between sensitive and resistant lines 
revealed that sensitive lines have a higher expression of cyclin D1, Rb1 and reduced 
Drug Palbociclib (Pfizer) (PD0332991,Ibrance)
Ribociclib (Novartis) 
(LEE011, Kisqali)
Abemaciclib (Eli Lilly) 
(LY2835219)
Structure
Approval 
status
FDA approved - 1st
and 2nd line ER+ 
HER2- metastatic 
breast cancer (2015)
FDA approved – 1st line 
ER+ HER2- metastatic 
breast cancer (2017)
FDA breakthrough
designation (2016)
IC50 (in vitro 
kinase assay)
CDK4 (D1): 11 nM
CDK4 (D3): 9 nM
CDK6 (D2): 15 nM
CDK1: >10 μM
CDK2: >10 μM 
CDK4: 10 nM
CDK6: 39 nM
CDK1: >100 μM
CDK2: >50 μM
CDK4 (D1): 0.6-2 nM
CDK6 (D1): 2.4-5 nM
CDK 9: 57 nM
CDK1: > 1 μM
CDK2: > 500 nM
PK Tmax 4.2-5.5 hrt½ 25.9-26.7 hr
Tmax 4 hr
t½ 24-36 h
Tmax 4-6 hr, t½ 17-38 hr
(crosses blood brain 
barrier)
PD
Reduced RB 
phosphorylation in 
paired tumor biopsies, 
and reduced fluoro-
thymidine-PET uptake
Reduced RB 
phosphorylation and 
Ki67 expression in 
paired tumor biopsies
Reduced RB 
phosphorylation and 
topoisomerase IIα 
expression in paired 
tumor and skin biopsies
Dosing 125 mg daily (3 weeks on 1 week off)
600 mg daily (3 weeks
on 1 week off)
200 mg twice daily 
(continuous dosing)
Dose-limiting 
toxicities
Neutropenia, 
Thrombocytopenia
Neutropenia, 
Thrombocytopenia Fatigue
Table 4: CDK4/6 inhibitors in breast cancer: Table showing the CDK4/6 inhibitors that are currently 
used in breast cancer and their characteristics.
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expression or loss of p16 (Finn, Dering et al. 2009). Mechanistically, palbociclib decreased Rb 
phosphorylation and induced G1 arrest exclusively in the sensitive cell lines (Finn, Dering et al. 
2009). A more recent study that examined the changes in gene expression in the MCF7 cell 
line following palbociclib treatment showed that unlike long term estrogen deprivation or anti-
estrogen treatment, palbociclib did not directly affect the ER target genes, but only reduced 
expression of the cell cycle regulatory genes (Knudsen and Witkiewicz 2016). The induction of 
palbociclib mediated G1 arrest and senescence has been verified further by numerous pre-
clinical studies including a study which showed that expression of FOXM1, a CDK4/6 target 
decreases with palbociclib treatment and is required for the induction of senescence by the 
drug (Anders, Ke et al. 2011). Moreover, palbociclib has been shown be synergistic in 
combination with tamoxifen in a tumor explant model of breast cancer, which showed a 
significant decrease in Ki67 and Rb protein in 11 out of the 13 explants (Dean, McClendon et 
al. 2012). A more recent study even evaluated the use of palbociclib in tamoxifen resistant 
tumors, expressing ESR1 mutations, and showed that the combination of palbociclib with 
SERDs such as fulvestrant was effective in decreasing growth of the patient derived xenograft 
(PDX) tumors (Wardell, Ellis et al. 2015). More detailed mechanistic studies have been 
discussed in Chapter 3 (in breast cancer) and Chapter 8 (in other solid tumors). These studies 
provided the pre-clinical basis for testing the use of palbociclib clinically in ER advanced 
positive breast cancer cell lines in combination with anti-estrogens (O'Leary, Finn et al. 2016).  
A phase I single arm dose finding and toxicity study in Rb positive advanced solid 
tumors, where patients received escalating doses of palbociclib (3 weeks on and 1 week off 
schedule) showed that neutropenia was the only significant toxicity suggested a dose of 125 
mg of palbociclib for future clinical studies (Flaherty, Lorusso et al. 2012). Further, a single-arm 
phase II clinical trial was conducted in 37 advanced breast cancer patients (acquired resistance 
to prior hormonal therapy), where patients were treated with a dose of 125 mg for three week 
on and on week off regiment (DeMichele, Clark et al. 2015). Results showed partial response in 
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2 patients and stable disease in 5 patients, with non-febrile (not accompanied by fever), 
neutropenia detected 50 to 60% of the patients, with no bone marrow damage (DeMichele, 
Clark et al. 2015). These studies showed that palbociclib is well-tolerated. Further clinical 
studies were conducted to interrogate the efficacy of palbociclib in advanced ER positive breast 
cancer in comparison with the current standard of care treatments, such as aromatase 
inhibitors and fulvestrant (studies summarized in Table 5).  
PALOMA-1, a randomized multicenter phase II study tested letrozole alone or letrozole 
in combination with palbociclib in postmenopausal advanced ER positive  /HER2-ve  breast 
cancer patients (Finn, Crown et al. 2015). Results showed that combining palbociclib with 
letrozole increased the median progression-free-survival from 10.2 months (letrozole alone 
arm) to 20.2 months, with neutropenia reported in 54% and leucopenia reported in 19% of 
patients who received the combination drug treatment (Finn, Crown et al. 2015). However, the 
overall survival of patients did not significantly change upon addition of the CDK4/6 inhibitor 
palbociclib to letrozole (37.5 months in combination arm vs 33.3 months in the letrozole arm) 
(Finn, Crown et al. 2015). The improved progression free survival in patients receiving 
palbociclib plus letrozole was further confirmed in phase III randomized clinical trial (PALOMA-
2) conducted in 666 ER+/HER2-  breast cancer patients (Finn, Martin et al. 2016). Results 
showed that the combination of palbociclib with letrozole increased the progression-free 
survival from 14.5 months to 24.8 months, compared to letrozole alone, with neutropenia (non-
febrile), however, detected in a majority (79%) of combination treated patients (Finn, Martin et 
al. 2016). Finally, the benefit of adding palbociclib to fulvestrant was tested in PALOMA-3, a 
phase III randomized study in 521 advanced ER+/Her-2- patients, who have relapsed on prior 
on endocrine therapy (Turner, Ro et al. 2015). Results revealed that addition of palbociclib to 
fulvestrant regimen prolonged the median progression-free survival to 11.2 months compared 
to 3.6 months with fulvestrant alone, with grade 3 and 4 neutropenia seen in 62% of the 
combination treated patients (similar to PALOMA-2) (Turner, Ro et al. 2015). Further, the pre- 
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clinical and the clinical studies examining the use of palbociclib in cancers other than breast 
have been discussed in detail in Chapter 8.  
 
1.4.3. RIBOCICLIB 
Ribociclib is another selective CDK4/6 inhibitor that inhibits phosphorylation of Rb in a 
dose dependent manner, inducing G1 arrest in vitro cell cycle arrest and delayed tumor growth 
in glioblastoma xenograft tumors in vivo (Rader, Russell et al. 2013). Ribociclib was first tested 
in patient in a phase I study with 132 advanced cancer patients including 18 breast cancer 
Trial Drugs Phase Results Identifier
PALOMA-1 PalbociclibLetrozole II
Median PFS: 20.2 months 
for the combination vs
10.2 months with letrozole 
alone
NCT00721409
NCT01740427
PALOMA-2 PalbociclibLetrozole III
Median PFS: 24.8 months 
for the combination vs
14.5 months with letrozole 
alone
NCT00721409
NCT01740427
PALOMA-3 PalbociclibFulvestrant III
Median PFS: 11.2 months 
for the combination vs
4.6 months with 
fulvestrant alone
NCT01942135
MONARCH-1 Abemaciclib II
Median PFS: 5.95 months 
for abemaciclib
monotherapy
NCT02102490
MONARCH-2 AbemaciclibFulvestrant III Not reported NCT02107703
MONARCH-3
Abemaciclib
Aromatase 
Inhibitors
III Not reported NCT02246621
MONALEESA-2 RibociclibLetrozole III
Median PFS: 25.3 months 
for the combination vs
16 months with letrozole 
alone
NCT01958021
MONALEESA-3 RibociclibFulvestrant III Not reported NCT02422615
Table 5: CDK4/6 inhibitor clinical trials in ER+ breast cancer: Table showing the seminal clincial trials 
that have been completed and are underway with CDK4/6 inhibitors in advanced ER+ve breast cancer
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patients, which showed neutropenia as being the only significant side-effect similar to 
palbociclib (Infante, Cassier et al. 2016). Further, MONALEESA-2, a multi-center randomized 
phase III study examined the efficacy of combining ribociclib with letrozole in 669 post-
menopausal advanced or metastatic ER positive breast cancer patients, with ribociclib given in 
a 3 week on 2 week off treatment regimen (Table 5) (Hortobagyi, Stemmer et al. 2016). Study 
results showed that addition of ribociclib significantly delayed the progression to 25.3 months 
compared to 16 months with letrozole alone (Hortobagyi, Stemmer et al. 2016). The study 
showed that toxicity with ribociclib treatment is similar to that seen with palbociclib, with 59% of 
the patients experience neutropenia and 21% of patients experience leukopenia (Hortobagyi, 
Stemmer et al. 2016). Further, a randomized phase III trial (MONALEESA-3) is currently 
underway examine the effect of the combination of ribociclib and fulvestrant in advanced ER 
positive breast cancer (Table 5). 
 
1.4.4. ABEMACICLIB 
Abemaciclib is the third CDK4/6 inhibitor currently under clinical investigation for breast 
and other solid tumors (O'Leary, Finn et al. 2016). It inhibits CDK4/6 at low nanomolar 
concentrations and reduced Rb1 phosphorylation in colorectal cancer and melanoma 
xenografts (Patnaik, Rosen et al. 2016).  
A phase I study examined the safety and efficacy of abemaciclib in solid tumors 
including 47 breast cancer patients, who received abemaciclib as a monotherapy (Patnaik, 
Rosen et al. 2016). Results showed that overall response was seen in almost 35% of the 
breast cancer patients, accompanied by a marked decrease in Ki67 expression in the tumor 
tissues (Patnaik, Rosen et al. 2016, 2017). In an expansion cohort, where abemaciclib was 
administered as a monotherapy in 25 patients with advanced HR+/HER2− disease, clinical 
benefit rate was seen in 72% of the patients, with only one of the partial responders receiving 
concomitant hormonal therapy (O'Leary, Finn et al. 2016, Patnaik, Rosen et al. 2016). Thus, 
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the ER positive subtype of breast cancer patients exhibited a median duration of response of 
13.4 months and median PFS of 8.8 months (Patnaik, Rosen et al. 2016), suggesting the 
clinical utility of abemaciclib as a single agent than palbociclib. Moreover, results from 
MONARCH-1, a phase II study of abemaciclib as monotherapy in 132 HR+/HER2- advanced 
breast cancer was recently reported (Maura N. Dickler 2017). Results showed a clinical benefit 
rate of 42.4%, with patients exhibited a median progression-free survival of 5.95 months and 
median overall survival of 22.3 months (Maura N. Dickler 2017).  
Unlike palbociclib and ribociclib, abemaciclib is administered to patients on a continuous 
daily or twice a day regimen, which has been shown to be highly tolerated (Patnaik, Rosen et 
al. 2016, Maura N. Dickler 2017). Further, the common dose limiting side-effects associated 
with abemaciclib fatigue and diarrhea, and not high-grade neutropenia and leukopenia as seen 
with palbociclib and abemaciclib (Patnaik, Rosen et al. 2016, Sherr, Beach et al. 2016, Maura 
N. Dickler 2017). While reason for this remains uncertain, it may be due to the preferential 
selectivity of abemaciclib for CDK4 over CDK6 and its reported potential activity against CDK9, 
although, preliminary studied show that this may not translate into inhibition of the cellular 
activity of CDK9 (Patnaik, Rosen et al. 2016, Sherr, Beach et al. 2016). Moreover, another 
characteristic of abemaciclib is its ability to cross the blood brain barrier and its appearance in 
the cerebrospinal fluid in animal models, which suggests that the drug might possess additional 
activity in treating brain metastasis in patients with breast cancer (Raub, Wishart et al. 2015, 
Tate, Burke et al. 2016).  
 
1.4.5. BIOMARKER STUDIES WITH CDK4/6 INHIBITORS 
 Since biomarkers are essentially for the selectivity of drug treatment, numerous pre-
clinical and clinical studies have been conducted to identify biomarkers for this treatment 
(O'Leary, Finn et al. 2016). While pre-clinical studies identified Rb, cyclin D and p16 among 
other proteins as biomarkers for the CDK4/6 inhibitors, clinical studies showed that none of 
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these proteins can efficiently predict response to therapy (Sherr, Beach et al. 2016). The 
summary and results of the pre-clinical and the clinical studies conducted with the CDK4/6 
inhibitors have been described in detail in Chapters 6 and 7. 
 
1.4.6. MECHANISMS OF RESISTANCE TO CDK4/6 INHIBITORS 
While CDK4/6 inhibitors have shown promising results in the clinic in ER positive breast 
cancer, about 16% of the ER positive cancer patients exhibit progression within 24 weeks, 
resulting in no overall survival benefit with the treatment (Finn, Martin et al. 2016). More than 
half the patients acquire clinical resistance with progression on therapy within 25 months (Finn, 
Martin et al. 2016), and it is expected that most will eventually become resistant to the drugs. 
Hence, numerous studies are currently underway in trying to understand the mechanism of 
resistance to CDK4/6 inhibitors, both intrinsic and acquired resistance (Sherr, Beach et al. 
2016). Early pre-clinical studies aimed at identifying biomarkers showed that loss of Rb 
mediates resistance to CDK4/6 inhibition in breast cancer cells lines and xenograft tumors 
(Finn, Dering et al. 2009). A study in breast cancer showed the activation of the PI3K mediated 
growth signaling pathways as a mode of resistance to CDK4/6 inhibitor (ribociclib) mediated 
growth inhibition and senescence, particularly in PIK3CA mutant cell lines (Vora, Juric et al. 
2014). Hence, combination treatment with PI3K inhibitor was synergistic with ribociclib in the 
ER positive breast cancer cell lines, MCF7 and T47D, and also prevented acquired resistance 
to ribociclib (Vora, Juric et al. 2014) 
Moreover, an ovarian cancer pre-clinical study showed that expression of cyclin E 
mediates resistance to palbociclib mediated growth inhibition and senescence (Taylor-Harding, 
Aspuria et al. 2015). Further, a more recent study showed that high levels of CDK2 and cyclin 
E can mediate early adaptation (intrinsic drug resistance) and acquired resistance in breast 
cancer (Herrera-Abreu, Palafox et al. 2016). This study showed that high CDK2 levels maintain 
Rb phosphorylation despite palbociclib treatment and showed that high expression of cyclin E 
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post mitotic exit determines early adaptation and resistance to CDK4/6 inhibitors (Herrera-
Abreu, Palafox et al. 2016). Another recently reported study confirmed this observation, by 
showing that cell lines that have a greater CDK high population are more resistant to 
palbociclib treatment since the CDK2 activity mediates mitotic exist and resistance to 
palbociclib mediated cell cycle arrest (Uzma Asghar 2016). Thus, knockdown of CDK2 or 
combined treatment with the CDK2 inhibitor, dinaciclib, was synergistic with the CDK4/6 
inhibitor, ribociclib and helped reverse drug resistance (Herrera-Abreu, Palafox et al. 2016, 
Jansen, Bhola et al. 2017). Finally, activation of the AKT1 signaling pathway via PI3K-PDK1 
has been shown to mediate resistance to ribociclib treatment, which was effectively reversed 
upon treatment with a PDK1 inhibitor (GSK2334470) or PI3K inhibitor (alisertib) in vitro and in 
vivo (Jansen, Bhola et al. 2017). 
Thus, while these studies have suggested potential mechanism of intrinsic and acquired 
resistance to palbociclib and other CDK4/6 inhibitors, more detailed study is essential to devise 
efficient treatment regimens to combat drug resistance.  
 
1.5. LIMITATIONS WITH CDK4/6 TREATMENT AND GAPS IN KNOWLEDGE 
Despite these promising clinical advances with CDK4/6 inhibitors in ER positive breast 
and other cancers, there are three major clinical limitations with this treatment strategy: (i) 
adverse events leading to treatment interruption/ discontinuation, (ii) lack of overall survival 
benefit and (iii) lack of predictive biomarkers.  
Both palbociclib and ribociclib treatment is associated with increased toxicity and 
adverse events in patients, with over 55% of the patients having grade 3&4 neutropenia and 
about 25% of patients having leukopenia (Finn, Crown et al. 2015) (Hortobagyi, Stemmer et al. 
2016). This often requires delay in treatment delays or even discontinuation of treatment, which 
might attenuating therapy benefit , thus highlighting the need to improve efficacy of CDK4/6 
inhibitor treatment (Finn, Crown et al. 2015, Turner, Ro et al. 2015). Further, about 16% of the 
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ER positive breast cancer patients do not respond (intrinsic resistance) exhibit progression 
within 24 weeks (early adaptive resistance) to palbociclib treatment (Finn, Martin et al. 2016). 
Additionally, more than half the patients develop clinical resistance accompanied disease 
progression within 25 months, resulting in no overall survival benefit (Finn, Martin et al. 2016). 
Finally, while previous in vitro studies showed that Rb, Cyclin D and p16 could predict response 
to palbociclib (Wiedemeyer, Dunn et al. 2010, Konecny, Winterhoff et al. 2011, Cen, Carlson et 
al. 2012), results from Phase II/III trials showed no significant correlation between progression-
free survival or clinical response and the expression of p16, CCND1 amplification (Finn, Crown 
et al. 2015), Ki67, PIK3CA or ESR1 mutational status (Turner, Jiang et al. 2016). Similarly, 
biomarker analysis with ribociclib also showed no correlation between response and the 
expression of Rb, p16, CDKN2A amplification, cyclin D and PIK3CA mutation (Hortobagyi, 
Stemmer et al. 2016). This leaves us with no established predictive biomarkers for CDK4/6 
inhibitors.  
 
1.6. GOAL OF THE PROJECT 
Thus, the goal of this thesis and project is to address the aforementioned limitations of 
CDK4/6 inhibitor therapy and to improve the selectivity and efficacy of CDK4/6 inhibition.  
This has been achieved in this project through a biomarker-driven combination treatment 
approach that targets CDK4/6 and autophagy in breast and other solid tumors. Further, the 
project also aims at understanding the mechanisms of acquired resistance to CDK4/6 
inhibition via palbociclib.  
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1. CELL LINES 
All cell lines used in this study were obtained from ATCC. MCF7, T47D, ZR75-1, MCF7-
T, MDA-MB-231, HCC38, HCC1806, MDA-MB-157, HeyA8, 59M, and FUOV1 were maintained 
in minimum essential medium Eagle alpha modification (alpha MEM) supplemented with 10% 
fetal bovine serum (FBS), 10mM HEPES, nonessential amino acids, 2mM L-glutamine, sodium 
pyruvate, and hydrocortisone. 293T and MDA-MB-468 cells were cultured in Dulbecco modified 
Eagle medium (DMEM) supplemented with 10% FBS. SUM-159 and BT-549 cells were 
cultured in a 1:1 mixture of alpha MEM and nutrient F-12 Ham medium supplemented with 10% 
FBS and 5% insulin. Calu-1, H358, A549, PC3, and Du145 cells were cultured in RPMI-1640 
medium supplemented with 10% FBS. The pancreatic cancer cell lines (Panc-1 and BxPC-3) 
were a gift from the laboratory of Dr. Anirban Maitra (MD Anderson Cancer Center) and were 
cultured in DMEM and RPMI 1640, respectively, supplemented with 10% FBS. The colon 
cancer cell lines (Colo-205, SW-620, and HCT-116) were obtained from the laboratory of Dr. 
Jae-II Park (MD Anderson Cancer Center) and cultured in DMEM supplemented with 10% 
FBS.  
The MCF7 aromatase expressing cells were maintained in DMEM supplemented with 
10% tet-free FBS + 4μg/ml blasticidin, 1 μg/ml puromycin (InvivoGen, San Diego, CA) and 400 
μg/ml G418. Prior to experimental setup, they were estrogen deprived for 4 days using phenol 
red free IMEM supplemented with 10% charcoal dextran treated tet-free FBS. During the 
experiment, the cells were maintained in estrogen deprivation condition in the presence of 
25nM 4-Androstene-3,17-dione. To induce the expression of empty vector and LMW-E, the 
cells were treated with 5 ng/ml Doxycyclin (Sigma) for 24 hours before the start of the 
experiment. The aromatase resistant cell lines were maintained in phenol red DMEM 
supplemented with 10% charcoal dextran treated FBS + 25nM 4-Androstene-3,17-dione + 400 
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μg/ml G418. All cell lines were maintained free of mycoplasma contamination and 
authenticated on a regular basis by karyotype and short tandem repeat analysis at MD 
Anderson’s Characterized Cell Line core facility. 
  
2.2. ANTIBODIES AND DRUGS 
Antibodies against p-Rb (Ser807/811), FOXM1, total Rb (4H1), PARP, caspase-7, 
LC3B, p62 (SQSTM1), Beclin-1, Atg-5, and p53 were purchased from Cell Signaling 
Technology (Danvers, MA). Antibodies against CDK4 (C-22), CDK6 (C-29), cyclin E (HE-12), 
and Mdm2 were purchased from Santa Cruz Biotechnology (Dallas, TX); antibodies against 
actin (C-4) and vinculin were purchased from Millipore and Sigma-Aldrich (St. Louis, MO). 
Palbociclib was obtained from Pfizer, Inc (San Diego, CA). It was diluted in dimethyl 
sulfoxide (DMSO) for in vitro use and in 0.5% methylcellulose (Sigma-Aldrich, St. Louis, MO) 
for in vivo use and administered to mice via oral gavage. Hydroxychloroquine sulfate (HCQ) 
was purchased from Sigma-Aldrich and Selleckem. Lys-05 was provided by Dr. Ravi 
Amaravadi (University of Pennsylvania). HCQ and Lys-05 were diluted in sterile water for in 
vitro use and in sterile phosphate-buffered saline solution (PBS) for in vivo use and 
administered to mice via intraperitoneal injection. N-acetyl-L-cysteine (NAC), trolox [(±)-6-
hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid], bafilomycin A1, spautin-1, and 
chloroquine diphosphate (CQ) were all purchased from Sigma-Aldrich. Ribociclib was 
purchased from Selleckem and abemaciclib from MedChem Express; NAC and CQ were 
diluted in sterile water. Trolox, bafilomycin A1, spautin-1, ribociclib, and abemaciclib were 
diluted in DMSO. 
 
2.3. siRNA KNOCKDOWN 
siRNA knockdown of CDK4 and CDK6 were generated as described 
previously(Jabbour-Leung, Chen et al. 2016). ON-TARGETplus SMARTpool siRNA for CDK4 
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(L-003238-00-0005) and CDK6 (L-003240-00-0005) were purchased from Dharmacon. Briefly, 
cells were plated on 6-well or 12 well plates and transfected with siRNA targeting CDK4 and/or 
CDK6 using JetPRIME transfection reagent (Polyplus transfection, New York, NY), as per 
manufacturer’s protocol. Non-coding siRNA pool (siNT) was used as a negative control for 
comparison. Cells were harvested 72 hours post transfection for western blot analysis, MDC 
analysis, CellROX assay and on days 3 and 6 for cell counting. 
 
2.4. shRNA KNOCKDOWN AND CYCLIN E OVEREXPRESSION 
Stable shRNA knockdown cells were generated as described previously(Jabbour-
Leung, Chen et al. 2016, Nanos-Webb, Bui et al. 2016). All shRNA constructs were purchased 
from Thermo Scientific (Open Biosystems, Waltham, MA). For single knockdown of CDK4, 
CDK6, Beclin-1, Atg-5, or Rb, GIPZ lentiviral shRNA was used [CDK4: V3LHS_641689, 
V3LHS_641690; CDK6: V2LHS_112906, V3LHS_404083; Beclin-1: V3LHS_349514, 
V3LHS_349513; Atg-5: V2LHS_67978, V3LHS_301131; Rb: V2LHS_130611, V2LHS_130606, 
V3LHS_340829]. For dual knockdown of CDK4 and CDK6, TRIPZ inducible shRNA for CDK6 
was utilized for better selection of knockdowns. To generate lentivirus expressing shRNA, HEK 
293T cells were transfected with pCMVdeltaR8.2, pMD2.G (produced by the Didier Trono 
laboratory and made available through the Addgene repository) and pGIPZ vector (scrambled 
shRNA or shRNA against gene of interest) using LipoD293 (SignaGen) or polyethylenimine 
transfection reagent according to manufacturer’s protocol. After 48 hours of transfection, the 
virus-containing medium was collected, filtered through a 0.45-µm filter, and added to the cells 
of interest in the presence of 8 μg/mL of polybrene (Millipore). GFP or RFP expression was 
confirmed and the lentivirus-infected cells were selected with 1 μg/mL puromycin (InvivoGen, 
San Diego, CA). MCF7 and T47D cells overexpressing different isoforms of cyclin E (vector, 
full-length cyclin E [EL], or low-molecular-weight cyclin E [LMW-E]) were generated 
previously(Akli, Zheng et al. 2004) and verified in this study by western blot. 
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2.5. DOSE-RESPONSE STUDIES 
For dose-response studies, 1000 to 3000 cells (depending on plating efficiency of each 
cell line; data not shown) were plated in each well of a 96-well plate and treated with increasing 
concentrations (0.01 to 12 μM) of palbociclib, ribociclib, or abemaciclib for 1, 2, 4, 6, or 8 days. 
The medium was replaced with drug-containing medium every other day. At completion of drug 
treatment, cultures were continued in drug-free medium (also replaced every other day) until 
day 12, after which they were stained with 0.5% crystal violet solution. The plates were then 
solubilized with a solution of 0.1% sodium citrate in 50% ethanol, and absorbance was 
measured at 570 nm using the Epoch Microplate Spectrophotometer (BioTek Instruments, Inc, 
Winooski, VT). Values were normalized to those of their no treatment controls and analyzed in 
GraphPad Prism by non-linear regression to obtain the half-maximal inhibitory concentrations 
(IC50 values) as used in Figure 1a.    
 
2.6. CELLULAR PROLIFERATION ASSAY  
For cell proliferation studies, 7,500 to 15,000 cells (depending on plating efficiency of 
each cell line; data not shown) were plated in each well of 6-well plates and treated with the 
indicated agents for 6 days and cells were allowed to recover for 4 days in the absence of drug 
to examine reversibility. The medium was replaced every other day during the course of the 
experiment, either with drug-containing medium (days 2 and 4) or drug-free medium (days 6 
and 8). Cells were then harvested and counted using the BioRad TC20 Automated Cell 
Counter on days 0, 3, 6, and 10.  
For clonogenic/colony-formation assay, 5,000 to 10,000 cells (depending on the plating 
efficiency of each cell line; data not shown) were plated in each well of 6-well plates, treated for 
6 days, and allowed to recover for 6 days in the absence of drug. Cells were then washed with 
	 42 
PBS and stained with a 0.5% crystal violet solution in 25% methanol for 10 minutes. Plates 
were then scanned to obtain pictures. 
 
2.7. CELL CYCLE AND BRDU ANALYSES 
Cells were plated (1´105 cells/plate) on 10-cm plates and treated with the indicated 
agents for 6 days; they were allowed to recover without drug(s) for 4 days to examine 
reversibility. Medium was replaced every other day during the course of the experiment, either 
with drug-containing medium (days 2 and 4) or drug-free medium (days 6 and 8). For cell cycle 
analysis, following treatment or treatment (6 days) and recovery (6 days + 4 days of recovery), 
cells were subjected to trypsinization, washed with PBS, and fixed with 3.5 mL ice-cold PBS 
and 1.5 mL of 95% ethanol. Cells were prepared as described previously(Jabbour-Leung, Chen 
et al. 2016) and incubated in a solution of propidium iodide (PI; 1 mg/mL) and RNAase (1 
mg/mL) at 4°C overnight. Samples were then analyzed on the Beckman Coulter Gallios Flow 
Cytometer, and data were analyzed with the Kaluza software (Beckman Coulter) after 
excluding doublet cells.  
For BrdU analysis, following treatment or recovery, cells were incubated with 10 μM 5-
bromo-2′-deoxyuridine (BrdU; Sigma-Aldrich) for 1 hour, after which they were subjected to 
trypsinization, washed with PBS, and fixed with 70% ethanol. Cells were then washed with PBS 
containing 0.5% bovine serum albumin (BSA) and denatured with a solution of 2M HCl + 0.5% 
Triton X-100 at room temperature for 20 minutes. Cells were washed again and incubated in 
200 μL 0.1 M sodium borate, pH 8.5, to neutralize any residual acid for 2 minutes at room 
temperature. Cells were then stained with fluorescein isothiocyanate–conjugated anti-BrdU (BD 
Biosciences) for 20 minutes at room temperature, protected from light. Cells were finally 
washed and incubated in a solution of 0.5 mL PI (10 µg/mL in PBS) for 30 minutes at room 
temperature, protected from light. Samples were analyzed on the Beckman Coulter Gallios 
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Flow Cytometer and data were analyzed with Kaluza software to obtain the percentages of 
BrdU-positive cells. 
 
2.8. MEASUREMENT OF SENESCENCE 
For in vitro studies, senescence was measured by the senescence-associated 
galactosidase (SA-ß gal) staining kit (Millipore, Billerica, MA) according to the manufacturer’s 
standard protocol. Briefly, cells were plated at a low density of 2,000 to 4,000 cells (depending 
on the plating efficiency of the cell line; data not shown) in each well of 12-well plates and 
treated with the indicated agents for 72 hours or 6 days. The medium was replaced every other 
day during the course of the experiment with drug-containing medium (days 2 and 4). Cells 
were then washed with PBS, fixed, and stained with SA-ß gal solution overnight. The cells were 
then photographed using the Evos XL Core cell imaging system (ThermoFischer, Waltham, 
MA) and senescent cells were quantified by counting 100 cells in three different fields for each 
replicate. A minimum of three technical and three biological replicates were performed for each 
condition. 
For in vivo studies, mouse tumors tissues were snap-frozen in liquid nitrogen, 
embedded in OCT, and cut into thin sections (5 μm). Senescence was measured by the SA-ß 
gal detection kit (Biovision, Milpitas, CA) by following the manufacturer’s protocol. Briefly, slides 
were washed with PBS and incubated in staining solution (prepared according to protocol) 
overnight. Slides were then washed with PBS and fixed in 70% glycerol. Images of the tissue 
sections were obtained by a Leica DM light microscope using the 20´ and 40´ optical lenses. 
Images were acquired with a SPOT Imaging Solutions camera and SPOT Advanced software.  
For quantitation of cellular granularity, cells were plated (1´105 cells/plate) on 10-cm 
plates and treated for 6 days; some of the cells were allowed to recover for 4 without drug. 
Following treatment, cells were harvested, stained with PI (1 mg/mL), and analyzed on the 
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Beckman Coulter Gallios Flow Cytometer. The data were then analyzed with the FlowJo 
software to obtain a distribution curve of side-scatter vs normalized cell counts.  
 
2.9. ANNEXIN V AND CASPASE-3 APOPTOSIS ASSAYS 
Apoptotic cells were measured by using the Alexa Fluor 488 Annexin V Dead Cell 
Apoptosis kit (Invitrogen, Waltham, MA) according to the manufacturer’s protocol. Briefly, cells 
were plated (1´105 cells/plate) on 10-cm plates and treated with the indicated agents for 6 days 
and allowed to recover for 4 days. Cells were harvested at the end of treatment (6 days) or 
after treatment + recovery, washed with 1´ Annexin binding buffer and stained with a solution 
of Alexa Fluor 488 Annexin V and PI (100 μg/mL) as directed by the protocol. Samples were 
then analyzed on the Beckman Coulter Gallios Flow Cytometer, and data were analyzed with 
Kaluza software to obtained the percentages of Annexin V–positive/PI-negative (early 
apoptosis) and Annexin V–positive/PI-positive (late apoptosis) cells.  
For the caspase-3 activity assay, following drug treatment, cells were harvested, 
washed with a solution of PBS with 2% FBS and fixed with 100 μL of the fixation solution from 
the Cytofix/CytoPerm kit (BD Biosciences). Cells were then washed with Perm/Wash buffer and 
stained with phycoerythrin-conjugated rabbit active caspase-3 antibody (BD Biosciences) for 30 
minutes on ice. Cells were finally washed, resuspended in the PBS with 2% FBS solution, and 
analyzed on the Becton Dickinson FACS Calibur Flow Cytometer to obtain the percentage of 
caspase-3–positive cells.  
 
2.10. CELLULAR ROS MEASUREMENT 
Cellular ROS levels were measured by using the CellROX Deep Red Flow Cytometry 
assay kit (ThermoFischer Scientific, Waltham, MA) according to the manufacturer’s protocol. 
Briefly, cells were plated (1´105 cells/dish) on 10-cm dishes and treated for 6 days. Cells were 
then harvested and stained with 500 nM CellROX reagent for 1 hour at 37°C. Samples were 
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analyzed on the Beckman Coulter Gallios Flow Cytometer using the 635-nm laser; data were 
analyzed with the FlowJo software, and mean fluorescence intensity (MFI) was obtained. 
 
2.11. MONODANSYLCADAVARINE MEASUREMENT  
Cells were seeded at a density of 1´105 cells on 10-cm plates and treated for 6 days 
with various concentrations of palbociclib. At the end of drug treatment, cells were incubated 
with 50μM monodansylcadavarine (MDC; Sigma-Aldrich) at 37°C for 45 minutes. Cells were 
then harvested, washed with PBS, and suspended in a solution of PBS with 1% FBS. Samples 
were analyzed on the Becton Dickinson FACS LSR II Flow Cytometer using the 355-nm 
ultraviolet laser. Data were analyzed with the FlowJo software, and percentages of MDC-
positive cells and Mean Fluorescence Intensity (MFI were obtained. 
 
2.12. IMMUNOFLUORESCENCE  
For the GFP-LC3 puncta assay, MCF7, MDA-MB-231 and MDA-MB-468 cells stably 
expressing GFP-LC3 were plated in 6-well plates and treated with drug for 48 hours. Following 
treatment, cells were washed with 1X PBS, fixed with 4% paraformaldehyde for 10 mins and 
mounted with Vectashield mounting media with DAPI. Cells were then visualized with Zeiss 
Confocal microscope LSM880 using the 488nm laser (GFP) for the presence of GFP-LC3 
puncta. The puncta was quantified using ImageJ. 
For RFP-GFP-LC3 dual reporter assay, cells were transfected with ptf-LC3 vector and 
analyzed as described previously(Kimura, Noda et al. 2007). Briefly, ptfLC3 vector was 
transfected using Lipofectamine 2000 as per manufacturer’s instructions. Cells were then 
treated with the drug for 48 hours, washed with 1X PBS, fixed briefly (for 10 mins) with 4% 
paraformaldehyde and mounted with Vectashield mounting media. They were then visualized 
using with Zeiss Confocal microscope LSM880 using the 488nm and 643nm channels to image 
the GFP+ve and RFP+ve LC3 puncta respectively. The puncta was quantified using ImageJ to 
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obtained the number of autophagosomes (yellow – RFP+ GFP+) and autophagolysosomes 
(red – RFP+). 
 
2.13. TRANSMISSION ELECTRON MICROSCOPY 
For cell lines, ~5000 cells were plated in each well of 12-well plates and treated with the 
drug for 6 days. For xenografts, tumors were harvested and samples were cut into 1-mm3 
pieces. The cell lines and tumor samples were processed similarly and Electron microscopy 
was performed at the High Resolution electron microscopy facility at MD Anderson Cancer 
Center as described previously(Chauhan, Goodwin et al. 2013). Briefly, they were fixed with a 
solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1M cacodylate buffer, 
pH 7.3. Samples were then washed in 0.1M sodium cacodylate buffer and treated with 0.1% 
Millipore-filtered cacodylate-buffered tannic acid. They were fixed with 1% buffered osmium 
tetroxide for 30 minutes and stained en bloc with 1% Millipore-filtered uranyl acetate. The 
samples were dehydrated in increasing concentrations of ethanol, filtrated, and embedded in 
LX-112 medium. They were then polymerized in a 60°C oven for approximately 3 days. 
Ultrathin sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL), stained with 
uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 1010 
transmission electron microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating voltage 
of 80 kV. Digital images were obtained at magnifications of 5000´, 25000´, and 50000´ using 
the AMT Imaging System (Advanced Microscopy Techniques Corp, Danvers, MA). 
 
2.14. IN VIVO XENOGRAFT STUDIES 
For all xenograft experiments, estrogen pellets (0.72 mg 17-beta estradiol pellet, 90-day 
release, Innovative Research of America, Sarasota, FL) were implanted subcutaneously into 4- 
to 6-week-old female nude mice. MCF7-T cells (5´106 in a 1:1 ratio with matrigel [BD 
Biosciences]) were injected into the 5th and 10th inguinal mammary fat pads bilaterally. For the 
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dose-determining experiment, once the tumors reached an average volume of 200 mm3, the 
tumor-bearing mice were randomized into five groups (n=3/group) and treated with vehicle 
(0.5% methylcellulose) or 25 mg/kg, 50 mg/kg, 75 mg/kg, or 150 mg/kg palbociclib. Palbociclib 
was administered daily via oral gavage for 7 consecutive days. For the combination treatment 
experiment, once the tumors reached an average volume of 250 mm3, the tumor-bearing mice 
were randomized into four groups (n=9/group) and treated with vehicle (0.5% methylcellulose 
and PBS), hydroxychloroquine (60mg/kg), palbociclib (25 mg/kg), or a combination of 
palbociclib (25 mg/kg) and hydroxychloroquine (60mg/kg). Drugs were administered daily via 
oral gavage (palbociclib) or intraperitoneally (HCQ) for 21 days.  
For Lys-05 toxicity experiment, non-tumor bearing female nude mice were treated with 
varying concentrations of Lys-05 (1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg) daily for 21 days 
via I.P. For the Lys-05 combination treatment experiment, once the orthotopic xenograft tumors 
reached an average volume of 250 mm3, the tumor-bearing mice were randomized into four 
groups (n=5/group) and treated with vehicle (0.5% methylcellulose and PBS), Lys-05 
(10mg/kg), palbociclib (25 mg/kg), or a combination of palbociclib (25 mg/kg) and Lys-05 
(10mg/kg). Drugs were administered daily via oral gavage (palbociclib) or intraperitoneally (Lys-
05) for 21 days. 
For all xenograft studies, tumor volumes [(L x W2) /2)] were measured twice per week 
with calipers and mouse weight was measured every day. At the end of the treatment and 
recovery periods, mice were euthanized and the tumors were collected for further analysis. At 
the time the mice were euthanized, blood (0.2 mL) was collected by cardiac puncture through 
the left ventricle. Blood samples were subjected to complete blood count analysis (white blood 
cells, platelets, and red blood cells) by the Siemens Adiva 120 Hematology System (Erlangen, 
Germany). Nude mice for all experiments were obtained from the Department of Experimental 
Radiation Oncology at The University of Texas MD Anderson Cancer Center, and mice 
received care in accordance with the Animal Welfare Act and the institutional guidelines of MD 
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Anderson Cancer Center. The protocol for this study was approved by the Institutional Animal 
Care and Use Committee (IACUC) at The University of Texas MD Anderson Cancer Center 
(Houston, TX). 
 
2.15. PATIENT-DERIVED XENOGRAFT STUDIES 
Breast tumor samples were obtained during routine surgery after informed consent was 
obtained under protocols approved by the MD Anderson Institutional Review Board. Patient-
derived xenograft (PDX) models were developed as previously described(McAuliffe, Evans et 
al. 2015). Briefly, fresh primary tumors were collected using sterile technique, and 
approximately 3-mm3 fragments of the tissue were transplanted to the fat pad of the 4th pair of 
mammary glands (both sides) in immunodeficient (SCID) mice within 1 hour of surgical 
resection. When the primary tumor outgrowths reached 10 mm in diameter, 3-mm3 fragments of 
the outgrowths were explanted to new hosts (n=3/tumor) as secondary passage. Since the 
tumor tissues can stably grow after two passages with our protocol, we considered the PDX 
line to have been successfully established at that point. The histology of the patient tumors of 
origin and the corresponding PDX lines were compared by hematoxylin and eosin (H&E) 
staining and had very similar histology (data not shown). For the drug treatment experiment, 3-
mm3 fragments of the PDX line were transplanted into the fat pat of the 4th mammary gland of 
female nude mice. Once the tumors reached an average volume of 200 mm3, mice were 
randomized into four groups (n=4/group) and treated with vehicle (0.5% methylcellulose and 
PBS), hydroxychloroquine (60mg/kg), palbociclib (25 mg/kg), or combination of palbociclib 
(25mg/kg) and hydroxychloroquine (60mg/kg). Drugs were administered daily via oral gavage 
(palbociclib) or intraperitoneally (HCQ) for 21 days. Tumor volumes [(L x W2) /2)] were 
measured twice per week with calipers, and mouse weight was measured every day. 
At the end of the treatment period, mice were euthanized and their tumors were 
collected for further analysis. All mice were obtained from the Department of Experimental 
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Radiation Oncology at The University of Texas MD Anderson Cancer Center and received care 
in accordance with the Animal Welfare Act and the institutional guidelines of MD Anderson 
Cancer Center. The protocol for this study was approved by the IUCUC at MD Anderson 
Cancer Center. 
 
2.16. IMMUNOHISTOCHEMISTRY ANALYSIS OF MOUSE TUMOR TISSUES 
For BrdU assessment, mice were administered BrdU solution (5 mg/kg intraperitoneally) 
2 hours before euthanasia. After death, the tumor was resected and snap-frozen in liquid 
nitrogen, embedded in OCT, cut, and utilized for measurement of senescence by SA-ß gal 
staining. The remaining tissue was fixed in formalin and used for assessment of histology and 
of proliferation by BrdU as described previously(Nanos-Webb, Bui et al. 2016). Briefly, 5-µm 
sections from the formalin-fixed, paraffin-embedded tumor tissues were stained with standard 
hematoxylin and eosin. Other sections of the tumor blocks were subjected to 
immunohistochemical (IHC) staining. After paraffin removal, tumor sections were heated in a 
water bath for 20 minutes in 10 mM sodium citrate buffer (pH 6.0) at 90°C to retrieve nuclear 
antigens. Endogenous peroxidase activity was quenched with a 3% hydrogen peroxide 
solution. Sections were blocked with 1.5% normal goat serum and incubated overnight at 4°C 
with rat monoclonal antibody to BrdU (clone BU1/75 [ICR1]; GeneTex Inc, San Antonio, TX) 
diluted at 1:500. Slides were developed using the VECTASTAIN Elite ABC kit (PK4004; Vector 
Laboratories, Burlingame, CA), followed by staining with DAB substrate (Vector Laboratories) 
and counterstaining with hematoxylin (DAKO), and then were mounted. Staining was evaluated 
with a Leica DM light microscope using the 40´ optical lenses. Images were acquired on a 
SPOT Imaging Solutions camera with SPOT Advanced software. BrdU was quantified as 
percentage of BrdU-positive cells, which was calculated as percentage of BrdU-positive nuclei 
from a total of 300 tumor cells from three fields of view.   
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For 4HNE and Anti-8OHdG immunostaining; after paraffin removal, heat induced 
antigen retrieval was performed for 10 minutes in 10 mM sodium citrate buffer (pH 6.0) at 98°C. 
Endogenous peroxidase activity was blocked with 3% hydrogen peroxidase for 15 minutes. 
Slides were then incubated for 1 hour with diluted rabbit blocking serum. The sections were 
incubated for overnight at 4 °C with Anti-8-OHdG mouse monoclonal antibody (clone N45.1, 
Genox, Baltimore, MD, 1:100 dilution) and Anti-4-HNE mouse monoclonal antibody (clone 
HNEJ-2, Genox, Baltimore, MD, 1:50 dilution). The slides were incubated for 30 minutes with 
diluted biotinylated secondary antibody and 30 minutes with Vectastain Elite ABC kit (Vector 
Laboratories, United States). For the evaluation of 4HNE and Anti-8OHdG antibody expression, 
slides were scored separately for percentage and intensity of the cells.  Percentage positivity 
was graded using 0 to 4 scale, where 0 represented no stained cells, 1 was 1 to 5% stained 
cells, 2 was 6 to 30% stained cells, 3 was 31 to 70% stained cells, and 4 was 71 to 100% 
stained cells. Staining intensity was scored as follows: 0, no staining; 1, weak positive; 2, 
intermediate positive; and 3, strong positive. H score calculated by multiplying the percentage 
of positive cells and intensity of staining.  
 
2.17. WESTERN BLOT ANALYSIS 
Western blot analysis was performed as described previously(Jabbour-Leung, Chen et 
al. 2016). Briefly, cells were seeded at a density of 1´105 cells on 10-cm plates and treated for 
6 days with the indicated drugs. Following treatment, cells were harvested and subjected to 
lysis with RIPA buffer (150 mM NaCl, 10 mM Tris, pH 7.3, 0.1% sodium dodecyl sulfate [SDS], 
1% Triton X-100, 1% deoxycholate, and 5 mM ethylene-diaminetetraacetic acid) containing 
protease inhibitors. For mouse tissues, the tumors were minced into small pieces on dry ice 
and immersed in RIPA buffer for lysis. Lysates were then subjected to centrifugation at 
45,000rpm for 45 minutes at 4°C to obtain the protein lysates in the supernatant. Protein 
concentration was determined by Bradford Protein Assay dye (Bio-Rad), and 50 μg of protein 
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per sample was resolved by SDS–polyacrylamide gel electrophoresis as described 
previously(Akli, Zheng et al. 2004). Blots were blocked with Blotto milk for 1 hour at room 
temperature and incubated with primary antibody overnight at 4°C. They were then incubated 
with goat anti-rabbit or goat anti-mouse immunoglobulin–horseradish peroxidase conjugates 
(Pierce, Rockford, IL) at a dilution of 1:5000 in Blotto for 1 hour. Blots were then washed and 
developed using a Renaissance chemiluminescence system (Perkin Elmer Life Sciences, Inc.) 
by following the manufacturer’s instructions. The developed and scanned blots were then 
analyzed by the ImageJ software to obtain densitometry values.  
 
2.18. RPPA AND DATA ANALYSIS 
The mouse tumor tissues were dissected on dry ice and subjected to lysis in RIPA 
buffer (1% Triton X-100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 
100 mM NaF, 10 mM Na pyrophosphate, 1 mM Na3VO4, 10% glycerol, and freshly added 
protease and phosphatase inhibitors; Roche Applied Science, Indianapolis, IN). Tumor lysates 
were then subjected to centrifugation and protein concentration was determined by using the 
Bradford reagent. Protein concentration was adjusted to 1.5 μg/μL and mixed with 4´ SDS 
Sample Buffer containing 40% glycerol, 8% SDS, 0.25M Tris-HCL, and 2-mercapto-ethanol at 
pH 6.8. Samples were boiled for 5 minutes, and the reverse-phase protein array (RPPA) 
analysis was performed by the Functional Proteomics core facility at MD Anderson Cancer 
Center. The slide images were quantified using MicroVigene 4.0 (Vigene-Tech, Carlisle, MA). 
The spot level raw data was processed with the R package SuperCurve (https://r-forge.r-
project.org/ projects/supercurve), which returns the estimated protein concentration (raw 
concentration) and a quality control (QC) score for each slide. The raw concentration data was 
then normalized by median-centering for each sample across all the proteins, to correct for 
loading bias. 
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For RPPA data analysis, one-way ANOVA was used to identify proteins that are 
differentially expressed between treatment groups. To adjust for multiple comparisons, 
Benjamini-Hochberg procedure was used to estimate false discovery rate (FDR). Tukey HSD 
tests were used for post hoc pairwise comparisons. To compare the different Palbociclib doses 
treatments in vivo (Vehicle, 25 mg/kg, 75 mg/kg and 150 mg/kg), proteins with 20% FDR in 
ANOVA, Tukey p < 0.05 and fold change > ±1.2 was identified as significantly differentially 
expressed between groups. A heat map was then drawn using significant proteins from the 
ANOVA analysis, and ordered based on KEGG cell cycle, senescence and 
autophagy/catabolism pathways. Pearson distance metric and Ward's minimum variance was 
used to cluster the samples in the heat map. For comparing the combination treatments 
(Vehicle, HCQ, Palbociclib, and Palbociclib + HCQ) in vivo, proteins with 15% FDR in ANOVA, 
Tukey p < 0.05 and fold change > ±1.2 were identified as significantly differentially expressed in 
pairwise analysis. Pathway score for cell cycle and senescence pathways was calculated using 
mean expression level (in log2 scale) of the selected proteins from ANOVA analysis.  
 
2.19. BIOINFORMATICS AND TCGA ANALYSIS 
Alterations in CDK4, CDK6, CCND1, Rb1 and CCNE1 were obtained using cBio Portal 
(Cerami, Gao et al. 2012) from the TCGA RNA seq data for breast, ovarian, lung, pancreatic, 
colon and prostate cancer. For biomarker analysis, gene expression data for the 23 cell lines 
under study was obtained from Kao et. al.(Kao, Salari et al. 2009), and Gene Set Enrichment 
Analysis (GSEA) was performed against the BioCarta gene sets(Subramanian, Tamayo et al. 
2005) to obtain a heat map of the cell cycle genes.  
 
2.20. BREAST CANCER PATIENT SAMPLES AND STATISTICAL ANALYSIS 
The Department of Medical Oncology at MD Anderson maintains a prospective curated 
database of patients from 1997 onward. This database was searched for all patients with 
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breast cancer who had received palbociclib, and this search was supplemented with a manual 
search. Key demographic, clinical, and pathologic data, cancer treatment details, and response 
to therapy were abstracted into a working database for analysis under an IRB-approved 
protocol. Outcomes of interest that were recorded included response, stable disease, and 
progression (based on the physician’s determination, but not always based on RECIST criteria) 
and associated durations of disease response and stability. To demonstrate the applicability of 
our staining procedure, blocks with the largest available tumor specimen was chosen for each 
patient and retrieved from the archives of the Department of Pathology at MD Anderson under 
an IRB-approved protocol; this included specimens from the primary tumor and/or local and/or 
metastatic recurrences. Our working database includes results of pathology reports, including 
tumor histology and grade and standard IHC analyses for ER and progesterone receptors for 
primary breast cancer biopsies and surgical specimens as well as local and distant recurrences 
that were subject to biopsy or surgical excision. 
Patient, tumor, and treatment characteristics were evaluated and compared between 
patients who were or were not free from progression; 6-month and 12-month progression rates 
were calculated for each of factor using the Kaplan-Meier method, and differences were 
examined using the log-rank test (Supplementary Tables 1 and 2).  Univariable and 
multivariable Cox model analyses were used to determine the influence of patient, tumor, and 
treatment factors of known or potential prognostic value on progression-free survival 
(Supplementary Tables 3 and 4). All factors with P ≤0.1 in the univariable analyses were 
entered into a full model, and the final model was selected by using a backwards elimination 
procedure.  Model performance was quantified using Harrell’s concordance index.(Gonen and 
Heller 2005) The discriminative ability of the model was assessed using the concordance index 
(C-index) for comparative purposes with the literature, as well as the concordance probability 
estimate (CPE) due to the high degree of censoring in the data.(Gonen and Heller 2005) The 
C-index can range from perfect concordance (1.0) to random predictions (0.5). Similar to the 
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area under the receiver operating characteristic curve, CPE can range from perfect 
concordance (1.0) to perfect discordance (0.0).  In addition, Akaike’s information criterion (AIC) 
was calculated.(Akaike 1974) The AIC takes into account how well the model fits the data as 
well as the complexity of a model, thereby reducing the risk of overfitting. After comparisons, 
the final model with the lowest AIC value and the highest C-index was reported. All statistical 
analyses were performed using R 3.3.2 (http://www.r-project.org/). All P values were two-tailed, 
and P≤0.05 was considered significant, and adjustments for multiple factors were not made.  
 
2.21. IMMUNOHISTOCHEMICAL STAINING OF PATIENT SAMPLES 
For the 109 breast cancer samples recovered, two serial 5-µm sections were cut and 
mounted on Superfrost Plus glass slides. The antigen retrieval and washing steps were 
performed as described for BrdU immunohistochemistry analysis. For cyclin E and Rb IHC, two 
commercially available primary antibodies were used: rabbit polyclonal antibody to cyclin E 
(clone C19; Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:1000 and Rb mouse 
monoclonal antibody (Clone 4H1; Cell Signaling Technology, Denvers, MA) diluted 1:100. 
Slides were developed using the VECTASTAIN Elite ABC kit (PK6101 and PK6102; Vector 
Laboratories, Burlingame, CA) followed by staining with DAB substrate (Vector) and 
counterstaining with hematoxylin (DAKO), and then were mounted. Tumor cell blocks known to 
express high levels of LMWE and Rb were included in each batch as positive controls, and 
negative controls were prepared by replacing the primary antibody with PBS buffer. Staining 
was evaluated with a Leica DM light microscope using the 20´ and 40´ optical lenses. Images 
were acquired by a SPOT Imaging Solutions camera and SPOT Advanced software.  
 
2.22. IMMUNOHISTOCHEMICAL SCORING OF RB AND CYCLIN E 
Cyclin E staining was scored by two pathologists blinded to patient outcomes (data not 
shown). Scores (0=negative, 1=weak staining, 2=moderate staining, and 3=strong staining) 
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were assigned for nuclear and cytoplasmic staining according to percentage of cells stained 
and intensity of staining, as described previously(Karakas, Biernacka et al. 2016). Each tumor 
sample was scored separately for nuclear and cytoplasmic cyclin E expression, and LMWE 
status was assigned as follows: LMWE negative was defined as no staining or nuclear staining 
only; LMWE positive was defined as nuclear + cytoplasmic staining or cytoplasmic staining 
only. 
For Rb staining, the intensity of staining and percentage of positive cells were evaluated 
separately. Staining intensity was scored as follows: 0, no staining; 1, weak positive (faint 
yellow staining); 2, intermediate positive; and 3, strong positive (brown staining). The number of 
positive cells was visually evaluated and stratified as follows: <1%, 0 (negative); 1 to <5% 
positive cells, 1 (weak); 5-50% positive cells, 2 (moderate); >50% positive cells, 3 (strong). The 
sum of the staining intensity and percentage of positive cell scores was used to determine the 
staining index for each section, with a minimum score of 0 and maximum score of 6; scores  >1 
were defined as Rb positivity. Using this cutoff, we compared Rb-positive to Rb-negative 
tumors. 
IHC analysis for Rb and cyclin E for the NCI TMA tumor samples were performed and 
scored as described above for the Palbociclib treated patient samples. 
 
2.23. MAMMOSPHERE FORMATION ASSAY 
To generate primary mammospheres, the cells were grown in serum-free, media in low 
attachment plates as previously described (Duong, Akli et al. 2013). Briefly, cells were 
trypsinized, and single cells seeded in 6-well ultra-low attachment plates (10,000 cells/ml) in 
serum-free MEM supplemented with 20 ng/ml bFGF, 20 ng/ml EGF and B27 (Invitrogen) and 
incubated for 5- 7 days. For secondary mammosphere assay, cells from primary 
mammospheres were dispersed with 0.05% trypsin, seeded in 6-well ultra-low attachment 
plates (7,500 cells/ml) in mammosphere media and incubated for 5-7 days. Mammospheres 
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with at least a size of 100μm were counted with an automated colony counter (Oxford Optronix, 
Oxford, UK) following MTT staining (Sigma Aldrich, St. Louis, MO). 
 
2.24. CD44/ CD24 FLOW CYTOMETRY ANALYSIS 
Cells were plated (1´105 cells/dish) on 10-cm dishes then harvested by trypsinization. 
Half a million cells were washed 3 times with PBS containing 1% horse serum and 
resuspended in 10 μl PE anti-mouse CD24, 10 μl APC anti-mouse CD44 (BD Pharmingen) and 
30 μl of the 1% serum PBS buffer. The samples were incubated for 20 minutes on ice, washed 
with 1% serum PBS buffer and analyzed with the Beckman Coulter Gallios Flow Cytometer. 
The data was analyzed by the Kaluza software to identify the CD44 high and CD24 low 
population of cells. Cells with only a single antibody staining were used to set up the gates for 
analysis. 
 
2.25. ALDEFLUOR ASSAY 
Measurement of cancer stem cells based on ALDH positivity was performed using the 
Aldefluor kit (StemCell technologies, Cambridge, MA) according to the manufacturer’s protocol. 
Briefly, cells were plated (1´105 cells/dish) on 10-cm dishes then harvested by trypsinization 
and resuspended in the Aldefluor buffer. Each sample was divided into two tubes, Control and 
Test, where the Aldefluor reagent was added to both tubes, while the Aldefluor DEAB reagent 
(specific inhibitor of Aldefluor) was also added to the control tube alone. The samples were 
incubated in 37C water bath for 30 minutes and then analyzed on the Beckman Coulter Gallios 
Flow Cytometer to obtain the percentage of Aldefluor (ALDH) positive cells. Measurement for 
each sample was done from the Test tube and using the control tube for gating the ALDH 
negative population. 
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2.26. MIGRATION ASSAY 
The in vitro migration assay was performed as described previously (Justus, Leffler et 
al. 2014). Briefly, cells were plated at a concentration of 0.5 million per well in a 6-well dish and 
grown until they reach 90% confluence. A scratch was made in the wells with a pipette tip, and 
cells were allowed to grow under normal culture conditions for 48 hours. Pictures were taken at 
0hr, 24hr and 48hr to measure the migration capacity of the cells. The distance moved by the 
cells divided by time was used to obtain the percentage of wound closure.   
 
2.27. STATISTICAL ANALYSIS 
All experiments were performed with a minimum of three technical and three biological 
replicates, and values reported are the mean of the three biological replicates, unless otherwise 
indicated. Error bars represent the standard deviation from the mean, unless otherwise 
indicated. Pairwise comparisons were analyzed using multiple t-tests (one unpaired t-test per 
row), with corrections applied (Holm-Sidak method) for multiple comparisons. When comparing 
data from experiments with multiple groups, a regular one-way ANOVA (no matching) was 
used with the Benjamini-Hochberg procedure to adjust for multiple comparisons. Tukey HSD 
tests were used for post hoc analysis. Kaplan-Meier survival analysis was performed by using 
the log rank (Mantel-Cox) test. For all tests, differences were considered statistically significant 
at a p-value of 0.05 or less. For all figures, ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001. All statistical analyses were performed using the GraphPad Prism software and 
R. 
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CHAPTER 3: CHARACTERIZING THE EFFECT OF CDK4/6 INHIBITION IN ER+ 
BREAST CANCER 
 
3.1. INTRODUCTION 
3.1.1. ROLE OF CDK4/6-CYCLIN D ON GROWTH OF BREAST CANCER 
 Deregulation of the cell cycle is a prevalent hallmark of cancers including breast cancer 
(Malumbres and Carnero 2003). The G1/S checkpoint is one of the key checkpoints that 
maintain cellular integrity and regulate passage through the cell cycle (Bertoli, Skotheim et al. 
2013). Typically, cells that have successfully crossed the G1/S checkpoint and entered the S or 
the DNA synthesis phase are committed to complete the cell cycle and undergo cellular 
division (Bertoli, Skotheim et al. 2013). The G1/S checkpoint is regulated by the 2 families of 
CDKs and cyclins: CDK/CDK6 - cyclin D and CDK2 – cyclin E (Figure 5) (Resnitzky, Gossen et 
al. 1994).  
 The D-type cyclins, comprising of cyclin D1, cyclin D2 and cyclin D3 are the key drivers 
of the G1/S checkpoint are often deregulated in several cancer such as breast, lung, bladder 
and head and neck cancer (Berenson, Koga et al. 1990, Proctor, Coombs et al. 1991, Wang, 
Pavelic et al. 1995). About 15% of all breast cancer patients exhibit amplification of the 11q13 
locus, which contains CCND1, the gene encoding for cyclin D1 (Schuuring, Verhoeven et al. 
1992). Further, about 50% of all breast cancers exhibit upregulation of cyclin D1 at both the 
mRNA and protein levels  (Arnold and Papanikolaou 2005). This suggests a crucial regulatory 
role for cyclin D1 in the process of cell cycle and tumorigenesis. Moreover, cyclin D1 
overexpression in transgenic mouse models resulted in the formation of mammary tumors, 
suggesting a breast cancer specific oncogenic role for the protein (Wang, Cardiff et al. 1994). 
Cyclin D1 in turn can be regulated by numerous pathways, including the estrogen receptor 
(ER) signaling pathway, Her-2 pathways and other major growth signaling pathways such as  
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PI3K and MAPK pathways, all of which have been shown to positive regulate cyclin D1 
expression (Zwijsen, Wientjens et al. 1997, Paternot and Roger 2009). Thus, cyclin D1 acts as 
a key point of convergence for growth signaling pathways and cell cycle progression, and an 
ideal drug target in cancer.  
 The canonical interacting partners of cyclin D1 involved in the regulation of the G1/S 
checkpoint are CDK4 and CDK6 (Otto and Sicinski 2017). These proteins work together with 
cyclin D to phosphorylate the tumor suppressor Rb, which gets further phosphorylated by the 
CDK2-cyclin E complex, inactivating the Rb protein and facilitates the release of E2F (Bertoli, 
Skotheim et al. 2013, Otto and Sicinski 2017). The transcription factor, E2F, in turn regulates 
expression of genes required for growth and progression through the cell cycle (Bertoli, 
Skotheim et al. 2013). Thus, the crucial role of CDK4/6 – cyclin D in tumorigenesis and cell 
Figure 5: Regulation of the G1/S checkpoint: Schematic showing how the cell 
cycle proteins CDK4, CDK6 and cyclin D regulate progression through the cell cycle, 
and how palbociclib treatment cause G1 arrest and senescence  
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cycle progression, specifically in ER positive breast cancer, has led to the development of 
drugs targeting this pathway in the recent years, the CDK4/6 inhibitors (Finn, Crown et al. 
2015, Finn, Martin et al. 2016). The CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib 
have shown great results in pre-clinical research and clinical trials, which has led to the FDA 
approval of these drugs (palbociclib, ribociclib) for the treatment of advanced ER positive 
breast cancer in combination with aromatase inhibitors (O'Leary, Finn et al. 2016, Sherr, Beach 
et al. 2016). 
 
3.1.2. MECHANISTIC STUDIES OF PALBOCICLIB IN BREAST AND OTHER CANCER 
Palbociclib (PD-0332991) the potent and specific CDK4/6 inhibitor has been tested in 
numerous pre-clinical cancer models including breast cancer (Toogood, Harvey et al. 2005). 
Treatment of cancer cell lines with palbociclib, specifically breast cancer cell lines, has been 
shown to decrease phosphorylation of Rb and induce a cell cycle arrest (G1 arrest) and 
senescence (Fry, Harvey et al. 2004, Finn, Dering et al. 2009). Palbociclib treatment also 
cause a reduction in Rb phosphorylation and Ki67 (marker of proliferation) in breast tumors in 
vivo and a dose-dependent decrease in the growth of mouse tumor xenografts (Fry, Harvey et 
al. 2004). One of the early studies in breast cancer with this drug examined the growth 
inhibitory effect of the drug and its half maximal inhibitory concentrations (IC50 values) across 
a panel of 44 breast cancer cell lines belonging ER positive, HER2 positive and TNBC 
subtypes (Finn, Dering et al. 2009). Results from this study showed that a majority of the cell 
lines that were sensitive to palbociclib belonged to the ER positive subtype of breast cancer 
(Finn, Dering et al. 2009). While, majority of the ER negative or TNBC cell lines were resistant 
to palbociclib, a small proportion of the sensitive cells belonged to this subtype (Finn, Dering et 
al. 2009).  The study also showed that the sensitive cell lines exhibited high expression of Rb, 
cyclin D1 and loss of p16 (Finn, Dering et al. 2009). Another study which examined the 
changes in gene expression following treatment with palbociclib in ER positive breast cancer 
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cell line showed a significant downregulation in the proliferative and cell cycle regulatory genes 
at the mRNA level (Knudsen and Witkiewicz 2016). These studies provided the rationale for 
further pre-clinical and clinical investigation of CDK4/6 inhibition in ER positive breast cancer.  
Additionally, numerous pre-clinical studies have been conducted with palbociclib in 
other cancers such as mantle cell lymphoma, myeloma, acute myeloid leukemia, glioblastoma, 
ovarian cancer, esophageal adenocarcinoma, mantle cell lymphoma and prostate cancer 
(Baughn, Di Liberto et al. 2006, Marzec, Kasprzycka et al. 2006, Wang, Wang et al. 2007, 
Michaud, Solomon et al. 2010, Ismail, Bandla et al. 2011, Konecny, Winterhoff et al. 2011, 
Leonard, LaCasce et al. 2012, Comstock, Augello et al. 2013). All of these studies showed 
significant and potent anti-proliferative activity accompanied by the induction of G1 arrest in 
tumor cell lines in vitro and anti-tumor activity in tumors in vivo with palbociclib treatment, and 
also showed an association between sensitivity to the drug and expression of Rb.  
A study conducted primarily in U2OS cells and verified in other cancers identified 
FOXM1 as a direct substrate of CDK4/6, which protects cells from the induction of senescence 
(Anders, Ke et al. 2011). Results from this study showed that palbociclib mediated 
downregulation of FOXM1 coupled with pRb and G1 arrest results in the induction of ROS-
mediated senescence (Anders, Ke et al. 2011). Another study in melanoma cells in vitro 
showed that prolonged treatment with the CDK4/6 inhibitor along with mTOR expression is 
required for the induction of an irreversible growth inhibition and senescence (Leontieva and 
Blagosklonny 2013). Recent studies also suggest a role for palbociclib in regulating EMT and 
cancer stem cells (Qin, Xu et al. 2015, Bonuccelli, Peiris-Pages et al. 2017). Finally, palbociclib 
mediated CDK4/6 inhibition has been shown to regulate increase mitochondrial mass and 
cause metabolic reprogramming in pancreatic cancer cell lines models, and regulate autophagy 
in fibroblasts and promyelocytic leukemia (Capparelli, Chiavarina et al. 2012, Acevedo, Vernier 
et al. 2016, Franco, Balaji et al. 2016). 
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3.1.3. INTERPLAY BETWEEN ROS AND SENESCENCE 
 The concept of senescence first originated from studies that showed that primary cells 
obtained from human tissues were mortal and had limited replicative potential (Hayflick and 
Moorhead 1961). This is associated with shortening of the telomere length, which in turn has 
been shown to trigger a DNA damage response leading to senescence (Harley, Futcher et al. 
1990, d'Adda di Fagagna, Reaper et al. 2003). However, in cancers, senescence can be 
induced even in the absence of telomere shortening, which may be stress induced, oncogene 
induced or tumor suppressor loss induced senescence (Kuilman, Michaloglou et al. 2010). The 
induction of senescence is typically characterized by the presence of prolonged cell cycle 
arrest, morphological transformation (cells acquire a large and flat morphology), activation of 
tumor suppressor networks such as p16 and p21, induction of SA-b gal activity, presence of 
senescence associated heterochromatin foci (SAHF) and senescence associated secretory 
phenotype (SASP) (pro-inflammatory cytokine factors that are secreted by senescent cells) 
(Dimri, Lee et al. 1995, Serrano, Lin et al. 1997, Campisi 2005, Kuilman, Michaloglou et al. 
2010).  
The well-established triggers of stress-induced senescence in cancer model systems 
include DNA damage and oxidative stress mediated by reactive oxygen species (ROS) (d'Adda 
di Fagagna 2008, Lu and Finkel 2008, Kuilman, Michaloglou et al. 2010). Reactive oxygen 
species (ROS) are highly reactive free radicals, ions or molecules that are generated as a 
result of response to stress due to increased metabolic activity, mitochondrial dysfunction, 
oncogene activity, etc. (Liou and Storz 2010, Jajic, Sarna et al. 2015). The levels of the reactive 
oxygen species in cancer cells can determine its pro-tumorigenic vs anti-tumorigenic role (Liou 
and Storz 2010). Low levels of ROS can promote tumor growth and cell cycle progression by 
directly regulating the expression of cell cycle proteins including G1/S cyclins such as cyclin 
B2, cyclin D3 and cyclin E (Felty, Singh et al. 2005, Liou and Storz 2010). However, 
significantly higher levels of ROS can induce cell cycle arrest, senescence, and even turn on 
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cell death signaling and apoptosis (Liou and Storz 2010). Moreover, numerous studies have 
shown that ROS is indispensable for the induction of senescence in cancers. For example, 
ROS has been shown to be required for anticancer drug induced DNA damage and 
senescence in lung cancer, p21 mediated senescence in lung fibroblasts and radiation induced 
senescence in human endothelial cells (Luo, Zou et al. 2011, Luo, Yang et al. 2013, Park, Kim 
et al. 2016). Finally, treatment with the CDK4/6 inhibitor palbociclib and abemaciclib induces 
ROS dependent senescence in cancers (Anders, Ke et al. 2011, Franco, Balaji et al. 2016, 
Patnaik, Rosen et al. 2016).    
 
3.1.4. GAP IN KNOWLEDGE 
While current pre-clinical mechanistic studies provide insight into the mechanism of CDK4/6 
inhibition mediated by palbociclib and other drugs, several questions remain:  
1. Is there a time dependent difference in the growth inhibition mediated by palbociclib? 
(i.e.) Is long term drug treatment required for the induction of senescence? 
2. Is there a dose dependent variation in palbociclib action? Is there an off-target effect of 
the drug observed at higher doses? 
3. Does palbociclib induce cytotoxic effects or apoptosis? 
4. Is ROS required for palbociclib mediated irreversible growth inhibition and senescence? 
5. Is ROS induced in ER+ve breast tumors in vivo? 
Thus, studies in this chapter are aimed at addressing these gaps in knowledge, which will 
provide valuable information in understanding the mechanism by which CDK4/6 inhibition 
impacts the growth ER positive breast cancer cells. 
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3.2. RESULTS 
3.2.1. DEREGULATION OF CDK4/6-CYCLIN D PATHWAY IN BREAST CANCER 
 To interrogate the importance of the G1/S checkpoint in breast tumors, The Cancer 
Genome Atlas's (TCGA) breast cancer dataset was examined to mine for mutations, 
amplifications, mRNA upregulation and protein upregulation of genes within the CDK4/6-Cyclin 
D pathway. TCGA’s breast tumor cohort comprises of 971 completely annotated tumors, with 
594 tumors belonging to the ER positive subtype, 58 tumors belonging to the Her2 positive 
subtype and 82 tumors belonging to Triple Negative Breast Cancer (TNBC) subtype. Detailed 
analysis revealed alterations in the CDK4/CDK6/Cyclin-D pathway in about 37% of all breast 
cancer patients (CDK4 - 7%, CDK6 – 8%, cyclin D – 22%) (Figure 6A). Further, 35% of ER 
positive breast cancer patients (CDK4 - 4%, CDK6 – 3%, cyclin D – 28%) (Figure 6A), 29% of 
the Her2+ breast cancer patients (CDK4 - 10%, CDK6 – 0%, cyclin D – 19%) (Figure 6D), and 
64% of TNBC patients (CDK4 - 22%, CDK6 – 37%, cyclin D – 5%) (Figure 6A) exhibited 
alterations in the CDK4/6-cyclin D pathway. Moreover, gene amplification and mRNA 
upregulation of cyclin D contributed the most to the pathway deregulation seen in the ER+ve 
and Her2 +ve subtypes of breast cancer (Figure 6B,D), while mRNA upregulation of CDK4 and 
CDK6 were the most prevalent alterations in the TNBC tumors (Figure 6C).  
Thus, these results reveal the importance of the CDK4/6 pathway in all subtypes of 
breast cancer and help identify ER positive breast cancer as an ideal population for targeting 
CDK4 and CDK6, since 70% of all breast cancers are of the ER positive subtype. 
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Figure 6: Deregulation of CDK4/6-Cyclin D pathway in Breast Cancer: A) Pie chart showing 
alterations in CDK4, CDK6 and cyclin D at the gene and protein levels based on The Cancer genome 
Atlas (TCGA) analysis of breast tumors. B,C) Detailed analysis of gene amplifications, mutations and 
proteins upregulations in CDK4, CDK6 and cyclin D genes in ER positive (B) and Triple negative (C) 
breast cancer as obtained from TCGA. D) Pie chart showing alterations in CDK4, CDK6 and cyclin D at 
the gene and protein levels and detailed analysis from TCGA database of Her2+ tumors.
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3.2.2. IMPACT OF siRNA OR shRNA KNOCKDOWN OF CDK4/6 
To interrogate the biological effect of downregulating CDK4 and CDK6, we utilized two 
independent methods knockdown the two proteins namely, i) short hairpin RNA (shRNA) and ii) 
small interfering RNA (siRNA). shRNA knockdown typically provides a stable downregulation of 
the mRNA and protein, while siRNA provides a transient or temporary (usually lasting 72 hours) 
but effective knockdown (Aagaard and Rossi 2007).  
First, we performed shRNA mediated knockdown of CDK4 and/ or CDK6 in two 
established ER positive breast cancer cell lines - MCF7 and T47D (Mackay, Tamber et al. 
2009) using at least 2 different shRNA constructs (Figure 7A and 7B). Results revealed that 
downregulation of the individual kinases had little to no growth inhibitory potential as measured 
by doubling time and cell counting over a 10-day period (Figure 7C and 7D). In comparison, a 
significant growth inhibition was observed upon combined shRNA knockdown of CDK4 and 
CDK6 (Figure 7D), concomitant with an increase in their doubling time when compared to 
Control (Scrambled) cells (Figure 7C).  
Since the short term transient knockdown effect obtained with siRNA is considered 
more similar to the effect observed in the presence of a pharmacological inhibitor, we next 
performed siRNA mediated downregulation of CDK4 or CDK6 using pooled siRNA constructs 
(used for better knockdown efficiency) (Figure 7E). Results from cell counting assay performed 
over 6-day period showed little to no growth inhibition upon knockdown of the individual 
proteins (Figure 7F). However, similar to the results from the shRNA experiments, siRNA-
mediated combined CDK4 and CDK6 knockdown (Figure 7E) elicited a significant growth 
inhibitory effect on the ER positive breast cancer cells (Figure 7F).  
Thus, these results provide a strong rational for combined targeting of CDK4 and CDK6 
in ER positive breast cancer. 
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Figure 7: Impact of siRNA or shRNA knockdown of CDK4/6: A) Schematic showing location of 
shRNAs on the CDK4 and CDK6 genes. B) Western blot analysis showing protein levels of CDK4 and 
CDK6 upon transfection with shRNA for CDK4 and CDK6 alone or in combination. C) Doubling time of 
MCF7 and T47D upon knockdown of CDK4 and/or CDK6 via shRNA when compared to Scrambled (Scr) 
cells. D) Cell counting to examine impact of shRNA knockdown of CDK4 and/CDK6 on proliferations of 
MCF7 and T47D cells. E) Western blot showing levels of CDK4 and CDK6 proteins in MCF7 and T47D 
cells after transfection with ON-TARGETplus SMARTpool siRNA non-targeting (siNT) or CDK4 and 
CDK6, separately or combined F) Impact of siRNA knocking down of CDK4 and/or CDK6 on the 
proliferation of MCF7 and T47D cells compared to NT siRNA transfected cells. All data represent 
mean±SD from three independent experiments; p-values were calculated in comparison to cells treated 
with SCR or siNT. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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3.2.3. DOSE DEPENDENT EFFECT OF PALBOCICLIB ON GROWTH, CELL CYCLE 
ARREST AND SENESCENCE 
 Having shown the impact of downregulating CDK4 and CDK6 in ER positive breast 
cancer, we next compared the growth inhibitory potential of the FDA approved CDK4/6 
inhibitor, palbociclib, in three ER positive breast cancer cell lines, MCF7, T47D and ZR75-1, in 
comparison with an immortalized human mammary epithelial cell line (HMEC - MCF10A). In 
order to examine the time and dose-dependent effect of the drug, we performed dose response 
studies where the cells were treated with varying concentrations of the drug for different time 
periods (1,2,4,6, or 8 days), and provided with a recovery time to interrogate the reversibility of 
drug action (Figure 8A). Results demonstrate that palbociclib inhibited the growth of ER 
positive breast cancer cell lines in a time and dose-dependent manner, resulting in a significant 
irreversible growth inhibition (Figure 8B), with half-maximal inhibitory concentrations (IC50) of 
0.73μM to 0.93μM following 8 days of continuous treatment and 4 days of recovery (Figures 
8C,D). In contrast, the HMEC cell line MCF-10A was more resistant to palbociclib, displaying a 
>5-fold (5.98μM) higher IC50 value than the ER positive cell lines (Figures 8B-3D). These 
results suggest that palbociclib induces a time and dose dependent growth inhibition that is 
specific to the ER positive breast cancer cells, but not in HMECs. 
To further investigate palbociclib mediated growth inhibition, we performed colony 
formation assay with 6 days of drug treatment and 6-day recovery, which revealed that 
palbociclib treatment of ER positive, but not HMEC cells, resulted in a dose-dependent 
reduction in colony counts (Figure 8E).  Next, to examine the ability of ER positive breast 
cancer cells to recover from palbociclib-mediated growth inhibition, cells were treated 
continuously for 6 days (which was the least duration of treatment having the lowest IC50 value 
from Figure 3C) with increasing concentrations of the drug, and cultured in the absence of 
palbociclib for another 4 days (Figure 8F). Cell counting and S-phase progression (BrDU 
incorporation measured via flow cytometry) assays revealed that treatment with palbociclib at 
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doses of 1μM or less resulted in a reversible growth inhibition (Figures 8G - compare solid 
lines to dashed lines and Figure 9A –compare black vs white shaded bars). On the other hand, 
higher doses of palbociclib (>2.5 μM) resulted in an irreversible inhibition of growth and S-
phase progression (measured by BrdU incorporation) in the ER positive breast cancer cells 
(Figures 8G - compare solid lines to dashed lines and Figure 9A –compare black vs white 
shaded bars). Strikingly, this effect of palbociclib on growth and proliferation was not observed 
in the HMEC cell lines MCF10A, where the growth inhibition induced was reversible at all 
doses (Figures 8G - compare solid lines to dashed lines and Figure 9A –compare black vs 
white shaded bars), thus demonstrating a dose-dependent growth inhibition mediated by 
palbociclib, specifically in ER positive cancer cells.   
Next, to interrogate the impact of palbociclib treatment on the cell cycle, we treated the 
cells for 6 days and allowed the cells to recover for 4 days to examine reversibility of the drug 
effect (Figure 8F). Results show that palbociclib treatment induces a dose-dependent cell cycle 
arrest (G1 arrest), which was readily reversible at the lower doses (<1uM), while higher doses 
of palbociclib induced an irreversible G1 arrest (Figure 9B and 9C - compare black vs white 
shaded bars). Additionally, this dose-dependent induction of G1 arrest was observed only in 
MCF7 and T47D cells and not in MCF10A (Figure 9B and 9C), further demonstrating 
specificity of palbociclib to ER positive cancer cells, and not HMECs. Further, western blot 
analysis showed a dose-dependent decrease in known palbociclib effectors such as Rb, pRb 
and FOXM1 (Anders, Ke et al. 2011), but no alteration in the protein levels of CDK4 and CDK6 
(Figure 9D).  
Finally, we examined if palbociclib induces senescence in the ER positive breast cancer 
cells, and if this occurs in a dose-dependent manner. Measurement of senescence activity by 
senescence associated- ß galactosidase (SA-ß gal) assay indicates that palbociclib induces 
moderate senescence at the lower doses (<1uM) and significant levels of senescence only at 
higher doses (>2.5uM) in MCF7 and T47D cells (Figure 10A). Moreover, no induction of 
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senescence was observed in the HMEC cell line, MCF10A at all doses of palbociclib (Figure 
10A). Further, cells undergoing senescence display a change in morphology as well as an 
increase in cellular complexity and granularity, which can be measured by changes in the side 
scatter (Anders, Ke et al. 2011, Bielak-Zmijewska, Wnuk et al. 2014). Flow cytometry analysis 
showed a significant increase in side-scatter of ER+ve breast cancer cells in a dose-dependent 
manner, which the increase being reversible at the lower doses and irreversible at higher doses 
of 5uM (Figure 10B). 
The summary of these results is shown in Figure 10C, which depicts the effects of 
palbociclib as a variant of dose: i) BrdU incorporation / cell proliferation – red solid line on the 
right Y-axis, ii) sustained G1 arrest (post recovery) – blue solid line on the right Y-axis, iii) 
protein levels of pRb (measured by densitometry) – orange solid line on the left Y-axis and iv) 
measurement of senescence – green solid line on the left Y-axis. Collectively, these results 
show that palbociclib treatment induces dose-dependent growth inhibition, G1 arrest, decrease 
in Rb phosphorylation and increase in senescence, specifically in the ER positive breast cancer 
cells. 
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Figure 9: Dose-dependent effect of palbociclib on cell cycle of ER+ breast cancer cells: MCF7, 
T47D, and MCF10A cells were treated with DMSO (Cnt) or varying concentrations of palbociclib for 6 days 
and subjected to A) flow cytometry analysis for BrdU-positive cells, a measure of S phase progression; B) 
cell cycle analysis via flow cytometry; and C) cell cycle analysis to determine percentage change in the G1 
phase. D) Western blot analysis of MCF7 and T47D cells treated with DMSO or palbociclib for levels of cell 
cycle proteins: Rb, p-Rb (S807), FOXM1, CDK4, and CDK6. Values show densitometry of the western 
blots as normalized to the loading control actin. All data represent mean±SD from three independent 
experiments; p-values were calculated by comparing values at the end of 6 day drug treatment with those 
at the end of drug + release. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 10: Effect of palbociclib on senescence in ER+ breast cancer cells: A) Senescence-
associated SA-ß gal staining (left) as a measure of senescence with representative images (right) 
in MCF7, T47D and MCF10A cells upon treatment with DMSO or palbociclib for 6 days. B) Side 
scatter analysis (left) and quantification (right) to assess granularity of MCF7 and T47D cells 
treated for 6 days with palbociclib with release for 4 days. C) Graph showing changes in pRb 
levels, G1 phase, BrdU postivity and SA-b gal cells with varying concentrations of palbociclib. All 
data represent mean±SD from three independent experiments; p-values were calculated by 
comparing values at the end of 6 day drug treatment with those at the end of drug + release. ns: 
p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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3.2.4. TIME DEPENDENT EFFECT OF PALBOCICLIB ON GROWTH, CELL CYCLE 
ARREST AND SENESCENCE 
 Having shown that the dose of palbociclib treatment has a significant impact of the drug 
effect, we next wanted to examine if the time of treatment plays a role, (i.e.) if long-term 
treatment is necessary to achieve a sustained effect on ER positive breast cancer cells. Since 
our previous results showing the induction of dose-dependent growth inhibition and 
senescence (Figures 2-5) were performed long-term (6 day) treatments with palbociclib, we 
wanted to examine the effect with shorter treatment times. Hence, we treated the ER positive 
breast cancer cells for 72 hours with 2 doses, low (1uM) and high (5uM) doses of palbociclib 
and then cultured the cells in the absence of the drug for another 3 days, to examine 
reversibility of drug effect. Cell counting assay showed that the growth inhibition induced by 
palbociclib was readily reversible at all concentrations once the drug was removed (Figure 
11A). Further, BrdU analysis (a measure of cellular proliferation and S phase progression), 
where cells were treated with varying concentrations of palbociclib, showed that 72 hour was 
only able to induce a reversible growth inhibition in ER+ve and HMEC cell lines (Figures 11B – 
compare black and white shaded bars). Finally, measurement of senescence activity by 
senescence associated- ß galactosidase (SA-ß gal) assay revealed that short-term palbociclib 
treatment (72 hours) does not induce significant levels of senescence in MCF7, T47D and 
MCF10A cells (Figure 11C). 
Thus, this data indicate that long term is required for palbociclib mediated CDK4/6 
inhibition to have a sustained and irreversible growth inhibitory effect in ER positive breast 
cancer. 
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Figure 11: Time-dependent effect of palbociclib on cell cycle of ER+ breast cancer cells: 
MCF7, T47D, and MCF10A cells were treated with DMSO (Cnt) or varying concentrations of 
palbociclib for 3 days with release for 3 days, and subjected to A) Cell counting to exmaine effect 
on proliferation; B) flow cytometry analysis for BrdU-positive cells, a measure of S phase 
progression and C) Quantification of Senescence-associated SA-ß gal staining. All data represent 
mean±SD from three independent experiments; p-values were calculated by comparing values at 
the end of 6 day drug treatment with those at the end of drug + release. ns: p>0.05; *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001.
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3.2.5. EFFECT OF PALBOCICLIB ON INDUCING APOPTOSIS IN ER+ve BREAST CANCER 
 Having shown that the CDK4/6 inhibitor palbociclib mediates a time and dose 
dependent growth inhibition, cell cycle arrest and senescence, we next wanted to investigate if 
palbociclib might have a cytotoxic effect in ER positive breast cancer. Flow cytometry analysis 
of Annexin V and PI stained MCF7 and T47D cells revealed no significant increase in early 
(Annexin V +ve /PI –ve) or late (Annexin V +ve /PI +ve) apoptotic cells upon treatment with the 
CDK4/6 inhibitor (Figure 12A). Further, cell cycle analysis to examine sub G1 population and 
Caspase 3 activity assay revealed no increase in sub G1 population (Figure 12B) and 
Caspase 3 activity (Figure 12C) with drug treatment. Finally, western blot analysis of known 
apoptotic genes, cleaved PARP, cleaved Caspase 7 showed no increase in apoptosis upon 
treated with palbociclib (Figure 12D).   
 Thus, these results show that treatment with the CDK4/6 inhibitor palbociclib does not 
induce a cytotoxic effect via apoptosis in ER+ve breast cancer cell lines. 
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Figure 12: Effect of palbociclib on inducing apoptosis in ER+ breast cancer cells: A) Flow 
cytometry measurement of apoptotic cells (early apoptosis: Annexin V+/ PI-; late apoptosis: Annexin
V+/PI+) in cells treated as in (a). B) Cell cycle analysis to determine percentage of cell in sub G1 
phase, as a measure of apoptosis. C) Percentage of caspase-3 positive cells determined by flow 
cytometry in T47D cells treated with DMSO, 3 μM staurosporine (positive control), or varying 
concentrations of palbociclib for 6 days. D) Western blot analysis of apoptotic proteins in MCF7 and 
T47D treated with DMSO or palbociclib (Palbo) for 6 days: PARP, cleaved PARP, caspase-7, and 
cleaved caspase-7, with actin as loading control. All data represent mean±SD from three independent 
experiments; p-values were calculated by comparing values at the end of 6 day drug treatment with 
those at the end of drug + release. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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3.2.6. ON-TARGET vs OFF-TARGET EFFECTS OF PALBOCICLIB 
Given that all kinase inhibitors can have potential off-target effects, we next wanted to 
examine if the different doses of palbociclib that induce growth inhibition and / or senescence in 
ER positive breast cancer cell lines are due to on-target (due to inhibition of CDK4 and CDK6) 
or off-target (due to inhibition of other kinases). A recent chemical proteomic study revealed 
that that the CDK4/6 inhibitor palbociclib interacts with targets other than CDK4 and CDK6, 
such as CDK9, Caesin kinase 2, PIK3R4 and other Class III PI3 kinases (Sumi, Kuenzi et al. 
2015).  
To examine the specificity of palbociclib to CDK4 and CDK6, the two genes were 
downregulated using either shRNA or siRNA technologies (Figure 7) in MCF7 and T47D cells. 
Treatment of cells with knockdown of CDK4 and/ or CDK6 with increasing concentrations of 
palbociclib showed that knockdown of either protein alone was not sufficient to recapitulate the 
effect of the drug, as downregulation of just one kinase did not result in “rescue” from 
palbociclib mediated growth inhibition (Figure 13A). However, combined knockdown of both 
CDK4 and CDK6, recapitulated palbociclib treatment and mediates resistance (i.e. rescue) to 
palbociclib-induced growth inhibition only at the lower concentrations (≤1µM) (Figure 13A). 
Intriguingly, higher concentrations of palbociclib (>1 µM) had a growth inhibitory effect of the 
CDK4/6 double knockdown cells, indicating potential off-target effects of palbociclib at these 
higher concentrations (Figure 13A). To further understand the on-target vs off-target effects of 
palbociclib in ER+ve breast cancer cell lines, we treated siRNA mediated CDK4/6 knockdown 
cells with low (1uM) and high (5uM) dose palbociclib. Results show that that while low-dose 
(1uM) palbociclib had no additional growth inhibitory effect on the CDK4/6 knockdown cells, 
higher doses (5uM) of palbociclib induced additional growth inhibition (Figure 13B).  
Thus, these results indicate that indicating that the irreversible grown inhibition and high 
levels of senescence observed at 5μM could be due to off-target effects at higher palbociclib 
concentrations.  
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Figure 13: On-target vs Off-target effects of palbociclib: A) Proliferation of MCF7 and T47D 
cells upon knockdown of CDK4 and/or CDK6 and treatment with DMSO or increasing 
concentrations of palbociclib (0.01 to 12 μM) for 6 days. B) Cell counting to examine 
proliferation of MCF7 and T47D cells upon dual siRNA against CDK4 and CDK6, and treated 
with 1uM or 5uM palbociclib. All data represent mean±SD from three independent experiments; 
p-values were calculated by comparing values at the end of 6 day drug treatment with those at 
the end of drug + release. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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3.2.7. INDUCTION OF REACTIVE OXYGEN SPECIES (ROS) BY CDK4/6 INHIBITION 
 Recent studies have shown that CDK4/6 inhibition via palbociclib and ribociclib can 
trigger and activate the reactive oxygen species (ROS) machinery (Anders, Ke et al. 2011, 
Franco, Balaji et al. 2016). This led us to hypothesize that palbociclib may induce ROS in a 
dose-dependent manner in ER positive breast cancer, and that levels of ROS may dictate the 
induction of senescence. Consistent with this, siRNA knockdown of CDK4/6 in MCF7 and T47D 
cell lines increased cellular ROS levels as measured by CellROX assay (Figure 14A). 
Similarly, treatment of ER positive cells with low concentration (1uM) of Palbociclib for 6 days 
also increased ROS levels, albeit moderately (measured by CellROX), while treatment with 
high concentration (5uM) resulted in a significant increase in ROS levels, and this corresponds 
to the palbociclib concentrations at which senescence is induced (Figure 14B). In contrast, 
treatment of HMEC cells did not result in any significant changes in ROS levels at both low 
(1µM) and high (5 µM) palbociclib concentrations (Figure 14B), indicating specificity of drug 
action. Further, short-term (72hr) treatment with low or high doses of palbociclib did not 
increase ROS levels or induce a senescence phenotype in ER positive breast cancer cells 
(Figure 14C and 14D).  
 These results indicate that CDK4/6 inhibition via palbociclib induced reactive oxygen 
species, which may be required for the induction of senescence by palbociclib. 
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Figure 14: Induction of ROS by CDK4/6 inhibition: A) Cellular reactive oxygen species 
(ROS) measurement and quantification (mean fluorescence intensity [MFI]) of ROS levels in 
MCF7 and T47D cells upon transfection with NT siRNA or siRNA against CDK4 and CDK6. 
B,C) Cellular reactive oxygen species (ROS) measurement (B) and quantification (mean 
fluorescence intensity [MFI]) of reactive oxygen species (ROS) levels (C) in MCF7, T47D and 
MCF10A cells upon treatment with DMSO or palbociclib for 6 days. D) Quantification (mean 
fluorescence intensity [MFI]) of ROS levels in MCF7 and T47D cells upon treatment with 
DMSO or palbociclib for 72 hours. All data represent mean±SD from three independent 
experiments; p-values were calculated in comparison to cells treated with DMSO (Control) or 
siNT unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
0 1 5 0 1 5
0
3
6
9
12
Palbociclib (µM)
C
el
lu
la
r R
O
S 
(M
FI
 x
10
3 ) MCF7 T47D
ns ns
ns
ns
D
MCF7 T47D MCF10A
Cellular ROS (CellROXfluorescence) Cellular ROS (CellROXfluorescence) Cellular ROS (CellROXfluores.)
Cnt
1μM
5μM
0 1 5 0 1 5 0 1 5
0
3
6
9
12
Palbociclib (µM)
C
el
lu
la
r R
O
S 
(M
FI
 x
10
3 )
MCF7 T47D MCF10A
*
*******
ns
ns
*
C
	 82 
3.2.8. IMPACT OF ROS ABLATION ON PALBOCICLIB INDUCED GROWTH INHIBITION 
AND SENESCENCE 
Given the well-established link between Reactive oxygen species (ROS) and cell cycle 
arrest and senescence and the known requirement of high ROS levels for the induction of 
senescence (Boonstra and Post 2004, Kuilman, Michaloglou et al. 2010), we wanted to 
examine if palbociclib induced ROS is required for the induction of sustained growth inhibition 
and senescence in ER positive breast cancer cells. To interrogate this, we ablated ROS using 
the ROS scavengers N-acetyl cysteine (NAC) or trolox (Hamad, Arda et al. 2010, Sun 2010), 
by treating the cells with NAC or trolox in combination with palbociclib for the 6 day period 
(Figure 15A). ROS ablation mediates significant resistance to the ability of palbociclib to 
induce a sustained growth inhibition even at higher doses of 5uM, as measured by clonogenic 
assay (Figure 15B). Further, measurement of cellular proliferation by cell counting after drug 
treatment for 6 days and recovery for 4 days (to measure reversibility) also showed ROS 
ablation by NAC or trolox prevented the induction of irreversible or sustained growth inhibition 
in MCF7 and T47D cells even with high doses of palbociclib (Figure 15C). Moreover, ablation 
of ROS by NAC or trolox also significantly decreased the induction of senescence by high 
doses (5uM) of palbociclib in MCF7 and T47D cell lines, as measured by SA-ß gal, wherein a 
significant decrease in SA-ß gal positive cells (blue staining) was observed with NAC or trolox 
treatment in combination with 5uM palbociclib, compared to palbociclib alone (Figure 15D). 
Thus, these results demonstrate the dependence of the palbociclib action (its ability to 
induce sustained growth inhibition and senescence) on elevated ROS levels. 
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Figure 15: Impact of ROS ablation on palbociclib induced growth inhibition and senescence: 
MCF7 and T47D cells were treated with DMSO (Cnt), 5 μM palbociclib (Palbo), or a combination of 
ROS scavenger (10 mM NAC or 0.1 mM trolox) with 5 μM palbociclib for 6 days and subjected to A) 
measurement of cellular ROS levels with CellROX deep red; B) clonogenic assay; C) cell counting 
to assess proliferation (p-values were calculated in comparison with cells treated with 5 μM
palbociclib) and D) Quantification and representative images of Senescence associated ß
galactosidase (SA-ß gal) activity as a measurement of senescence. All data represent mean±SD
from three independent experiments; p-values were calculated in comparison to cells treated with 
DMSO (Control) or siNT unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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3.2.9. PALBOCICLIB MEDIATED TUMOR GROWTH INHIBITION AND SENESCENCE IN 
VIVO 
We next set out to translate our findings from cultured cells in vitro to tumor xenografts 
in vivo.  For the in vivo studies, since MCF7 cells are not very tumorigenic (ability to form 
tumors in mice), we established MCF7T cells by passaging MCF7 cells through mice and 
verified that they behave similar to MCF7 cells in response to CDK4/6 inhibition via palbociclib 
in vitro. Results show that treatment of MCF7-T cells with increasing concentrations of 
palbociclib resulted in a time and dose-dependent growth inhibition (Figure 16A and 16B) and 
cell cycle arrest (G1 arrest) (Figure 16C), that were very similar to what observed in the MCF-7 
cells (Figure 2-5). Further, palbociclib induced senescence in a dose-dependent manner in 
MCF7-T cells (Figure 16D). Palbociclib treatment in MCF7-T cells also induced autophagy 
(Figure 16E) and responded to autophagy inhibition (Figure 16F), similar to MCF7 cells 
(described in Chapter 4 and 5). Thus, these results show that MCF7-T cells behave similar to 
MCF7 and can be utilized for the in vivo mouse studies.  
Next, to assess the therapeutic effect of CDK4/6 inhibition in vivo, we established a 
mouse orthotropic xenograft model by injecting MCF7T cells into the mammary fat pad of 
immunocompromised nude mice. Once the tumors reached an average volume of 200mm3, the 
mice were treated with Vehicle (0.5% Methylcellulose) or varying concentrations of Palbociclib 
(25, 50, 75 or 150 mg/kg/day) via oral gavage for 7 days (Figure 17A). Treatment with 
palbociclib significantly decreased tumor volume in a dose-dependent manner, when compared 
to the vehicle treated mice (Figures 17B and 17C). This resulted in significantly smaller tumors 
and decreased tumor weight upon 7-day treatment with palbociclib in a dose-dependent 
manner (Figure 17D). To examine palbociclib-mediated toxicity in mice, we measured mouse 
weight every day during the 7-day treatment period. While treatment with Vehicle, 25 mg/kg 
and 50 mg/kg Palbociclib was well tolerated by the mice, a moderate decrease in mouse 
weight was observed with 75mg/kg and 150 mg/kg palbociclib (Figures 17E and 17F) This 
	 85 
suggests potential toxicity by palbociclib at the higher concentrations, and emphasizes the 
need to optimize the use of lower drug concentrations.  
Treatment of in vivo xenograft tumors with palbociclib also resulted in decrease in 
protein levels of G1/S checkpoint proteins and known palbociclib targets – Rb, pRb and 
FOXM1 as measured by western blot analysis (Figure 17G). Next, the tumor tissues were 
harvested, sectioned and stained with hematoxylin and eosin (H&E), to examine the 
morphology of the tumor cells post treatment (Fischer, Jacobson et al. 2008).  
The remaining tumors were sectioned for further immunohistochemistry (IHC) analysis, 
which revealed that palbociclib treatment increased SA- ß gal activity (measure of induction of 
senescence) and decreased expression of BrdU (indicator of decreased proliferation), 
indicating the induction of a dose-dependent tumor growth inhibition and senescence (Figure 
18A). Consistently, RPPA analysis of tumors (Figure 18B) treated with palbociclib showed a 
dose-dependent downregulation of cell cycle and proliferation proteins, such as pRb, FOXM1, 
cyclin B, CDK1, cdc25c, cdc2, PLK1, ARID1, BRD4, ATM and Wee1 (Figure 18C). A 
concomitant up-regulation of proteins within the senescence pathway, such as Chk1, YAP, 
TAZ, E!F4E, IGFFBP2, PEA15, 14-3-3-beta, 14-3-3-zeta and c-IAP (Figure 18D), when 
compared to vehicle treated tumors. 
Collectively, these results show that CDK4/6 inhibition via palbociclib induces a dose-
dependent reduction in tumor growth and induction of senescence in ER positive tumor 
xenografts.  
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Figure 16: Characterization of MCF7-T cell in-vitro: A) Proliferation of MCF7-T cells treated 
with DMSO or increasing concentrations (conc) of palbociclib (0.01 to 12 μM) for 1, 2, 4, 6, or 8 
days. MCF7-T cells were treated with DMSO (Cnt) or varying concentrations (0.5, 1, or 5 μM) 
of palbociclib for 6 days and allowed to recover for 4 days (release, or rel) to examine 
reversibility. Cells were then subjected to B) cell counting to assess the effect on growth; C) 
cell cycle analysis to determine percentage change in G1 phase (p-values were calculated by 
comparing values at the end of drug treatment with those at the end of drug + release); and D) 
quantification of senescence-associated SA-ß gal positive cells. E) Monodansylcadavarine
(MDC) positive MCF7-T cells were quantified with flow cytometry after treatment with DMSO 
or varying concentrations of palbociclib for 6 days. F) Cell counting was used to assess effect 
on growth of MCF7-T cells treated with a combination of DMSO or palbociclib (Palbo; 0.5 or 1 
μM) and autophagy inhibitor hydroxychloroquine (HCQ; 15 µM) for 6 days. Cells were allowed 
to recover for 4 days to examine reversibility. All data represent mean±SD from three 
independent experiments; p-values were calculated in comparison to cells treated with DMSO 
(Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001
C
D
A B
FE
	 87 
	
MCF7-T 
0" 4"Days 7"
  Orthotopic  
   xenograft 
Palbociclib 
0 1 2 3 4 5 6 7
-40
-20
0
20
40
Days of treatment
%
 c
ha
ng
e 
in
 tu
m
or
 v
ol
um
e
Vehicle (0.5% MC)
25 mg/kg Palbociclib
50 mg/kg Palbociclib
75 mg/kg Palbociclib
150 mg/kg Palbociclib
0 1 2 3 4 5 6 7
10
15
20
25
30
35
40
Days after treatment
M
ou
se
 W
ei
gh
t (
g)
Vehicle (0.5% MC)
25 mg/kg Palbociclib
50 mg/kg Palbociclib
75 mg/kg Palbociclib
150 mg/kg Palbociclib
0 25 50 75 150
-30
-20
-10
0
10
20
Palbociclib conc (mg/kg)
%
 c
ha
ng
e 
in
 m
ou
se
 w
ei
gh
t
**
*
0 25 50 75 150
0
100
200
300
400
500
Palbociclib conc (mg/kg)
Tu
m
or
 w
ei
gh
t (
m
g)
** ** ** ***
0 1 2 3 4 5 6 7
-50
-25
0
25
50
Days of treatment
%
 c
ha
ng
e 
in
 tu
m
or
 v
ol
um
e
Vehicle (0.5% MC)
25 mg/kg Palbociclib
50 mg/kg Palbociclib
75 mg/kg Palbociclib
150 mg/kg Palbociclib
******
***
***
0 25 50 75 150
Rb-p807
Palbo(mg/kg)
Rb
Vinculin
FOXM1
p62
LC3B
0 25 50 75 150
Rb-p807
Palbo(mg/kg)
Rb
Vinculin
FOXM1
p62
LC3B
C
A
B
G
D
F
E
Figure 17: Palbociclib mediated tumor growth inhibition in vivo: A) Schematic showing 
treatment schedule of orthotopic MCF7-T xenograft mice with vehicle (0.5% methylcellulose 
[MC]) or varying concentrations of palbociclib for 7 days. B) Percentage change in tumor 
volume (normalized to Day 0) upon treatment with vehicle or palbociclib (n≥4 tumors per 
group) daily for 7 days. C) Percentage change in tumor volume of orthotopic xenograft mice 
(normalized to volume on Day 0) of individual tumors treated with vehicle (0.5% 
methylcellulose) or varying concentrations of palbociclib daily for 7 days via oral gavage (n³4 
mice tumors/treatment group). D) Tumors were harvested at the treatment for tumor weight 
measurement. E) Mean mouse weights for each treatment group after 7 days of treatment as 
described in A. F) Percentage change in mouse weights after 7 days treatment as described in 
A. G) Western blot of harevsted tumors upon treatment with palbociclib analyzed for cell cycle 
proteins (phospho-Rb, Rb, FOXM1). All data represent mean±SD; p-values were calculated in 
comparison to mice treated with vehicle (Control) unless indicated. ns:p>0.05; *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001.
	 88 
 
 
Vehicle
(0.5% MC) 25
Palbociclib (mg/kg)
50 75 150
Br
dU
8-
O
Hd
G
H 
& 
E
4-
HN
E
SA
-β
 g
al
0 25 75 150
-2
-1
0
1
2
Palbociclib (mg/kg)
N
or
m
. l
og
2 
R
PP
A
 le
ve
l
RPPA - Cell Cycle
**** *****
0 25 75 150
-0.4
-0.2
0.0
0.2
0.4
Palbociclib (mg/kg)
N
or
m
. l
og
2 
R
PP
A
 le
ve
l RPPA - Senescence
**
***
*
Ch
k1 YA
P
TA
Z
EIF
4E
IG
FB
P2
PE
A1
5
14
-3-
3-b
eta
14
-3-
3-z
eta
c-I
AP
-0.4
-0.2
0.0
0.2
N
or
m
. l
og
2 
R
PP
A
 le
ve
l
RPPA - Senescence
pR
b
FO
XM
1
Cy
cli
n-B
CD
K1
cd
c2
5c
cd
c2
PL
K1
AR
ID
1
BR
D4 AT
M
We
e1
-2
-1
0
1
2
N
or
m
. l
og
2 
R
PP
A
 le
ve
l
RPPA - Cell Cycle
Vehicle
25 mg/kg Palbociclib
75 mg/kg Palbociclib
150 mg/kg Palbociclib
Cell Cycle
Senescence
Autophagy
Vehicle 25 75 150
Palbociclib
(mg/kg)
BrdU
0 25 50 75 150
0
10
20
30
Palbociclib (mg/kg)
%
 o
f B
rd
U 
+v
e c
ell
s
*
***
****
**
Vehicle
(0.5% MC) 25
Palbociclib (mg/kg)
50 75 150
B
rd
U
8-
O
H
dG
H
 &
 E
4-
H
N
E
SA
-β
 g
al
Figure 18: Palbociclib mediated cell cycle arrest and senescence in vivo: A) Quantification (BrdU) 
and representative images of hematoxylin and eosin (H&E), BrdU and SA-ß gal immunohistochemical
staining of tumor tissues harvested after treatment with vehicle (0.5% methylcellulose [MC]) or varying 
concentrations of palbociclib for 7 days. Scale bars equal 50μm. B) Heat map obtained from RPPA 
analysis of tumors harvested after treatment as described in A and ordered based on Cell cycle, 
senescence and autophagy pathways. Pathway scores and expression (normalized log2 level) of 
individual proteins within the C) cell cycle (n=10 proteins) and D) senescence pathways (n=13 proteins) 
determined from RPPA analysis of tumors harvested after 7 days treatment as described in A. All data 
represent mean±SD; p-values were calculated in comparison to mice treated with vehicle (Control) unless 
indicated. ns:p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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3.2.10. PALBOCICLIB MEDIATED INDUCTION OF ROS IN VIVO 
 Since our results showed that palbociclib mediated CDK4/6 inhibition has been shown 
to induce ROS in ER positive breast cancer cell line model systems (Figure 14), which is 
required for the induction of senescence (Figure 15), we wanted to examine if palbociclib would 
induce ROS in vivo as well. For this purpose, we utilized tumors harvested post treatment with 
vehicle or varying concentrations of palbociclib (25mg/kg, 50mg/kg, 75mg/kg and 150mg/kg) 
(Figure 12A), and performed immunohistochemistry (IHC) analysis for known markers of 
Reactive oxygen species (ROS): i) 8-hydroxydeoxy-guanosine (8-OHdG), a marker of oxidative 
stress induced DNA damage (Valavanidis, Vlachogianni et al. 2009) and ii) 4-hydroxynonenal 
4-HNE, a marker of oxidative stress induced lipid peroxidation (Liou and Storz 2015). Results 
showed a significant dose dependent up-regulation of 8-OHdG and 4-HNE staining, with 
highest staining with 150 mg/kg palbociclib, which has been shown to induce senescence 
(Figures 19A and 19B). Further, RPPA analysis of the palbociclib treated tumors exhibited 
downregulation a ROS sequestering gene Caveolin (CAV-1) (Chen, Barman et al. 2014) and 
upregulation of SOD-2, which is known to be induced by higher ROS levels (Figure 19C).  
 Thus, palbociclib mediated CDK4/6 inhibition in vivo induces ROS levels, which is 
required for the sustained tumor growth inhibition and senescence in vivo. 
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Figure 19: Palbociclib mediated induction of ROS in vivo: A) Representative images of ROS 
markers, 8-hydroxydeoxy-guanosine (8-OHdG) and 4-hydroxynonenal (4-HNE) 
immunohistochemical staining of tumor tissues harvested after 7 days of treatment with vehicle 
(0.5% methylcellulose [MC]) or varying concentrations of palbociclib. Scale bars equal 50μm. B) 
Quantification (H-score) of 8-OHdG and 4-HNE staining in tumors after 7 days of treatment with 
vehicle or increasing concentrations of palbociclib. C) Expression (normalized log2 level) of ROS 
associated proteins, SOD-2 and Caveolin (CAV-1) as determined from RPPA analysis of tumors 
harvested after treatment as described in A. All data represent mean±SD; p-values were 
calculated in comparison to mice treated with vehicle (Control) unless indicated. ns:p>0.05; 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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3.3. DISCUSSION 
  Most preclinical studies conducted thus far with palbociclib have used the drug at low 
conc. (<1uM) and for short exposure times (<72 hrs.). Under these treatment conditions, the 
drug only induces a reversible cell cycle arrest at these conditions, leading to a poor 
recapitulation of the effect seen in clinic, where patients are treated continuously for 3 weeks 
(DeMichele, Clark et al. 2015). Hence in this study, we examined the action of the CDK4/6 
inhibitors as a function of both time and dose, and also interrogated the reversibility of the drug 
effect; making it the first clinically relevant model to investigate the mechanism of Palbociclib 
action. Our results demonstrated that a biphasic effect was seen with palbociclib treatment in 
ER positive breast cancer cells in vitro, where lower doses of the drug (~1uM) were more 
specific to CDK4/6 and was able to induce only a reversible inhibition of growth and cell cycle 
(G1 arrest), while the higher doses of the drug (>2.5uM) resulted in an irreversible inhibition of 
cellular proliferation, an irreversible G1 arrest and senescence. Further, results show that long-
term treatment with palbociclib is necessary for the induction of sustained drug effect and 
senescence. While a previous study suggested that long-term treatment may be required to 
prevent reversibility in the growth inhibition induced by palbociclib (Leontieva and Blagosklonny 
2013), this has not been elucidated in detail. Further, the higher doses which resulted in the 
induction of senescence (5uM) is significantly higher than higher than the clinically achievable 
dose and the plasma concentration, which 3.4uM (Pfizer-Inc-and-Affiliates 2011).  
Hence, understanding the dose-dependent mechanism of action of palbociclib is crucial to 
improve the efficacy of CDK4/6 inhibition and potentially lower the dose of the drug 
administered in patients.  
  Further, treatment with palbociclib failed to induce any apoptosis or cytotoxic effects, 
indicting that the mechanism of drug mediated growth inhibition is likely due to the induction of 
senescence. This was observed both in cultured cells in vitro and tumors in vivo, and 
corroborates with previous studies (Anders, Ke et al. 2011). This effect might be specific to 
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palbociclib since studies with the other CDK4/6 inhibitors such as abemaciclib have been 
showed to induce apoptosis in breast cancer cells in vitro (Patnaik, Rosen et al. 2016). 
  Intriguingly, the induction of senescence observed at the higher doses of palbociclib 
was coupled with drug effects not necessarily specific to CDK4/6 inhibition, indicating the 
presence of potential off-target effects for palbociclib at the higher doses. A mass spectrometry 
based chemoproteomics study in lung cancer aimed at identifying all possible direct and 
indirect kinase targets of the CDK4/6 inhibitors, palbociclib and ribociclib, showed that apart 
from CDK4 and CDK6, palbociclib has targets other kinases such as CDK9, casein kinase 2, 
PIK3R4 (regulator of autophagy) and lipid kinases such as PIK3CD and PIP4K2A/B/C (Sumi, 
Kuenzi et al. 2015). By pathway analysis, this study also showed that palbociclib treatment 
affect PI3K signaling and autophagy apart from cell cycle regulation (Sumi, Kuenzi et al. 2015). 
Hence, it is highly likely that palbociclib hits secondary targets at the higher concentrations 
(5uM or 150mg/kg) and this accounts for the biphasic effect observed with palbociclib 
treatment.  
 The results presented in this chapter also show that CDK4/6 inhibition and 
palbociclib treatment induces oxidative stress, measured by reactive oxygen species (ROS) in 
a dose-dependent manner, and that the high levels of ROS is required for the induction of 
senescence. However, the molecular mechanism by which CDK4/6 inhibition induces ROS 
remains unclear. Cyclin-D1 has been shown to bind to and phosphorylates Nrf1, which is a 
regulator of mitochondrial biogenesis and ROS, and this occurs in a CDK dependent manner 
(Wang, Li et al. 2006). Hence, it is possible that CDK4/6-cyclin D1 inhibition via palbociclib 
increases Nrf1 levels, thus increasing ROS activity. The levels of ROS and the subsequent 
induction of senescence, in turn, might also be controlled by c-jun through a previously 
elucidated mechanism involving the ROS genes, MnSOD and catalase(Katiyar, Casimiro et al. 
2010).  This provides a direct molecular mechanism by which CDK4/6-cyclin D regulates ROS 
through Nrf2 and c-jun. Alternatively, the induction of ROS might be mediated directly by the 
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Rb targets FOXM1 and BIRC5 (survivin), which have been shown to negatively regulate 
oxidative stress (Kwee, Luque et al. 2008, Park, Carr et al. 2009, Lim, Heo et al. 2015), 
providing a novel link between Rb and the ROS machinery. Concordantly, we and others have 
reported a significant decrease in FOXM1 levels (Figures 1G and 4C) (Anders, Ke et al. 2011), 
and observed a decrease in Survivin mRNA levels. This suggests that downregulation of 
FOXM1 and BIRC5, among other ROS regulating proteins might be the potential mechanism 
by which Rb regulates oxidative stress, under palbociclib treatment conditions, and this 
warrants further investigation. 
 These results suggest that there are potential mechanisms that are induced at the 
lower doses of palbociclib, which prevent the high ROS levels and the induction of senescence. 
Understanding this / these process(es) would help improve the efficacy of the drug at the lower 
doses as we have addressed in Chapters 4 and 5.  
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CHAPTER 4: INDUCTION OF AUTOPHAGY IN RESPONSE TO CDK4/6 INHIBITION 
IN ER+ BREAST CANCER 
 
4.1. INTRODUCTION 
4.1.1. AUTOPHAGY – DEFINITION AND REGULATION 
Autophagy, which is derived from the Greek word “eating of self” is a catabolic process 
in cells that recycles cellular constituents as an efficient way of generating energy (Deter and 
De Duve 1967). There are three types of autophagy: i) Macroautophagy, the most common 
form of autophagy mediated by cellular structures such as autophagosomes and lysosomes, ii) 
Micro autophagy, where the cellular components are directly transported to the lysosomes for 
degradation and iii) Chaperone mediated autophagy (CMA), where the chaperone protein 
Hsp70 mediates transport of the cargo to the lysosome by association with the lysosomal 
protein, LAMP2A (Saftig, Beertsen et al. 2008, Glick, Barth et al. 2010).  
Macroautophagy, the most well-characterized and common form of autophagy 
(illustrated in Figure 20) begins with the formation of an isolation membrane, which surrounds 
the cargo or the cellular components to the degraded and the develops into a double-
membraned vesicle called “autophagosomes” (Mizushima 2007). This is the structure that can 
be visualized as double-membrane electron dense vesicles by Transmission Electron 
Microscopy (TEM), which is the gold standard experiment to examine the induction of 
autophagy (Yla-Anttila, Vihinen et al. 2009). The autophagosomes, containing the cargo, fuse 
with the lysosomes, forming structures called autophagolysosomes, where the lysosomal acids 
facilitate degradation of the cargo, thus generating energy (Glick, Barth et al. 2010). Autophagy 
can be specific (degrades a single organelle) or non-specific (degrades multiple components), 
and can target several types of cellular components for degradation including individual 
proteins, protein aggregates, or entire organelles such as mitochondria (mitophagy), nucleus 
(nucleophagy), peroxisomes (pexophagy) and ribosomes (ribophagy) (Glick, Barth et al. 2010). 
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 While the molecular regulation of the autophagy pathway has not been fully 
characterized, numerous studies have identified key points of regulation within the pathway and 
characterized genes involved in this process. This primarily comprises of the core autophagy 
related genes or Atg genes, which were originally identified in yeast, but have mammalian 
homologs (Lamb, Yoshimori et al. 2013). About 32 genes belonging to the Atg family have 
been identified and characterized to play key roles at different steps of the autophagic process 
(Lamb, Yoshimori et al. 2013). Some of the crucial autophagy steps regulated by the Atg 
proteins are detailed here (Figure 20). The process of nucleation or phagophore formation is 
controlled by Atg6 or Beclin-1 which dissociates from the Bcl2/Beclin-1 complex to form a 
complex with the class III PI3K protein Vps34, at the stage of autophagy initiation (Glick, Barth 
et al. 2010). The next crucial step is the formation of the Atg5-Atg12-Atg16L complex, which is 
facilitated by Atg7 and Atg10 and is required for the elongation of the phagophore and the 
formation of the autophagosomes (Lamb, Yoshimori et al. 2013). Finally, the conjugation of the 
microtubule-associated protein light chain 3 (LC3B) protein with phosphatidylethanolamine 
(PE) to form the active LC3B-II is regulated by Atg3, Atg4 and Atg7 (Satoo, Noda et al. 2009). 
Apart from these core autophagy proteins, there are several other molecular pathways that 
regulate the process such as AMPK, PI3K/AKT and mTOR pathways (Mizushima 2007). 
Deregulation of the autophagic process resulting from gains and losses of the 
autophagy genes has been linked to numerous diseases including cancer, cardiovascular 
Figure 20: Regulation of autophagy: Schematic showing the steps and processes 
involved in autophagy and its molecular regualtion. 
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disease and neurodegenerative disorders (Mizushima 2007, Glick, Barth et al. 2010). 
Deregulation of autophagy plays an integral role in neurodegenerative diseases such as 
Alzheimer’s, ALS and Parkinson’s disease. For example, the ubiquitin ligase, Parkin and its 
upstream kinase PINK1, which play key role in mitophagy are frequently mutated in 
Parkinson’s disease (Lynch-Day, Mao et al. 2012). Further, in Alzheimer’s disease, autophagy 
facilitates the removal of protein aggregates formed due to mutations in the tau gene (Zare-
Shahabadi, Masliah et al. 2015). This has led to research aimed at developing drugs that 
upregulate autophagy in a tissue specific manner in these disease settings. 
 
4.1.2. ROLE OF AUTOPHAGY IN CANCER 
 The precise role of autophagy in oncogenesis has been a widely-debated topic for 
numerous years, since studies have shown opposing roles for autophagy in cancer – as a pro-
survival process (oncogenic role) and as a pro-death mechanism (tumor suppressor role) 
(White, Mehnert et al. 2015). In normal cells, autophagy primarily plays a housekeeping role 
wherein it removes the defective and damaged proteins and organelles, to maintain the 
integrity of cells, survive stress and provide energy when needed (Mizushima 2007). Research 
has shown that the role of autophagy in cancer is highly context-dependent – dependent on the 
type of tumor, stage of development of the tumor, whether it is basal or induced autophagy, etc. 
(White, Mehnert et al. 2015). Autophagy has been primarily shown to a play a tumor 
suppressing role early on in the tumorigenesis, but later utilized by tumors as a mechanism to 
maintain proliferation capacity even in the presence stresses such as hypoxia, metabolic 
stress, hypoxia or drug induced stress (Mathew, Karantza-Wadsworth et al. 2007, White, 
Mehnert et al. 2015).  
One of the crucial autophagy proteins, Beclin-1, a Bcl-2 interacting protein, is 
monoallelically deleted in about 40- 75% of all human cancers, including breast, ovarian and 
prostate cancers (Aita, Liang et al. 1999). Reintroduction of Beclin-1 into established cancer 
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cells such as MCF7, which exhibits a heterozygous loss of Beclin-1 resulted in a significant 
reduction in cellular proliferation, clonogenicity and tumorigenic potential in vivo (Aita, Liang et 
al. 1999). Further, allelic loss of Beclin-1 makes mice more susceptible to spontaneous tumor 
formation such as lymphoma, breast, lung liver cancers, and also makes them prone to Wnt1 
mediated mammary tumorigenesis (Cicchini, Chakrabarti et al. 2014, White, Mehnert et al. 
2015). Similar observations have been seen with other autophagy genes such as Atg5, whose 
loss has been shown to promote extensive liver damage and carcinoma, and the formation of 
benign tumors in the case of pancreatic cancer (Takamura, Komatsu et al. 2011, Rosenfeldt, 
O'Prey et al. 2013). These studies elucidate the tumor suppressive role of autophagy mainly at 
the early stages of tumor development.  
 However, at the later stages of tumor development, autophagy is believed to play a pro-
survival function, since the cells can now use autophagy as a recycling facility to backup 
energy to survive under stress and maintain viability (Mathew, Karantza-Wadsworth et al. 2007, 
White 2015). Atg7 deletion in a K-ras G12D driven lung cancer mouse model resulted in tumor 
cells accumulating defective mitochondria, activating autophagy and the p53 tumor suppressor 
protein resulting in lower cell proliferation and increased apoptosis (Guo, Karsli-Uzunbas et al. 
2013). Further the tumors developed upon knockdown of Atg7 in mouse models at early stages 
remained benign (Takamura, Komatsu et al. 2011). Also, deficiency of p62 causes suppression 
of autophagy induced tumorigenesis in cell lines and mouse models (Jiang, Overholtzer et al. 
2015, White, Mehnert et al. 2015). Moreover, recent studies in pancreatic cancer and other 
Ras-driven tumors have shown that these cancers are addicted to autophagy to survive 
metabolic stress and maintain oxidative metabolism and survive (White, Mehnert et al. 2015). 
Finally, studies have shown an association between higher expression of autophagy proteins 
like LC3B and aggressiveness of the tumor or the presence of residual disease post 
chemotherapy (Karantza-Wadsworth and White 2007, Chen, Jiang et al. 2013).  
Thus, these studies provide evidence for the dual role played by autophagy in cancers, 
	 98 
and highlights the oncogenic or pro-survival role of autophagy in developed tumors, which be 
required for the maintenance of the tumor phenotype and drug resistance. 
 
4.1.3. CDK4/6 INHIBITION AND AUTOPHAGY 
 While the role of the G1 checkpoint proteins CDK4/6-cyclin D in cell cycle and cellular 
proliferation is well established, its role in autophagy is very poorly understood. A study in a 
breast cancer model showed that cyclin D1 can suppresses autophagy in mammary 
tumorigenesis, since mice deficient in cyclin D1 upregulate autophagy and failed to induce 
ErbB2 induced senescence (Brown, Jeselsohn et al. 2012). Further, genetic or 
pharmacological downregulation of cyclin D1 in human mammary epithelial cells (HMEC) 
showed significant upregulation of autophagy, the inhibition of which resulted in an increase in 
senescence (Brown, Jeselsohn et al. 2012).  
 Lastly, two recent studies suggest a role for CDK4/6 inhibition in inducing autophagy. A 
study in cancer-associated fibroblasts showed that CDK inhibitors such as p16, p21 and 
pharmacological CDK inhibitors such as palbociclib can upregulate proteins involved in both 
senescence and autophagy (Capparelli, Chiavarina et al. 2012). In addition, a recent study in 
promyelocytic leukemia reported that palbociclib induces autophagy-dependent degradation of 
the DNA methyl transferase DNMT1, which facilitates the induction of senescence in these 
cancers (Acevedo, Vernier et al. 2016). 
 
4.1.4. GAP IN KNOWLEDGE 
While these previous studies highlight the importance of autophagy in cancers and its role as a 
stress response process, the following questions remain to be addressed:  
1. Does knockdown of CDK4/6 induce autophagy in breast cancer? 
2. Does palbociclib induce autophagy in ER positive breast cancer? 
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3. Is the autophagy induced by palbociclib functional (ie) does it have an intact autophagic 
flux?  
4. Is there a dose dependence in the induction of autophagy by palbociclib – effects of on-
target vs off-target doses? 
5. Does ROS play a role in mediating the induction of autophagy by palbociclib?  
Thus, the experiments conducted in this chapter aimed at addressing these questions, since 
the ability of CDK4/6 inhibition to induce autophagy and its potential implications has not been 
well understood. 
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4.2. RESULTS 
4.2.1. INDUCTION OF AUTOPHAGY WITH CDK4/6 KNOCKDOWN AND LOW DOSES OF 
PALBOCICLIB 
 Autophagy is an adaptive cellular stress response that recycles dysfunctional cellular 
organelles for energy and facilitates cancer cell survival (Glick, Barth et al. 2010). Hence, we 
hypothesized that CDK4/6 inhibition-mediated cell cycle arrest (on-target effect at 1μM 
palbociclib) triggers autophagy as a stress response, which mediates the reversal of sustained 
growth inhibition and prevents the induction of senescence at these doses. To interrogate the 
induction of autophagy upon knockdown of CDK4 and CDK6, we used Monodansylcadavarine 
(MDC) staining, a marker of acidic vesicles including autophagosomes (Biederbick, Kern et al. 
1995). Results showed a significant increase in MDC positive cells in MCF7 and T47D cells 
upon double siRNA knockdown of CDK4 and CDK6, when compared to NT (Figure 21A).  
Further, to examine the induction of autophagy upon palbociclib treatment, we used 
several different assays in MCF7 and T47D cells: i) Monodansylcadavarine (MDC) staining, a 
marker of acidic vesicles including autophagosomes, ii) Transmission Electron Microscopy 
(TEM), which helps visualize the presence of double-membrane electron dense 
autophagosomes (Yla-Anttila, Vihinen et al. 2009), iii) GFP-LC3 puncta, iv) qRT-PCR and 
Reverse Phase Protein Array (RPPA) analysis to measure levels of key autophagy related 
proteins and v) Western blot analysis of LC3B II, the active and phosphatidylethanolamine (PE) 
conjugated form of microtubule-associated protein light chain 3 (LC3B) located on the surface 
of autophagosomes (Satoo, Noda et al. 2009) and SQSTM1/ p62, an autophagy receptor 
whose degradation can be indicative of an intact autophagic flux (Mathew, Karp et al. 2009). 
Results showed that treatment of MCF7 and T47D cells with increasing concentrations of 
palbociclib significantly increased levels of MDC staining (Figure 21B) and expression of key 
autophagy proteins, such as BNIP3 (Figure 21C), Atg-7, Beclin-1 (Figure 21D), while 
decreasing levels of BCl2 (a known inhibitor of autophagy (Pattingre, Tassa et al. 2005)) 
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(Figure 21D). Further, western blot analysis showed increase in LC3B II protein levels, while 
decreasing SQSTM1 levels, indicating the induction of autophagy with palbociclib treatment 
(Figure 21E) in ER positive breast cancer cell lines. Additionally, Transmission Electron 
Microscopy (TEM) performed by comparing the Control (DMSO treated) vs the palbociclib 
treated cells, showed significant accumulation of double-membrane electron-dense vesicles, 
which are indicative of autophagosomes upon treatment with low dose (1uM) of palbociclib 
(Figure 22A – red arrows). Further, examination of GFP positive puncta in MCF7 cells stably 
expressing GFP-LC3 showed accumulation of LC3 puncta (indicative of autophagosomes) 
upon treatment with 1uM palbociclib (Figure 22B).  
Collectively, these results indicate that CDK4/6 inhibition and palbociclib treatment at 
low concentrations induces autophagy in ER positive breast cancer cell lines. 
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Figure 21: Palbociclib mediated induction of autophagy: A) Measurement of 
monodansylcadavarine (MDC)-positive acidic vesicles, including autophagosomes, by flow 
cytometry in MCF7 and T47D cells treated with siNT and dual siRNA against CDK4 and CDK6. 
B) Measurement of MDC positive MCF7 and T47D cells treated with varying concentrations of 
palbociclib for 6 days. C) mRNA level of BNIP3 (normalized to GAPDH) in MCF7 and T47D cells 
treated with 1 μM palbociclib. D) Expression (normalized log2 level) of LC3B, Atg-7, BCl2 and 
Beclin-1 determined by RPPA analysis of MCF7 and T47D cell lines treated with palbociclib for 6 
days. E) Western blot analysis of autophagy proteins, LC3B I, II and p62 in MCF7 and T47D 
cells upon treatment with palbociclib for 6 days. All data represent mean±SD from three 
independent experiments; p-values were calculated in comparison to cells treated with DMSO 
(Control) or siNT unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 22: Palbociclib mediated induction of autophagy: A) Representative 
Transmission Electron microscopy (TEM) microphotographs of MCF7 and T47D cells 
treated with DMSO (Cnt) or 1 μM palbociclib (Palbo) for 6 days. Red arrows indicate 
double-membraned autophagosomes. Scale bars equal 500 nm. B) Quantification and 
representative confocal images of GFP-LC3 expressing MCF7 cells treated with 25 μM
CQ (for 1 hour), 1 μM palbociclib or combination of palbociclib and CQ for 48 hours. Scale 
bars are 50 μm. All data represent mean±SD from three independent experiments; p-
values were calculated in comparison to cells treated with DMSO (Control) unless 
indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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4.2.2. INDUCTION OF INTACT AUTOPHAGIC FLUX WITH LOW DOSES OF PALBOCICLIB 
While our results show the induction of autophagy with CDK4/6 inhibition, examination 
of the presence of an intact autophagic flux, which indicates completion of the autophagy 
pathway and efficient recycling of the cellular cargo, is more critical than the induction of 
autophagy. Hence, we examined the presence of an intact autophagic flux following palbociclib 
treatment by: i) flux ratio (LC3B-II to LC3B-I and LC3B-II to p62), ii) treatment with lysosomal 
block chloroquine (CQ), which elevates lysosomal pH and impairs autophagic flux 
(Chittaranjan, Bortnik et al. 2015), iii) GFP-LC3 puncta with CQ treatment and iv) RFP-GFP-
LC3 dual-reporter assay (Kimura, Noda et al. 2007).  
Treatment with low dose (concentrations lower than 2.5μM) palbociclib, exhibited higher 
flux ratios, as indicated by the ratio of LC3BII protein levels to LC3BI (Figure 23A) and the ratio 
of the protein levels of LC3BII to SQSTM1 (Figure 23B). Further, short term (1 hour) with 
treatment with the lysosomal block, 25uM chloroquine significantly increases the protein levels 
of LC3B-II, compared to treatment with palbociclib alone, as measured by western blotting 
analysis (Figure 23C) and as quantified by densitometry analysis (Figure 23D). Additionally, 
CQ treatment significantly increased GFP positive LC3 puncta compared to palbociclib 
treatment alone at the on-target low doses of 1uM (Figure 22B). Finally, to confirm the 
induction of an intact autophagy, we performed the RFP-GFP-LC3 dual-reporter assay 
(Kimura, Noda et al. 2007), where pH-dependent degradation of GFP in the lysosomes enables 
the differential visualization of autophagosomes ( as RFP+ve GFP+ve puncta – yellow puncta) 
and autophagolysosomes (as RFP+ve puncta). Our results reveal that the presence of an intact 
autophagic flux, which is indicated here by the increase in both RFP+ve GFP+ve puncta 
(autophagosomes) and RFP+ve puncta (autophagolysosomes) as observed in cells treated 
with 1uM palbociclib treatment (Figure 23E), while an impaired autophagic flux would be 
indicated by the accumulation of only autophagosomes (yellow puncta). 
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Thus, results demonstrate the presence of an intact autophagy flux at the low and on-
target concentrations of palbociclib. 
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Figure 23: Induction of intact autophagy with low doses of palbociclib: A) Autophagic flux, 
calculated as ratio of LC3B-II to LC3B-I from densitometry values (normalized to corresponding 
levels of actin) of western blots from Figure 15E. B) Autophagic flux, calculated as ratio of LC3B-II 
to p62 from densitometry values (normalized to corresponding levels of actin) of western blots 
from Figure 15E. C) Western blot of LC3B and p62 in MCF7 and T47D cells treated with a 
combination of 25µM Chloroquine (CQ) for 1 hour and palbociclib for 6 days. D) Densitometry 
values for western blots in Figure 17C to obtain LC3B-II protein levels (normalized to 
corresponding levels of actin). E) Quantification of RFP-GFP-LC3 puncta representative confocal 
images of RFP-GFP-LC3 expressing MCF7 cells treated with 1 μM palbociclib for 48 hours. Scale 
bars are 50 μm. All data represent mean±SD from three independent experiments; p-values were 
calculated in comparison to cells treated with DMSO (Control) unless indicated. ns: p>0.05; 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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4.2.3. DEREGULATED AUTOPHAGIC FLUX AT HIGH DOSES OF PALBOCICLIB 
 While our results show that autophagy induced by palbociclib at low (1μM) and on-
target doses have an intact flux (Figure 16 and 17), the induction of autophagy at the higher 
palbociclib doses remain unexplored. Understanding this would help shed light on the 
processes regulating the dose-dependent effect of palbociclib in ER positive breast cancer 
cells. To interrogate this, we performed the autophagy assays as described in Figures 16 and 
17 upon treatment with higher doses (>2.5μM) of palbociclib in the ER positive breast cancer 
cell lines, MCF7 and T47D. 
Measurement of autophagy by MDC analysis showed significant increase in the 
percentage of MDC positive cells (Figure 24A), and western blotting analysis showed increase 
in the protein levels of LC3B-II, but no decrease in p62 (Figure 24B) in MCF7 and T47D cell 
lines. This indicated that high doses of palbociclib also induce autophagy, but the autophagy 
induced at these doses has a deregulated flux, defined by the presence of an incomplete 
autophagic process and no recycling of the cellular cargo occurs. This was confirmed by high 
flux ratios as calculated by the ratio of LC3B-II to LC3B-I (Figure 23A) and the ratio of LC3B-II 
to p62 (Figure 23B). Further, to examine the autophagic flux induced at the higher dose, MCF7 
and T47D cells treated with palbociclib, were subjected to short term (24 hour) treatment with 
the lysosomal block, chloroquine (CQ) and examined for the presence of MDC positivity. 
Results show no significant change in the MDC levels, indicating that the flux was already 
impaired (Figure 24C). Finally, deregulated autophagy at the higher off-target doses of 
palbociclib was also corroborated by the presence of either dysfunctional lysosomes (multi-
lamellar structures indicated by blue colored arrows) or early autophagosomes (non-electron 
dense structures indicated by black colored arrows) in Transmission Electron Microscopy 
(TEM) images (Figure 24D). 
These results indicate that while higher doses of palbociclib induces autophagy at the 
higher doses as well, the autophagic flux appears to be deregulated. 
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Figure 24: Deregulated autophagy flux at high doses of palbociclib: A) Measurement of MDC 
positive MCF7 and T47D cells treated with varying concentrations of palbociclib for 6 days. B)
Western blot analysis of autophagy proteins, LC3B I, II and p62 in MCF7 and T47D cells upon 
treatment with varying concentrations of palbociclib for 6 days. C) Measurement of MDC positive 
MCF7 and T47D cells treated with a combination of 25µM Chloroquine (CQ) for 1 hour and 
palbociclib for 6 days. D) Representative Transmission Electron microscopy (TEM) 
microphotographs of MCF7 and T47D cells treated with DMSO (Cnt) or 5 μM palbociclib (Palbo) for 
6 days. Blue arrows indicate multi-lamellate structures indicative of dysfunctional lysosomes. Black 
arrows indicate early stage autophagosomes. Scale bars equal 500 nm. All data represent mean±SD
from three independent experiments; p-values were calculated in comparison to cells treated with 
DMSO (Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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4.2.4. DEPENDENCE OF PALBOCICLIB-INDUCED AUTOPHAGY ON THE INDUCTION OF 
ROS 
 Results from Figure 9 show that treatment of ER positive breast cancer cell lines with 
palbociclib results in the induction of ROS at both on- and off-target doses. Given that 
palbociclib treatment at low on-target doses induces autophagy, and that ROS is known to 
induce autophagy (Kongara and Karantza 2012), we hypothesized that CDK4/6 inhibition 
mediated by on-target effects of palbociclib (1μM) may induce ROS, which in turn triggers 
autophagy. 
 Initially, we confirmed the induction of ROS at the on-target doses of palbociclib by 
Reverse phase protein array (RPPA) analysis for ROS-related proteins, SOD-1, CAV-1 and 
SOD-2, which showed a significant decrease in ROS ablating proteins SOD-1 (Papa, Manfredi 
et al. 2014) and CAV-1 (Chen, Barman et al. 2014), while an increase SOD-2, which is known 
to positively regulate ROS was observed (Figure 25A). This in combination with the results 
showed in Figure 9B confirm the induction of ROS at the low (on-target) doses of palbociclib in 
ER positive breast cancer cell lines. 
 Next, to directly interrogate the dependence of palbociclib-induced autophagy on ROS 
induction, ROS was ablated using the ROS scavengers, NAC and Trolox (Hamad, Arda et al. 
2010, Sun 2010) in palbociclib treated ER positive cancer cells, which resulted in a significant 
decrease in MDC staining (Figure 25B). A concomitant decrease in LC3B-II protein expression 
levels was also observed with ROS ablation in cells treated with low doses of palbociclib 
(Figure 25C, 25D).  
 Thus, these results suggest that palbociclib-induced autophagy is dependent on ROS 
induction and the levels of ROS levels. 
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Figure 25: Dependence of palbociclib induced autophagy on the induction of ROS: A) 
Expression (normalized log2 level) of SOD-1, CAV-1 and SOD-2 determined by RPPA analysis of 
MCF7 and T47D cell lines treated with palbociclib for 6 days. B) Quantification (MFI) of MDC 
staining in MCF7 and T47D cells treated with a combination of ROS scavenger (10 mM NAC or 
0.1 mM trolox) and DMSO or 1 μM palbociclib for 6 days. C,D) Western blot analysis showing 
levels of LC3B and p62 proteins (C) and densitometry values of LC3B-II (D) in MCF7 and T47D 
cells treated as in B. All data represent mean±SD from three independent experiments; p-values 
were calculated in comparison to cells treated with DMSO (Control) or siNT unless indicated. ns: 
p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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4.2.5. PALBOCICLIB MEDIATED INDUCTION OF DOSE-DEPENDENT AUTOPHAGY IN 
VIVO 
To assess the ability of the CDK4/6 inhibitor palbociclib to induce autophagy in vivo, 
ER+ve mouse orthotopic xenograft tumors were treated with varying concentrations of 
Palbociclib (25 mg/kg, 50mg/kg, 75 mg/kg or 150 mg/kg/day) daily via oral gavage for 7 days 
and subject to autophagy assays: i) RPPA analysis, ii) Western blot analysis and flux 
quantification and iii) Transmission electron microscopy (TEM).  
Analysis of the altered pathways from RPPA analysis showed up-regulation of 
autophagy related proteins (Figure 18B). Specifically, a significant increase in the protein 
levels of LC3B and Atg-7 was observed in the palbociclib treated tumors in a dose-dependent 
manner (Figure 26A). Further, western blot analysis of the tumors treated with palbociclib 
exhibited an increase in the levels of LC3B-II, indicating the induction of autophagy in vivo in a 
dose-dependent manner (Figure 26B). Specifically, tumor tissues treated with 25mg/kg 
palbociclib showed increased protein levels of LC3BII and decreased levels of SQSTM1/p62 
via western blot analysis, thus demonstrating an induction of autophagy with an intact flux at 
this concentration (Figure 26B). This was confirmed by high autophagic flux ratio (calculated 
by LC3B-II to LC3B-I) upon treatment with 25mg/kg palbociclib (Figure 26C). Additionally, TEM 
showed the presence of double-membrane electron dense autophagosomes on the residual 
tumors treated with 25mg/kg palbociclib (Figure 26D), demonstrating the induction of 
autophagy.  
However, in comparison, while treatment with 150mg/kg Palbociclib increased protein 
levels of LC3B-II and Atg-7 (Figure 26A), this concentration failed to decrease SQSTM1 levels 
(Figure 26B), exhibited low autophagic flux ratio (figure 26C), and displayed presence of 
dysfunctional lysosomes (Figure 26D - multi-lamellar structures indicated by blue colored 
arrows). These results are indicative of autophagy with impaired flux induced with high dose of 
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palbociclib (150mg/kg), and are similar to results observed in vitro with the higher off-target 
doses (>2.5μM) of palbociclib. 
Collectively, these results show the induction of autophagy in vivo with palbociclib 
treatment in a dose-dependent manner. 
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Figure 26: Induction of dose-dependent autophagy in vivo by palbociclib: A) Expression 
(normalized log2 level) of LC3B and Atg-7 protein levels as determined from RPPA analysis of 
tumors harvested after treatment with Vehicle (0.5% Methylcellulose) or varying doses of 
palbociclib via oral gavage for 7 days. B) Western blot for autophagy proteins, LC3B and p62 in 
mice tumors upon 7 days of drug treatment as described in A. C) Autophagic flux, calculated as 
ratio of LC3B-II to LC3B-I from densitometry values (normalized to the corresponding levels of 
actin) of western blots from B. D) Representative TEM microphotographs of tumors harvested from 
mice treated with vehicle (0.5% MC), 25 mg/kg or 150 mg/kg of palbociclib for 7 days. Red arrows 
indicate double-membraned autophagosomes. Blue arrows indicate multi-lamellate structures 
indicative of dysfunctional lysosomes. Scale bars equal 500 nm. All data represent mean±SD from 
three independent experiments; p-values were calculated in comparison to mice treated with 
vehicle (Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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4.3. DISCUSSION  
 Collectively, results from this chapter demonstrate that genetic downregulation of 
CDK4/6 and pharmacological inhibition via palbociclib induces autophagy in a dose-dependent 
manner. Palbociclib treatment of ER positive breast cancer induces ROS, which at low doses 
triggers autophagy, while elevated levels lead to the induction of sustained growth inhibition 
and induction of senescence (Figure 27B).  
 While the relationship between CDK4/6-cyclin D and autophagy is very poorly 
understood, recent studies have suggested that CDK4/6 inhibitors such as palbociclib can 
induce autophagy in fibroblast and promyelocytic leukemia as described in detail in the 
introduction of this chapter (Brown, Jeselsohn et al. 2012, Capparelli, Chiavarina et al. 2012, 
Acevedo, Vernier et al. 2016). Studies conducted in this chapter provided detailed evidence 
corroborating this hypothesis and establishing that palbociclib treatment of the ER positive cell 
lines in fact does trigger autophagy. Further, a biphasic effect on autophagy was observed with 
palbociclib treatment, both in vitro and in vivo, wherein at lower or on-target doses, the 
autophagy induced had an intact flux, while higher and possibly off-target doses of palbociclib 
induced a defective autophagy (Figure 27A).  
 However, the molecular mechanism by which autophagy is induced by palbociclib has 
not been understood yet. A possible mechanism could be that the drug directly regulates 
autophagy by altering expression of the autophagic proteins required for this process such as 
Beclin-1 or other class III PI3K proteins that are present in complex with Beclin-1, such as 
Vps34 (Hammond, Brunet et al. 1998). Phophorylation of Beclin-1 and / or Vps34 has been 
shown to regualate the induction of autophagy in cancer, CDKs have been known to directly 
phosphorylate these proteins (Abrahamsen, Stenmark et al. 2012). This suggests a potential 
mechanism by which palbociclib induces autophagy that needs to be explored further. 
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Figure 27: Working model: A) Schematic showing the biphasic (on-target vs off-target 
effect of palbociclib on ER+ breast cancer cells, with respect to the induction of autophagy. 
B) Schematic showing the mechanism by which palbociclib regulates ROS, autophagy and 
senescence in ER+ve breast cancer.  
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 A recent study in lung cancer revealed that palbociclib has unique kinase targets, apart 
from CDK4 and CDK6, such as PIK3CD and PIK3R4 (Sumi, Kuenzi et al. 2015). Intriguingly, 
PIK3R4 / Vps15 is a class III Phosphatidylinositol 3-Kinase (PI3K) that has been shown to be 
required for autophagic clearance of proteins, and defects in Vps15 in the skeletal muscles 
leads to autophagic vascular myopathy and dysfunctional lysosomes (Lindmo, Brech et al. 
2008, Nemazanyy, Blaauw et al. 2013). This closely resembles the multi-lamellar electron 
dense structures which represent defective lysosomes when treated with the higher doses 
(5uM in vitro and 150 mg/kg in vivo) of palbociclib. Hence, it is highly likely that Palbociclib hits 
secondary targets at the higher concentrations (5uM or 150mg/kg), and this accounts for the 
inhibition of autophagic flux at these doses and the observed off-target effects with siRNA 
against CDK4/6. This might also explain why treatment with the other CDK4/6 inhibitors 
(ribociclib and abemaciclib) failed to elicit a biphasic response, given that these secondary 
kinase targets were shown to be specific to palbociclib and not hit by ribociclib (Sumi, Kuenzi et 
al. 2015). 
 Autophagy is regulated by several stress signals including oxidative stress (Poillet-
Perez, Despouy et al. 2015). Accumulation of oxidative stress induces ROS, which has been 
shown to have both a tumor promoting role and tumor suppressing role and this is most often 
controlled by the levels of ROS molecules (Azad, Chen et al. 2009, Liou and Storz 2010). 
Lower or moderate induction of ROS typically promotes cell cycle progress and stress 
response and survival processes such as autophagy (Boonstra and Post 2004). Results from 
this chapter show that the low / moderate levels of ROS induced with low doses of palbociclib, 
induces ROS-dependent autophagy in the ER positive breast cancer cells. Since autophagy 
has been shown to eliminate ROS (Scherz-Shouval and Elazar 2011), it is possible that 
autophagy induction also plays a role in maintaining the ROS levels low enough, such that it 
prevents the induction of irreversible cell cycle arrest and senescence. This will be examined in 
Chapter 5. 
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Collectively, the studies presented in this Chapter results show that palbociclib 
treatment intact autophagy in ER positive breast cancer in vitro and in vivo. Further, these 
studies suggest that the autophagy induced is a stress response to treatment with palbociclib 
and it may mediate resistance to palbociclib mediated sustained growth inhibition and 
senescence at the on-target doses. The implications of this hypothesis is that inhibition of 
autophagy could improve the efficacy of CDK4/6 inhibitor treatment, a topic that has been 
explored in detail in Chapter 5. 
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CHAPTER 5: IN VITRO AND IN VIVO SYNERGY BETWEEN CDK4/6 AND 
AUTOPHAGY INHIBITION IN ER+ BREAST CANCER 
 
5.1. INTRODUCTION 
5.1.1. AUTOPHAGY AS A STRESS RESPONSE PROCESS IN CANCER 
Autophagy, the cell’s recycling machinery, can be considered as a quality control 
mechanism within cells, which recycles damaged cellular components and organelles to 
maintain optimal cellular function and generate energy (White 2015). In established cancers, 
the physiological role of autophagy is that it is a stress response process, enabling cancer cells 
to combat various types of stresses, including nutrient deprivation, ER (endoplasmic reticulum) 
stress, DNA damage, oxidative stress and drug-induced stress (White, Mehnert et al. 2015). 
Many of these stresses are intrinsic to drug resistance suggesting that autophagy may mediate 
resistance to numerous cancer targeting therapies  
For example, studies in the past few years have demonstrated the induction of pro-
survival (oncogenic) autophagy in response to drugs such as chemotherapy and targeted 
therapy (Sui, Chen et al. 2013) Several of these agents are listed in Table 6, which lists the 
agents that have been shown to induce autophagy along with the type of stress they induce 
and the pathway the drugs activate leading to autophagy. These studies have shown that 
autophagy is induced in response to chemotherapy such as platinum agents (i.e. cisplatin and 
oxalating) in breast, ovarian and other solid cancers allowing the tumor cells to be rescued from 
the toxic effects of these therapies (Li, Hou et al. 2010, Liu, Yang et al. 2011, Sun, Chen et al. 
2011, Sasaki, Tsuno et al. 2012, Wang and Wu 2014). Similar induction of autophagy has been 
reported in response to other targeted agents such as the angiogenesis inhibitor bevacizumab, 
sarafenib in hepatocellular carcinoma (Shi, Ding et al. 2011, Guo, Li et al. 2013) and tyrosine 
kinase inhibitors such as erlotinib, NVP-BEZ235 and imatinib in glioma, lung and renal cancer 
(Shingu, Fujiwara et al. 2009, Han, Pan et al. 2011, Zhao, Yang et al. 2011, Li, Jin et al. 2013).  
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In breast cancer, autophagy has been shown to be induced and mediate resistance to 
epirubicin, aurora kinase inhibitor and antiestrogen treatment with tamoxifen (Schoenlein, 
Periyasamy-Thandavan et al. 2009, Sun, Chen et al. 2011, Zou, Yuan et al. 2012). Thus, these 
Drug Target / Stress Cancer type Reference
Aurora kinase A mTOR Breast (Zou, Yuan et al. 2012)
Suberoylanilide
hydroxamic acid 
(SAHA)
HDAC inhibitor CML (Carew, Nawrocki et al. 2007)
Tamoxifen Antiestogen Breast (Sun, Chen et al. 2011)
Epirubicin (EPI) Anthracyclines Breast (Schoenlein, Periyasamy-Thandavan et al. 2009)
5-Fluorouracil Thymidylate synthase inhibitor Colorectal
(Li, Hou et al. 2010, Sasaki, 
Tsuno et al. 2012)
Irinotecan MAPK14/p38α Colorectal (Paillas, Causse et al. 2012)
Cisplatin Genotoxic stress
Esophageal (Liu, Yang et al. 2011)
Ovarian (Wang and Wu 2014)
Oxaliplatin Genotoxic stress Hepatocellular carcinoma (Guo, Li et al. 2013)
Bevacizumab Angiogenesis inhibitor
Hepatocellular 
carcinoma (Guo, Li et al. 2013)
Sorafenib ER stress Hepatocellular carcinoma (Shi, Ding et al. 2011)
High-mobility group 
box 1 protein 
(HMGB1)
DAMP molecule CML (Zhao, Yang et al. 2011)
Gefitinib or Erlotinib EGFR tyrosine kinase inhibitor Lung (Han, Pan et al. 2011)
Topotecan Genotoxic stress Lung (Kang, Tang et al. 2010)
NVP-BEZ235 PI3K/AKT/mTOR inhibitor Renal (Li, Jin et al. 2013)
Ursolic acid Genotoxic stress Prostate (Shin, Kim et al. 2012)
Imatinib Tyrosine kinase inhibitor Glioma
(Shingu, Fujiwara et al. 
2009)
Table 6: Drug-induced autophagy in cancer: Summary of studies showing the induction of pro-
survival autophagy in response to chemotherapy and targeted therapy in cancers.
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studies indicate that autophagy may be a promising target in cancer, and has led to further 
research aimed at understanding the role of autophagy in response to drug induced stress.   
 
5.1.2. PHARMACOLOGICAL INHIBITORS OF AUTOPHAGY  
For autophagy process to be successful in recycling components, the autophagic flux 
has to be intact and the process needs to undergo completion, which involves the formation of 
the autophagosomes and its subsequent fusion with the lysosomes leading to cargo 
degradation (Mizushima 2007). Hence, autophagy can be inhibited at multiple steps and the 
most common points of inhibition are i) initiation, where inhibitors prevent the formation of the 
autophagosomes and ii) lysosomal fusion, where inhibitors prevent the fusion of the 
autophagosomes to the lysosome, thus inhibiting the autophagic flux and resulting in 
accumulation of autophagic vesicles (Yang, Hu et al. 2013, Wang, Hu et al. 2016). Thus, 
research over the years has led to the development of drugs targeting autophagy at these two 
points of intervention (Table 7) (Sui, Chen et al. 2013, Yang, Hu et al. 2013, Wang, Hu et al. 
2016).  
Given the key role of the class III PI3K proteins in the formation of the phagophore and 
autophagosomes (initiation and elongation steps of autophagy), several drugs targeting these 
proteins have been developed including 3-Methyladenine, Wortmannin, LY294002, etc, which 
have the ability to effectively suppress autophagy (Table 7) (Yang, Hu et al. 2013). Recently, 
Spautin-1, a drug that indirectly targets the class III PI3K complexes was developed, which 
inhibits the activity of USP10 and USP13, causing proteosomal degradation of Class III PI3K 
complexes and blocking autophagy induction (Shao, Li et al. 2014). Additionally, drugs 
(MRT68921 and MRT67307) that specifically inhibit the kinase activity of Ulk1 and Ulk2 (crucial 
for phagosome formation) have also been recently developed (Sui, Chen et al. 2013).  
Drugs that inhibit the fusion of autophagosomes and lysosomes function either by 
altering the pH of the lysosomes or by targeting the vacuolar-type H (+)-ATPases (V-ATPases)  
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that are found on the lysosomal membrane (Yang, Hu et al. 2013). BaflomycinA1, a specific 
inhibitor of the V-ATPase, blocks the acidification of the lysosome and prevents maturation of 
the autophagosomes, thus inhibiting autophagic flux (Yamamoto, Tagawa et al. 1998). The 
other class of late stage autophagy inhibitors are lysosomal lumen alkalizers, which includes 
the most commonly used autophagy drugs, chloroquine (CQ) and its analog hydroxychloro- 
quine (HCQ) (Homewood, Warhurst et al. 1972, Wang, Hu et al. 2016). They prevent the fusion 
of the lysosomes with the autophagic vesicles, thus inhibiting flux and resulting in accumulation 
of autophagosomes in cells (Wang, Hu et al. 2016). These drugs are widely used as anti-
malarial and anti-rheumatoid agents and are currently the only clinically relevant autophagy 
inhibitors (Homewood, Warhurst et al. 1972). A more recently developed modified analog of 
HCQ is Lys-05, which has been shown to be 10-fold more potent as an autophagy inhibitor 
Drug Target Stage of autophagy inhibited
Chloroquine Lysosomal pH Fusion with lysosomes
Hydroxychloroquine Lysosomal pH Fusion with lysosomes
Bafilomycin A 1 Vacuolar-type H(+)-ATPase inhibitor Initiation / Expansion
3-Methyladenine Class III PI3K inhibitor Initiation / Expansion
Wortmannin Class III PI3K inhibitor Initiation / Expansion
LY294002 Class III PI3K inhibitor Initiation / Expansion
Pyrvinium Class III PI3K inhibitor Initiation / Expansion
Lys-05 Lysosomal pH Fusion with lysosomes
Spautin-1 USP10/13 inhbitor Initiation / Expansion
MRT68921, MRT67307 Ulk1/2 inhibitor Initiation / Expansion
Table 7: Autophagy targeting drugs: Table summarizing the list of that target autophagy 
and the stage in the pathway they inhibit
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than HCQ in vitro and in vivo (McAfee, Zhang et al. 2012). It inhibits autophagy similar to CQ 
and HCQ, by accumulating within and deacidifying the lysosome, resulting in impaired 
autophagy (Amaravadi and Winkler 2012, McAfee, Zhang et al. 2012).  
 While there are several drugs available for targeting autophagy, the specificity of these 
drug to the autophagy process has been under question, highlighting the need to develop more 
specific and potent autophagy inhibitors.  
 
5.1.3. CLINICAL DEVELOPMENT OF AUTOPHAGY INHIBITORS 
While there are several autophagy inhibitors that are currently used for pre-clinical 
studies (Table 7), their lack of specificity in inhibiting the autophagy pathways and high toxicity 
in vivo has limited their translation into the clinic (Sui, Chen et al. 2013). Chloroquine (CQ) and 
hydroxychloroquine (HCQ) are the only autophagy inhibiting drugs that are currently FDA 
approved for human use (Sui, Chen et al. 2013, Wang, Hu et al. 2016). Clinical studies have 
shown with CQ and HCQ have shown that compared to CQ, HCQ can be safely dose 
escalated in cancer patients (Gunja, Roberts et al. 2009). This, coupled with the strong 
rationale of targeted autophagy in cancer has led to about 175 clinical trials currently open 
around the world with HCQ, more than 90% of which are in cancers (http://clinicaltrials.gov/). 
Table 8 provides a list of the phase II clinical trials that are currently in progress with HCQ in 
combination with chemo or targeted therapy in various cancers. A recent phase I study in 22 
patients with relapsed myeloma showed that the addition of HCQ to the proteasome inhibitor 
resulted in partial response in 28% of the patients and a stable disease in 45% of the patients 
(Vogl, Stadtmauer et al. 2014). Similar phase I studies in melanoma and solid tumors showed 
that the addition of HCQ to the current therapy of mTOR or HDAC inhibitors resulted in 
improved survival and improved response (Mahalingam, Mita et al. 2014, Rangwala, Chang et 
al. 2014).  
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Cancer type Drugs Phase Identifier
Recurrent Breast 
cancer
HCQ+everolimus II NCT3132406
Breast cancer HCQ+ixabepilone I/II NCT00765765
Platinum resistant 
Ovarian cancer
HCQ+itraconazole I/II NCT03081702
NSCLC HCQ+gefitinib I/II NCT00765765
Advanced NSCLC HCQ+carboplatin, paclitaxel, bevacizumab
II NCT01649947
NSCLC HCQ+carboplatin /gemcitabine II NCT02722369
Advanced NSCLC and 
(EGFR) mutations
HCQ+erlotinib II NCT00977470
Pancreatic cancer HCQ+gemcitabine/abraxane I/II NCT01506973
Pancreatic cancer HCQ+gemcitabine I/II NCT01128296
Pancreatic cancer HCQ+gemcitabine/abraxane II NCT01978184
Pancreatic cancer HCQ+capecitabine+radiation II NCT01494155
Hepatocellular 
carcinoma
HCQ+sorafenib II NCT03037437
Prostate cancer HCQ+docetaxal II NCT00786682
Prostate cancer HCQ+abiraterone+ABT-263 II NCT01828476
Colorectal cancer HCQ+vorinostat+regorafenib II NCT02316340
Colorectal cancer HCQ+XELOX+bevacizumab II NCT01006369
Colorectal cancer HCQ+FOLFOX/bevacizumab I/II NCT01206530
Melanoma HCQ+trematinib I/II NCT02257424
Renal cell carcinoma HCQ and IL-2 I/II NCT01550367
Renal cell carcinoma HCQ and RAD001 I/II NCT01510119
Soft tissue sarcoma HCQ+sirolimus II NCT01842594
Glioblastoma HCQ+temozolomide I/II NCT00486603
Multiple myeloma HCQ+bortezomib I/II NCT00568880
CML HCQ+imatinib II NCT01227135
Table 8: Phase-II clinical trials with HCQ: Table summarizing the phase II clinical trials that 
are currently ongoing in cancers in combination with the autophagy inhibitor hydroxychloroquine
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While hydroxychloroquine is currently used as a bonafide autophagy inhibitor, a 
concern with the use HCQ is the high doses required in humans to achieve successful 
blockade of autophagy. This emphasizes the need to identify more specific, potent and 
clinically relevant inhibitors. The recently developed inhibitor Lys-05, has been shown to be 10-
fold more potent than HCQ and has a better therapeutic index (Amaravadi and Winkler 2012). 
Hence numerous phase I and II clinical trials are currently underway utilizing Lys-05 in 
combination with chemotherapy or targeted therapy in cancers (Rebecca and Amaravadi 
2016). 
 
5.1.4. GAP IN KNOWLEDGE 
While results from Chapter 4 show that CDK4/6 inhibition via palbociclib results in the induction 
of autophagy, the following questions remain:  
1. What is the role of the autophagy induced by palbociclib? Is it tumor suppressing or pro-
survival and tumor promoting? 
2. What is the impact of genetically ablating autophagy in breast cancer cells? 
3. Would pharmacological inhibition of autophagy be synergistic with palbociclib in breast 
cancer cells? 
4. Would pharmacological inhibition of autophagy be synergistic with other CDK4/6 
inhibitors (ribociclib, abemaciclib) in breast cancer cells? 
5. Would pharmacological inhibition of autophagy be synergistic with palbociclib in breast 
cancer cells? 
6. Would HCQ treatment be synergistic with palbociclib in breast cancer cells resistant to 
the aromatase inhibitors? 
7. What is the effect of combinatorial inhibition of the CDK4/6 and autophagy pathways in 
vivo? 
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Given the minimal work carried out in investigating the relationship between CDK4/6 and 
autophagy, studies conducted in this chapter are aimed at addressing the above gaps in 
knowledge.  
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5.2. RESULTS 
5.2.1. IMPACT OF BECLIN1 OR ATG5 DOWNREGULATION ON PALBOCICLIB ACTION 
To interrogate the hypothesis that autophagy protects ER positive breast cancer cells 
from palbociclib-induced senescence molecularly, we downregulated two crucial autophagy 
genes, Beclin-1 and Atg-5, which play key roles in the initiation and elongation of the 
autophagosomes respectively (Hammond, Brunet et al. 1998, Liang, Yu et al. 2001, Kang, Zeh 
et al. 2011) (Figures 28A, B). While shRNA mediate knockdown of Beclin-1 and Atg-5 had no 
significant impact on the growth of ER positive breast cancer cell lines (Figure 28C), 
downregulation of Beclin-1 or Atg-5 significantly increased the sensitivity of MCF7 and T47D 
cells to palbociclib, resulting in a 5-fold decrease in IC50 values (as measured by dose 
response assay, where cells were treated for 6 days with a 6-day recovery), when compared to 
cells with Scrambled shRNA (SCR) (Figure 28D, E). Further, cell counting assay and cell cycle 
analysis showed that Beclin-1 or Atg-5 knockdown resulted in an irreversible growth inhibition 
and irreversible G1 arrest respectively, when treated with low (on-target) doses of palbociclib 
(0.5μM and 1μM), compared to Scr cells which exhibited a reversible growth inhibition at these 
concentrations (Figure 28F, 29A). Additionally, Beclin-1 or Atg-5 knockdown significantly 
elevated SA-ß gal activity with 6 day treatment, even at low on-target palbociclib concentrations 
(1μM), indicating the induction of senescence when autophagy is ablated (Figure 29B).  
Thus, these results suggest that ablation of autophagy significantly augments the drug’s 
ability to induce a sustained growth inhibition and senescence, suggesting a pro-survival and 
drug resistance mediating role for the autophagy induced by CDK4/6 inhibition. 
 
 
 
 
 
	 127 
 
B
D
Figure 28: Impact of Beclin-1 or Atg-5 downregulation on palbociclib mediated growth 
inhibition: A) Schematic depicting locations of the shRNA sequences on the autophagy-
associated Beclin-1 and Atg5 genes. B) Western blot for Beclin-1 and Atg-5 in MCF7 and T47D 
cells after transfection with Scrambled (Scr), Beclin1 or Atg5 shRNA. C) Crystal violet OD 
measured on day 12 from drug response studies performed in MCF7 Scr and Beclin1 or Atg5 
knockdown cells. D,E) MCF7 and T47D cells with Beclin1 or Atg5 knocked down were treated with 
varying concentrations of palbociclib for 6 days and subjected to dose response assay after 6 days 
of recovery (D) and their corresponding half-maximal inhibitory concentrations (IC50) values (E). F) 
Beclin-1 or Atg5-knockdown MCF7 and T47D cells were treated with 0.5 or 1 μM of palbociclib 
(Palbo) for 6 days and recovery for 4 days (release) to examine reversibility and subjected to cell 
counting to assess proliferation. p-values were calculated in comparison to cells treated with 
Scramble shRNA [SCR] and 1 μM palbociclib. All data represent mean ±SD from three 
independent experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 29: Impact of Beclin-1 or Atg-5 downregulation on palbociclib mediated G1 
arrest and senescence: A) Cell cycle analysis to determine the percentage change in G1 
phase in Beclin-1 or Atg5-knockdown MCF7 and T47D cells treated with 0.5 or 1 μM of 
palbociclib (Palbo) for 6 days and recovery for 4 days (release) to examine reversibility. p-
values were calculated by comparing values at the end of drug treatment with those at the 
end of drug + release. B) SA-ß galactosidase assay as a measurement of senescence with 
representative images in Scr, Beclin1 or Atg5 knockdown cells treated with palbociclib for 6 
days. p-values calculated in comparison with SCR –1µM palbociclib. All data represent 
mean ± SD from three independent experiments; ns: p>0.05; *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001.
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5.2.2. SYNERGY BETWEEN siRNA OR shRNA MEDIATED KNOCKDOWN OF CDK4/6 AND 
AUTOPHAGY INHIBITION  
 Having shown that molecular ablation of autophagy sensitizes ER positive breast 
cancer cells to CDK4/6 inhibition via palbociclib, we next investigated if combined molecular 
downregulation of CDK4 and CDK6 would synergize with pharmacological autophagy 
inhibition. To interrogate this, we first downregulated CDK4 and CDK6 via siRNA mediated 
knockdown. Cell counting and clonogenic assays were performed to measure proliferation 
showed while that dual siRNA against CDK4 and CDK6 had moderate effect on cell 
proliferation, that its combination with autophagy inhibition (treatment with hydroxychloroquine) 
resulted in enhanced and synergistic growth inhibitory effect (Figure 30A - compare red to 
orange solid lines and 30B). Similarly, shRNA mediated knockdown of CDK4 and CDK6 was 
also synergistic in combination with autophagy inhibition via HCQ, resulting in significantly 
enhanced growth inhibition of the ER+ve cell lines, MCF7 and T47D (Figure 30C – compare 
red to orange lines) 
 These results show that genetic ablation of CDK4 and CDK6 is synergistic with 
pharmacological inhibition of autophagy.  
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Figure 30: Synergy between siRNA or shRNA mediated knockdown of CDK4/6 and 
autophagy inhibition: A,B) MCF7 and T47D cell lines were transfected with siNT or 
siRNA against CDK4 and CDK6 for dual knockdown and cells were treated with DMSO 
or 15uM HCQ for 6 days and subjected to A) Cell counting and B) Clonogenic assay to 
assess proliferation. C) Cell counting to asses proliferation of MCF7 and T47D cells with 
shRNA mediated dual knockdown of CDK4 and CDK6 and treatment with DMSO or 15 
μM HCQ for 6 days and recovery for 4 days. All data represent mean ±SD from three 
independent experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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5.2.3. IMPACT OF AUTOPHAGY INHIBITION ON PALBOCICLIB MEDIATED GROWTH 
INHIBITION, CELL CYCLE ARREST, ROS AND SENESCENCE 
 We next interrogated if pharmacological inhibition of autophagy would synergize with 
pharmacological CDK4/6 inhibition via low dose (on-target) palbociclib (< 2.5 µM) to induce 
senescence. To this end, MCF7 and T47D cells were treated with the autophagy inhibitor, 
Hydroxychloroquine (HCQ), in combination with low dose palbociclib (0.5μM or 1μM) for 6 days 
and recovery for 4 days, and results revealed that this combination induced a sustained and 
irreversible inhibition of growth (measured via cell counting – Figure 31A – compare purple to 
light blue lines and red to orange lines) and colony formation (Figure 31B), when compared to 
the reversible inhibition induced by palbociclib alone. Next, to examine if combined treatment of 
palbociclib (low and on-target dose) and HCQ could result in sustained and long-term growth 
inhibition, MCF7 and T47D cells were treated for 6 days and allowed to recover in the absence 
of the drug for 12 days. Results revealed that combination of palbociclib and HCQ was able to 
achieve a sustained long lasting growth inhibition, compared to low-dose palbociclib alone 
(Figure 31C – compared red to orange line).  
 Furthermore, treatment of ER positive cells (MCF7 and T47D) with low dose Palbociclib 
in combination with HCQ resulted in an irreversible G1 arrest even after 4 days of recovery in 
the absence of the drug (white bars) and was even comparable to continuous drug treatment 
for 10 days (grey bars) (Figure 31D). However, combination treatment with on-target doses of 
palbociclib (0.5 and 1uM) and HCQ did not did not trigger apoptosis, measured by Annexin V 
positivity (Figure 31E).  
 Given our previous findings that elevated ROS levels is required for palbociclib-induced 
senescence, and the known role of autophagy in protecting cells from oxidative stress by 
eliminating ROS (Kongara and Karantza 2012), we interrogated if inhibition of autophagy can 
also modulate ROS levels. Consistently, exposure of palbociclib treated ER positive breast 
cancer to the autophagy inhibitor, hydroxychloroquine (HCQ), resulted in a significant increase 
	 132 
in ROS levels (Figure 32A). This suggests that the autophagy induced by low (on-target) 
doses of palbociclib degrades ROS, accounting for the lower ROS levels and the resistance to 
the induction senescence at these concentrations. Additionally, a significant increase in SA-ß 
gal activity (Figure 32B) and a shift in side-scatter (Figure 32C), upon treatment with the 
combination of palbociclib and HCQ, when compared to treatment with palbociclib alone, 
demonstrating the synergistic effect of the two drugs in inducing senescence.  
Taken together, these results suggest that autophagy induced in response to palbociclib 
eliminates ROS and has a pro-survival role in ER positive breast cancer. Hence, 
pharmacological inhibition of autophagy via HCQ induces a synergistic response when 
combined with palbociclib treatment, resulting in a sustained growth inhibition and significantly 
elevated senescence. 
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Figure 31: Impact of autophagy inhibition on palbociclib mediated growth inhibtion and G1 
arrest: A,B) MCF7 and T47D cells were treated with combination of palbociclib and 15µM 
hydroxychloroquine (HCQ) for 6 days. Cells were allowed to recover for 4 or 6 days in drug-free 
media and subjected to A) Cell counting and B) Clonogenic assay. C) Effect on cell viability when 
treated with a combination of DMSO or palbociclib (Palbo - 0.5 or 1 μM) and autophagy inhibitor 
hydroxychloroquine (HCQ; 15 μM) for a) 6 days and allowed to recover for 12 days to examine 
long-term reversibility. p-values were calculated in comparison to cells treated with 1 μM
palbociclib. D,E) MCF7 and T47D cells were treated with 15 μM HCQ and/or palbociclib (0.5 or 1 
μM) for 6 days and subjected to D) cell cycle analysis to determine the percentage change in G1 
phase (p-values were calculated by comparing values at the end of 6 days drug treatment with 
those at the end of drug + release) and E) flow cytometry measurement of apoptotic cells (early 
apoptosis: Annexin V+/PI-; late apoptosis: Annexin V+/PI+). All data represent mean ±SD from 
three independent experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 32: Impact of autophagy inhibition on palbociclib induced ROS and 
senescence: MCF7 and T47D cells were treated with 15 μM HCQ and/or palbociclib (0.5 or 
1 μM) for 6 days and subjected to A) CellROX assay to measure cellular reactive oxygen 
species (ROS) levels and it quantification (Mean fluorescence intensity), B) Quantification of 
SA-ß gal assay to measure senescence and representative images and C) measurement 
and quantification of side scatter analysis to assess cellular granularity. All data represent 
mean ± SD from three independent experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.
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5.2.4. SYNERGY BETWEEN AUTOPHAGY INHIBITION (HCQ) AND OTHER CDK4/6 
INHIBITORS – RIBOCICLIB AND ABEMACICLIB 
 Given that autophagy inhibition synergizes with palbociclib to induce a sustained growth 
inhibition, we next wanted to examine the effect of other clinically available CDK4/6 inhibitors, 
abemaciclib and ribociclib. We first performed dose response studies by treating the ER 
positive breast cancer cells, MCF7 and T47D, with ribociclib and abemaciclib (range of 
concentrations from 0.01 to 12uM) for 6 days (Figure 33A), which revealed the IC50 values of 
the two drugs to be ~4uM and 1.4uM respectively (Figure 33B). Next, the effect of the 
combination treatment of ribociclib or abemaciclib along with the autophagy inhibitor, HCQ in 
MCF7 and T47D cells was examined cell counting and colony formation / clonogenic assay 
with treatment for 6 days and recovery for 4 or 6 days to examine reversibility of the drug 
mediated effect. Results revealed the combined treated of CDK4/6 and autophagy inhibitors 
induced a sustained inhibition of growth and colony formation when compared to control (no 
treatment) or treatment with single drugs alone (Figures 33C-F). Additionally, co-treatment of 
abemaciclib with autophagy inhibition (HCQ) resulted in significant apoptosis in a dose-
dependent manner, when compared to treatment with abemaciclib alone (Figure 33G).  
These results show that CDK4/6 inhibitors other than palbociclib also synergize with 
autophagy inhibition to induce an irreversible growth arrest or apoptosis, in the case of 
abemaciclib. 
 
 
 
 
 
 
	 136 
 
 
B
Figure 33: Synergy between autophagy inhibition (HCQ) and other CDK4/6 inhibitors – ribociclib 
and abemaciclib: A,B )Proliferation of MCF7 and T47D cells treated with DMSO or increasing 
concentrations (conc) of ribociclib or abemaciclib (0.01 to 12 μM) for 6 days (A) and their corresponding 
half-maximal inhibitory concentration (IC50) values (B). C,D) Cell counting (C) Clonogenic assay (D) to 
assess proliferation of MCF7 and T47D cells treated with a combination of DMSO (Cnt) or ribociclib (1 or 5 
μM) and 15 μM hydroxychloroquine (HCQ) for 6 days and recovery for 4 or 6 days. E,F) Cell counting (E) 
and Clonogenic assay (F) to evaluate proliferation upon combined treatment with 5 μM abemaciclib and 
HCQ for 6 days and recovery for 4 or 6 days. G) Flow cytometry measurement of apoptosis (early 
apoptosis: Annexin V+/PI-; late apoptosis: Annexin V+/PI+) in cells treated with 5μM abemaciclib combined 
with 15 μM HCQ for 6 days. p-values were calculated in comparison to cells treated with DMSO (Control). 
All data represent mean ±SD from three independent experiments; ns: p>0.05; *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001. 
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5.2.5. SYNERGISM BETWEEN PALBOCICLIB AND OTHER AUTOPHAGY INHIBITORS  
Finally, we interrogated if autophagy inhibitors other than hydroxychloroquine also 
synergize with low dose palbociclib to mediate sustained growth inhibition. To this end, we 
utilized four additional autophagy-inhibiting drugs, which target the autophagy pathway at 
different stages (Table 7): i) Chloroquine (a lysosomal blocker that acts similar to 
hydroxychloroquine), ii) Lys05, a potent and selective autophagy inhibitor that blocks the 
lysosomal fusion with the autophagosomes (McAfee, Zhang et al. 2012), iii) BaflomycinA1, a 
drug that inhibits the fusion of autophagosomes and lysosomes (Yamamoto, Tagawa et al. 
1998) and iv) Spautin-1, which inhibits activity of USP10 and USP13, causing proteosomal 
degradation of Class III PI3K complexes and blocking autophagy induction (Shao, Li et al. 
2014) (Figure 34A).  
Results revealed that treatment of ER positive breast cancer cells (MCF7 and T47D) 
with the combination of low-dose or on-target dose of palbociclib and the autophagy inhibitors 
that target the lysosomal fusion, CQ or BaflomycinA1 results in an irreversible arrest of growth 
(measured by cell counting assay where cells are treated for 6 days with a 4 day recovery in 
the absence of the drug) and colony formation (with 6 day treated and 6 day recovery), when 
compared to the single drug or no treatment (Cnt) controls (Figures 34B-D). Combination 
treatment of palbociclib with the upstream autophagy inhibitor, Spautin-1 also resulted in a 
similar synergistic effect with low-dose palbociclib resulting in an irreversible and sustained 
inhibition of growth and colony formation (Figures 35A,B). Finally, treatment of on-target doses 
of palbociclib with the more potent autophagy inhibitor, Lys-05 also results in an irreversible 
growth inhibition (measured by cell counting assay) when compared to treatment with 
palbociclib alone (Figure 35C – compare red to orange lines).  
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Collectively, these results confirm the synergy between CDK4/6 and autophagy 
inhibitors in ER positive breast cancer cell lines, irrespective of the drug used to achieve the 
pharmacological inhibition. 
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B
Figure 34: Synergism between palbociclib and other autophagy inhibitors (CQ, 
BafA1): A) Schematic of the autophagy pathway indicating the points of genetic and 
pharmacological interventions described in Fig. 2. B,C) MCF7 and T47D cells were treated 
with 1μM palbociclib and 15μM chloroquine (CQ) for 6 days and allowed to recover for 4 or 
6 days. The effects on growth were examined by cell counting (B) and clonogenic assay 
(C). D,E) Cell counting (B) and Clonogenic assay (C) was used to assess proliferation of 
MCF7 and T47D cells treated with a combination of 1μM palbociclib and 1nM Bafilomycin 
(BafA1) for 6 days and allowed to recover for 4 or 6 days. All data represent mean ±SD 
from three independent experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.
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B
Figure 35: Synergism between palbociclib and other autophagy inhibitors (Spautin-
1, Lys-05): A, B) cell counting (A) and Clonogenic assay (B) in MCF7 and T47D cells 
treated with 10µM spautin-1 or 1nM bafilomycin-A1 (Baf-A1) combined with 1µM 
palbociclib for 6 days and recovery for 4 or 6 days. C) Cell counting to assess proliferation 
of MCF7 and T47D cells treated with the combination of 1 μM palbociclib and 7.5 μM Lys-
05 for 6 days. Cells were allowed to recover for 4 days to examine reversibility. All data 
represent mean ±SD from three independent experiments; ns: p>0.05; *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001.
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5.2.6. SYNERGY BETWEEN CDK4/6 AND AUTOPHAGY INHIBITOR IN AROMATASE 
INHIBITOR RESISTANT CELLS 
 Advanced ER positive breast cancer patients who are currently being treated with the 
CDK4/6 inhibitor, palbociclib have in most cases received prior therapy including aromatase 
inhibitors such as letrozole and anastrazole. Hence, we wanted to examine the sensitivity of 
aromatase resistant cells to CDK4/6 inhibition as a single agent and in combination with 
autophagy inhibitors. To do so, we made MCF7 aromatase expressing cells resistant to 
letrozole or anastrazole by long term treatment with the respective drugs. Dose-response 
studies showed that the letrozole resistant cells were 10-fold resistant to letrozole and 
anastrazole resistant cells were 6-fold resistant to anastrazole (Figure 36A). 
 Interestingly the aromatase inhibitor resistant MCF7 and T47D cells remained sensitive 
to palbociclib as a single agent (Figure 36B), exhibiting IC50 values for palbociclib comparable 
to that of the parental cells (Figure 36C). Further, palbociclib treatment of the letrozole and 
anastrazole resistant cells resulted in a dose-dependent growth inhibition similar to that 
observed in the MCF7 aromatase expressing parental cells (Figure 36D). Further, 
monodansylcadavarine (MDC) staining revealed induction of autophagy in response to 
palbociclib treatment in the letrozole and anastrazole resistant MCF7 cells (Figure 36E). 
Therefore, similar to the MCF7 parental cells, the aromatase resistant (letrozole or anastrazole) 
were highly responsive to the combination of palbociclib and autophagy inhibition, resulting in 
an irreversible and sustained growth inhibition even with low and on-target doses of palbociclib 
(Figure 36F). 
Thus, these results show that the aromatase inhibitor resistant cells remain sensitive to 
CDK4/6 inhibition and highlights the clinical utility of the drug combination in the aromatase 
inhibitor resistance setting. 
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Figure 36: Synergy between CDK4/6 and autophagy inhibitors in aromatase inhibitor 
resistant cells: A) Half-maximal inhibitory concentration (IC50) values of letrozole and anastrazole 
in parental vs letrozole or anastrazole resistant cells respectively. B, C) Dose-response studies (B) 
in MCF7 parental, letrozole and anastrazole resistant cells by treating with varying concentrations 
of palbociclib for 6 days and recovery for 6 days, and their corresponding IC50 values (C). MCF7 
parental and letrozole or anastrazole resistant cells were treated with varying concentrations of 
palbociclib (Palbo) for 6 days with recovery for 4 days and subjected to D) cell counting to assess 
cell proliferation, E) flow cytometry to quantify monodansylcadavarine (MDC) staining, a marker of 
autophagic vesicles and F) cell counting to measure growth inhibition combination with 15μM 
hydroxychloroquine (HCQ) for 6 days. All data represent mean ±SD from three independent 
experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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5.2.7. SYNERGY BETWEEN PALBOCICLIB AND AUTOPHAGY INHIBITION BY HCQ IN 
VIVO 
 Having shown the synergy between CDK4/6 and autophagy inhibitor in vitro, we 
interrogated if concomitant treatment of mice with an autophagy inhibitor and low dose 
palbociclib can mediate a synergistic response. Previously, we showed that palbociclib induces 
autophagy with an intact flux at 25mg/kg (Figure 20), which provided the optimal dose of 
palbociclib for the combination study. To this end, MCF-7T cells were injected into the 
mammary fat pad of nude mice, once the tumors grew to an average size of 250mm3, we 
randomized them into 4 treatment arms: (i) vehicle, (ii) hydroxychloroquine (60mg/kg), (iii) low 
dose palbociclib (25mg/kg/day) and (iv) HCQ + palbociclib (25mg/kg/day). Mice were treated 
for 21 days (treatment phase) and maintained for an additional 21 days without treatment 
(recovery phase) to examine the ability of the drug treatment to induce a sustained tumor 
growth inhibition (Figure 37A). 
Results revealed that mice treated with combination of low dose palbociclib and HCQ 
had significantly decreased tumor volume at the end of treatment, compared to single drug or 
vehicle arms (Figure 37B-D – at the end of 21-day treatment phase). More strikingly, the tumor 
volumes in the HCQ + palbociclib combination arm did not increase even after the treatment 
was stopped, while the tumor volumes in the palbociclib alone arm readily increased during the 
end of the treatment phase and during the recovery phases of the experiment (Figure 37B-D – 
at the end of the treatment + recovery phase). A concomitant decrease in tumor weight was 
observed with the palbociclib + HCQ combination arm both at the end of the treatment and the 
treatment + recovery phases compared to the vehicle or the single treatment controls. These 
results suggest that co-treatment with HCQ enabled the induction of a sustained tumor growth 
inhibition even at a low dose (25mg/kg) of palbociclib, which is one-fifth the dose of palbociclib 
(150mg/kg) used in most preclinical studies (Fry, Harvey et al. 2004, Michaud, Solomon et al. 
2010, Wardell, Ellis et al. 2015). 
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To illustrate the induction of a cell cycle arrest and senescence at the end of the 21 day 
treatment phase, we examined the protein levels of cell cycle proteins Rb and pRb via western 
blot analysis, which showed that combination treated led to a more significant decrease in both 
Rb and pRb compared to treatment with palbociclib alone (Figure 38A). Additionally, RPPA 
analysis of tumors post 3 weeks of treatment demonstrated a significant enrichment for the  
senescence and growth inhibition related proteins and a significant decrease in cell cycle 
related proteins in the combination treatment arm, when compared to no treatment arms and 
palbociclib alone arm (Figure 38B,C). As a proof of autophagy inhibition with the palbociclib + 
HCQ combination arm, western blot analysis showed impaired autophagic flux as indicated by 
increased LC3B-II levels and no decrease in p62, when compared to palbociclib alone arm, 
which confirmed the induction of autophagy with 21 days treatment with palbociclib (Figure 
38A).  
Further, immunohistochemistry (IHC) analysis showed that combination treatment with 
palbociclib and HCQ significantly increased SA-ß gal activity (marker of senescence) and 
decreased expression of BrdU (a proliferation marker) at the end of the 21 day treatment period 
and following the 21 day recovery phase, while the vehicle and HCQ arms showed no change 
in BrdU or SA-ß gal staining (Figures 39A,B). The palbociclib alone arm, on the other hand, 
showed an increase in SA-ß gal and decrease in BrdU staining only at the end of the 21 
treatment period, while these levels increased at the end of the recovery phase, demonstrating 
that palbociclib only induces a reversible tumor growth inhibition as a single agent (Figures 
39A,B). Moreover, palbociclib + HCQ in vivo treatment resulted in significantly higher ROS 
levels (measured by IHC by 8-OHdG and 4-HNE staining) at the end of both treatment and 
recovery phases compared to the vehicle and HCQ treatment, while palbociclib alone treatment 
arm exhibited a moderate increase in ROS levels only at the end of the treatment phase 
(Figures 39A,C,D). 
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Lastly, we examined the tolerability and the toxicity of the drug treatments in mice by 
examining the changes in body weight and complete blood counts (given the induction of 
neutropenia and leukopenia in patients) at the end of the treatment and treatment + recovery 
phases. Measurement of mice weight every day during the 21-day treatment phase showed no 
significant changes in body weight in any of the treatment arms including the combination arm 
(Figure 40A). Additionally, analysis of the complete blood count profile revealed no significant 
changes in WBC, RBC, platelet, Neutrophils. RBC and WBC differential count in any of the 
treatment arms (including combination treatment), at the end of the treatment and treatment + 
recovery phases (Figures 40B-D). These results suggest that the administered drug 
treatments, including the combination of HCQ and low dose palbociclib, were well tolerated by 
the mice at both time intervals assessed (treatment and treatment + recovery). 
Collectively, these results suggest that autophagy inhibition (via HCQ) synergizes with 
low doses of palbociclib to induce an irreversible tumor growth inhibition in mice xenograft 
tumors in vivo. 
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Figure 37: Synergy between palbociclib and autophagy inhibition by HCQ in vivo: A) Schematic 
showing treatment schedule of orthotopic MCF7-T xenograft mice with vehicle (veh; 0.5% 
methylcellulose and PBS), 60 mg/kg hydroxychloroquine (HCQ), 25 mg/kg palbociclib (Palbo); or 
combination of palbociclib (25mg/kg) and hydroxychloroquine (60mg/kg) for 21 days (treatment 
phase), followed by a recovery phase of 21 days without treatment. B,D) Percentage change in mean 
(B) or individual (D) tumor volumes (normalized to Day 0) upon treatment as described in A at the end 
of treatment and treatment + recovery phases. C) Representative images of tumors harvested at the 
end of the treatment phase and at the end of the recovery phase. E) Tumor weights measured at the 
end of treatment phase and treatment + recovery phase (n=6 mice/treatment group). All data represent 
mean±SD; p-values were calculated in comparison to mice treated with vehicle (Control) unless 
indicated. ns:p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 38: Impact of palbociclib and autophagy inhibition on cell cycle, senescence 
and autophagy in vivo: A) Western blot analysis of tumors harvested post treatment with 
vehicle (Cnt), 60 mg/kg hydroxychloroquine (HCQ), 25 mg/kg palbociclib (Palbo) or 
combination of palbociclib (25mg/kg) and hydroxychloroquine (60mg/kg) for 21 days to 
measure expression of cell cycle (phospho-Rb, Rb) and autophagy (LC3B, p62) proteins. 
B,C) Pathway score and expression (normalized log2 expression level) of individual proteins 
belonging to the cell cycle (n=10 proteins) and senescence pathways (n=13 proteins) 
determined from RPPA analysis of tumors harvested after treatment as described in A. All 
data represent mean±SD; p-values were calculated in comparison to mice treated with 
vehicle (Control) unless indicated. ns:p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 39: Impact of palbociclib and autophagy inhibition on growth, senescence and ROS in 
vivo: A) Representative images of hematoxylin and eosin (H&E), BrdU, 8-hydroxydeoxy-guanosine 
(8-OHdG), 4-hydroxynonenal (4-HNE) and senescence-associated SA-ß gal immunohistochemical
staining on tumor tissues harvested at the end of the 21 days treatment with vehicle, 60 mg/kg 
hydroxychloroquine (HCQ), 25 mg/kg palbociclib (Palbo) or combination of palbociclib and HCQ, or 
post 21 days of recovery in the absence of drug. Scale bars equal 50 μm. B) Quantification of BrdU 
positive cells or H-score of 8-OHdG and 4-HNE staining on tumors harvested at the end of treatment 
phase and treatment + recovery phase. All data represent mean±SD; p-values were calculated in 
comparison to mice treated with vehicle (Control) unless indicated. ns:p>0.05; *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001.
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Figure 40: Toxicity profile of palbociclib and autophagy inhibitor treatment in vivo: 
A) Mean mouse weight and Weight of individual mice upon 21 days treatment with vehicle, 
60 mg/kg hydroxychloroquine (HCQ), 25 mg/kg palbociclib (Palbo) or combination of 
palbociclib and HCQ. Mice were treated for 21 days as described in A and blood samples 
collected at the end of treatment phase and at the end of the treatment + recovery phase 
(21 days post treatment) and subjected to B) complete blood counts (red blood cells [RBC], 
white blood cells [WBC], platelets, and neutrophils [Neutro]), C) RBC differential counts and 
D) WBC differential count. All data represent mean±SD; p-values were calculated in 
comparison to mice treated with vehicle (Control) unless indicated. ns:p>0.05; *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001.
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5.2.8. SYNERGY BETWEEN PALBOCICLIB AND AUTOPHAGY INHIBITION (LYS-05) IN 
VIVO 
Having showing the in vivo synergy between CDK4/6 and autophagy inhibition via HCQ, 
we wanted to further confirm the synergy of the combination in vivo using another autophagy 
inhibitor, Lys05, a more potent inhibitor of autophagy compared to HCQ (McAfee, Zhang et al. 
2012). To first examine the toxicity profile of Lys-05 as a as a single agent, non-tumor bearing 
mice were treated with varying concentrations of Lys-05 (1mg/kg, 5mg/kg, 10mg/kg or 
20mg/kg) every day for 21 days and the mouse weight and their blood count were analyzed to 
examine toxicity. Results show that treatment with different doses of Lys-05 had no deleterious 
effect on mouse weight over the 21-day treatment period (Figure 41A). Similarly, there was no 
difference in the complete blood counts, RBC and WBC differential counts upon treatment with 
the varying concentrations of Lys-05 (Figures 41B-D). 
Next, xenograft tumor-bearing mice (established by mammary fat pad injection of 
MCF7T cells and tumors were allowed to reach an average of 200mm3) were treated with 
vehicle, 10mg/kg/day Lys05 (chosen based on previous studies showing autophagy inhibition 
at this dose), 25mg/kg/day palbociclib or the combination of palbociclib and Lys05 for 21 days 
(treatment phase) with a recovery phase of 14 days. Treatment with the combination of 
palbociclib + Lys05 significantly decreased tumor volume during both the treatment and 
recovery phases, compared to no treatment (vehicle) or treatment with Lys-05 or palbociclib as 
a single agent (Figures 42A,B). Further, combination treatment with palbociclib + Lys-05 
resulted in significantly smaller tumors (Figure 42D) with lesser tumor weight (Figure 42C), 
compared vehicle or single treatment controls. Treatment with the combination of palbociclib 
and Lys-05 also resulted in prolonged mouse survival, with none of the mouse tumors reaching 
1000mm3, compared to the other treatment arms, whose tumors grew to above 1000mm3 and 
had to be sacrificed prior to the end of the experiment at 35 days (Figure 42E).   
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Collectively, these results demonstrate that autophagy inhibition mediated by an 
alternative inhibitor, Lys-05 also synergizes with low doses of palbociclib to induce irreversible 
tumor growth inhibition in vivo. 
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Figure 41: Toxicity profile of Lys-05 in vivo: A) Weight of individual non-tumor bearing 
mice treated with varying concentrations of Lys-05 daily for 21 days via I.P (n=2 
mice/treatment group). Mice were treated for 21 days as described in A and blood samples 
were collected at the end of treatment and subjected to B) complete blood counts (red 
blood cells [RBC], white blood cells [WBC], platelets, C) RBC differential counts and D) 
WBC differential count. All data represent mean±SD; p-values were calculated in 
comparison to mice treated with vehicle (Control) unless indicated. ns:p>0.05; *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001.
3 6 9 12 15 18 21
10
15
20
25
30
35
40
Days after treatment
M
ou
se
 W
ei
gh
t (
g)
1 mg/kg Lys05 
5 mg/kg Lys05 
10 mg/kg Lys05 
20 mg/kg Lys05 
WBC (x103) RBC (x106) Platelet (x105)
0
2
4
6
8
10
12
14
C
ou
nt
 / 
ul
Complete Blood Count
1 mg/kg Lys05 
5 mg/kg Lys05 
10 mg/kg Lys05 
20 mg/kg Lys05 
Neutro Lymphs Monos Eos
0
20
40
60
80
Pe
rc
en
ta
ge
 o
f W
B
C
White Blood Cell Diff. Count
1 mg/kg Lys05 
10 mg/kg Lys05 
20 mg/kg Lys05 
5 mg/kg Lys05 
Hgb 
(g/dl)
Hematocrit 
(%)
MCV 
(fL)
MCH 
(pg)
MCHC 
(g/dL)
RDW 
(%)
0
20
40
60
80 Red Blood Cell Diff Count
B
	 153  
B
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Figure 42: Synergism between palbociclib and Lys-05 mediated autophagy inhibition 
in vivo: A,B) Percentage change in mean (A) or individual (B) tumor volumes (normalized 
to Day 0) upon treatment with Vehicle, 5mg/kg palbociclib, 10mg/kg Lys-05 or combination 
of palbociclib and Lys-05 daily for 21 days (treatment phase) and recovery phase of 14 
days. Data represented as Mean±SEM. n≥5 for each group. C) Weights od tumors 
harvested after treatment and recovery as described in A. D) Representative pictures of 
tumors harvested after 21 days treatment and 14 days recovery. E) Kaplan Meier survival 
curve with death and tumors exceeding 1000mm3 as endpoint upon treatment as in A. n≥5 
for each group. F,G) Mean mouse weight (F) and weight of individual mice )G) during 21 
days treatment phase. All data represent mean±SD; p-values were calculated in 
comparison to mice treated with vehicle (Control) unless indicated. ns:p>0.05; *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001.
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5.3. DISCUSSION 
Collectively, studies in this chapter demonstrate that inhibition of autophagy significantly 
improves the efficacy of CDK4/6 inhibition and effectively induces a sustained growth inhibition 
and senescence in vitro and in vivo, even at low doses of palbociclib (Figure 43).  
 While research has shown opposing roles for autophagy – as a pro-survival and a pro-
death mechanism, numerous recent studies have highlighted the importance of autophagy as a 
mediator of drug resistance, specifically in breast cancer (Chen, Jiang et al. 2013, Chittaranjan, 
Bortnik et al. 2014, Lefort, Joffre et al. 2014). These studies have shown an association 
between high expression of autophagy proteins like LC3B and tumor aggressiveness, providing 
strong rationale for using autophagy inhibitors to combat drug resistance. Further, while 
previous studies with the CDK4/6 inhibitor palbociclib, suggested a potential induction of 
autophagy with drug treatment (Capparelli, Chiavarina et al. 2012), the role of the autophagy 
induction was not examined. Hence this chapter provides a detailed analysis of drug induced 
autophagy performed by downregulating autophagy genes Atg-5 and Beclin-1 and using 
numerous pharmacological inhibitors of autophagy to show that targeting autophagy 
significantly improves the efficacy of palbociclib treatment.  
 A potential issue with the molecular ablation of autophagy via Beclin-1 knockdown 
might arise from the fact that Beclin-1 has been shown to have autophagic independent 
functions in cancer (Rohatgi and Shaw 2016). Recent study shows that apart from its role in 
autophagy, Beclin-1 can also regulate growth factor signaling pathways such as Pi3K (Rohatgi 
and Shaw 2016). However, we observed similar results with both Atg5 and Beclin1 knockdown, 
which would eliminate the possibility of autophagy independent functions of Beclin1 playing a 
role in this scenario. Another issue that might be of concern is the specificity of the autophagy 
inhibiting drugs utilized in the study. To address this, we employed 5 different autophagy drugs 
in vitro, which target the pathway at multiple sites (Autophagosome initiation -  Spautin-1;  
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lysosome fusion – CQ, HCQ, Lys-05 and Baf-A1 (Wang, Hu et al. 2016)), all which yielded 
similar results. We even performed in vivo xenograft studies with two different  
autophagy inhibitors, HCQ and Lys-05, both of which showed a similar synergistic effect 
between CDK4/6 and autophagy inhibition.  
  Further, the in vivo drug dose used for palbociclib in most preclinical studies is 150 
mg/kg, which translates to plasma concentration of 7.7uM, significantly higher than the clinically 
achievable dose of 3.4 µM (Pfizer-Inc-and-Affiliates 2011). Our study with the combination of 
CDK4/6 and autophagy inhibition was able to reduce the dose of palbociclib to one-fifth the 
dose - 25mg/kg (1.4uM plasma concentration and corresponds to low and on-target dose used 
in cell lines), and still achieve significance tumor inhibition. Thus, the combination treatment 
Figure 43: Working Model: Schematic showing the synergistic effect 
between CDK4/6 and autophagy inhibitors in ER+ve breast cancer cells in 
vitro and in vivo resulting in senescence.
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strategy that we have identified in this study (palbociclib + HCQ) has the potential to 
significantly improve palbociclib efficacy, while lowering toxicity mediated by palbociclib. 
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CHAPTER 6: BIOMARKER IDENTIFICATION FOR PALBOCICLIB AND ITS 
COMBINATION WITH AUTOPHAGY INHIBITOR IN ER+ BREAST CANCER 
 
6.1. INTRODUCTION 
6.1.1. RB PROTEIN IN BREAST CANCER 
 The retinoblastoma (Rb) protein is a major regulator of the G1/S checkpoint of the cell 
cycle and consists of two family members, the Rb-like proteins, p107 and p130 (Weinberg 
1995). These proteins, known as pocket proteins, bind to the transcription factor, E2F, keeping 
it in its inactive state and preventing transcription of E2F target genes (Weinberg 1995). Thus, 
Rb serves as a molecular determinant as to whether the cells would pass through the G1/S 
checkpoint and a tumor suppressor (Giacinti and Giordano 2006). Given its tumor suppressive 
function, Rb is often inactivated in cancers, via mutations or partial deletions among other 
mechanism (Giacinti and Giordano 2006). In breast cancer, the inactivation of the Rb pathway 
occurs by loss of heterozygosity of the Rb gene, seen in about 20 to 30% of breast cancers, or 
due to other mutually exclusive mechanisms that affect the Rb pathway (Ertel, Dean et al. 
2010). This includes amplification of the cyclin D genes (CCND1) seen in over 50% of breast 
cancers, which results in aberrant phosphorylation and inactivation of Rb (Arnold and 
Papanikolaou 2005). Further, inactivation of the CKI, p16 (CDKN2A) also contributes to the 
deregulation and silencing of Rb (Dublin, Patel et al. 1998). A recent study showed that in ER 
positive breast cancer cells, knockdown of Rb makes the cells resistant to the anti-proliferative 
action of tamoxifen in vitro and the anti-tumor effect of the drug in vivo, establishing a link 
between deregulation of Rb and endocrine resistance (Bosco, Wang et al. 2007). This was 
verified by an analysis of tumor tissues from post-menopausal breast cancer patients treated 
with tamoxifen. Which showed that deregulation of Rb correlated with high Ki67 staining, an 
indication that there tumors were resistant to tamoxifen treatment (Lehn, Ferno et al. 2011).  
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6.1.2. CYCLIN E AND LMWE IN BREAST CANCER 
 Cyclin E, when bound to CDK2, phosphorylates Rb and is a key regulator of cellular 
progression through the G1/S checkpoint (Sherr 1994). Cyclin E is overexpressed 
(independent of subtype) and amplified (MDA-MB-157 cell line) in breast cancer cell lines when 
compared to normal mammary epithelial cells (Keyomarsi and Pardee 1993). Amplification or 
overexpression of cyclin E in breast cancer mediates resistance to trastuzumab and endocrine 
therapy, and is a predictor of poor prognosis in these patients (Keyomarsi, Tucker et al. 2002, 
Scaltriti, Eichhorn et al. 2011, Caldon, Sergio et al. 2012).  
 Moreover, post-translational modification (proteolytic cleavage) of the full length cyclin E 
by the serine protease, elastase, generates a more oncogenic form of the protein termed as 
Low Molecular Weight isoforms of cyclin-E (LMWE) (Keyomarsi, Conte et al. 1995, Wang, 
Rosales et al. 2003). Cleavage of full length cyclin E generates four isoforms of the protein, 
comprising of two doublets, EL2 and EL3, which are collectively called as Trunk 1 (T1), and 
EL5 and EL6, collectively called as Trunk 2 (T2) (Figure 44) (Mull, Cox et al. 2009). LMWE, 
which was originally discovered in breast cancer by our laboratory, and subsequently by others 
(Taneja, Maglic et al. 2010, Tokai, Maeda et al. 2011, Mombelli, Cochaud et al. 2015, 
Montazeri, Bouzari et al. 2015), has recently been the subject of a number of review 
articles(Loeb and Chen 2012, Moore 2013, Rath and Senapati 2014). These isoforms are also 
found in ovarian (Bedrosian, Lu et al. 2004, Davidson, Skrede et al. 2007), melanoma(Bales, 
Mills et al. 2005), colorectal(Corin, Di Giacomo et al. 2006, Milne, Carvalho et al. 2008, Corin, 
Larsson et al. 2010, Zhou, Xie et al. 2011), lung(Koutsami, Tsantoulis et al. 2006), and renal 
cell carcinomas(Nauman, Turowska et al. 2007). Numerous studies have been conducted to 
elucidate the biological role of LMWE. Studies show that while both full length and low forms of 
cyclin E can bind to and activate CDK2 kinase activity, the LMWE isoforms are able to bind 
stronger to CDK2 and exhibit increases kinase activity (Harwell, Mull et al. 2004). 
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This was detected in both breast cancer cell lines and human tumor tissue samples. 
(Harwell, Mull et al. 2004). This results hyperphosphorylation of Rb, which makes the LMWE 
resistant tumors resistant to inhibition by the endogenous CKIs, p21 and p27 (Akli, Zheng et al. 
2004). Moreover, this makes the cell or tumors resistant to anti-estrogens, induce higher 
genomic instability and mediate resistance to fulvestrant and letrozole (Harwell, Porter et al. 
2000, Akli, Zheng et al. 2004, Wingate, Puskas et al. 2009, Akli, Bui et al. 2010). To further 
understand the significance of LMWE in breast cancer, transgenic animal models with EL and 
LMWE under the MMTV promoter were generated, which showed that LMWE transgene 
expressing mice had increased mammary tumorigenesis compared to full length (EL) 
transgene (Akli, Van Pelt et al. 2007). Further, introduction of LMWE in HMEC cells lines 
resulted in increased ability of these cell to form tumors in nude mice compared to EL 
expressing cells (Duong, Akli et al. 2013). Cells overexpressing LMWE were also shown to 
have enrichment of the of EMT phenotype and increased expression of breast cancer stem 
cells (CD44high/CD24low subpopulation of cells) compared to full length (EL) expressing cells 
(Duong, Akli et al. 2013).  
Our laboratory also reported an analysis of 395 patients with breast cancer in which it 
was demonstrated that overexpression of LMWE, as measured by Western blot analysis, is 
associated with distant metastases and reduced overall survival (Keyomarsi, Tucker et al. 
Figure 44: Low molecular weight isoforms of cyclin E (LMWE): Schematic 
showing how elastase generates LMWE by cleaving the full length cyclin E protein at 
two sites
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2002). Subsequently, our laboratory discovered that LMW-E, which now lacks its N-terminus 
nucluear localization signal is now localized predominantly in the cytoplasm, where it binds to 
CDK2 and has greater kinase activity than full-length cyclin E (Delk, Hunt et al. 2009). This 
finding was further verified by a recent study in 1676 breast cancer patients revealed that 40% 
of all breast cancer patients exclusively expressed the cytoplasmic form of cyclin E (Delk, Hunt 
et al. 2009). This finding was further verified by a recent study in 1676 breast cancer patients 
revealed that 40% of all breast cancer patients exclusively expressed the cytoplasmic form of 
cyclin E, with majority of these patients (85.1%) also expressing for cytoplasmic p-CDK2 
(Karakas, Biernacka et al. 2016). More importantly, this study also showed that cytoplasmic 
expression of cyclin-E (LMWE expression) is strongly associated with higher histologic tumor 
grade and worse prognosis compared to other patients, demonstrating the utility of LMWE or 
cytoplasmic cyclin E as a reliable prognostic indicator in breast cancer (Karakas, Biernacka et 
al. 2016), which can be functionally attributed the overexpression and mislocalization (to the 
cytoplasm) of these proteins.    
 
6.1.3. PRE-CLINICAL BIOMARKER STUDIES FOR PALBOCICLIB IN BREAST CANCER 
 Identification of a reliable biomarker that can predict response is necessary for all 
targeted therapy, to improve the selectivity and the efficacy of the drug treatment. Hence, 
numerous pre-clinical studies in breast and other cancers have been carried out to identify 
reliable predictive biomarkers of response for CDK4/6 inhibitors such as palbociclib (Asghar, 
Witkiewicz et al. 2015). Multiple studies have shown that an intact Rb pathway is required for 
the CDK4/6 inhibitor mediated cell cycle arrest and senescence and hence proteins belonging 
to the Rb pathway proteins such as Rb, cyclin D, p16 and cyclin E have been identified as 
biomarkers in vitro (Wiedemeyer, Dunn et al. 2010, Konecny, Winterhoff et al. 2011, Cen, 
Carlson et al. 2012). A study examined palbociclib treatment in a range of breast cancer cells 
and analyzed the gene expression profile of sensitive cell lines in comparison with resistant 
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cells (Finn, Dering et al. 2009). Results revealed that the sensitive cells had significantly higher 
expression of cyclin D1, Rb1 and lower expression levels of p16 compared to the resistant cells 
(Finn, Dering et al. 2009). Further, studies in glioblastoma and ovarian cancer cell lines and 
xenografts showed that the presence of Rb and loss of p16 dictate response to palbociclib 
(Konecny, Winterhoff et al. 2011, Cen, Carlson et al. 2012). Moreover, a study in ovarian 
cancer shows that expression of cyclin E mediates resistance to palbociclib treatment and can 
hence serve as a biomarker (Taylor-Harding, Aspuria et al. 2015). Additionally, a recent study 
with palbociclib in breast cancer showed that development of early adaptation (intrinsic 
resistance) and acquired resistance to palbociclib is characterized by Rb loss and cyclin E 
(CCNE1) amplification (Herrera-Abreu, Palafox et al. 2016). This study also showed the 
resistant cells failed to decrease phosphor-Rb upon treatment with palbociclib (Herrera-Abreu, 
Palafox et al. 2016). Finally, studies with abemaciclib show that the presence of estrogen 
receptor (ER) and Rb can predict response to abemaciclib (Patnaik, Rosen et al. 2016). 
Unfortunately, while numerous biomarkers have been suggested based on pre-clinical studies, 
none have been effective in predicting CDK4/6 inhibitor response in the clinic and this will be 
discussed in detail in the next chapter.  
 
6.1.4. GAP IN KNOWLEDGE 
While previous pre-clinical studies have suggested biomarkers for CDK4/6 inhibition, this was 
shown to be ineffective in the clinic, highlighting the need for more clinical relevant biomarkers. 
Thus, the following questions remain:  
1. What is the importance of the G1/S checkpoint in response to CDK4/6 inhibitors? 
2. Which proteins within the G1/S checkpoint have the best prediction value for palbociclib 
response?  
3. Is p53 required for response to palbociclib in ER positive breast cancer?  
4. Is Rb required and sufficient to predict sensitivity to palbociclib? 
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5. Can cyclin E and its low molecular weight isoforms mediate resistance to palbociclib? 
6. Can the status of G1/S checkpoint proteins (Rb and LMWE) be utilized to predict 
sensitivity to the combination of palbociclib and autophagy inhibitors? 
7. Can the status of Rb and LMWE be utilized to predict sensitivity to the triple 
combination of palbociclib, aromatase inhibitor and autophagy inhibitor? 
Thus, experiments in this chapter are aimed at directly addressing these gaps in knowledge.  
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6.2. RESULTS 
6.2.1. GENE SET ENRICHMENT ANALYSIS TO IDENTIFY BIOMARKERS FOR 
PALBOCICLIB IN BREAST CANCER  
To identify biomarker(s) of response to palbociclib as a single agent and the 
combination of palbociclib and HCQ combination, we examined the gene expression of cell 
lines known to be sensitive or resistant to palbociclib (Finn, Dering et al. 2009), focusing on the 
cell cycle and autophagy pathways. Gene set enrichment analysis (GSEA) of the 
Kegg_Regulation_of_Autophagy gene set showed no distinct gene expression signature 
between the palbociclib sensitive and the resistant cells (Figure 45A). This indicates that while 
breast cancer cells activate autophagy in response to palbociclib treatment, the basal 
expression of the autophagy genes in breast cancer cell lines may not be able to predict 
responsiveness of the cells to CDK4/6 inhibition. 
Examination of the Biocarta_Cell_Cycle Pathway gene set via GSEA analysis produced 
a distinct gene expression signature between the palbociclib sensitive and resistant breast 
cancer cell lines (Figure 45B). Palbociclib sensitive cell lines exhibited low expression of 
CDKN2A / p16 and high expression of Cyclin-D1, which corroborates previous in vitro and pre-
clinical studies with palbociclib in breast and other cancers (Konecny, Winterhoff et al. 2011, 
Cen, Carlson et al. 2012) (Figure 45C – highlighted in purple). Notably, a striking correlation 
was observed between sensitivity to palbociclib and the expression of both Rb and Cyclin-E; 
with the Palbociclib sensitive cell lines displaying high levels of Rb and low expression of 
Cyclin-E (Figure 45C - blue arrows).  
These results led us to hypothesize that Cyclin-E expression in combination with Rb 
may serve as effective biomarkers to predict response to palbociclib as a single agent and the 
combination of CDK4/6 and autophagy inhibitors.  
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B
Figure 45: Gene set enrichment analysis to identify biomarkers for palbociclib in breast 
cancer: A,B) Heat map constructed using the Gene Set Enrichment Analysis (GSEA) program, 
denoting expression of genes from the KEGG Regulation of autophagy (A) and Biocarta Cell Cycle (B) 
gene sets in the indicated breast cancer cell lines, classified as being sensitive or resistant to 
palbociclib. C) Heat map denoting the top unregulated and downregulated genes within the Biocarta
cell cycle gene set when comparing palbociclib sensitive and resistant cell lines
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6.2.2. ROLE OF p53 IN DETERMINING RESPONSE TO PALBOCICLIB IN ER+ BREAST 
CANCER 
p53 is a tumor suppressor gene that plays a key role in maintaining the integrity of the 
G1/S checkpoint and has been shown to be a predictor of palbociclib response in glioma 
(Barton, Misuraca et al. 2013). Given the status of p53 in the two ER positive cells lines utilized 
in this study (MCF7- WT p53; T47D- heterozygous p53 mutant), and their comparable 
sensitivity to palbociclib, we hypothesized that p53 may not play a role in predicting sensitivity 
to the CDK4/6 inhibitor in ER positive breast cancer.  
To interrogate this, western blot analysis of the p53 pathway proteins (p53 and Mdm2) 
were performed, which revealed no alteration in their protein levels upon treatment with 
palbociclib for 6 days (Figure 46A). Further, p53 was downregulated in the MCF7 cell lines 
using two independent shRNAs (Figures 46B,C). shRNA mediated p53 knockdown did not 
alter the sensitivity of MCF7 cells to palbociclib (Figure 46D), with no significant change in 
IC50 values of palbociclib in MCF7 parental p53 knockdown cells (Figures 46E,F). 
Thus, these results indicate that p53 does not play a significant role in mediating 
sensitivity to CDK4/6 inhibition in ER positive breast cancer.    
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Figure 46: Role of p53 in determining response to palbociclib in ER+ve breast cancer: 
A) Western blot analysis in MCF7 cells treated with varying concentrations of palbociclib to 
determine the expression of p53 pathway proteins: p53 and Mdm2. B) Schematic showing 
the location of the shRNA against p53 on the gene. C) Western blot showing the expression 
of p53 in the Scr and p53 knockdown (#1, #2) cells. D) Dose response assay to examine the 
effect of treatment with c. All data represent mean±SD from three independent experiments; 
p-values were calculated in comparison to cells treated with DMSO (Control) unless 
indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. MCF7 p53 knockdown 
cells were generated by Dr. Dong Yang, post-doc in the Keyomarsi lab
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6.2.3. ROLE OF RB IN MEDIATING PALBOCICLIB INDUCED ROS AND SENESCENCE 
Given the role of Rb and its downstream effectors in regulating senescence, autophagy 
and ROS (Macleod 2008, Chicas, Wang et al. 2010, Jiang, Martin et al. 2010, Anders, Ke et al. 
2011, Imai, Takahashi et al. 2014), we hypothesized that Rb plays a crucial role in mediating 
palbociclib action by regulating ROS, autophagy and senescence, and hence could serve as a 
predictor of sensitivity to CDK4/6 inhibition.  
 To directly test this hypothesis, we downregulated Rb in MCF7 and T47D cells via 
shRNA mediated stable knockdown (Figure 47A,B). Treatment of Control (Scrambled – SCR) 
or Rb knockdown MCF7 or T47D cells with increasing concentrations of palbociclib revealed a 
significant reduction in sensitivity to palbociclib (Figure 47C), with a 4 to 6 fold increase in IC50 
values (Figures 47D,E). Further, ablation of Rb abolished the ability of palbociclib mediated 
CDK4/6 inhibition to induce a decrease in colony formation (Figure 47F) or a sustained growth 
inhibition (Figure 47G) upon treatment for 6 days and recovery for 4 or 6 days, compared to 
the scrambled shRNA cells.  
Moreover, while palbociclib treatment of Rb knockdown MCF7 and T47D cells induced 
a G1 arrest, the cell cycle arrest was readily reversible, indicating the necessity of Rb 
expression to mediate palbociclib induced irreversible G1 arrest (Figure 48A).  Next, given the 
ability of ROS in regulating both palbociclib induced autophagy and senescence, and the role 
of Rb in mediating these two processes, we interrogated if Rb also modulates the ability of 
palbociclib to induce oxidative stress via ROS. Results revealed that shRNA mediated 
knockdown of Rb in MCF7 and T47D cells significantly reduced the ability of ER positive breast 
cancer cells to increase cellular ROS levels upon treatment with palbociclib, when compared to 
the Scrambled shRNA cells (Figure 48B). Additionally, downregulation of Rb in ER positive 
breast cancer cell lines also prevented the induction of senescence upon long term (6 days) 
treatment with palbociclib (Figure 48C).  
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Taken together, these results demonstrate the vital role of Rb in mediating palbociclib-
induced irreversible growth inhibition, cell cycle arrest, ROS and senescence in ER positive 
breast cancer cell lines, highlighting the potential utility of Rb as a biomarker for CDK4/6 
inhibition. 
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B
Figure 47: Role of Rb in mediating palbociclib induced growth inhibition: A) Schematic 
depicting locations of the shRNA sequences on the Rb1 gene. B) Western blot showing levels of 
Rb protein in MCF7 and T47D cells after transfection with shRNA for Scrambled (Scr) or Rb.  C-E) 
Impact of knocking down Rb on the growth of MCF7 and T47D treated with DMSO or increasing 
concentrations (conc) of palbociclib (0.01 to 12 μM) for 6 days (C) and their corresponding half-
maximal inhibitory concentration (IC50) values. F,G) Clonogenic (F) and cell counting (G) assay in 
Rb-knockdown MCF7 and T47D cells treated with DMSO (Cnt) or palbociclib (1 or 5 μM) for 6 
days and allowed to recover for 4 or 6 days. All data represent mean±SD from three independent 
experiments; p-values were calculated in comparison to cells treated with DMSO (Control) unless 
indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 48: Role of Rb in mediating palbociclib induced ROS and senescence: Rb-
knockdown MCF7 and T47D cells were treated with varying concentrations of palbociclib (Palbo) 
for 6 days and allowed to recover for 4 days (release) to examine reversibility. Cells were then 
subjected to A) cell cycle analysis to determine the percentage change in G1 phase (p-values 
were calculated by comparing values at the end of drug treatment with those at the end of 
release), B) CellROX assays to measure cellular ROS levels and C) Senescence activity by SA-
ß-gal assay with representative picture. All data represent mean±SD from three independent 
experiments; p-values were calculated in comparison to cells treated with DMSO (Control) 
unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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6.2.4. ROLE OF RB IN MEDIATING PALBOCICLIB INDUCED AUTOPHAGY 
Since recent studies have demonstrated a role for the Rb-E2F pathway in regulating 
autophagy in tumor cells (Tracy, Dibling et al. 2007, Jiang, Martin et al. 2010), we next asked if 
Rb might also regulate the induction of autophagy by palbociclib. Monodansylcadavarine 
(MDC) staining revealed that shRNA knockdown of Rb abolished the ability of ER positive 
breast cancer cells (MCF7 and T47D) to induce autophagy in response to palbociclib 
treatment, as demonstrated by the absence of double-membrane autophagic vesicles (Figure 
49A) and the lack of a significant increase in MDC staining (Figure 49B).  
Further, treatment with the autophagy inhibitor, hydroxychloroquine (HCQ) in 
combination with palbociclib had no significant effect on the colony formation of ER positive 
cells when Rb was knocked down, compared to treatment with palbociclib alone (Figure 49C). 
Additionally, the combination of palbociclib and HCQ had no significant impact on the 
proliferation of MCF7 and T47D cells (Figure 49D).  
These results suggest that Rb is required for palbociclib-induced autophagy and 
substantiates the role of autophagy as a stress response process that is triggered by the ER 
positive breast cancer cells only under conditions in which Palbociclib elicits a growth inhibitory 
effect. Moreover, this suggests that Rb could serve as a biomarker of sensitivity to the 
combination of CDK4/6 and autophagy inhibitors in ER breast cancer 
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A
Figure 49: Role of Rb in mediating palbociclib induced autophagy: A) 
Representative TEM microphotograph of parental (Par) and Rb-knockdown 
MCF7 and T47D cells treated with DMSO or 1 µM palbociclib for 6 days. Scale 
bars equal 500nm. B) Flow cytometry to quantify monodansylcadavarine (MDC) 
staining, a marker of autophagic vesicles in Rb-knockdown MCF7 and T47D 
cells treated with palbociclib for 6 days. C,D) Rb-knockdown MCF7 and T47D 
cells were treated with the combination of 1µM palbociclib and 15µM 
hydroxychloroquine (HCQ) for 6 days, allowed to recover for 6 or 4 days and 
subjected to Clonogenic assay (C) and Cell counting (D).
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6.2.5. ROLE OF LMWE IN MEDIATING PALBOCICLIB ACTION 
 While our findings suggest that Rb is required for the growth inhibitory action of 
palbociclib and its combination with autophagy inhibition, results from recent studies focusing 
on biomarker discovery indicate that Rb alone may not be sufficient to effectively predict patient 
response to palbociclib (DeMichele, Clark et al. 2015). Results from our GSEA analysis (Figure 
50) indicate that expression of cyclin E correlates with sensitivity to palbociclib in breast cancer 
cell lines. Moreover, since Rb loss is not common in ER positive breast cancer, we also 
interrogated the role of cyclin E in predicting sensitivity to CDK4/6 inhibition. As described in 
the introduction to this chapter, our laboratory discovered that LMWE, the elastase mediated 
proteolytic cleavage products of full length cyclin E, are oncogenic, uniquely expressed in 
tumors, hyperphosphorylate Rb, and are strong prognostic indicators in breast cancer. 
(Keyomarsi, Conte et al. 1995, Wingate, Puskas et al. 2009, Akli, Bui et al. 2010, Hunt, 
Karakas et al. 2016, Karakas, Biernacka et al. 2016). 
 Hence, to interrogate if high Cyclin-E, particularly the LMWE isoforms could mediate 
resistance to palbociclib, we overexpressed either empty vector (Vec), full length Cyclin-E (EL) 
or the LMW-E isoforms in MCF7 and T47D cell lines (Figure 50A). Results revealed that 
expression of LMW-E, but not full length Cyclin-E significantly reduced the sensitivity of the ER 
positive breast cancer cells, MCF7 and T47D to palbociclib (Figure 50B), with a 4 to 6 fold 
increase in IC50 values when compared to Vector and full length cyclin E (EL) (Figures 50C, 
D). Furthermore, expression of LMW-E, but not full length Cyclin-E, bypasses the ability of 
palbociclib to inhibit colony formation (Figure 50E) or exert irreversible growth inhibition 
(Figure 50F) in ER positive breast cancer cell lines.  
 Next, to examine the effect of LMW-E and full length cyclin E expression on palbociclib 
mediated cell cycle arrest, we performed flow cytometry and examined the expression of key 
cell cycle proteins following palbociclib treatment in EL or LMW-E overexpressing cells. Results 
showed that LMW-E expression but not full length cyclin E mediated resistance to palbociclib 
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mediated induction of G1 arrest (Figure 51A) and decrease in cell cycle proteins, pRb and Rb 
(Figure 51B). Further, expression of LMW-E abolished the ability of palbociclib to induce a 
dose-dependent increase in cellular ROS levels, in comparison with Vector and full length 
cyclin E (EL) expressing cell lines (Figures 51C,D). Expression of LMW-E thus prevented the 
ability of palbociclib mediated CDK4/6 inhibition to induce senescence in the ER positive breast 
cancer cells (Figures 52A,B).  Finally, to interrogate if Rb downregulation would further 
decrease sensitivity of LMW-E expressing cells to palbociclib, we downregulated Rb in the 
T47D cells expressing Vector, full length cyclin E (EL) or LMW-E and dose-response studies 
showed that downregulation of Rb further decreased sensitivity to palbociclib in the LMW-E 
expressing T47D cells, with an increase in IC50 value from ~5.5 to ~7.5uM (Figure 52C). 
 Collectively, these results demonstrate that expression of the low molecular weight 
isoforms of cyclin E (LMWE) mediate resistance to CDK4/6 inhibition via palbociclib, and 
indicate that LMWE could serve as a selective biomarker to identify ER positive breast cancer 
cells responsive to palbociclib treatment.     
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Figure 50: Role of LMWE in mediating palbociclib action: A) Western blot showing levels 
of cyclin E protein in MCF7 and T47D cells stably overexpressing full-length cyclin E (EL) or 
low-molecular-weight isoforms of cyclin E (LMW-E). Par, parental cells; Vec, vector-
transfected cells. B-D) Impact of overexpressing vector, EL, or LMW-E on the growth of MCF7 
and T47D cells treated with DMSO or increasing concentrations (conc) of palbociclib (0.01 to 
12 μM) for 6 days (B) and their corresponding half-maximal inhibitory concentration (IC50) 
values. E,F) MCF7 and T47D cells overexpressing vector, EL, or LMW-E were treated with 
DMSO (Cnt) or varying concentrations of palbociclib (Palbo) for 6 days and recovery for 4 and 
6 days, and subjected to clonogenic (E) and cell counting assay (F) to assess cell 
proliferation. All data represent mean±SD from three independent experiments; p-values were 
calculated in comparison to cells treated with DMSO (Control) unless indicated. ns:p>0.05; 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. EL and LMWE expressing cells were generated 
with the help of Dr. Said Akli from the Keyomarsi lab.
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Figure 51: Role of LMWE in mediating palbociclib induced ROS and G1 arrest: MCF7 and 
T47D cells overexpressing vector, EL, or LMW-E were treated with DMSO (Cnt) or varying 
concentrations of palbociclib (Palbo) for 6 days and subjected to A) cell cycle analysis to examine 
the change in G1 phase and B) western blot analysis of Rb and p-Rb expression, markers of cell 
cycle arrest. C) Cellular reactive oxygen species (ROS) levels and its quantification (mean 
fluorescence intensity – MFI) measured in vector, EL, or LMW-E overexpressiong MCF7 or T47D 
cells treated with DMSO or palbociclib (1 μM or 5 μM) for 6 days. D) Quantification of ROS levels 
by MFI in Scramble (Scr) or Rb-knockdown (KD) MCF7 and T47D cells treated with DMSO or 
palbociclib (1 μM or 5 μM) for 6 days. All data represent mean±SD from three independent 
experiments; p-values were calculated in comparison to cells treated with DMSO (Control) unless 
indicated. ns:p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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values calculated from dose response studies in T47D cells expressing Vector, EL or LMW-
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6.2.6. LMWE AS A MEDIATOR OF RESISTANCE TO THE COMBINATION OF CDK4/6 AND 
AUTOPHAGY INHIBITOR 
 Having shown that LMWE expression mediates resistance to the growth inhibitory 
action of palbociclib as a single agent, and that autophagy is a drug response observed in ER 
positive breast cancer cells, we wanted to examine if the LMWE could also serve as a marker 
of resistance to the combination of palbociclib and autophagy inhibition. To interrogate this, we 
treated MCF7 and T47D cells expressing empty vector, full length cyclin E (EL) or low 
molecular weight isoforms of cyclin E (LMWE) with the combination of low-dose (on target 
dose) of palbociclib and Hydroxychloroquine. The combination treatment while being 
synergistic to mediate irreversible and sustained growth inhibition in Vector and EL expressing 
cells, had no impact on the growth of palbociclib treated LMW-E cells (Figure 53).  
This indicates that LMWE apart from being a biomarker to identify the ER positive 
breast cancer cells that respond to palbociclib as a single agent, can serve as a reliable 
biomarker for the combination of CDK4/6 and autophagy inhibition. 
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Figure 53: LMWE as a mediator of resistance to the combination of CDK4/6 and 
autophagy inhibitors: Cell counting was used to assess growth of MCF7 and T47D cells 
stably overexpressing Vector, EL, or LMW-E upon treatment with DMSO, palbociclib, 15μM 
hydroxychloroquine (HCQ) or the combination of palbociclib + HCQ for 6 days with recovery 
for 4 days to examine reversibility. All data represent mean±SD from three independent 
experiments; p-values were calculated in comparison to cells treated with DMSO (Control) 
unless indicated. ns:p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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6.2.7. LMWE AS A MEDIATOR OF RESISTANCE TO THE TRIPLE COMBINATION OF 
CDK4/6, LETROZOLE AND AUTOPHAGY INHIBITOR 
Since the CDK4/6 inhibitor palbociclib is currently used clinically in combination with the 
aromatase inhibitor letrozole in advanced ER positive breast cancer patients, we wanted to 
interrogate how palbociclib and letrozole combination compares to our proposed combination 
of palbociclib and HCQ. Treatment of MCF7 aromatase expressing cells with the combination 
of palbociclib and letrozole induced autophagy at levels similar to that of palbociclib treatment 
alone (Figure 54A), indicating the potential to examine the effect of the triple combination of 
palbociclib, letrozole and HCQ in ER positive breast cancer. Treatment of MCF7 aromatase 
expressing cells with the combination of palbociclib and HCQ had a significantly higher growth 
inhibitory effect (measured by cell counting and effect on long term colony formation), 
compared to palbociclib and letrozole as a single agent or in combination (Figure 54C,D). 
Further, treatment with the triple combination of palbociclib, letrozole and HCQ exhibited the 
highest reduction in colony formation (Figure 54C) and the induction of irreversible growth 
inhibition (Figure 54D).  
Further, we overexpressed empty vector (Vector) or LMWE in MCF7 aromatase 
expressing cells (Figure 54B), in order to examine the impact of LMWE expression on the 
triple combination treatment. Results showed that expression of LMWE, but not empty vector in 
MCF7 cells mediated resistance to the ability of the combination of palbociclib and letrozole 
and the triple drug combination to inhibit colony formation (Figure 54E) and induce of a 
sustained and irreversible growth inhibition (Figure 54F). 
 Thus, these results show that the proposed combination of CDK4/6 and autophagy 
inhibitor is more effective in mediating a sustained growth inhibition than the currently clinically 
used combination (i.e. CDK4/6i + aromatase inhibitors), and, and demonstrates that LMWE 
expression can also serve as a biomarker for the potential triple combination of CDK4/6, 
aromatase and autophagy inhibitor. 
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B C
Figure 54: LMWE as a mediator of resistance to the triple combination of CDK4/6, 
letrozole and autophagy inhibitor: A) Measurement of monodansylcadavarine (MDC) 
positive acidic vesicles, including autophagosomes, by flow cytometry in MCF7 aromatase 
expressing cells treated with 1 μM palbociclib in combination with 1 μM letrozole for 6 days. B) 
Western blot showing levels of cyclin E and aromatse protein in MCF7 cells stably 
overexpressing aromatase (Par) and empty vector (Vec) or low-molecular-weight isoforms of 
cyclin E (LMW-E). C,D) Clonogenic (C) and Cell counting (D) assay to assess proliferation 
upon treatment with 1µM palbociclib, 1µM letrozole and 15µM HCQ in the indicated 
combinations. E,F) Impact of overexpressing empty vector (Vec) or LMWE in MCF7 aromatase 
expressing cells measured by clonogenic (E) and cell counting (F) assay following treatment 
with 1µM palbociclib, 1µM letrozole and 15µM HCQ in the indicated combinations. All data 
represent mean±SD from three independent experiments; p-values were calculated in 
comparison to cells treated with DMSO (Control) unless indicated. ns:p>0.05; *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. Aromatase expressing cells were generated by Dr. Iman 
Doostan, graduate student from the Keyomarsi lab. 
+ HCQ
Cnt
Let    
Palbo
Palbo
+ Let
0 3 6 10
0
2
4
6
8
25
50
Days
C
el
l N
um
be
r (
 x
10
5 )
MCF7
Cnt
HCQ 
Let
Let + HCQ
Palbo + Let
Palbo + Let 
+ HCQ
Palbo
Palbo + HCQ
*
**
0 3 6 10
0
2
4
6
8
20
40
Days
C
el
l N
um
be
r (
 x
10
5 )
MCF7 LMW-E
Cnt
Let    
Palbo
Palbo
+Let
MCF7 LMWE
+ HCQ
0 3 6 10
0
2
4
6
8
10
25
50
Days
C
el
l N
um
be
r (
 x
10
5 )
MCF7 Vector
Cnt
HCQ 
Let
Let + HCQ
Palbo + Let
Palbo + Let 
+ HCQ
Palbo
Palbo + HCQ
*
*
Full length
Cyclin-E
Aromatase
Par    Vec LMWE
LMW-E
Actin0
20
40
60
80
%
 o
f M
D
C
 +
ve
 c
el
ls
Letrazole (1µM)
Palbociclib (1µM)
-
- -
-+
+
+
+
****
****
ns
Cnt
Let    
Palbo
Palbo
+Let
MCF7 Vec
+ HCQ
A
D E
F
	 182 
 
6.3. DISCUSSION 
Taken together, results from this chapter highlight that the G1/ S checkpoint is crucial 
for response to palbociclib, and that deregulation the G1/S point pathway proteins, either by 
loss of Rb or expression of low molecular weight isoforms of Cyclin E (which deregulates the 
checkpoint by hyperphosphorylating Rb) mediates resistance to the drug and its combination 
with autophagy inhibitor (Figure 55).  
Numerous studies have shown that the expression of Rb protein is required for breast 
cancer and other tumors to be sensitive to treatment with the CDK4/6 inhibitors, recent findings 
have shown that Rb alone is insufficient to effectively predict patient response to palbociclib 
(DeMichele, Clark et al. 2015). Further, since the loss or deregulation of Rb is not common in 
the ER positive subtype of breast cancer, it is crucial to identify a secondary or more reliable 
biomarker. Thus, results from this chapter show that the Rb and LMWE together can serve as 
reliable biomarkers for predicting response to palbociclib and its combination with autophagy 
inhibitors in vitro.  
Further, while our results suggest that Rb might play a direct role in regulating ROS, the 
molecular mechanism by which this occurs remains unclear. Recent reports have shown that 
the downstream targets of Rb such as FOXM1 and BIRC5 (Survivin) can negatively regulate 
oxidative stress (Kwee, Luque et al. 2008, Park, Carr et al. 2009, Lim, Heo et al. 2015), 
providing a novel link between Rb and the ROS machinery. This suggests that downregulation 
of FOXM1 and BIRC5, among other ROS regulating proteins might be the potential mechanism 
by which Rb regulates oxidative stress, under palbociclib treatment conditions, and this 
demands further investigation. 
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CHAPTER 7: RB AND CYCLIN E AS PROGNOSTIC BIOMARKERS OF 
PALBOCICLIB ACTION IN ADVANCED ER+ BREAST CANCER PATIENTS 
 
7.1. INTRODUCTION 
7.1.1. CLINICAL STUDIES AND BIOMARKER ANALYSIS 
 Based on pre-clinical studies, numerous biomarkers have been tested in breast cancer 
patients clinically to examine their ability to predict response to CDK4/6 inhibitors (Sherr, Beach 
et al. 2016). A summary of these clinical studies and the biomarkers tested are shown in Table 
9.  
Despite strong pre-clinical evidence, results from PALOMA-2, the randomized phase II 
clinical study testing the efficacy of combining palbociclib and letrozole showed that CCND1 
amplification and / or loss of p16 did not predict sensitivity to palbociclib, with no difference in 
progression-free survival observed between the groups (Finn, Crown et al. 2015). Further 
analysis of response data showed no significant difference in the hazard ratio even when 
separated based on the expression levels of cyclin D and p16, indicating that the sample size 
might be small to conclude the predictive value of these proteins (Finn, Crown et al. 2015). A 
similar analysis following results from a short-term pre-operative trial with palbociclib as a 
single agent showed no correlation between response to palbociclib and expression of Rb, 
CCND1 or PIK3CA (Monica Arnedos 2016). However, results showed that the non-responders 
(measured by change in Ki67) were characterized by no change in pRb levels (Monica Arnedos 
2016). A similar result was also seen with the CDK4/6 inhibitor, abemaciclib, which showed a 
significant correlation between clinical efficacy and modulation of pRb (Patnaik, Rosen et al. 
2016) 
Results from PALOMA-3, the phase III clinical trial testing the combination of palbociclib 
and fulvestrant showed that while ER positivity is required, that the expression levels of ER do  
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not correlate with response (Cristofanilli, Turner et al. 2016). Analysis from this study also 
showed that there is no correlation between response to progression-free survival and PIK3CA 
mutation or ESR1 mutations (Cristofanilli, Turner et al. 2016, Fribbens, O'Leary et al. 2016), 
indicating that palbociclib treatment is equally responsive in these mutant tumors as those not 
harboring either mutations.  Lastly, results of biomarker analysis from MONALEESA-2, the 
phase III combination study between ribociclib and letrozole showed no significant difference in 
Treatment Setting Phase n Biomarkers studied
Palbociclib early Window of opportunity  100
IHC, phospho-protein, gene 
expression, whole exome, 
TIL
Palbociclib +
Anastrazole early
Neoadjuvent
(NeoPalAna) 50
IHC, gene expression, 
PIK3CA, NGS
Abemaciclib +
Anastrazole early
Neoadjuvent
(MONARCH-3) 220 Gene expression, TIL
Palbociclib +
letrozole
Metastatic 
ET sensitive
Phase II 
randomized
(PALOMA-1)
165 CCND1 / p16 expression
Palbociclib +
letrozole
Metastatic 
ET sensitive
Phase III 
randomized
(PALOMA-2)
666 Rb, cyclin D, p16
Ribociclib +
letrozole
Metastatic 
ET sensitive
Phase III 
randomized
(MONALEESA-2)
668
Palbociclib +
fulvestrant
Metastatic 
ET resistant Registration trial 521 ESR1 mutation, PIK3CA
Abemaciclib Metastatic resistant
Phase I
(MONARCH-1) 47 Phospho-Rb
Table 9: Clinical studies and biomarker analysis: Summary of clinical studies performed in 
ER+ve breast cancer with the CDK4/6 inhibitors and the biomarkers assessed as a part of the study.
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the hazard ratio or correlation between progression free survival and expression of Rb protein, 
p16 protein, CDKN2A mRNA, CCND1 mRNA, basal Ki67 levels, ESR1 mRNA and PiK3CA 
mutation (Hortobagyi, Stemmer et al. 2016). Biomarkers to predict drug sensitivity may be 
prognostic or predictive. A prognostic biomarker measure patient outcome without comparing 
the effect of the treatment under study, while a predictive biomarker takes into account both the 
effect of the treatment and the patient outcome (Justus, Leffler et al. 2014). Thus, a prognostic 
biomarker is evaluated from a single arm study of treated patients where the response of 
patients in the presence or absence of the marker is examined, as done in this chapter. 
However, for a predictive biomarker, a double arm study is needed, to examine the response of 
patients in the presence or absence of the marker, in combination with the treatment effect 
(Justus, Leffler et al. 2014) 
 
7.1.2. GAP IN KNOWLEDGE 
While the completed and ongoing clinical studies investigated numerous biomarkers of 
response, there is still no actionable and reliable clinical biomarker that can be used a predictor 
of response for palbociclib treatments. Hence this chapter aims at addressing the following 
questions:  
1. Would the biomarkers identified in our in vitro studies (Rb and cyclin E) be successful in 
predicting response to palbociclib in patients? 
2. What proportion of the breast cancer patients would benefit from palbociclib treatment 
(based on biomarker analysis)?  
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7.2. RESULTS 
7.2.1. TCGA ANALYSIS SHOWING DEREGULATION OF RB AND CYCLIN E IN BREAST 
AND OTHER SOLID CANCER PATIENTS 
 Our in vitro and in vivo results thus far have shown Rb and cyclin E can serve as 
reliable biomarkers to identify which tumors would benefit from treatment with CDK4/6 
inhibitors and its potential combination with autophagy inhibitors. Hence, to estimate the 
percentage of patients who would benefit from the combination treatment of palbociclib and 
hydroxychloroquine, we analyzed the TCGA database for the expression of Rb and cyclin E at 
the mRNA levels.  
 Analysis of mRNA levels from the breast TCGA database, comprising of 817 breast 
cancer patients showed that about 85.4% of all breast tumors had measurable expression of 
Rb and low (no overexpression) of cyclin E (Figure 56A). Detailed analysis of the subtypes 
within breast cancer showed that a higher proportion of the ER positive breast tumors (97.1%) 
were Rb positive and cyclin E negative compared to 40.7% within the TNBC subtype (Figure 
56A). This indicates that a large proportion of breast cancer tumors are Rb+ve cyclin E-ve, and 
that they could benefit from treatment with CDK4/6 inhibitor and its potential combinations. 
 Next, we performed a similar analysis within the TCGA database for other solid tumor 
subtypes analyzed in this study. Results revealed that 80.8%, 89.3% 86.1%, 92.9% and 95.7% 
of ovarian, pancreatic, lung, colorectal and prostate cancer patients respectively are positive for 
Rb and have low / no expression of Cyclin-E (Figure 56B). This indicates that a large 
proportion of patients with these solid tumors could benefit from treatment with the CDK4/6 
inhibitor. 
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C
Figure 56: TCGA analysis showing deregulation of Rb and cyclin E in breast and 
other solid cancer patients: A) Alterations in Rb and cyclin E RNA levels in all breast 
(n=817), ER+/Luminal A and B (n=321) and TNBC/Basal (n=81) tumors from the TCGA 
database of breast cancer patients. B) Alterations in Rb and cyclin E RNA levels in tumors 
from patients with ovarian (n=557), lung (n=230), pancreas (n=178), colon (n=379), or 
prostate (n=333) cancer taken from the TCGA database. C) Plot showing correlation 
between mRNA and protein levels of Rb among 817 tumors from the TCGA database of 
breast cancer patients. 
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7.2.2. ALTERATIONS IN RB AND LMWE PROTEIN IN BREAST CANCER PATIENTS 
 While the TCGA analysis provides a reliable estimate of the proportion of patients who 
could benefit from the CDK4/6 inhibitor therapy, these analyses are based on the RNA levels of 
Rb and cyclin E. Hence, the TCGA analysis cannot accurately predict protein expression of Rb 
(Figure 56C), nor can it differentiate between full-length cyclin E (nuclear) and LMWE 
(cytoplasmic). Thus, a direct analysis based on protein expression of Rb and LMWE is required 
to accurately estimate the breast cancer who would benefit from therapy. 
To do this, we examined LMWE and Rb protein expression in tissue microarray 
samples from a cohort of 879 early stage breast cancer patients from the NCI Cancer 
Diagnosis Program (Hunt, Karakas et al. 2016, Karakas, Biernacka et al. 2016). LMWE and Rb 
staining was performed by immunohistochemistry in the formalin-fixed paraffin-embedded 
slides of breast cancer tumors from this cohort (Figure 57A). Results revealed that 33% of all 
breast tumor samples were positive for Rb and negative for LMWE (Figure 57B), indicting the 
patients who could benefit from therapy. Further, this percentage of Rb+ve LMWE-ve tumors 
was higher (40%) in the ER positive subtype compared to the TNBC (13.5%) subtype (Figure 
57B). Moreover, Kaplan Meier analysis showed that the patient groups which had deregulated 
cyclin E or LMWE, Rb+ LMWE+ (red lines) and RB- LMWE+ (purple lines) had a worse overall 
prognosis compared to the other subgroups which did not express the cytoplasmic cyclin E, 
emphasizing the prognostic ability of LMWE in breast cancer (Figure 57C). This was also true 
in both the ER positive and the TNBC subtypes (Figure 57C).  
These results suggest that over 33% of all breast cancer patients (Figure 57B) 
(regardless of ER status) may benefit from treatment with the palbociclib and its combination 
with HCQ, thus highlighting the clinical utility of this regimen.   
 
 
 
	 190 
 
 
B
Figure 57: Alterations in Rb and LMWE protein in breast cancer patients: A) Representative 
images from immunohistochemical analysis of Rb and LMW-E in tumors from the NCI patient 
cohort (n=879). Scale bars equal 50 μm. B) Percentage of breast cancer patients exhibiting 
alterations in Rb and LMW-E as determined via immunohistochemical staining of tumor samples 
from the NCI patient cohort (n=879). C) Kaplan Meier curves showing survival of breast cancer 
patients from the NCI patient cohort when classified based on Rb and LMW-E. IHC analysis was 
performed by Dr. Cansu Karakas from the Keyomarsi lab.
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7.2.3. CORRELATION BETWEEN EXPRESSION OF RB AND LMWE AND RESPONSE TO 
PALBOCICLIB IN ADVANCED ER POSITIVE BREAST CANCER PATIENTS 
 Next, we wanted to directly test the utility of Rb and LMWE protein expression as 
prognostic biomarkers in advanced metastatic breast cancer. For this purpose, we utilized a 
cohort of 493 patients with advanced ER+ breast cancer who were/are currently being treated 
with the combination of palbociclib and letrozole (aromatase inhibitor) or fulvestrant at MD 
Anderson Cancer Center (Figure 58A), whose clinical, pathological and treatment 
characteristics are detailed in Table 10,11. Since the biopsy blocks for most of these patients 
were not available at MD Anderson, the archival, pre-treatment biopsy specimens from 221 
patients from primary tumor and/or local or metastatic recurrence were obtained with consent 
for each patient. However, only 109 of the tumors obtained had tissues in sufficient amount for 
immunohistochemistry (IHC) analysis (Figure 58A). To estimate the protein expression, these 
tissues were then subjected to immunohistochemistry staining and scoring for cyclin E and Rb 
(Figure 58C).  
The majority (102/109) of the samples were positive for Rb, while only 49.5% (54/109) 
were positive for LMWE (Figure 58B). Moreover, about 50% of the treated ER breast cancer 
patients were Rb+ve and LMWE-ve, which is the group we predicted would respond best to 
CDK4/6 inhibitor therapy (Figure 58B). The Rb+ve and LMWE+ve subgroup accounted for 
about 43% of patients and Rb-ve and LMWE+ve subgroup accounted for 6.5% of patient 
tumors, and no tumors stained negative for both Rb and LMWE in the patient cohort tested 
(Figure 58B). Analysis of clinical and pathologic variables revealed that the patients with 
LMWE expression or RB loss exhibited higher rates of progression at 6 and 12 months 
(assessed by Kaplan Meier methods), with the heavily treated fulvestrant group experiencing 
greater progression rate at 12 months as expected (Table 10,11). The significant variable in 
this analysis included tumor stage at diagnosis, exposure to adjuvant chemotherapy, PR 
status, Rb and LMWE status. Among these, the expression Rb and LMWE as single variables 
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correlated significantly with progression rates for both the palbociclib with letrozole group (Rb: 
p=0.02, LMWE: p=0.01) and the palbociclib with fulvestrant treatment group (Rb: p=0.03, 
LMWE: p=0.009) (Table 10,11). Moreover, a significantly higher correlation was seen when Rb 
and LMWE expression were treated as combined variable in palbociclib with letrozole 
(p=0.006) and palbociclib with fulvestrant (p=0.009) treatment groups (Table 10,11). 
Univariate Cox proportional hazards model showed that the factors that were 
significantly associated with progression-free interval included adjuvant chemotherapy, PR 
status, Rb and LMWE status, as measured by hazard ratio, which is a measure of the influence 
a parameter under study has on the response to therapy (Table 12). Importantly, Rb and 
LMWE (as single and combined variables) were significantly associated with the progression-
free interval with in palbociclib with letrozole treatment group, with hazard ratios of 0.2 for Rb 
alone, 3.2 for LMWE alone, and 9.2 for Rb and LMWE combined (Table 12). A similar 
correlation was also observed in the palbociclib with fulvestrant treatment group, exhibiting 
hazard ratios of 0.09 with Rb alone, 5.2 with LMWE alone, and 23.8 with Rb and LMWE 
combined (Table 12). Further, results showed that 81.8% (45 out of 55 patients) of Rb+ve 
/LMWE-ve patients exhibited stable disease in response to palbociclib treatment, compared to 
62.9% in the other patient groups combined (Figure 59A). Separation of the patients based on 
their treatment with palbociclib and letrozole or palbociclib and fulvestrant showed a significant 
84.2% and 82.4% response rate (stable disease) respectively, in the Rb+ve LMWE-ve patient 
subgroup (Figure 59A). This showed that Rb and LMWE in combination have a good 
prognostic value for palbociclib treatment in breast cancer. 
Kaplan-Meier progression-free survival (PFS) plots for the 109-patient cohort separated 
based on the protein expression of Rb and LMWE revealed that the patients with Rb+ve and 
LMWE-ve tumors have the longest PFS time (median >36.5 months), compared to 
Rb+/LMWE+ patients (median= 13.4 months) and Rb-/LMWE+ patients who had the shortest 
PFS time (median= 4.2 months) (Figure 59B). A similar trend was observed when the 
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palbociclib treated ER positive breast cancer patients were separated by letrozole (n=78) or 
fulvestrant (n=31) treatment in combination, and correlated with Rb/LMWE expression, where 
Rb+ and LMWE- patients had the longest PFS time (median >36.5 months with letrozole; 10.7 
months with fulvestrant), compared to Rb+/LMWE+ patients (median= 17 months with letrozole 
and 4.7 months with fulvestrant) and Rb-/LMWE+ patients (median= 3.5 months with letrozole 
and 4.2 months with fulvestrant) (Figure 59B). Additionally, the concordance indices calculated 
based on the multivariate analysis model showed substantial gains when Rb and LMWE were 
included as single variables, compared to the model without Rb and cyclin E, and a much 
larger increase was observed upon including Rb and LMWE as combined variables (Figure 
59C and Table 13). 
Collectively, these results provide evidence that LMWE and Rb can serve as reliable 
prognostic biomarkers for CDK4/6 inhibitors in advanced estrogen receptor positive breast 
cancer patients. 
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Table 10: Clinical, pathologic, and treatment characteristics of patients 
treated with palbociclib + letrozole
Variable
N 6-month 
progression rate 
(%)
12-month 
progression rate 
(%)
P value
Univariate)
All patients 78 22.2 31.0
Race 0.3
White 55 25.1 33.2
Others 23 14.6 24.1
Clinical tumor stage at diagnosis 0.004
0/I 12 28.7 52.5
II 20 26.3 36.8
III 19 38.1 54.2
IV 25 0 0
Unknown 1 0 0
Tumor Histology 0.9
Ductal 67 21.6 31.2
Others 11 27.1 27.1
Lymphatic/vascular invasion 0.2
Yes 52 15.2 24.5
No 24 37.5 45.3
Adjuvant Chemotherapy 0.004
No 64 16.1 21.5
Yes 14 48.7 69.2
Tumor grade 0.4
I/II 57 25.3 38.9
III 21 15.3 15.3
Progesterone receptor status 0.02
Positive 69 16.2 26.2
Negative 9 70.8 70.8
Rb status 0.02
Negative 5 66.7 0
Positive 73 20.3 29.2
LMWE status 0.01
Negative 38 14.4 18.0
Positive 40 30.9 44.2
Rb/LMWE status 0.006
Rb+/LMWE- 38 14.4 18.0
Rb+/LMWE+ 35 27.4 41.4
Rb-/LMWE+ 5 66.7 0
Bone /soft tissue vs. any visceral 0.03
Bone / soft tissue 51 13.7 20.7
Any visceral 27 37.1 47.6
Prior therapy for metastatic disease 0.1
None 56 16.6 25.8
Hormonal 4 25.0 25.0
Chemotherapy and/or hormonal 18 40.9 50.7
Time from completion of adjuvant hormonal therapy 
(years)
0.2
None (de novo metastatic) 42 15.8 23.5
< 1 year 5 0 0
> 1 year 31 33.0 42.9
*p value calculated after excluding unknown. 
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Table 11: Clinical, pathologic, and treatment characteristics of patients 
treated with palbociclib + fulvestrant
Variable
N 6-month 
progression 
rate (%)
12-month 
progression rate 
(%)
P value
Univariate
All patients 31 17.4 58.0
Race 0.9
White 25 15.9 63.8
Others 6 20.0 20.0
Clinical tumor stage at diagnosis 0.2
0/I 7 0 33.3
II 7 20.0 40.0
III 11 14.3 31.4
IV 6 46.7 -
Tumor Histology 0.7
Ductal 25 15.3 54.4
Others 6 25.0 -
Lymphatic/vascular invasion 0.8
Yes 15 16.4 61.0
No 16 17.5 45.0
Adjuvant Chemotherapy 0.06
No 16 25.0 80.3
Yes 15 10.0 25.0
Tumor grade 0.6
I/II 27 19.3 55.3
III 4 0 -
Progesterone receptor status 0.6
Positive 28 18.4 0
Negative 3 58.6 -
Rb status 0.03
Negative 2 - -
Positive 29 13.7 56.1
LMWE status 0.009
Negative 17 0 52.1
Positive 14 58.4 79.2
Rb/LMWE status 0.009
Rb+/LMWE- 17 0 52.2
Rb+/LMWE+ 12 52.6 76.3
Rb-/LMWE+ 2 - -
Bone /soft tissue vs. any visceral 0.2
Bone / soft tissue 20 13.2 62.8
Any visceral 1 23.8 68.3
Prior therapy for metastatic disease 0.9
None 9 16.7 -
Hormonal 14 16.4 68.7
Chemotherapy and/or hormonal 8 20.0 46.7
Time from completion of adjuvant hormonal therapy 
(years)
0.5
None 14 18.0 -
< 1 year 7 25.0 -
> 1 year 10 12.5 41.7
*p value calculated after excluding unknown. 
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Figure 58: Expression of Rb and LMWE in advanced ER positive breast cancer patients 
treated with palbociclib: A) Schematic showing the total number of palbociclib treated patient 
tissues obtained and stained for Rb and cyclin-E. B) Proportion of 107 breast cancer patients 
treated with palbociclib with Rb+/LMWE-, Rb+/LMWE+ or Rb-/LMWE+ status. C) Representative 
images from immunohistochemical analysis of Rb and LMW-E in tumors from patients with ER+ 
breast cancer treated with palbociclib, classified on the basis of response and Rb/LMW-E status. 
Scale bars equal 50 μm and insert scale bars equal 20 μm. Patient database were created and 
maintained by collaborators from Breast Medical Oncology department at MD Anderson - Dr. Debu
Tripathy, Dr. Meghan Karuturi and Akshara Raghavendra. IHC analysis was performed by Dr. 
Cansu Karakas from the Keyomarsi lab.
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Figure 59: Correlation between expression of Rb and LMWE and response to 
palbociclib in advanced ER positive breast cancer patients: A) Proportion of 109 
breast patients treated with palbociclib with Rb+/LMW-, Rb+/LMWE+ or Rb-/LMWE+ 
status and their disease progression (response to palbociclib). B) Kaplan-Meier 
curves showing progression-free survival duration (in months) among 109 patients 
with advanced ER+ breast cancer classified on the basis of their tumoral expression 
of Rb and cyclin E and separated based on letrozole and fulvestrant. Survival curves 
were censored at disease progression or date of last follow-up. C) Concordance-
index (C-index) of the multivariate cox model with progesterone receptor, prior 
therapy for metastatic disease only (without Rb) and the addition of Rb and LMW-E. 
ns:p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. IHC analysis was 
performed by Dr. Cansu Karakas, Keyomarsi lab. Statistical analysis was performed 
Min Yi, Breast Surgical oncolgy. 
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Table 12: Cox model for univariate analyses for the factors associated with 
PFS
Factor Palbociclib + letrozole (n=78) Palbociclib + fulvestrant (n=31)
HR P value 95% CI HR P value 95% CI
Age at diagnosis, years 1.0 0.06 0.9-1.0 1.0 1.0 0.9-1.1
Height (cm) 0.6 0.3 0.2-1.7 1.2 0.02 1.02-1.3
Weight 1.0 0.8 0.9-1.1 1.0 0.6 0.96-1.02
Race 
White Referent Referent
Others 0.99 0.3 0.96-1.01 0.8 0.9 0.1-6.8
Clinical tumor stage at diagnosis
0/I Referent Referent
II 0.7 0.5 0.2-2.2 2.0 0.6 0.2-21.9
III 1.3 0.7 0.4-3.9 1.7 0.7 0.2-18.7
IV 0.1 0.02 0.01-0.6 6.1 0.1 0.7-55.0
Tumor Histology
Ductal Referent Referent
Others 0.9 0.9 0.2-3.8 1.4 0.7 0.3-7.1
Lymphatic/vascular invasion
Yes Referent Referent
No 1.8 0.2 0.7-4.2 0.9 0.8 0.2-3.3
Adjuvant Chemotherapy
No Referent Referent
Yes 3.4 0.007 1.4-8.2 0.3 0.09 0.1-1.2
Tumor grade
I/II Referent Referent
III 0.6 0.4 0.2-1.8 1.7 0.6 0.2-14.6
Progesterone receptor status
Positive Referent Referent
Negative 3.2 0.02 1.2-8.9 -
Rb status
Negative Referent Referent
Positive 0.2 0.04 0.04-0.9 0.09 0.09 0.01-1.4
LMWE status
Negative Referent Referent
Positive 3.2 0.02 1.2-8.2 5.2 0.02 1.3-20.3
Rb/LMWE status
Rb+/LMWE- Referent Referent
Rb+/LMWE+ 2.9 0.03 1.01-7.6 4.7 0.03 1.1-19.3
Rb-/LMWE+ 9.2 0.008 1.8-47.4 23.8 0.04 1.3-450.1
Bone /soft tissue vs. any visceral
Bone / soft tissue Referent Referent
Any visceral 2.6 0.03 1.1-6.2 2.2 0.2 0.6-8.3
Prior therapy for metastatic 
disease
None Referent Referent
Hormonal 0.9 0.9 0.1-6.8 0.8 0.8 0.1-4.6
Chemotherapy and/or 
hormonal
2.6 0.04 1.03-6.7 0.6 0.7 0.1-5.5
Time from completion of 
adjuvant hormonal therapy 
(years)
None Referent Referent
< 1 year 7.32e-16 1.0 0- 2.1 0.4 0.3-13.0
>= 1 year 1.9 0.2 0.8-4.4 0.7 0.7 0.2-3.4
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Table 13: Cox model for multivariable analyses for the factors associated 
with PFS
Palbociclib + letrozole Palbociclib + fulvestrant
Factor HR P value 95% CI HR P value 95% CI
Progesterone receptor status
Positive Referent Referent
Negative 4.5 0.007 1.5-13.4 NS
Prior therapy for metastatic 
disease
None Referent Referent
Hormonal 2.4 0.4 0.3-21.4 NS
Chemotherapy and/or 
hormonal
4.1 0.006 1.5-11.2 NS
Rb status
Negative Referent Referent
Positive 0.2 0.06 0.04-1.03 0.2 0.3 0.01-3.3
LMWE status
Negative Referent Referent
Positive 3.2 0.03 1.1-8.7 4.7 0.03 1.1-19.3
C-index 0.76
CPE 0.73
AIC 153.3
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7.3. DISCUSSION 
  Identification of reliable predictive biomarkers for palbociclib has proven challenging, 
given the large patient sample that would be required, since a predictive biomarker identifies 
factors affecting both patient survival and response to the drug.  While previous in vitro studies 
showed that Rb, cyclin D, and p16 could predict response to palbociclib (Wiedemeyer, Dunn et 
al. 2010, Konecny, Winterhoff et al. 2011, Cen, Carlson et al. 2012), results from Phase II/III 
trials showed no significant correlation between drug response and the expression of p16 
(Finn, Crown et al. 2015), Ki67, CCND1 amplification (Clark, Karasic et al. 2016), PIK3CA or 
ESR1 (Turner, Jiang et al. 2016) mutational status, leaving no established prognostic or 
predictive biomarkers (Cristofanilli, Turner et al. 2016). Further, a number of recent clinical trials 
with ribociclib (MONALEESA-2) and abemaciclib (MONARCH-1) also incorporated extensive 
biomarker analysis testing for a potential correlation between expression of Rb, cyclin D, p16, 
PIK3CA mutation and ESR1 mutation Hortobagyi, Stemmer et al. 2016)(Maura N. Dickler 
2017) . However, no significant difference in the hazard ratios were observed with any of these 
genes or proteins as a single molecule biomarker (Maura N. Dickler 2017)Hortobagyi, Stemmer 
et al. 2016).  
 One consistent observation across the clinical studies is that the tumors from the 
resistant patients exhibited no decrease in Ki67 and pRb following CDK4/6 inhibitor treatment 
Hortobagyi, Stemmer et al. 2016)(Patnaik, Rosen et al. 2016). However, none of the 
biomarkers tested can predict the hyperphosphorylation of Rb (Akli, Bui et al. 2010). 
Interestingly, the low molecular weight isoforms of cyclin E (LMWE) has been previously 
documented to mediate hyperphosphorylation of Rb (Akli, Bui et al. 2010). This is the 
mechanism by which LMWE mediate deregulation of the G1/S checkpoint and resistance to 
letrozole mediated G1 arrest. This suggests that LMWE (in combination with Rb) might be the 
most reliable biomarker for palbociclib and other CDK4/6 inhibitors as shown in this chapter.  
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 An interesting observation from our immunohistochemistry analysis was the difference 
is the difference in the number of subgroups seen when patients were classified based on 
protein expression of Rb and LMWE. In the first cohort of 829 early stage patients, we 
observed four subgroups, while in the metastatic cohort of patients who received palbociclib, 
the subgroup of Rb- LMWE- patients were not present. Interestingly, this subgroup of patients 
had the best prognosis, despite the loss of Rb. Hence it is possible that these patients had 
lower proliferation and tumor grade, resulting in better response and hence they did not 
metastasize or have relapse of tumor.  
 Thus, results from this chapter use a dual biomarker strategy and show that Rb and 
LMWE proteins are reliable prognostic biomarkers in advanced estrogen receptor positive 
breast cancers. Since we did not have a parallel treatment arm in the absence of palbociclib 
treatment, the effect of the therapy could not be examined and hence Rb and LMWE could not 
be evaluated as predictive biomarkers of palbociclib. Future clinical trial investigations in early 
stage breast cancer patients, in the neoadjuvant setting, where patients are treated with either 
palbociclib + letrozole or letrozole alone, would reveal the predictive utility of these proteins for 
palbociclib treatment. Thus, we propose that a simple immunohistochemical assay for Rb and 
LMW-E can be used clinically to identify patients who are likely to have a response to 
palbociclib and its combination with autophagy inhibitor. 
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CHAPTER 8: SYNERGISM BETWEEN CDK4/6 AND AUTOPHAGY INHIBITION IN 
TNBC AND OTHER SOLID TUMORS 
 
8.1. INTRODUCTION 
8.1.1. PRE-CLINICAL STUDIES WITH CDK4/6 INHIBITORS IN TNBC 
 The cell line based screen performed to examine the sensitivity of a range of breast 
cancer lines to the CDK4/6 inhibitor showed that the majority of the cells that are sensitive to 
palbociclib belonged to the ER positive subtypes (Finn, Dering et al. 2009). These results led to 
further pre-clinical and clinical studies using the CDK4/6 inhibitors in the ER positive breast 
cancer, which were highly successful (Asghar, Witkiewicz et al. 2015). However, careful 
examination of the cell lines used for the original study revealed that there are numerous HER2 
positive and a few triple negative breast cancer (TNBC) cell lines (MDA-MB-435, MDA-MB-231, 
HCC1395, HS578T) which were seen to be sensitive to palbociclib treatment, albeit, TNBC 
cells comprised a smaller proportion of the sensitive cell lines (Finn, Dering et al. 2009). A more 
recent study showed that palbociclib has an effect in the TNBC cell line MDA-MB-231 in vitro 
and in vivo and inhibits cancer metastasis in these cells through a DUB3-SNAIL mediated 
mechanism. Through this mechanism, CDK4/6 directly phosphorylates the deubiquitinase 
DUB3, which is essential to stabilize SNAIL1, a key EMT gene (Liu, Yu et al. 2017). Another 
study which examined the subtypes of TNBC and their sensitivity to palbociclib showed that the 
luminal AR (LAR) TNBC subtype was most sensitive to palbociclib, with the basal subtype 
being the most resistant (Uzma Asghar 2016). They also showed that the basal subtype had a 
greater CDK2 high population and higher cyclin E expression than the LAR subtype which 
enabled caused them to be resistant to palbociclib induced cell cycle arrest (Uzma Asghar 
2016). Thus, these studies suggest potential utility for palbociclib in TNBC subtypes of breast 
tumors as well, and this requires further investigation. 
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8.1.2. PRE-CLINICAL STUDIES WITH CDK4/6 INHIBITORS IN SOLID TUMORS 
 Over the recent years, several studies have examined the anti-proliferative and anti-
tumor effect of the CDK4/6 inhibitors in cancers other than breast cancer and Table 14 
summarizes these pre-clinical studies. Numerous cancers apart from breast cancer exhibit 
upregulation or over activation of the G1/S due to amplification or overexpression of proteins 
such as cyclin D1 and CDK4, making them susceptible to CDK4/6 inhibition by palbociclib, as 
shown by studies in mantle cell lymphoma (Marzec, Kasprzycka et al. 2006), acute myeloid 
leukemia (Wang, Wang et al. 2007), multiple myeloma (Baughn, Di Liberto et al. 2006), ovarian 
cancer (Konecny, Winterhoff et al. 2011, Taylor-Harding, Aspuria et al. 2015), lung 
adenocarcinoma (Sumi, Kuenzi et al. 2015), pancreatic (Franco, Balaji et al. 2016), prostate 
(Comstock, Augello et al. 2013), liposarcoma (Zhang, Sicinska et al. 2014), hepatocellular 
carcinoma (Rivadeneira, Mayhew et al. 2010), glioblastoma (Michaud, Solomon et al. 2010, 
Cen, Carlson et al. 2012), renal cancer melanoma (Yoshida, Lee et al. 2016) and colorectal 
cancer (Lee, Helms et al. 2016). All these studies show that palbociclib treatment of the cancer 
cell lines in vitro results in the induction of G1 arrest, growth inhibition and senescence, while 
inducing significant anti-tumor effects in xenograft tumors in vivo (Table 14). Further, some of 
these studies also examined biomarkers of sensitivity to palbociclib, most of which showed the 
importance of the Rb positivity and or loss of p16 for drug response (Konecny, Winterhoff et al. 
2011, Cen, Carlson et al. 2012, Franco, Balaji et al. 2016). A study in ovarian cancer also 
showed that cyclin E expression mediates resistance to CDK4/6 inhibitor treatment (Taylor-
Harding, Aspuria et al. 2015).  
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Cancer type Drug Cell culture
Animal 
Model Biomarkers
Ovarian cancer Palbociclib Yes Yes Rb, p16INK4A, cyclin E
Lung
adenocarcinoma Palbociclib Yes Yes -
Pancreatic cancer Palbociclib Yes Yes -
Prostate cancer Palbociclib Yes Yes -
Liposarcoma Palbociclib,ribociclib Yes Yes CDK4
Hepatocellular
carcinoma Palbociclib Yes Yes Rb, p16INK4A
Glioma Palbociclib Yes Yes Rb, p16INK4A
Melanoma Palbociclib, abemaciclib Yes Yes -
Colon cancer Palbociclib Yes Yes -
Mantle cell
lymphoma Palbociclib Yes Yes -
Acute
myeloid
leukemia
Palbociclib Yes Yes -
Multiple
myeloma Palbociclib Yes Yes -
Table 14: Pre-clinical studies with CDK4/6 inhibitors in other cancers:Summary of 
pre-clinical studies in cancers with the CDK4/6 inhibitors
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8.1.3. CLINICAL STUDIES WITH CDK4/6 INHIBITORS IN SOLID TUMORS 
 The pre-clinical studies detailed above has led to numerous clinical studies in solid 
tumors and hematological malignancies, a summary of which is described in Table 15. This 
includes clinical studies testing for the safety, toxicity and efficacy of the CDK4/6 inhibitors as 
single agent in numerous solid tumors (Sherr, Beach et al. 2016). Most of these studies 
showed significant clinical response with the CDK4/6 inhibitors, resulting in pathological 
complete response or stable disease in over 40% of the patients treated (Sherr, Beach et al. 
2016). For example, a phase I study in 17 heavily pre-treated mantle cell lymphoma patients, 
palbociclib treatment exhibited significant reduction in tumor proliferation (as measured by Ki67 
and fluorothymidine PET) and Rb phosphorylation in most patients, with 5 out of the 17 patients 
achieving a progression-free survival of greater than 1 year (Leonard, LaCasce et al. 2012). 
Moreover, in a phase II clinical study of 30 liposarcoma patients whose tumors were Rb 
positive and CDK4 amplified, 66% of the patients achieved progression-free status at the end 
of 12 weeks, with 8 patients remaining on the study for more than 40 weeks (Dickson, Tap et 
al. 2013). Further, to improve the selectivity of the drug treatment, several of these clinical trials 
are designed to select patients based on biomarkers identified in pre-clinical studies such as 
Rb, loss of p16 and cyclin D amplification (O'Leary, Finn et al. 2016). However, it is not clear if 
these biomarkers could be predictive indicators of palbociclib, as none of the aforementioned 
trials were designed to examine the predictive value of these biomarkers. Finally, some of the 
more recent clinical trials have been designed to test the combination of the CDK4/6 inhibitors 
with drugs such as MEK inhibitors (Sherr, Beach et al. 2016).   
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Cancer type, 
Identifier Drugs, phase Trial design
Solid tumors
NCT00141297
Palbociclib 
(Phase 1)
Drug dose was established; Stable disease 
realized in 19 of 74 patients
Advanced solid 
tumors 
NCT01237236
Ribociclib 
(Phase 1)
Drug dose was established; Stable disease in 14% 
of patients
Advanced solid 
tumors 
NCT01394016
Abemaciclib 
(Phase 1)
Dose finding and toxicity studies; drug efficiently 
crossed blood brain barrier
Advanced tumors 
NCT02187783
Ribociclib 
(Phase 2)
Determine efficacy of CDK4/6 treatment in tumors 
with p16 loss or cyclin D1/D3 amplification
Mantle cell 
lymphoma 
NCT00420056
Palbociclib 
(Phase 1)
most patients out of 17 showed reduction in 
proliferation with PFS of > 1 year.
Mantle cell 
lymphoma 
NCT01739309
Abemaciclib 
(Phase 2)
5 out of 22 patients had partial response and 9 
patients with stable disease.
Liposarcoma 
NCT01209598
Palbociclib 
(Phase 2)
66% of 30 patients were progression-free after 12 
weeks with 8 patients on study for >40 weeks
Non-small cell 
lung cancer 
NCT01291017
Palbociclib 
(Phase 2)
8 of 16 patients with CDKN2A loss were 
progression-free > 4 months.
Non-small cell 
lung cancer 
NCT01394016
Abemaciclib 
(Phase 1)
In 15 of 31 patients, overall disease control rate 
was 49% with 6 month PFS in 26%. 
Glioblastoma 
multiforme 
NCT01394016
Abemaciclib 
(Phase 1)
2of 17 patients showed prolonged time to 
progression.
Melanoma 
NCT01394016
Abemaciclib 
(Phase 1)
1 out 26 patients with NRAS mutation and 
CDKN2A loss achieved partial response
RAS-mutant 
cancers 
NCT02022982
Palbociclib 
PD0325901 
(Phase 1/2)
Phase 1 trial with expansion in KRAS mutant 
NSCLC; not reported
RAS-mutant 
cancers 
NCT02065063
Palbociclib 
Trametinib 
(Phase 1)
Phase 1 trial with expansion in NRAS mutant 
melanoma; not reported
Mantle Cell 
Lymphoma 
NCT02159755
Palbociclib 
Ibrutinib
(Phase 1)
Trial of palbociclib and ibrutinib in previously 
treated MCL; not reported
Table 15: Clinical studies with CDK4/6 inhibitors in other cancers:Summary of 
completed and ongoing clinical studies with the CDK4/6 inhibitors in other cancers
	 207 
8.1.4. GAP IN KNOWLEDGE 
While few studies in TNBC have suggested an efficacy for CDK4/6 inhibition by palbociclib, a 
detailed analysis has not been conduction with the goal of improving efficacy and identifying 
biomarkers. Further, studies in other solid cancers are still preliminary leaving us with several 
unanswered questions:  
1. Can Rb and cyclin E be used to identify the most responsive TNBC cell lines? 
2. Would the addition of autophagy inhibitor improve efficacy of palbociclib treatment in 
TNBC cell lines?  
3. Can intact G1/S checkpoint (Rb+ LMWE-) be used to identify responders to palbociclib 
among other solid tumor cell lines? 
4. Will the combination of palbociclib and autophagy inhibitors be synergistic in other solid 
cancers? 
Thus, this chapter aims at addressing these questions in detail and devising palbociclib based 
treatment strategies for TNBC and other solid tumors.   
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8.2. RESULTS 
8.2.1. PALBOCICLIB MEDIATED GROWTH INHIBITION IN TNBC CELL LINES 
While the CDK4/6 inhibitor, palbociclib is currently used clinically for the treatment of 
advanced ER positive breast cancer, we wanted to examine the potential of treating other 
subtypes of breast cancer, such as Triple Negative Breast Cancer (TNBC) with CDK4/6 
inhibitor treatment, when selected based on reliable biomarkers. The Cancer Genome Atlas 
(TCGA) analysis showed that about 64% of TNBC patient tumors (CDK4 - 22%, CDK6 – 37%, 
cyclin D – 5%) had deregulation in the CDK4/6-Cyclin D pathway, with mRNA upregulation of 
CDK4 and CDK6 being the most prevalent alteration in TNBC tumors (Figure 6A,6C). This 
highlights the importance of the G1/S checkpoint in these cancers. 
To interrogate the response of TNBC cell lines to CDK4/6 inhibition, we examined 7 
TNBC cell lines (HCC38, MDA-MB-231, SUM-159, BT-549, MDA-MB-468, HCC-1806 and 
MDA-MB-157) with varying protein expression levels of Rb and cyclin E (Figure 60A), and 
examined the ability of Rb and LMWE to predict sensitivity to palbociclib. Palbociclib dose 
response studies showed that cell lines that were positive for Rb and negative for LMWE 
(HCC38, MDA-MB-231, SUM-159) were significantly more sensitive than cell lines with 
deregulated Rb and / or LMWE (Figures 60B,C), exhibiting 6-8 fold lower IC50 values (Figure 
60D,E). Additionally, palbociclib treatment resulted in a significant dose-dependent irreversible 
G1 arrest with 6 days of treatment and 4 days of recovery in cell lines with intact Rb and Cyclin 
E, MDA-MB-231 and SUM-159 (Figures 60F,G). This induction of G1 arrest upon palbociclib 
treatment was absent in the cell lines with deregulated Rb and / or LMWE +ve status, MDA-
MB-468 and MDA-MB-157 (Figure 53F). Moreover, palbociclib treatment in cell lines with intact 
Rb and Cyclin E (MDA-MB-231 and SUM-159) resulted in a significant dose-dependent 
reduction in colony formation (Figure 61A) and induction of sustained growth inhibition (Figure 
61B), but not in cell lines with deregulated Rb and / or LMWE + status (MDA-MB-468 and 
MDA-MB-157). Finally, long term treatment (6 days) of TNBC cell lines with the CDK4/6 
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inhibitor, palbociclib induced dose-dependent senescence (indicated by an increase in SA-ß 
gal activity) only in cell lines that are Rb+ve and LMWE-ve, MDA-MB-231 and SUM-159 
(Figure 61C) 
Thus, these results demonstrate that CDK4/6 inhibition also has the potential to treat 
TNBC cell lines, given that they are chosen based on the expression of Rb and LMWE 
proteins. 
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Figure 60: Palbociclib mediated induction of growth inhibition and cell cycle arrest in TNBC 
cell lines: A) Western blot for Rb and Cyclin-E in Triple negative breast cancer (TNBC) cell lines. B) 
IC50 values from drug response experiments in TNBC cell lines treated with palbociclib for 6 days. C-
E) Impact on the growth of the indicated triple-negative breast cancer (TNBC) cell lines of treatment 
with DMSO or increasing concentrations (conc) of palbociclib (0.01 to 12 μM) for 6 days. Crystal 
violet staining was performed on day 12 to assess viability and determine the half-maximal inhibitory 
concentration (IC50) values (E). F,G) MDA-MB-231, SUM-159, MDA-MB-468, and MDA-MB-157 
cells were treated with DMSO or varying concetrations of palbociclib 6 days, allowed  to recover for 
4 days and subjected to F) cell cycle analysis to assess change in G1 phase and G) cell cycle 
analysis to determine the effect of recovery (release) on change in the G1 phase. All data represent 
mean±SD from three independent experiments; p-values were calculated in comparison to DMSO 
(Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 61: Palbociclib mediated induction of growth inhibition and senescence in TNBC 
cell lines: A) Clonogenic assay in TNBC cell lines MDA-MB-231, SUM-159, MDA-MB-468, and 
MDA-MB-157 cells treated with DMSO (Cnt) or palbociclib (1μM, 5μM) for 6 days and allowed to 
recover for 6 days. MDA-MB-231, SUM-159, MDA-MB-468, and MDA-MB-157 cells were treated 
with DMSO or palbociclib (Palbo; 1μM, 5μM) for 6 days and allowed to recover for 4 days to 
examine reversibility. Cells were then subjected to B) cell counting to assess proliferation and C) 
Senescence measurement by SA-ß gal staining and representative images. All data represent 
mean±SD from three independent experiments; p-values were calculated in comparison to DMSO 
(Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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8.2.2. SYNERGISM BETWEEN PALBOCICLIB AND AUTOPHAGY INHIBITION IN TNBC 
CELL LINES 
We next asked if the combination of CDK4/6 and autophagy inhibition may be 
synergistic in TNBC cell lines and if Rb and LMWE expression could be utilized to identify 
response cell lines. First, we wanted to interrogate if CDK4/6 inhibition via palbociclib treatment 
induces autophagy, at levels comparable to that induced in ER positive breast cancer cell lines. 
Measurement of Monodansylcadavarine (MDC) staining showed that treatment with palbociclib 
at low and on-target doses significantly increased the MDC staining in ER positive and TNBC 
cell lines that were Rb+ve and LMWE-ve (MDA-MB-231, SUM-159), but not in TNBC cell lines 
with a deregulated G1/S checkpoint (MDA-MB-468) (Figure 62A). Moreover, palbociclib 
treatment resulted in significant increase in GFP+ve LC3 puncta in the G1/S checkpoint intact 
MDA-MB-231 cells, but not in MDA-MB-468 cells that have a deregulated G1/S checkpoint 
(Figures 62B,C). Further, treatment with the lysosomal block, chloroquine (CQ) further 
increased the GFF-LC3 puncta in MDA-MB-231 cells, indicating that the autophagy induced by 
palbociclib has an intact flux (Figure 62B,C), similar to the autophagy induced in ER positive 
breast cancer cell lines. 
Since palbociclib mediated CDK4/6 inhibition induces autophagy in TNBC cell lines with 
an intact G1/S checkpoint, we next examine if the combination of CDK4/6 and autophagy 
inhibition would be synergistic in these cells. Treatment with the combination of low or on-target 
dose of palbociclib and autophagy inhibitor, HCQ resulted in greater reduction in colony 
formation (Figure 63A) and induction of an irreversible growth inhibition (Figure 63B), in TNBC 
cell lines which are Rb+ve and LMWE-ve, MDA-MB-231 and Sum-159. This synergistic effect 
was not observed in the TNBC cell lines with deregulated Rb or/ and cyclin E (MDA-MB-157 
and MDA-MB-468) (Figure 63A,B), which are also resistant to palbociclib as a single agent. 
Finally, treatment with the autophagy inhibitor, HCQ further sensitized Rb+/LMWE- cells (MDA-
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MB-231 and SUM-159) to palbociclib, inducing significantly elevated senescence even at lower 
palbociclib doses (Figure 63C). 
 Thus, these results show that TNBC lines with a intact G1/S checkpoint (Rb+ve / 
LMWE-ve) are responsive to treatment with the CDK4/6 inhibitor palbociclib and can be 
effectively treated by the combination of CDK4/6 and autophagy inhibition.  
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B
Figure 62: Palbociclib mediated induction of autophagy in TNBC cell lines: A) 
Measurement of monodansylcadavarine (MDC) positive acidic vesicles, including 
autophagosomes, by flow cytometry in ER positive (MCF7, T47D, ZR75-1) and TNBC 
(MDA-MB-231, SUM-159, MDA-MB-468) cell lines treated with varying concentrations of 
palbociclib for 6 days. B) Representative confocal images of GFP-LC3 expressing MDA-
MB-231 and MDA-MB-468 cells treated with 25 μM CQ (for 1 hour), 1 μM palbociclib or 
combination of palbociclib and CQ for 48 hours. Scale bars are 50 μm. C) Quantification of 
GFP-LC3 puncta in MDA-MB-231 and MDA-MB-468 cells treated with 1µM palbociclib 
and/or 25µM Chloroquine (CQ) for 48 hours. All data represent mean±SD from three 
independent experiments; p-values were calculated in comparison to DMSO (Control) 
unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 63: Synergism between palbociclib and autophagy inhibition in TNBC cell 
lines: MDA-MB-231, SUM-159, MDA-MB-468, and MDA-MB-157 cells were treated with 
DMSO or palbociclib (Palbo; 1μM, 5μM) and/or 15 μM autophagy inhibitor 
hydroxychloroquine (HCQ) for 6 days. Cells were allowed to recover for 4 or days to 
examine reversibility and subjected to A) Clonogenic assay, B) cell counting to assess 
proliferation (p-values calculated in comparison with 1 μM palbociclib), and C) SA-ß
galactosidase assay to measure senescence with representative images. All data 
represent mean±SD from three independent experiments; p-values were calculated in 
comparison to DMSO (Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001.
A
0
20
40
60
80
%
 S
en
es
ce
nc
e 
+v
e 
ce
lls
Palbo (µM)
HCQ (15µM)
-
-
-
-+
1 1
+
-
-
-
-+
1 1
+
MB-231 SUM-159
** **
SUM
159
MB(
231
Cnt HCQ0000Palbo Palbo
(15μM)0 0(1μM)000+0HCQ
MB(
468
MB(
157
Se
ns
iti
ve
R
es
is
ta
nt
0 3 6 10
0
2
4
6
8
10
30
35
40
Days
C
el
l N
um
be
r (
 x
10
5 )
SUM 159
*
0 3 6 10
0
20
40
60
Days
C
el
l N
um
be
r (
 x
10
5 )
MDA-MB 157
ns
0 3 6 10
0
5
10
15
20
25
50
60
70
Days
C
el
l N
um
be
r (
 x
10
5 )
MDA-MB-231
Cnt
15µM HCQ 
1µM Palbo
1µM Palbo + 
15µM HCQ
**
0 3 6 10
0
5
10
15
20
Days
C
el
l N
um
be
r (
 x
10
5 )
MDA-MB 468
ns
C
	 216 
8.2.3. SYNERGISM BETWEEN PALBOCICLIB AND AUTOPHAGY INHIBITION IN TNBC 
PDX MODEL 
 Having shown the synergism between palbociclib and autophagy inhibition in TNBC cell 
in vitro, we next examined this synergy in vivo, using patient derived xenograft (PDX) tumors 
that has been characterized to be Triple Negative and have high levels of Rb and low Cyclin-E. 
Once established, the PDX tumors were randomized into four treatment arms i) vehicle, ii) 
palbociclib (25 mg/kg/day), iii) hydroxychloroquine (60 mg/kg/day) and iv) combination of 
palbociclib and HCQ for 21 days (Figure 64A).  
Treatment with the drug combination of palbociclib and HCQ significantly decreased 
tumor growth (Figure 64C), resulting in much smaller tumors (Figure 64B), compared to 
treatment with vehicle or palbociclib or HCQ as single agent. Combination treatment of the 
PDX tumors also resulted in a significant decrease in tumor weights compared to the other 
treatment arms (Figure 64D). Moreover, treatment with the combination of palbociclib and 
HCQ significantly prolonged the survival of the mice compared to the other treatment arms 
(Figure 64E). Finally, to evaluate the toxicity with the drug treatments, we measured the weight 
of the mice during the treatment period and found no significant difference in the weight of the 
mice with all the treatment arms (Figure 64F), indicating that the treatment including the 
combination is well tolerated.  
Thus, these results demonstrate that the combination of CDK4/6 and autophagy 
inhibitors are synergistic in TNBC tumors in vivo, given that they have an intact G1/S 
checkpoint (Rb+ve LMWE-ve). 
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Figure 64: Synergism between palbociclib and autophagy inhibition in TNBC PDX model: 
A) Schematic showing establishment and treatment schedule of patient-derived xenograft (PDX) 
tumors with vehicle (0.5% methylcellulose and PBS), 60 mg/kg HCQ, 25 mg/kg palbociclib, or 
palbociclib+ HCQ for 21 days. B) Representative PDX tumor images from each treatment group 
harvested at end of 21 days treatment as described in A. C) Percentage change in volume 
(normalized to Day 0) of patient derived xenograft (PDX) tumors upon treatment after treatment 
as described in A for 21 days. Data represented as Mean±SEM. n=4 for each group. D) Weight 
of PDX tumors treated harvested after 21 days of treatment as described in A. n=4 for each 
group. E) Kaplan Meier survival curves of mice with PDX tumors treated as in A. Death of mice 
and tumors exceeding 1000mm3 were utilized as cut-off endpoints for the curve. F) Individual 
mouse weights during 21 days of treatment as described in A. p-values were calculated in 
comparison to treatment with vehicle (Control). ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001. PDX tumors were developed by Dr. Xian Chen, psotdoc from Keyomarsi lab.
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8.2.4. PALBOCICLIB TREATMENT IN OTHER SOLID TUMOR CELL LINES 
While the CDK4/6 inhibitor is currently approved for clinical use only in ER+/Her2- 
advanced breast cancer, numerous pre-clinical and clinical studies have shown activity for 
Palbociclib in other cancers such as Melanoma, Ovarian, Prostate, Glioblastoma, Gastric, 
Colorectal (CRC), Head and neck squamous cell carcinoma (HNSCC), Pancreatic ductal 
adenocarcinoma (PDAC) and lung adenocarcinoma (Fry, Harvey et al. 2004, Baughn, Di 
Liberto et al. 2006, Michaud, Solomon et al. 2010, Konecny, Winterhoff et al. 2011, Cen, 
Carlson et al. 2012, Comstock, Augello et al. 2013, Witkiewicz, Borja et al. 2015, Lee, Helms et 
al. 2016, Tao, Le Blanc et al. 2016, Yoshida, Lee et al. 2016, Ziemke, Dosch et al. 2016). 
With this rationale, we hypothesized that CDK4/6 inhibition would be effective in other 
solid tumors as well, given that Rb and cyclin E are used as biomarkers to predict response. To 
test this hypothesis, we examined several Ovarian (HeyA8, 59M, FUOV1), Pancreatic (Panc-1, 
BxPc-3), Lung (Calu-1, H358, A549), Colorectal (Colo-205, SW-620, HCT116) and Prostate 
(PC3, Du145) cancer cell lines, with varied protein levels of Rb and Cyclin-E (Figure 65A). 
Palbociclib dose response studies revealed that cell lines with an intact Rb and low cyclin E (no 
LMWE) namely HeyA8, 59M, Panc-1, BxPc-3, Calu-1, H358, Colo-205, SW-620 and PC3, 
showed significant dose-dependent growth inhibition upon palbociclib treatment, with low 
(within the on-target range) IC50 values (<2uM) (Figures 65B,C). In contrast, cell lines with 
loss of Rb and / or high levels of LMWE, such as FUOV1, A549, HCT116 and Du145 showed 
significant resistance to palbociclib treatment, with higher IC50 values (4 - 10uM) (Figure 
65B,C).  
Further, palbociclib treatment for 6 days with 6 days of recovery induced a significant 
dose-dependent reduction in colony formation in cancer cell lines with intact G1/S checkpoint, 
irrespective of the cancer type (Figure 65D).  In contrast, cell lines that have deregulated a Rb 
and/or LMWE expression exhibited significant resistance to the induction of palbociclib 
mediated reduction in colony formation (Figure 65D).  
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 Thus, these results indicate that palbociclib mediated CDK4/6 inhibition induces a dose-
dependent sustained growth inhibition in solid tumor cell lines with an intact G1/S checkpoint. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 220 
 
Figure 65: Palbociclib treatment in other solid tumor cell lines: A) Western blot of Rb and Cyclin-
E in ovarian, pancreatic (PDAC), lung, colon and prostate cancer cell lines. B) IC50 values from drug 
response experiments in the mentioned cancer cell lines treated with palbociclib for 6 days and 
recovery for 4 days. C) Dose response studies to measure the impact of treatment with increasing 
concentrations (conc) of palbociclib (0.01 to 12 μM) on the growth of the indicated ovarian, lung, 
pancreatic, colon, and prostate cancer cell lines for 6 days. D) Clonogenic assay in the indicated cell 
lines treated with DMSO (Cnt) or palbociclib (1μM, 5μM) for 6 days and allowed to recover for 6 days. 
All data represent mean±SD from three independent experiments; p-values were calculated in 
comparison to DMSO (Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.
A
C
D
Ovarian
Rb
Full,length,
Cyclin4E
LMW
Cyclin4E
Vinculin
Lung ColonPDAC Prostate
He
yA
8
59
M
FU
OV
1
Pa
nc
-1
Bx
Pc
-3
Ca
lu-
1
H3
58
A5
49
Co
lo2
05
SW
62
0
HC
T1
16 PC
3
Du
14
5
0
2
4
6
8
10
12
Pa
lb
oc
ic
lib
 IC
50
 (µ
M
)
no LMW-E
LMW-E
Rb +ve
Rb -ve
Ovarian PDAC Lung Colon Prostate
Calu%1
(Lung)
Sensitive
HeyA8
(Ovar)
Resistant
FUOV1
(Ovar)
Panc%1
(Panc)
A549
(Lung)
Du145
(Prostate)
SW620
(Colon)
Ovarian
0.1 1 10
0
20
40
60
80
100
Palbociclib conc (µM)
%
 V
ia
bl
ilit
y
59M
HeyA8
FUOV1
Lung
0.1 1 10
0
20
40
60
80
100
Palbociclib conc (µM)
%
 V
ia
bl
ili
ty
H358
A549
Calu-1
Pancreatic
0.1 1 10
0
20
40
60
80
100
Palbociclib conc (µM)
%
 V
ia
bl
ili
ty
BxPc-3
Panc-1
Colon
0.1 1 10
0
20
40
60
80
100
Palbociclib conc (µM)
%
 V
ia
bl
ili
ty
Colo-205
HCT-116
SW-620
Prostate
0.1 1 10
0
20
40
60
80
100
Palbociclib conc (µM)
%
 V
ia
bl
ilit
y
PC3
Du-145
Sensitive
59M
(Ovar)
BxPc43
(Panc)
PC3
(Prostate)
Cnt
1μM
5μM
B
	 221 
8.2.5. SYNERGISM BETWEEN PALBOCICLIB AND AUTOPHAGY INHIBITION IN OTHER 
SOLID TUMOR CELL LINES 
 Given that palbociclib treatment was effective in non-breast tumor cell lines with an 
intact G1/S transition, we next wanted to examine if the combination of palbociclib and 
autophagy inhibitor, HCQ might be synergistic in these solid tumors resulting in sustained and 
irreversible growth inhibition. In cancer cell lines exhibiting expression of intact Rb and low 
Cyclin E (and no LMWE), such as HeyA8, Panc-1, BxPc-3, Calu-1, SW-620 and PC3, 
combination treatment with palbociclib and HCQ resulting in enhanced reduction in colony 
formation, compared to treatment with low dose palbociclib alone (Figure 66A).  However, cell 
lines with a deregulated G1/S checkpoint (loss of Rb and / or high levels of LMWE), namely 
FUOV1, A549 and Du145 showed significant resistance to palbociclib mediated reduction in 
colony formation (Figure 66A). Moreover, treatment with the autophagy inhibitor, HCQ further 
sensitized the Rb positive LMWE negative cells to palbociclib, thus inducing a sustained and 
irreversible growth inhibition in ovarian (HeyA8, 59M), pancreatic (Panc-1, BxPc-3), lung (Calu-
1), colon (SW620) and prostate (PC-3) cancer cell lines (Figure 66B,C).   
Collectively, these results demonstrate the utility of combining palbociclib with an 
autophagy inhibitor in solid tumors with an intact G1/S checkpoint. 
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Figure 66: Synergism between palbociclib and autophagy inhibition in other solid 
tumor cell lines: A) Clonogenic assay to measure colony formation in the indicated solid 
tumor cell lines treated with DMSO or 1 μM palbociclib (Palbo) and/or HCQ (15 μM) for 6 
days and allowed to recover for 6 days. B,C) Cell counting to assess proliferation of the 
indicated solid tumor cell lines treated with 1 μM palbociclib and/or 15 μM
hydroxychloroquine (HCQ) for 6 days and allowed to recover for 4 days to examine 
reversibility. p-values were calculated in comparison to cells treated with 1 μM palbociclib. All 
data represent mean±SD from three independent experiments; p-values were calculated in 
comparison to DMSO (Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.
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8.3. DISCUSSION 
 Results from the studies described in this chapter are highly translatable and clinically 
relevant since they provide strong pre-clinical data to expand the CDK4/6 inhibitor treatment to 
other solid tumors other than breast cancer. Further, analysis across all cancer types (breast, 
ovarian, lung, colon, pancreatic and prostate) showed a strong correlation between sensitivity 
to palbociclib (measured by IC50 values) and the combined expression of Rb and cyclin E 
(specifically LMWE) (Figure 67A). This indicates that the immunohistochemistry based dual 
biomarker strategy proposed and tested in chapter 7 can also be employed in other solid tumor 
to select for patients who would respond to CDK4/6 inhibition. Further inhibition of autophagy 
(genetic ablation of autophagy genes Beclin1 and Atg5 or pharmacological inhibition by HCQ) 
further decreased the IC50 value of palbociclib in the RB+ LMWE- cell lines across all cancer 
types (Figure 67B). This suggests synergy and potential utility of the combination therapy in 
TNBC and other solid tumors.  
 CDK4/6 inhibitors are not used currently in the clinic to treat non-ER positive subtype of 
breast cancer, more specifically, the triple negative breast cancer (TNBC) tumors. However, 
early preclinical studies in breast cancer show that a small percentage of the TNBC cell lines 
do respond to palbociclib treatment (Finn, Dering et al. 2009, Robinson, Liu et al. 2013). 
However, has not been investigated further thus far, possibly because only a small proportion 
of the TNBC cell lines appeared to be responsive to CDK4/6 inhibition and there are no reliable 
biomarkers to predict the population of responsive TNBC patients. The role of CDK4/6 
inhibition in TNBC has gained attention with a recent study that examined the utility of 
palbociclib in TNBC cell lines and attempted at identifying the subtype of TNBC that would 
respond best to this treatment (Uzma Asghar 2016). In this chapter, we have performed 
extensive in vitro and in vivo studies, including treatment studies in TNBC patient derived 
xenograft (PDX) tumors, which showed that TNBC tumors would also be responsive to 
palbociclib. We also show that the drug efficacy in these cell lines and tumors can be further  
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Figure 67: Synergism between CDK4/6 and autophagy inhibition in cancers 
with an intact G1/S checkpoint: A) Correlation between palbociclib half-maximal 
inhibitory concentration (IC50) values (obtained from dose-response studies in all 
cancer cell lines) and levels of Rb and low-molecular-weight cyclin E isoform (LMW-
E) proteins. B) Correlation between palbociclib IC50 values (from dose-response 
studies in all cancers) and levels of Rb and cyclin E proteins, with and without 
inhibition of autophagy (Beclin-1/Atg5 knockdown or HCQ treatment). C) Schematic 
depicting the mechanism by which palbociclib inhibits growth of Rb+/LMWE- breast 
cancer cells by regulating ROS, autophagy, and senescence.
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increased by the addition of autophagy inhibitors and by using the combination of Rb and 
LMWE as reliable markers to predict response. The G1/S checkpoint tends to be more often 
deregulated in the TNBC tumors, with a higher proportion of the tumors being Rb negative and 
expressing LMWE (Giacinti and Giordano 2006, Karakas, Biernacka et al. 2016). While this 
indicates that a smaller proportion of tumors are likely to respond to CDK4/6 inhibitor therapy, 
the TNBC tumor subtype have no effective treatments thus far, apart from chemotherapy, 
highlighting the importance of this study. 
Taken together, the results in chapters 4 through 8 demonstrate that the combination 
CDK4/6 and autophagy inhibitor can be utilized to effectively treat solid tumors such as breast 
(irrespective of subtype), ovarian, pancreatic, prostate, colon and lung cancer, and that the 
expression of Rb and Cyclin-E (LMWE) can serve as effective and reliable biomarkers to 
predict response to this drug combination (Figure 67C). The model shows that the inhibition of 
CDK4/6 via palbociclib in tumors that have Rb and do not express LMWE, increases ROS, 
which in turn activates autophagy and prevents the induction of senescence. Hence combined 
treatment with CDK4/6 and autophagy inhibitors further increased ROS levels and induces 
senescence.  
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CHAPTER 9: MECHANISM OF ACQUIRED RESISTANCE TO PALBOCICLIB 
 
9.1. INTRODUCTION 
9.1.1. MECHANISMS OF ACQUIRED RESISTANCE TO CDK4/6 INHIBITION 
 While ER positive breast cancer patients perform well on the CDK4/6 inhibitors, about 
25% of the patients become resistant to the drug within 6 months, and it is expected that all 
patients will eventually acquire resistance to the treatment. However, there are very few studies 
till date that have examined the mechanisms of acquired resistance to palbociclib and other 
CDK4/6 inhibitors. Given the importance of the Rb protein, loss of Rb leading to deregulation of 
the G1/S checkpoint is a mechanism of acquired resistance to palbociclib (DeMichele A 2016). 
A study in ER positive breast cancer cells showed that acquired resistance to palbociclib arises 
from bypass or deregulation of the G1/S checkpoint, and this occurs through CCNE1 (cyclin E) 
amplification or loss of Rb (Herrera-Abreu, Palafox et al. 2016). A more recent study in 
understanding the mechanism of acquired resistance to abemaciclib, showed that the resistant 
clones showed amplification of CDK6 kinase, resulting in increased CDK6 expression and 
resistance to reduction of pRb with abemaciclib treatment (Yang, Li et al. 2016). This study also 
confirmed the loss of Rb and amplification of CCNE1 in the abemaciclib resistant cells (Yang, 
Li et al. 2016).  
 While most current studies on acquired resistance to palbociclib have focused on the 
G1/S checkpoint, there are numerous other pathways that can contribute to drug resistance. 
Some of the pathways seen with other targeted therapies including aromatase inhibitors are 
mutations of the target genes, activation of alternate growth signaling pathways that can enable 
the cells to proliferate even in the presence of the drugs and increased EMT and cancer stem 
cell phenotype, which has been strongly associated with therapy resistance in breast and other 
cancers (Dean, Fojo et al. 2005, Ma, Reinert et al. 2015).  
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9.1.2. CANCER STEM CELLS, EMT AND DRUG RESISTANCE 
Cancer stem cells (CSCs) are considered as a population of cells within the tumor that 
have a high self-renewal capacity (Siminovitch, McCulloch et al. 1963). Studies have shown 
that they can mediated resistance to cancer therapy in several tumor types including breast 
cancer (Phillips, McBride et al. 2006, Touil, Igoudjil et al. 2014). In 2003, breast cancer stem 
cells were first isolated based on the surface markers CD44 and CD24 as being CD44+/high 
CD24−/low population of cells (Al-Hajj, Wicha et al. 2003). Later aldehyde dehydrogenase 
(ALDH) was identified as a new marker of breast cancer stem cells (Ginestier, Hur et al. 2007). 
Breast cancer stem cells are also characterized by their ability to generate tumors in mice even 
when transplanted into mammary fat pad with as low as 100 cells were (Al-Hajj, Wicha et al. 
2003). Another feature linked with cancer stem cells is their ability to undergo epithelial 
mesenchyme transition (EMT) and metastasis to distant organ sites. EMT is typically 
accompanied by decrease of epithelial markers like E-cadherin (CDH1) and increase in 
mesenchymal markers such as vimentin and N-cadherin, which transforms the cells into being 
higher migratory and invasive (Yang, Mani et al. 2004). Several studies have established a link 
between EMT and cancer stemness, including a study in immortalized mammary epithelial 
cells, where the expression of the EMT, Snail and Twist induced cancer stem cell phenotype, 
concomitant with increase in CD44high CD24low population and enhanced tumorigenicity in vivo 
(Mani, Guo et al. 2008).  
 Further studies have established a link between cancer stem cells and resistance to 
therapy, both intrinsic and acquired resistance (Dean, Fojo et al. 2005). For example, ALDH 
staining of tumor tissue samples before and after chemotherapy showed a significant 
association between ALDH staining and resistance to therapy or worse prognosis (Tanei, 
Morimoto et al. 2009). A study in Her2 positive breast cancer also showed that tumor tissues 
with high expression of CD44 protein were intrinsically resistant to chemotherapy (Li, Lewis et 
al. 2008). Moreover, studies have also shown a link between cancer stem cells and resistance 
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to anti-estrogen therapy like aromatase inhibitors (Creighton, Li et al. 2009). This study showed 
a significant increase in EMT genes such as MMP2 and MMP3 and an increase in CSC gene 
signature post treatment with letrozole when compared to matched pre-treatment samples 
(Creighton, Li et al. 2009).  
 
9.1.3. IL-6/STAT-3 PATHWAY – ROLE IN CSC AND BREAST CANCER 
 Signal transducer and activator of transcription 3 (STAT3) belong to the STAT family of 
transcription factors that regulates numerous cellular processes (Banerjee and Resat 2016). 
STAT3 is constitutively activated in numerous cancers, including about 50 to 60% of breast 
cancer (Banerjee and Resat 2016). STAT-3 is activated upon phosphorylation which results in 
dimerization of the STAT3 proteins, which then translocate into the nucleus, where it binds to 
the promotor sequence of the target genes and initiate their transcription (Yu and Jove 2004). 
One of the common upstream activators of STAT-3 is the IL-6 family of cytokines (Dethlefsen, 
Hojfeldt et al. 2013). Studies in breast cancer have shown that IL-6 is secreted by the tumor 
microenvironment, which activated the STAT-3 signaling in the breast cancer cells in a 
paracrine or fashion allowed the STAT-3 signaling to remain constitutively active (Dethlefsen, 
Hojfeldt et al. 2013). The tumor tissue specific expression of STAT-3 indicates that the pathway 
plays a major role in breast cancer tumorigenesis (Carpenter and Lo 2014). In vitro and tumor 
tissue based studies have shown that the downstream target genes of the STAT-3 pathway are 
involved in numerous cellular functions including proliferation, apoptosis, survival, EMT and 
metastasis, angiogenesis and cancer stem cells (Banerjee and Resat 2016).  
 The IL-6/STAT-3 pathway has been shown to be preferentially expressed within the 
CD44high CD24low population of breast cancer cells, indicating its role in mediating cancer stem 
cells (Marotta, Almendro et al. 2011). A study specifically in ER positive HER2 positive tumors, 
HER2 mediated phosphorylation and activation of STAT-3, which causes upregulation of 
cancer stem cell and EMT markers, leading to resistance to herceptin treatment (Chung, Giehl 
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et al. 2014). Further, combined treatment with a STAT-3 inhibitor in combination with herceptin 
caused decrease in CD44high CD24low population and migration, thus reversing the resistance to 
herceptin (Chung, Giehl et al. 2014). Another study in HER2 positive breast cancer shows that 
PTEN deletion activates the IL-6 inflammatory loop, which induces breast cancer stem cell 
population with an EMT phenotype, thus making the cells resistant to anti-HER2 therapy via 
trastuzumab (Korkaya, Kim et al. 2012). Further, treatment with an anti-IL6R antibody reverses 
resistance to trastuzumab in in vitro and in xenograft models (Korkaya, Kim et al. 2012). 
Finally, a more recent study in ER positive breast cancer showed that acquired resistance to 
hormonal therapy mediates downregulation of ER and abrogation of the OXPHOS pathway, 
resulting in increased expression of CD133high cancer stem cells (Sansone, Ceccarelli et al. 
2016). Thus, inhibition of the IL-6 / Notch-3 pathway decreases the CD133high cancer stem cells 
and re-sensitizes cells to hormonal therapy (Sansone, Ceccarelli et al. 2016). 
  
9.1.4. TARGETING DNA REPAIR PATHWAY IN BREAST CANCER 
 Targeting the DNA repair defect or deficiency has been a commonly employed 
technique of drug targeting in cancers over the years (Kelley, Logsdon et al. 2014). One of the 
most promising targeted therapy developed based on this concept are the PARP inhibitors 
(Kelley, Logsdon et al. 2014). Poly ADP ribose polymerase (PARP) plays a crucial role in the 
alternate DNA repair pathway termed as base excision repair (BER) (Eustermann, Videler et al. 
2011, Langelier, Planck et al. 2011). This pathway is usually activated when there is a defect or 
mutation in the homologous recombination (HR) pathway, regulated by the genes BRCA1 and 
BRCA2 (Moynahan, Chiu et al. 1999). Thus, cells with a mutation in the BRCA gene are unable 
to repair double strand breaks in DNA, forcing them to rely on the PARP dependent BER 
pathway (Moynahan, Chiu et al. 1999). This results in synthetic lethality between BRCA 
mutation and PARP, causing the BRCA mutant breast cancer cells to be sensitive to PARP 
inhibitors induced genomic instability and apoptosis (Kelley, Logsdon et al. 2014). Treatment of 
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Brca1−/−, p53−/− mouse model (TNBC tumors) respond effectively to PARP inhibitor, 
AZD2281 (Rottenberg, Jaspers et al. 2008). Further, combination of the PARP inhibitor with 
cisplatin resulted in improved survival compared to the vehicle and single drug treatment arms 
(Rottenberg, Jaspers et al. 2008). Further, a phase II clinical trial to examine the safety and 
tolerability of the PARP inhibitor, olaparib in 54 advanced breast cancer patients with BRCA1 or 
BRCA2 mutation, showed that 41% of patients had objective clinical response (Tutt, Robson et 
al. 2010). This has led to the FDA approval of the PARP inhibitors, olaparib, rucaparib and 
more recently niraparib have been for the treatment of advanced BRCA mutant ovarian 
cancers (2017, Lin and Kraus 2017). They are currently one of the most promising targeted 
therapies under investigation for TNBC, and the combination of the PARP inhibitors with 
standard chemotherapy have also been shown to be beneficial for breast cancer patients 
(2014, 2017, Lin and Kraus 2017). 
 
9.1.5. GAP IN KNOWLEDGE 
 Given that studies at understanding the mechanisms of acquired resistance to CDK4/6 
inhibition are just beginning to emerge, an extensive exploratory study is needed to identify 
drugs that can effectively target the acquired resistant tumors. While Rb loss and CCNE1 
amplification, which are known mechanisms of G1/S deregulation, are the currently predicted 
mechanisms of acquired resistance, it is possible that the resistant cells have alterations that 
are beyond the cell cycle. Hence, experiments performed in this chapter aim at answering 
these voids in the current literature and devising a durable and effective treatment strategy for 
acquired resistance to palbociclib and other CDK4/6 inhibitors.  
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9.2. RESULTS 
9.2.1. DEVELOPMENT AND CHARACTERIZATION OF PALBOCICLIB RESISTANT CELLS 
To interrogate the mechanism of acquired resistance to palbociclib, the ER positive 
breast cancer cell lines, MCF7 and T47D were treated with increased with increasing doses of 
palbociclib over a 6-month period (Figure 68A). The treatment was started at the IC50 value of 
palbociclib, at 1uM. Once the cells began proliferating at this dose, the concentration was 
increased by 2-fold (i.e. to 2uM) and maintained at that dose until the cells proliferate at that 
dose. This was continued until the cells reached a dose of 6uM, to generate the palbociclib 
resistant cell lines (pool). With the goal of identifying multiple different mechanisms by which 
cells might acquire resistance to the drugs, numerous clones were isolated from the resistant 
cell pools, of which 3 from each cell lines were utilized for further analysis.  
Next, dose response study was performed to examine the proliferation of the three 
MCF7 and T47D resistant clones in the presence of palbociclib and results showed a 
significant (upto 10-fold difference compared to the parental cells) resistance to palbociclib 
(Figure 68B – left and middle panels). Moreover, one of the most resistant clones in each cell 
lines (cl3 for MCF7 and cl2 for T47D) were chosen for further analysis and henceforth referred 
to as MCF7 Res and T47D Res (Figure 68B – right panel). Additionally, clonogenic assays 
showed that palbociclib treatment had no significant on the proliferation of MCF7 and T47D 
resistant cells, while inducing a dose-dependent reduction in colony formation the parental cell 
(Figure 68C). Moreover, cell cycle analysis showed that palbociclib treatment did not induce a 
G1 arrest in the MCF7 and T47D cells (Figure 68D), indicating that the resistant cells are 
indeed resistant to palbociclib induced G1 arrest. Finally, to examine if the palbociclib resistant 
cells are also resistant to the other CDK4/6 inhibitors such as ribociclib and abemaciclib, dose 
response studies were performed, which showed that the palbociclib resistant MCF7 and T47D 
cells were also significantly cross resistant to ribociclib and abemaciclib (Figure 68E), 
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exhibiting a >5-fold and >10-fold increase in IC50 values respectively (Figure 68F), when 
compared to the parental cells.  
Thus, these results showed that the acquired resistant cells developed are resistant to 
palbociclib and cross-resistant to the other CDK4/6 inhibitors as well. 
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Figure 68: Development and characterization of palbociclib resistant cells: A) Schematic 
showing the method by which the resistant cells were developed from MCF7 and T47D parental cells. 
B) Dose response studies measuring the impact of treating with varying concentrations of palbociclib 
(0.01 to 12 uM) on the proliferation of MCF7 and T47D parental and resistant cell lines. MCF7 and 
T47D cells parental and resistant cells were treated with palbociclib (Palbo) for 6 days and and 
subjected to C) clonogenic assay to measure impact on cell proliferation and D) flow cytometry to 
measure effect on cell cycle. E,F) Dose response studies measuring the impact of treating with 
varying concentrations of ribociclib or abemaciclib (0.01 to 12 uM) on the proliferation of MCF7 and 
T47D parental and palbociclib resistant cell lines, and their corresponding IC50 values (F). 
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9.2.2. GENE EXPRESSION PROFILE OF PALBOCICLIB RESISTANT CELLS 
 Understanding the changes in gene and protein expression between the sensitive 
(parental) and the resistant cell lines will help design treatments to overcome drug resistance. 
Hence, we performed genome-wide expression analysis via mRNA-seq on the isolated clones 
belonging to MCF7 and T47D cell lines to detect change in mRNAs and examine the pathways 
altered between the parental and the resistant cell lines (Figure 69A). Results from the RNA 
seq analysis by non-hierarchical clustering (clustering based on gene expression) revealed that 
2888 genes were differentially expressed (p<0.05) when compared to parental (sensitive) 
(Figure 69B), showing that acquired resistance significantly alters the gene expression profile 
of the ER positive breast cancer cells. 
 To understand the functional significance of these mRNA alterations and identify the 
pathways that are altered, gene set enrichment analysis (GSEA) was performed which 
compared the change in expression between the parental and the resistant T47D cells, 
focusing on the 50 hallmark gene sets (Figure 69C). This showed that some of the top 
upregulated pathways in the resistant cells include epithelial mesenchymal transition (EMT) 
and developmental or cancer stem cell (CSC) associated pathways such as IL-6/STAT-3, 
Notch and Wnt signaling pathways (Figure 69C). Further, one of the crucial and actionable 
downregulated pathways includes the DNA repair and the double DNA repair pathways (Figure 
69C). The estrogen response (early and late) pathways were also shown to be downregulated 
in the resistant cells (Figure 69C), indicating that the ER positive breast cancer cells may not 
be less dependent on estrogen signaling. Moreover, the list of upregulated pathways also 
includes numerous immune response pathways such as Interferon alpha, Interferon gamma, 
TNF alpha via NFKb, cytokine biosynthesis and production, cytokine chemokine signaling and 
IL-6 STAT-3 pathway (Figure 69C). This indicates that resistance to palbociclib might be 
activating an immune response in these cells, and can be investigated in the future as a 
potential avenue for therapy.  
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 Thus, gene expression analysis study showed a distinctly altered gene expression 
profile in the resistant cells and identifies numerous pathways that can be potentially targeted 
upon acquired resistance to CDK4/6 inhibitors.   
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Figure 69: Gene expression profile of palbociclib resistant cells: A) Schematic 
showing how the resistant cells and clones were developed and utilized for RNA-seq
analysis. B) Heat map constructed by non-hierarchical clustering to show the differential 
expression of genes between the parental and resistant cells as determined by RNA-seq
analysis. Heat map shows genes with FDR < 25% and p-value <0.05. C) Graph showing 
the top 12 upregulated and downregulated pathways in the palbociclib resistant cells as 
obtained from Gene set enrichment analysis (GSEA) in comparison with the parental cells 
from the RNA-seq data.
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9.2.3. EMT AND CANCER STEM CELL PROPERTIES IN PALBOCICLIB RESISTANT 
CELLS 
 Given the phonotypic changes observed in the resistant cells (resistant cells have a 
more mesenchymal phenotype compare to the epithelial MCF7 and T47D parental cells), and 
the upregulation of the EMT pathway by GSEA analysis (Figure 70A), we next wanted to 
directly examine if the resistant cells have acquired an EMT phenotype. To test this, we first 
examined the mRNA levels of EMT markers and transcriptional factors in the parental vs 
resistant cells via qRT-PCR, which showed a significant decrease in the epithelial marker, E-
cadherin and a significant increase in the mesenchymal markers, Vimentin and N-cadherin 
(Figure 70B). Further, there was a significant increase in the mRNA levels of the known EMT 
transcription factors such as Snail, Twist and Slug in the resistant cells compared to parental 
cells (Figure 70B). We also examined the migratory ability of the resistant cells via scratch 
assay, which showed that the MCF7 and T47D palbociclib resistant cells had a much higher 
percentage of wound closure compared to the parental cells (Figure 70C).   
 Cancer stem cells (CSCs) are known to mediate resistance to numerous therapies 
including aromatase inhibitors in ER positive breast cancer. This, along with the enrichment of 
numerous developmental pathways in the resistant cells measured by GSEA analysis (Figure 
69C), led us to examine any changes in the cancer stem cell population. First, we examined 
the CSC markers and transcription factors, which showed significant upregulation CD133, a 
cancer stem cells, CD44, FoxC2 and ALDH1, markers of breast cancer stem cells and other 
known stem cell makers, Oct4, Sox2 and Nanog (Figure 70D). Next, we used flow cytometry 
analysis to measure the percentage of CD44high/CD24low and ALDH+ve population in the 
resistant cells, both established markers and measures of breast cancer stem cells. Results 
showed that the palbociclib resistant MCF7 and T47D cells have a significantly CD44high/ 
CD24low (Figure 71A) and ALDH+ve population (Figure 71B) compared to the respective 
parental cell lines, indicating increased cancer stem cells with drug resistance. To further 
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confirm this, we performed the mammosphere assay, which measures the sphere forming 
ability of the cells, another measure of breast cancer stem cells, with mammosphere formation 
over passages (primary and secondary mammosphere) being a better indictor (Rota, Lazzarino 
et al. 2012). Results showed that the palbociclib resistant cells have a significantly increased 
ability (larger and greater number of mammospheres) to form both primary and secondary 
mammospheres compared to the MCF7 and T47D parental cells (Figure 71C).  
 Thus, these results show that the palbociclib resistant cells have increased EMT and 
cancer stem cell phenotype, which might be the significant contributor of resistance in these 
cells. Hence, targeting these processes might prove as an ideal strategy to combat drug 
resistance. 
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B
Figure 70: EMT properties in palbociclib resistant cells: A) Enrichment plot of the Epithelial 
Mesenchymal Transition (EMT) pathway obtained by Gene set enrichment analysis (GSEA) 
between T47D resistant and parental cell lines. B) qRT-PCR measuring the mRNA expression 
of EMT genes relative to GAPDH in palbociclib sensitive vs resistant cells C) Scratch assay 
used to measure migration ability of the MCF7 and T47D parental vs resistant cells and its 
quantification (% wound closure). D) qRT-PCR measuring the mRNA expression of cancer stem 
cell related genes relative to GAPDH in palbociclib sensitive vs resistant cells. p-values were 
calculated in comparison to Parental (sensitive) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001.
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B
Figure 71: Cancer stem cell properties of palbociclib resistant cells: A) Flow cytometry 
analysis measuring the percentage of CD44 high CD24 low population of cells and quantification 
in palbociclib sensitive vs resistant cells. B) Flow cytometry analysis measuring the percentage 
of ALDH high cells in palbociclib sensitive vs resistant cells. C) Representative pictures and 
quantification of primary and secondary mammospheres in the parental vs resistant cells. p-
values were calculated in comparison to Parental (sensitive) unless indicated. ns: p>0.05; 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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9.2.4. TARGETING IL-6/STAT-3 PATHWAY IN PALBOCICLIB RESISTANT CELLS 
Next, we utilized the gene expression and GSEA data (Figure 62) to identify which 
cancer stem cell regulating pathway can be targeting in the palbociclib resistant cells. Given the 
recently elucidated role of the IL-6/STAT-3 pathways in modulating cancer stem cells and drug 
resistance (Lin, Hutzen et al. 2013, Sansone, Ceccarelli et al. 2016), and the observed 
increase in the IL-6/STAT-3 pathway in the palbociclib resistant cells from GSEA analysis 
(Figure 72A), we focused on this pathway. As a first step, we examined IL-6 mRNA levels, 
which exhibited a >12-fold in the palbociclib resistant cells compared to the MCF7 and T47D 
parental cells (Figure 72B). Further, to interrogate the role of STAT-3 in the palbociclib 
resistant cells, we treated with two known STAT-3 inhibitors, Stattic and napabucasin 
(Marcucci, Rumio et al. 2016), which significantly decreased proliferation of the MCF7 and 
T47D resistant cells and these drugs were relatively more specific to the resistant cells 
compared to parental (Figure 72C). Napabucasin is a recently developed STAT-3 inhibitor that 
has been specifically shown to target cancer stem cells (Marcucci, Rumio et al. 2016, Zhang, 
Jin et al. 2016). Hence, we interrogated the role of STAT-3 in increasing cancer stem cells and 
mediating drug resistance by CD44high/CD24low measurement and mammosphere assay. 
Results showed that treatment with a STAT-3 inhibitor, napabucasin significantly decreased the 
CD44high/CD24low CSC population (Figure 72D) and mammosphere formation (Figure 72E).  
Thus, these results indicate that the IL-6/STAT-3 pathway plays a crucial role in driving 
cancer stem cells and palbociclib acquired resistance ER positive breast cancer. 
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Figure 72: Targeting IL-6/STAT-3 in palbociclib resistant cells: A) Enrichment plot of the 
IL-6 STAT-3 pathway pathway obtained by Gene set enrichment analysis (GSEA) between 
T47D resistant and parental cell lines. B) qRT-PCR measuring the mRNA expression of IL-6 
relative to GAPDH in palbociclib sensitive vs resistant cells C) Dose response studies 
measuring the impact of treating with treatment with the STAT-3 inhibitors, napabucasin and 
stattic on the proliferation of MCF7 and T47D parental and resistant cell lines. MCF7 and 
T47D parental and resistant cells were treated with 1uM napabucasin for 72 hours and 
subjected to D) Flow cytometry analysis measuring the percentage of CD44 high CD24 low 
population of cells and E) primary and secondary mammosphere formation. p-values were 
calculated in comparison to Parental (sensitive) unless indicated. ns: p>0.05; *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001.
A
C D
E
0.1 1 10
0
20
40
60
80
100
Napabucasin (uM)
%
 V
ia
bl
ili
ty
MCF7 Par
MCF7 Res
T47D Par
T47D Res
MCF7 T47D
0
3
6
9
12
15
18
R
el
at
iv
e 
G
en
e 
ex
pr
es
si
on
IL-6 Par
Res
**
**
MCF7 Res T47D Res
0
25
50
75
%
 C
D
44
+ 
/ C
D
24
- c
el
ls
Cnt Napabucasin
Res + NapabucasinMCF7 Resistant
Res + NapabucasinT47D Resistant
Res + Napabuc – 2oMCF7 Resistant – 2o
Res + Napabuc – 2oT47D Resistant – 2o
MCF7 T47D
0
200
400
600
N
o.
 o
f m
am
m
os
ph
er
es
20 Mamm
MCF7 T47D
0
200
400
600
800
N
o.
 o
f m
am
m
os
ph
er
es Cnt
Napabucasin
10 Mamm
1 10
0
20
40
60
80
100
Sttatic (uM)
%
 V
ia
bl
ili
ty
MCF7 Par
MCF7 Res
T47D Par
T47D Res
B
	 243 
9.2.5. TARGETING DNA REPAIR DEFICIENCY IN PALBOCICLIB RESISTANT CELLS 
 Given that the DNA repair and double stranded break repair are one of the top 
downregulated pathways in the RNA-seq and GSEA analysis (Figure 66A), and that cells 
deficient in DNA repair can be hypersensitive to DNA damaging agents and PARP inhibitors, 
we examined the possibility of targeting DNA repair deficiency in palbociclib resistant cells. 
First, we examined the expression of crucial double strand break repair genes, Rad51, BRCA1 
and BRCA2, all of which significantly decreased in the palbociclib resistant MCF7 and T47D 
cells compared to the parental (Figure 73B). Further, the sensitivity of the resistant cell to the 
PARP inhibitors, olaparib and niraparib were examined through a dose-response assay (72 
hour treatment and 9 days recovery), which caused significant dose-dependent reduction in 
cellular proliferation specifically in the palbociclib resistant cells compared to the parental 
(Figure 73C). A similar response was seen with the Wee1 kinase inhibitor, AZD1775 (shown 
previously to induce genomic instability (Vriend, De Witt Hamer et al. 2013), where the resistant 
cells exhibit durable and increased sensitivity (Figure 73C). However, as expected, treatment 
with the PARP inhibitors (olaparib and niraparib) or the Wee1 kinase inhibitor did not affect the 
increase cancer stem cell population in the resistant cells (Figure 73D), indicating these drugs 
possible affect the proliferation of the non-cancer stem cell population in the resistant cells. 
This indicates that targeting the DNA repair deficiency with PARP inhibitors could be an 
effective therapy to treat palbociclib resistance.  
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Figure 73: Targeting DNA repair deficiency in palbociclib resistant cells: A) Enrichment plot of 
the DNA repair pathway pathway obtained by Gene set enrichment analysis (GSEA) between 
T47D resistant and parental cell lines. B) qRT-PCR measuring the mRNA expression of DNA 
repair genes (Rad51, BRCA1, BRCA2) relative to GAPDH in palbociclib sensitive vs resistant cells
C) Dose response studies measuring the impact of treating with treatment with the PARP inhibitors, 
olaparib and niraparib and the Wee1 kinase inhibitor (AZD1775) on the proliferation of MCF7 and 
T47D parental and resistant cell lines. D) Flow cytometry analysis measuring the percentage of 
CD44 high CD24 low population of cells in MCF7 and T47D parental and resistant cells upon 
treatment with the PARP inhibitors or Wee1 kinase inhibitor for 72 hours. 
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9.2.6. COMBINED TREATMENT WITH STAT-3 AND PARP INHIBITORS IN PALBOCICLIB 
RESISTANT CELLS 
 While PARP inhibitors have anti-proliferative effects in palbociclib resistant cells, they 
do not affect the cancer stem cell population, which comprises of >60% of the cells in the 
resistant cell lines. Hence we examined if combining the PARP inhibitors with the drugs 
targeting the IL-6/STAT-3 pathway would facilitate killing of both the cancer stem cells and non-
cancer stem population within the resistant cells. 
 First, to examine the synergy between the two drugs, olaparib (PARP inhibitor) and 
napabucasin (STAT-3 inhibitor), we performed dose response studies with 72 hour treatment 
(and 9 days of recovery) of both the drugs, followed by calcusyn analysis in the palbociclib 
resistant MCF7 and T47D cells. The calcusyn software measures the combined effectiveness 
of two drugs from growth inhibition curves, generating combination index (CI) values, with 
values CI>1 as meaning antagonism, CI=1 meaning additivity and CI<1 meaning synergism 
between the two drugs being tested (Bijnsdorp, Giovannetti et al. 2011). Results indicated that 
the combination of the two drugs were highly synergistic, with CI values of 0.65 and 0.75 in the 
MCF7 and T47D resistant cells respectively (Figure 74A). Further, the combination of olaparib 
and napabucasin significantly decreased colony formation (Figure 74B) and inhibited growth 
(Figure 74C), compared to no treatment or treatment with either drugs as a single agent, in 
MCF7 and T47D palbociclib resistant cells. Finally, combined treatment with olaparib and 
napabucasin increased cell death via apoptosis in the palbociclib resistant cells (Figure 84D), 
when compared to no-treatment or single treatment controls. The increase in apoptosis was 
observed both at the end of treatment and 72 hour (in the absence of drug) post treatment, 
which showed further increase in apoptosis (Figure 74D). 
 Thus, these results indicate that combined treatment with the STAT-3 and PARP 
inhibitors is effective in targeting the palbociclib resistant cells. 
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Figure 74: Combined treatment with with STAT-3 and PARP inhibitors in palbociclib 
resistant cells: A) Combination indices (CI values) calculated from Calcusyn which 
measures synergy upon treatment with the combination of 0.5uM napabucasin and a 
varying concentrations of olaparib. B) Flow cytometry analysis to measure the percentage 
of CD44 high CD24 low population of cells upon treatment with 0.5uM napabucasin and 
1uM olaparib as a single drug or in combination for 72 hours. MCF7 and T47D parental and 
resistant cells were treated with the combination of 0.5uM napabucasin and 1uM olaparib
for 72 hours and subjected to C) clonogenic assay to measure change in proliferation, D) 
cell counting to measure proliferation and E) Annexin V PI staining to measure apoptosis at 
the end of treatment and after 3 days of recovery in the absence of the drugs.
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9.3. DISCUSSION 
 Studies in this chapter have identified novel mechanisms by which the ER positive 
breast cancer cells acquire resistance to palbociclib and through detailed gene expression 
arrays and validations, found treatment options that could work effectively in the resistant 
tumors. Taken together, the results show that targeting IL-6/STAT-3 mediated cancer stem 
cells and DNA repair deficiency by PARP inhibitors in combination can effective treat acquired 
resistance to palbociclib.  
 GSEA analysis of the RNA-seq data showed upregulation of numerous cytokine 
pathways including the IL-6/STAT-3 pathway. However, the origin or source of the IL-6 has not 
been interrogated in this chapter. One possibility is that the IL-6 is secreted by the tumor cells 
and undergoes autocrine activation of the pathway. Alternatively, the cytokines including IL-6 
may be secreted by cells when they undergo senescence in response to palbociclib in the early 
stage of development of the resistant cells. This phenomenon of the senescent cells secreting 
cytokines is terms as senescence associated secretory phenotype (SASP), and helps recruit 
immune cells to the tumor and eliminate the senescent cells (Coppe, Desprez et al. 2010).  
 Further, while studies in this chapter show that the IL-6 / STAT-3 pathway mediate the 
induction of cancer stem cells, there could be other pathways involved in this process. Results 
from chapter 4 show that CDK4/6 inhibition and palbociclib treatment triggers autophagy in the 
ER positive cells, which limit the efficacy of palbociclib. Moreover, studies have shown that 
autophagy induces and maintains cancer stem cells, mediating chemo-resistance, tumor 
recurrence and metastasis (Ojha, Bhattacharyya et al. 2015, Vitale, Manic et al. 2015). Hence, 
it is possible that apart from IL-6 / STAT-3, the autophagy pathway might also play a role in the 
induction of cancer stem cells in the palbociclib resistant cells.  
 Finally, GSEA analysis from the RNA-seq show the abundance of immune response 
pathways that are upregulated in the palbociclib resistant cells. While breast cancer tumors are 
not inherent tumorigenic, recent efforts have focused on making the breast tumors immune hot, 
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such that they recruit tumor infiltrating lymphocytes (TILs) and are made sensitive to 
immunotherapy such as checkpoint blockade, PD-1, PDL-1 and CTLA-4 therapy (Hartkopf, 
Taran et al. 2016). Thus, it is possible that the upregulation of these pathways might be 
indicative of immune response in these resistant tumors, which in turn can be targeted by 
immunotherapy. However, the model used for resistance studies have limitations since it a 
breast cancer cell lines model and is devoid of the system needed to study the effect of the 
microenvironment.   
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CHAPTER 10: CONCLUSIONS AND FUTURE DIRECTIONS 
 
10.1. MAJOR FINDINGS 
 Deregulation of the cell cycle is a common hallmark of cancer leading to uncontrolled 
proliferation and tumorigenesis. This makes the cell cycle an attractive target for drug 
development and have led to the development of the CDK4/6 inhibitors in the recent years. The 
CDK4/6 inhibitors, palbociclib and ribociclib are currently FDA approved in combination with 
aromatase inhibitors, for the treatment of ER positive breast cancer. Further, they are currently 
under clinical investigation for other indications and other cancers, while a third drug, 
abemaciclib is under FDA review. Despite these promising clinical advances with CDK4/6 
inhibitors, the treatment has some major clinical limitations, addressing which was the main 
goal of the project.  
 First, to understand the mechanism by which the CDK4/6 inhibitor acts, we utilized ER 
positive breast cancer cells, MCF7 and T47D and xenograft mouse models developed from the 
MCF7 cell lines. Our results showed that palbociclib treatment induced a dose-dependent 
induction of sustained growth inhibition, cell cycle arrest (G1 arrest) and ROS-mediated 
senescence in vitro and in vivo. The study further demonstrated that on-target (low doses) 
inhibition of CDK4/6 via palbociclib failed to mediate a durable and irreversible growth inhibition 
or significant senescence in this model system. Upon investigation, it was found that these 
doses of palbociclib or genetic inhibition of CDK4/6 triggers autophagy, a stress response 
process, that enables the cells to proliferate and survive even in the presence of the inhibitor. 
This phenomenon was seen in cell lines in vitro and xenograft tumors in vivo, and mediates 
resistance to the induction of senescence by palbociclib (Figure 75).  
More significantly, molecular ablation or pharmacological inhibition of autophagy 
significantly improves the efficacy of the CDK4/6 inhibitors, palbociclib, ribociclib and  
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abemaciclib, resulting in the induction of an irreversible growth inhibition, cell cycle arrest and 
senescence even at low doses of the palbociclib. This synergistic effect between palbociclib 
and autophagy inhibitors was verified in vivo using two different autophagy inhibitors, 
hydroxychloroquine and Lys-05, both of which showed significant improved tumor growth 
inhibition and senescence in combination with low dose palbociclib. This synergistic effect 
of the combination was also observed in triple negative breast cancer (TNBC) cell lines in vitro 
and TNBC PDX models in vivo. Synergism between palbociclib and autophagy inhibition was 
also observed in other cancers such as ovarian, lung, colon, pancreatic and prostate 
Cancer'cells'with'
intact'G1/S'checkpoint
(Rb+'/'LMWE=)
Autophagy Senescence
Low'
dose
Palbo
Low'
dose
Palbo
Autophagy
inhibitor
Autophagy
Residual0ROS
Irreversible
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Reversible0G10arrest
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Figure 75. Overall working model: Schematic depicting the role of CDK4/6 
inhibition (i.e., palbociclib [Palbo]) and combined CDK4/6 and autophagy inhibition in 
regulating autophagy, reactive oxygen species (ROS), and senescence in cancer 
cells with intact G1/S transition. 
	 251 
cancer, where the combination induced a sustained and irreversible growth inhibition even with 
low dose of palbociclib. 
Further, biomarker identification studies showed that an intact G1/S checkpoint is 
crucial for the cancer cells to response to CDK4/6 inhibition and mediate a sustained growth 
inhibition and senescence. We show that the intact G1/S checkpoint can be identified by 
presence of Rb and absence or low expression of LMWE (low molecular weight isoforms of 
cyclin E). This ability of Rb and LMWE (cytoplasmic cyclin E) in combination to predict 
response to palbociclib was performed in tumor tissues from palbociclib treated patients, which 
showed that Rb and LMWE are reliable prognostic markers for palbociclib, Our immediate 
goals are to evaluate the predictive values of Rb/LMWE in pre and post palbociclib treated 
patients and interrogate if those patients with an intact G1 to S transition respond better to 
therapy as compared to those patients whose tumors show a deregulation of the G1/S 
transition. Further, since autophagy induction is a response to palbociclib mediated drug action, 
we show that Rb and LMWE can also serve as biomarkers for the combination of CDK4/6 
and autophagy inhibitors.   
 Finally, studies to identify acquired resistance to palbociclib showed that the acquired 
resistant cells had a significantly different gene expression profile compared to the parental 
(sensitive) cells, with numerous upregulated and downregulated pathways. Functionally, we 
show that the resistant cells exhibit IL-6/STAT-3 mediated upregulation of EMT and cancer 
stem cell pathways and downregulation of the DNA repair pathway. Thus, targeting these 
pathways in combination using STAT-3 and PARP inhibitors proved highly effective in reducing 
the cancer stem cell population and inducing cell death in the palbociclib resistant cells. We 
also show that there is a strong cross resistance between palbociclib and other CDK4/6 
inhibitors, suggesting that alternative drug strategies need to be devised to treat all the patients 
who are being treated with any of the CDK4/6 inhibitors. 
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10.2. SIGNIFICANCE 
 Results from this study are highly translatable and clinically relevant with the potential of 
making a significant impact on the lives of patients with breast and other cancers.  
 While there are numerous mechanistic studies with the CDK4/6 inhibitors, no study till 
date has examined in the detail dose dependent effect of the drug and its reversibility. Further, 
most studies examine a short-term effect of the drug (72 hour treatment with concentrations 
lower than 1uM), which based on our studies can only induce a reversible growth inhibition and 
G1 arrest. Thus, our study addresses this limitation by examining the time and dose-dependent 
effect, making it a very clinically relevant model system to understand palbociclib mechanism.  
 Notably, the study unravels a novel link between palbociclib mediated CDK4/6 
inhibition, ROS, autophagy and senescence. This is the first detailed study till date to examine 
the ability of CDK4/6 inhibitors to induce autophagy in breast and other cancers. Given the 
protective nature of autophagy, this result has great therapeutic implications, which have been 
extensively analyzed in this study. With autophagy inhibitors, such as chloroquine and 
hydroxychloroquine being FDA approved, it makes translation of the combination therapy 
between CDK4/6 and autophagy inhibitors feasible and highly clinically relevant. Details of the 
proposed clinical trial are mentioned in the next section and a draft of the clinical trial protocol is 
in the appendix of this thesis.  
The proposed clinical trial with the drug combination would significantly improve the 
efficacy of the current treatment with CDK4/6 and aromatase inhibitors, and even improve the 
overall survival of patients – a result that has not been achieved with the current CDK4/6 
inhibitor treatments. This is based on our in vitro and in vivo preclinical data which showed that 
the drug combination improves efficacy not just in the presence of the drug, but helps achieve a 
lasting or durable effect even after drug removal. Further, the enhanced anti-tumor effect 
achieved in the ER positive xenografts and the TNBC PDX tumors in vivo were at a palbociclib 
dose of 25mg/kg, which is on-fifth the dose (150mg/kg), used in most pre-clinical studies with 
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palbociclib thus far. This suggests that the drug combination can help decrease the dose of 
palbociclib in the clinic, which would help lower adverse events in patients and prevent the 
need for any therapy discontinuation.  
This study also has identified reliable biomarkers for palbociclib, which is the need of 
the hour given that none of the previously predicted pre-clinical biomarkers were effective in the 
clinical setting. The study is novel since it proposes a dual biomarker strategy, that is simple to 
use in the clinical and can effectively identify responsive patients. Moreover, recent 
unpublished clinical data shows that the only reliable predictor of drug resistance in patients is 
the resistance to reduction in the phosphorylation or the hyperphosphorylation of Rb. Low 
molecular weight isoforms of cyclin E (LMWE), one of our proposed biomarkers is known to 
hyperphosphorylate Rb, making a clinically relevant biomarker. 
Finally, given that CDK4/6 inhibitors are currently the standard of care for ER positive 
breast cancer patients, and even responsive patients would eventually acquire resistance to 
therapy, understanding the mechanisms of acquired resistance to the drug is important. Thus, 
results from this study have identified two clinically relevant and druggable pathways that can 
be targeted in combination to effectively combat drug resistance. Further, the gene expression 
analysis performed also provided avenues for future research and drug development to target 
acquired resistance to CDK4/6 inhibitors. 
 Taken together, this is a highly comprehensive study that improves the selectivity and 
efficacy of CDK4/6 inhibitor treatment in the sensitive setting and has identified ways to target 
acquired resistance to the drug. 
 
10.3. FUTURE DIRECTIONS 
We report here that cancer cells activate autophagy in response to palbociclib, and that 
blockade of autophagy significantly improves the efficacy of CDK4/6 inhibition in vitro and in 
vivo in cancers with an intact G1/S transition.  
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Thus, this study provides strong pre-clinical data for a biomarker integrated clinical trial 
utilizing hydroxychloroquine (or other autophagy inhibitors such as Lys05) to potentiate the 
action of palbociclib. Given that HCQ is well tolerated and is currently in clinical trials to reverse 
hormonal and cytotoxic drug resistance, we first propose a Phase II clinical trial (in the 
neoadjuvant setting) in postmenopausal advanced ER+/HER2- breast cancer patients, treating 
them with the combination of low-dose palbociclib (75mg/day compared to the current standard 
dose of 125mg/day), HCQ, and letrozole using surrogate biomarkers such as Ki67 staining. 
Eligible patients will be selected on the basis of Rb and LMW-E expression assessed from 
baseline biopsy specimens. Prior to the combination treatment, patients would receive 
palbociclib for a week following which the levels of LC3 would be evaluated by IHC, comparing 
it to pre-treatment biopsy tissues. This would help confirm that autophagy is being induced in 
the patients upon treatment with palbociclib and provide a clinical rationale for the combination 
treatment. Details of this clinical trial protocol, which is currently under evaluation is attached to 
the appendix of this thesis.  
Results from this clinical trial would further support initiation of a definitive Phase III trial 
for the triple combination, possibly even extending this treatment to the TNBC subtype of 
breast cancer and other tumors evaluated in this study. Additionally, this would also support the 
utility of palbociclib + HCQ combination to treat RB+/LMWE- ER+ve breast cancer in the neo-
adjuvant setting. We predict that the combination of continuous low-dose palbociclib and HCQ 
would be more beneficial than standard-dose palbociclib (21 days on, 7 days off), allowing us 
to minimize palbociclib-mediated toxicities, avoid proliferative bursts that occur when 
palbociclib is stopped, and prolong overall patient survival – a goal that has not yet been met 
with currently approved palbociclib treatment combinations. Finally, given the pre-clinical data 
from this study, the combination of CDK4/6 and autophagy inhibition can be extended to the 
other CDK4/6 inhibitors as well clinically, further expanding the applicability of the study. 
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 While results from this study show that CDK4/6 inhibition induces autophagy, the 
molecular mechanism by which this occurs is not known. Some of the crucial autophagy genes 
such as Beclin-1 or class III PI3K proteins that are present in complex with Beclin-1, such as 
Vps34, are phophorylated as a mechanism of regualting autophagy induction (Hammond, 
Brunet et al. 1998). These proteins have direct CDK phosphorylation sites, although the role of 
CDK4 or CDK6 has not been shown in this process (Abrahamsen, Stenmark et al. 2012). 
Moreover, treatment with palbociclib was synergistic with the autophagy inhibitor Spautin-1, 
which regulates Beclin-1 through USP proteins (Shao, Li et al. 2014), suggesting that 
palbociclib mediated regulation of autophagy might occur at the initiation step. Hence, it is 
possible that the drug directly regulates autophagy by phosphorylating and regulating the 
activation of the autophagy proteins, Beclin-1 and Vps34, a potential mechanism that needs to 
be investigated further. 
Another important application of the study would be in the acquired resistance setting. 
Results the gene expression and GSEA analysis of the acquired resistant cells showed a 
significant enrichment in the immune response pathways. While, the system is not optimal to 
examine immune regulation due to the absence of the microenvironment, it still suggests that 
acquired resistance might be making the cells immune responsive. This would potentially make 
the ER positive breast tumors that have progressed on CDK4/6 inhibitors responsive to 
immune checkpoint blockade drugs such as PD-1, PDL-1 or CTLA-4 antibodies among others. 
This would open put a new avenue of treatment options for these patients and further advance 
the field immunotherapy in breast cancer. 
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Phase I/II Safety and Efficacy Study of Autophagy Inhibition with Hydroxychloroquine to 
Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib plus 
Letrozole for Stage I-III Estrogen Receptor-Positive and HER2-negative Breast Cancer 
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STUDY	SYNOPSIS	
	
Title Potentiation of palbociclib and letrozole with autophagy inhibition using 
hydroxychloroquine in the neoadjuvant setting (title on Pfizer IIT application) 
 
Phase I/II Safety and Efficacy Study of Autophagy Inhibition with Hydroxychloroquine 
to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib 
plus Letrozole for Stage I-III estrogen receptor-positive and HER2-negative Breast 
Cancer 
 
Study Type Phase I/II, Open Label, Interventional with biomarkers 
 
Overall 
Goal 
 
To demonstrate the clinical and biological impact of adding autophagy inhibition using 
hydroxychloroquine to palbociclib and letrozole in estrogen receptor-positive and 
HER2-negative early stage breast cancer 
 
Objectives 
(Phase I) 
Primary:  
 
Secondary:  
•  
Objectives 
(Phase II) 
Primary: 
To determine whether hydroxychloroquine added to low dose palbociclib and letrozole 
can increase the proportion of patients whose tumors achieve complete cell cycle arrest 
(CCCA, proportion with Ki67 ≤ 2.7%) 
 
Secondary 
• To determine the impact of adding hydroxychloroquine to low dose palbociclib and 
letrozole on breast tumor indices of proliferation, autophagy, senescence, cell cycle 
control and other intersecting pathways 
• Determine longer term clinical tumor responsiveness and tumor biomarkers indices 
(for patients who have extended pre-operative therapy, maximum 24 weeks) 
• To perform exploratory studies on blood-based tumor protein, DNA and RNA 
biomarkers 
• Obtain additional safety information for the combination of low dose palbociclib, 
letrozole and hydroxychloroquine 
 
Design Single center pre-operative (neoadjuvant)/”window” study, open-label with a lead-in 
Phase I dose escalation/safety/feasibility and dose-finding study, followed by a single 
arm Phase II efficacy study using primary endpoint of validated surrogate tumor 
biomarker of change in Ki67-based complete cell cycle arrest (CCCA) 
 
Sample 
Size 
Phase I:  18 patients 
Phase II: 30 patients 
 
Inclusion 
Criteria 
1. Signed written informed consent 
2. ECOG performance status 0-1 
3. Stage I-III estrogen invasive breast cancer, estrogen receptor-positive and HER2-
negative by ASCO/CAP criteria1, 2.  If Stage I, clinical tumor size must be ≥1.5 cm. 
4. Female and age ≥ 18 years and postmenopausal defined by: 
a. Age ≥ 55 years and 1 year or more of amenorrhea 
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b. Age < 55 years and 1 year or more of amenorrhea with LH and/or FSH 
levels in the postmenopausal range 
c. Age < 55 with prior hysterectomy but intact ovaries with LH and/or FSH 
levels in the postmenopausal range 
d. Status after bilateral oophorectomy (≥ 28 days prior to first study treatment) 
5. Surgical candidate and appropriate for pre-operative endocrine (endocrine) therapy 
6. Normal hematological, renal, hepatic function 
a. ANC ≥ 1500 cells/µl 
b. Platelet count ≥ 100,000/µl 
c. Serum creatinine concentration < 1.5 x ULN 
d. Bilirubin level < 1.5 x ULN 
e. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <3 x 
ULN 
 
Exclusion 
Criteria 
1. Inoperable or metastatic breast cancer based on standard evaluation 
2. Inflammatory breast cancer or any clinical T4 disease 
3. History of retinal disease or active visual disturbances(normal baseline retinal exam 
required) 
4. Prior therapy for breast cancer (medical, surgical or radiation therapy) 
5. Acute illness, including infections requiring medical therapy, known bleeding 
diathesis or need for anticoagulation 
6. Treatment with any of the following medications within 4 weeks before the 
baseline diagnostic biopsy is taken: 
a. Oral estrogens, including hormone replacement therapy (but prior depot 
estrogen use not allowed); 
b. Investigational agents (or 5 half-lives, whichever is longer) 
7. Psychological, familial, sociological or geographical conditions that do not 
permit compliance with the study protocol. 
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1.0 		INTRODUCTION	
	
1.1 Background	
	
1.1.1 Hormone	receptor-positive	breast	cancer	
Breast cancer is the most common female cancer in the United States. It is estimated 
that 252,710 American women will be diagnosed with breast cancer and 40,610 will die from 
the disease in 2017.3 A major cause of death in these patients is disease progression and 
incurable metastasis. The SEER database estimates that ~40,000 breast cancer patients a 
year either present at diagnosis (n=13,900) with metastatic disease or exhibit progression with 
metastatic disease, sometimes many years after completing therapy for early stage disease 
(n=36,000).4 Of these, an estimated 30,000 have estrogen receptor (ER)-positive breast 
cancers.4 Hence, patients with ER+ metastatic breast cancer (MBC) represent a majority of 
breast cancer who die of their disease, the vast majority due to metastatic progression. 
 
1.1.2 Therapies	for	hormone	receptor-positive	breast	cancer	
In early stage estrogen receptor-positive (ER+) breast cancer, the use of adjuvant 
endocrine therapy (tamoxifen or aromatase inhibitors) lowers the relative risk of recurrence at 
10 years by 45 to 50% and that of mortality by breast cancer death by 30%.5 In the metastatic 
setting endocrine therapy can induce responses and delay progression of disease. However, in 
the metastatic setting, it has been difficult to demonstrate a survival benefit of endocrine 
therapy.  Few modern-day trials have compared endocrine therapy to no endocrine therapy in 
the absence of chemotherapy since treatment induces clear palliation.  More recent trials 
comparing single-agent to combination endocrine therapy agents (e.g. aromatase inhibitors 
plus the ER downregulator fulvestrant) have yielded mixed results.6, 7 In the last few years, the 
addition of biological therapies that were designed to address mechanisms of resistance or with 
demonstration of preclinical synergy have shown improvements in disease-free survival when 
added to endocrine therapy, but no impact on overall survival - although these trials were not 
designed with the statistical power to survival differences, with disease-free survival designated 
as the primary endpoint.  The addition of the mTOR inhibitor everolimus doubled median 
disease-free survival from 4.1 to 10.6 months when added to the aromatase inhibitor 
exemestane as second-line therapy and was approved by the FDA with final survival analysis 
showing no significant difference in that outcome (median survival of 31.0 vs. 26.6 months).8, 9 
Other biological agents such as PI3 kinase inhibitors, histone deacetylase inhibitors and cyclin-
dependent kinase CDK) inhibitors are being actively tested in first, second and later lines of 
therapy - so far CDK 4/6 inhibitor palbociclib has been approved by the FDA as outlined in the 
next section.  
In summary, the treatment of ER+ breast cancer is focused on using endocrine therapy 
initially as trials have not shown clear benefits of more aggressive chemotherapy up front, and 
such approaches are only recommended for rapidly progressing visceral and high burden 
disease.  Sequential use of endocrine therapies (including with approved biological drugs 
everolimus and palbociclib) upon progression is the standard approach, with a switch to 
chemotherapy when it is felt that the tumor is unresponsive to any endocrine therapy.10 In 
contrast to HER2+ breast cancer, where the use of HER2-targeted drugs, particularly the 
antibodies trastuzumab and pertuzumab have yielded significant survival benefits, the same 
advances are lacking in ER, HER2-negative breast cancer, representing a majority of all cases 
and hence representing a clear unmet need.  Finally, it should be noted that the definition of 
hormone receptor-positive breast cancer includes tumors that are positive for either estrogen or 
progesterone receptor (ER or PR).1 While the ER+/PR- subgroup is relatively common, about 
one third of all cases, and is clearly responsive to endocrine therapy, the same cannot be said 
for the rare ER-/PR+ group and hence this trial is only focusing on ER+ cases. 
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1.1.3 Palbociclib	and	use	in	breast	cancer	
Palbociclib	is	a	potent	and	specific	cyclin-dependent	kinase	4/6	(CDK4/6)	inhibitor	and	anti-
proliferative	agent	that	induces	G1	arrest	and	prevents	breast	cancer	cell	growth,	most	notably	in	ER+	
cell	lines	and	other	preclinical	models,	which	led	to	the	clinical	development	of	this	class	of	inhibitors	in	
hormone	receptor-positive	breast	cancer.11-13	Palbociclib	was	approved	by	the	FDA	in	February,	2015	
based	on	improved	time	to	disease	progression	in	the	first	and	second-line	settings	for	ER+/HER2-
negative	metastatic	breast	cancer	(MBC).14-17	In	the	pivotal	first-line	Phase	III	trial,	progression-free	
survival	(primary	endpoint)	was	improved	from	14.5	to	24.8	months	with	the	addition	of	palbociclib	to	
the	standard	first-line	aromatase	inhibitor	letrozole.15	In	the	second-line	setting,	the	addition	of	
palbociclib	to	the	standard	second-line	estrogen	downregulate	fulvestrant	in	a	Phase	III	trial	also	
demonstrated	a	significant	improvement	in	time	to	progression	from	3.8	to	9.2	months.		
However	in	the	first	line	setting,	66%	of	patients	on	the	palbociclib	experienced	grade	3	and	4	
neutropenia,	and	adverse	events	necessitate	a	palbociclib	dose	reduction	in	36%	and	discontinuation	in	
7.4%	of	patients.15	Additionally,	palbociclib	must	be	dosed	with	a	7-day	break,	which	was	shown	to	be	
associated	with	a	proliferative	burst	in	a	separate	neoadjuvant	serial	biopsy	study.18	Also,	a	precise	
biological	mechanism	of	palbociclib’s	action	is	still	unknown	and	there	are	no	known	independent	
biomarkers	to	predict	response	and/or	resistance	to	palbociclib	–	many	patients	do	not	respond	to	
therapy,	and	most	importantly,	virtually	all	eventually	develop	resistance.		Biomarkers	that	may	
influence	response	to	endocrine	therapy	and	CDK	inhibitors	including	estrogen	receptor-alpha	(ESR1)	
and	PIK3CA	mutations,	loss	of	the	retinoblastoma	protein	function,	proliferative	antigen	Ki67	
expression,	cyclin	D	1	amplification	or	loss	of	the	cyclin-dependent	kinase	inhibitor	p16	have	not	shown	
to	be	related	to	palbociclib-associated	response	or	time	to	progression.13,	17,	19	Importantly,	no	survival	
benefit	yet	observed	in	either	of	the	larger	randomized	trials	or	smaller	Phase	II	trial,	although	these	
trials	were	not	powered	for	survival	differences	and	diversity	of	therapies	that	patients	may	receive	in	
their	subsequent	management	may	cloud	future	survival	update	analyses.		
	
1.2 Mechanisms	of	Resistance	to	Endocrine	Therapy	and	Rationale	for	the	use	of	Autophagy	
inhibition	with	Hydoxychloroquine	
	
While	specific	mechanisms	of	resistance	to	palbociclib	have	not	been	well	characterized,	there	
are	several	mechanisms	of	resistance	to	conventional	endocrine	therapies	such	as	tamoxifen	and	
aromatase	inhibitors,	which	include	activation	of	receptor	tyrosine	kinase	signaling	pathways	(notably	
the	PI3K/Akt/mTOR	pathway),	activation	mutations	in	ESR1	and	other	more	general	alterations	such	as	
epigenetic	regulation	of	gene	expression	other	intersecting	pathways	like	NFKB	and	JAK/STAT.20	As	
described	earlier,	mTOR	and	CDK4/6	inhibition	with	everolimus	and	palbociclib	are	now	approved	as	
biological	agents	in	combination	with	endocrine	therapy,	while	strategies	using	inhibitors	of	PI3K,	Akt,	
histone	deacetylase	are	undergoing	testing,	none	so	far	has	been	able	to	induce	durable	enough	
responses	to	affect	survival,	and	clinical	resistance	still	emerges	with	all	available	therapies.	
	
Our	laboratory	research	group,	led	by	Khandan	Keyomarsi,	PhD,	Professor	of	Experimental	
Radiation	Oncology	at	MD	Anderson,	has	an	extensive	investigational	track	record	in	area	the	cell	cycle	
pathways	in	breast	cancer.	We	have	shown	that	at	low	concentrations	of	the	palbociclib,	ER+	breast	
cancer	cells	arrest	in	the	G1	phase	of	the	cell	cycle,	but	this	arrest	is	reversible	due	to	the	activation	of	
autophagy.	However,	at	high	concentrations	of	palbociclib,	the	cells	are	arrested	irreversibly	in	G1,	do	
not	undergo	autophagy	and	instead	undergo	senescence.	The	low	concentration	of	palbociclib	are	on-
target	and	are	specific	for	inhibition	of	CDK4	and	CDK6,	as	shown	with	siRNA	assays	where	CDK4	and	
CDK6	where	knocked	down.		The	high	concentrations	of	palbociclib,	induce	senescence,	but	these	are	
off	target	effects	of	the	drug.	We	also	demonstrated	that	if	we	combine	palbociclib	with	an	autophagy	
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inhibitor	such	as	hydroxychloroquine	(HCQ),	we	can	achieve	senescence	at	a	much	lower	(i.e.	on-	
target)	and	continuous	dosing	of	palbociclib,	in	both	in	vitro	and	in	vivo	models.	Moreover,	concomitant	
treatment	with	HCQ	and	palbociclib	can	mediate	a	synergistic	response	in	ER+	xenograft	(MCF7)	mouse	
tumor	volume	and	weight	compared	to	palbociclib	alone.	More	strikingly,	the	tumor	volumes	with	
combination	treatment	did	not	increase	even	after	the	treatment	was	stopped,	while	the	tumor	
volumes	with	either	palbociclib	or	HCQ	alone	continuously	increased	during	both	the	treatment	and	
recovery	phases	of	the	experiment.	Combination	treatment	showed	the	desired	and	expected	
impairment	in	autophagic	flux.	Decrease	in	Rb	phosphorylation,	a	direct	readout	of	CDK	4/6	inhibition,	
was	more	pronounced	with	the	addition	of	HCQ.	These	results	suggest	that	autophagy	inhibition	
significantly	improves	the	efficacy	of	low	dose	(on	target)	palbociclib	in	vivo	and	facilitates	the	
induction	of	an	irreversible	tumor	growth	inhibition.	We	propose	that	palbociclib	activates	the	
autophagy	pathway	to	protect	ER+	breast	cancer	cells	from	palbociclib-induced	senescence	and	
inhibition	of	autophagy	sensitizes	cells	to	lower	doses	of	palbociclib	in	vitro	and	in	vivo	(Figure	1).		
	
We	therefore	propose	using	HCQ	to	inhibit	autophagy	in	patients	treated	with	low	dose	(on	
target)	palbociclib	and	letrozole	to	demonstrate	enhanced	
anti-proliferative	effect.		An	anti-
proliferative	effect	of	endocrine	therapy	
using	quantification	of	the	proliferative	
Ki67	antigen	has	been	validated	as	a	long-
term	predictor	of	outcome.			HCQ	is	a	
commonly	used	and	generally	safe	drug	
used	to	treat	malaria	and	as	a	remittive	
agent	for	various	autoimmune	diseases	
(see	more	expanded	description	in	Section	
6.2).	This	trial	will	therefore	provide	
evidence	of	a	promising	therapeutic	effect	
with	lower	dose	palbociclib	plus	letrozole	
for	a	greater	therapeutic	effect	with	less	
side	effects.	This	is	needed	before	
proceeding	with	a	more	definitive	trial	that	
could	be	potentially	practice-changing.	
	 	
Figure	1:		Model	for	Hydroxychloroquine	to	
Inhibit	Autophagy	and	Potentiate	Palbociclib	
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1.3 Rationale	for	the	Use	of	Pre-operative	(Neoadjuvant)	or	“Window”	Endocrine	Therapy	
	
We	have	chosen	to	perform	this	trial	using	the	combination	of	letrozole,	palbociclib	and	HCQ	in	the	pre-
operative	(neoadjuvant)	“window”	setting	after	careful	deliberation	internally	and	advice	from	both	
internal	and	external	advisory	board	members	during	the	process	of	a	grant	proposal	submission	that	
led	to	the	successful	funding	of	both	the	laboratory	and	clinical	trial	aims	of	this	project.			
The	following	rationale	support	this	approach:		
• Palbociclib	is	already	FDA-approved	for	metastatic	breast	cancer	with	an	excellent	safety	
record.	It	is	currently	in	several	clinical	trials	in	both	the	neoadjuvant	and	adjuvant	settings.	
• Treatment	will	include	letrozole,	a	standard	endocrine	therapy	as	is	used	clinically	for	early	
stage	breast	cancer.	
• HCQ	is	an	approved	drug	commonly	used	for	malaria	and	autoimmune	disease	and	particularly	
safe	when	used	at	the	doses	and	timeframes	proposed	(see	more	expanded	description	in	
Section	6.2).	
• This	model	allows	for	safe	biopsies	as	needed	for	the	correlative	tissue	aims	and	eliminates	
artifact	and	variability	due	to	prior	therapies	as	all	patients	will	be	previously	untreated.	
• The	design	gives	patients	and	their	physicians	the	option	of	a	brief	“window”	trial	with	4	weeks	
on	study	drug	(2	weeks	on	low	dose	palbociclib	plus	letrozole,	then	2	weeks	with	the	addition	
of	HCQ)	then	to	proceed	with	surgery	follow	by	standard	of	care,	or,	if	there	is	a	proliferative	
benefit	with	complete	cell	cycle	arrest	(CCCA)	at	the	4	week	timepoint,	patients	can	stay	on	
treatment	with	the	typical	full	duration	of	neoadjuvant	endocrine	therapy,	up	to	12-20	weeks	
longer	then	proceed	with	surgery	as	long	as	there	is	no	clinical	progression	or	significant	side	
effect	of	therapy.		This	longer	duration	may	allow	clinically	significant	downstaging	that	has	
been	shown	to	improve	breast	conserving	rates	and	from	the	study	standpoint	will	allow	
additional	exploratory	observations	of	the	more	prolonged	effects	of	palbociclib,	letrozole	and	
HCQ	on	tumor	size	and	tumor	biological	endpoints.	
	
There	is	ample	clinical	experience	and	clinical	trial	to	support	the	use	of	neoadjuvant	endocrine	
therapy	as	method	to	downstage	tumors	and	allow	more	patients	to	undergo	breast-conserving	
surgery.21	Additionally,	the	neoadjuvant	model	is	a	well-established	research	tool	to	assess	newer	drugs	
when	added	to	endocrine	therapy	to	evaluate	both	clinical	as	well	as	biomarker	based-responses.22		For	
hormone	receptor-positive	and	HER2-negative	breast	cancer,	the	use	of	change	in	the	proliferative	
antigen	Ki67	pre	to	post	treatment	has	been	extensively	validated	as	index	that	correlates	with	the	
likelihood	of	achieving	a	complete	pathological	response	and	with	longer	term	outcomes	specifically	in	
trials.23-31	The	key	metrics	using	this	model	in	both	the	Phase	I	and	Phase	II	portion	are	obtained	after	2	
weeks	of	low	dose	palbociclib	and	then	2	addition	weeks	with	the	addition	of	HCQ	(see	Sections	2.0	and	
3.1).			
Therefore,	patients	can	come	off	study	after	4	weeks	and	proceed	with	standard	therapy	
(“window”	approach),	which	would	include	standard	neoadjuvant	endocrine	therapy	(typically	
aromatase	inhibitor),	neoadjuvant	chemotherapy	if	the	patient	is	known	to	have	the	stage,	grade	and	
other	indices	that	warrant	chemotherapy.		Alternatively	they	can	proceed	with	definitive	breast/axillary	
node	surgery.	In	addition,	if	the	biopsy	after	both	2	and	4	weeks	show	suppression	of	proliferative	index	
that	is	used	as	the	main	endpoint	of	the	study	(see	Section	2.2.1),	patient	can	stay	on	therapy	for	the	
typical	full	neoadjuvant	endocrine	therapy	course	which	is	typically	16-24	weeks.	These	pragmatic	
alternatives	will	maximize	accrual	and	allow	patients	and	their	physicians	to	opt	for	the	best	path	that	
matches	the	patient’s	clinical	situation.	
Expected	results,	alternative	strategies.		
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We	expect	that	autophagy	effects	will	be	seen	even	at	low	doses	of	HCQ.		However,	if	our	indices	
(changes	in	LC3B/p62	ratio	from	T1	to	T2)	do	not	suggest	autophagy	inhibition,	then	we	will	consider	
adding	a	cohort	at	1200	and	even	1600	mg	day,	doses	that	have	been	used	in	other	trials.	We	can	also	
consider	the	use	of	alternative	autophagy	inhibitors	such	as	Lys05,	a	more	potent	chloroquine	analog	
poised	to	soon	enter	clinical	trials.	In	the	phase	I	trials,	if	we	observe	too	high	a	rate	of	CCCA	prior	to	
the	addition	of	HCQ,	(eg.	4	or	more	of	6	in	the	first	cohort),	we	will	lower	the	PD	dose	to	75	mg	twice	a	
week	(Mon/Thurs).	We	may	encounter	problems	with	compliance	or	patient	refusal	to	complete	all	
biopsies.	However,	in	our	experience	with	similar	trials,	this	is	rare	and	we	engage	the	help	of	patient	
advocates	for	education	and	outreach.	If	there	are	safety	concerns	raised	by	the	IRB	regarding	the	use	
of	this	experimental,	albeit	low-risk	treatment	in	a	curable	population,	we	will	amend	our	dose-limiting	
toxicity	(DLT)	criteria	for	dose	escalation	to	be	more	stringent,	and/or	only	escalate	dose	if	no	DLTs	(as	
opposed	to	0-1)	are	seen	in	each	cohort	of	six	patients.	
	
1.4 Risk/Benefit	Assessment	
Patients	on	this	study	will	be	receiving	standard	of	care	therapy	(endocrine	therapy	with	
letrozole)	and	palbociclib,	an	FDA-approved	and	relatively	non-toxic	therapy	that	doubles	time	to	
progression	in	the	metastatic	setting,	but	not	approved	in	the	adjuvant	or	neoadjuvant	setting	(see	
additional	description	of	palbociclib	in	Section	6.1).	HCQ	is	an	approved	drug	used	for	malaria	and	
autoimmune	disorders	that	also	had	a	very	good	safety	profile	(see	additional	description	of	HCQ	in	
Section	6.2).	One	concern	of	retinal	toxicity	that	is	typically	seen	only	after	prolonged	exposure,	will	be	
mitigated	by	baseline	ophthalmological	exam	covered	by	the	study	funding,	and	exclusion	of	those	who	
are	felt	to	be	at	risk	for	retinal	toxicity	as	established	by	the	by	the	American	Academy	of	
Ophthalmology	to	exclude	preexisting	maculopathy.32		
The	benefits	of	participation	of	this	trial	cannot	be	fully	ascertained,	but	the	addition	of	
palbociclib	has	been	shown	to	achieve	a	high	rate	of	complete	cell	cycle	arrest,	a	surrogate	biomarker	
of	long-term	benefit.18	While	short	term	exposure	(4	weeks)	may	not	affect	outcome,	patients	who	stay	
on	study	for	a	total	of	16-24	weeks	prior	to	surgery	may	have	a	greater	degree	of	downstaging	and	
more	conservative	surgery	(e.g.	breast	conservation,	sentinel	node	biopsy	as	opposed	to	axillary	
dissection).	
	
2.0 	STUDY	AIMS	AND	OBJECTIVES	
	
2.1 Phase	I	Safety	Component	(metastatic	disease)	Objectives	and	Endpoints	
	
2.1.1 The	primary	objective	of	the	Phase	I	portion	in	the	metastatic	cohorts	
is	to	determine	the	safety	of	adding	hydroxychloroquine	to	standard	
dose	palbociclib	and	letrozole	and	to	determine	the	recommended	
phase	2	dose	for	hydroxychloroquine.	
	
Primary	endpoint	is	safety,	to	be	assessed	continuously	using	CTCAE	
V4.03,	with	physical	examination	and	laboratory	assessments	as	
indicated	on	the	study	schedule		
	
2.2 Phase	II	Window/Neo-adjuvant	Component	Objectives	and	Endpoints	
	
2.2.1 Phase	II	-	Part	1	Primary	Objectives	and	Endpoints	
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• To	determine	the	dose	responsiveness	of	2	dose	levels	of	hydroxychloroquine	added	to	low	
dose	palbociclib	and	letrozole	on	breast	tumor	indices	of	proliferation	(including	Ki67),	
autophagy,	senescence	and	cell	cycle	control.		
	
2.2.2 Phase	II	-	Part	1	Secondary	and	Additional	Objective	and	Endpoints	
• Determine	longer	term	clinical	tumor	responsiveness	(tumor	volume)	and	tumor	biomarker	
indices	(for	patients	who	have	extended	pre-operative	therapy,	maximum	24	weeks).		
• To	perform	exploratory	studies	on	blood-based	tumor	protein,	DNA	and	RNA	biomarkers.			
	
	
2.2.3 Phase	II	Part	2	Primary	Objective	and	Endpoints	
To	determine	whether	hydroxychloroquine	added	to	low	dose	palbociclib	and	letrozole	can	increase	
the	proportion	of	patients	whose	tumors	achieve	complete	cell	cycle	arrest	(CCCA,	proportion	
with	Ki67	≤	2.7%	comparing	T1	to	T1	as	shown	in	Figure	2,	see	Section	5.3.4).		
	
The	primary	endpoint	is	the	increase	in	percentage	of	all	patients	who	achieve	CCCA	with	low	dose	
palbociclib	and	letrozole	(at	week	2,	time	T1)	compared	to	that	of	low	dose	palbociclib	and	
letrozole	with	the	addition	of	HCQ	(at	4	weeks,	time	T2).			
	
A	previously	conducted	trial	of	neoadjuvant	aromatase	inhibitor	(anastrozole)	plus	standard	dose	PD	
estimated	the	CCCA	probability	to	be	44%	with	aromatase	inhibitor	alone	and	powered	their	
study	to	detect	a	50%	increase	of	44%	to	66%6.	A	26%	CCCA	probability	was	seen	with	
anastrozole	alone	and	86%	with	the	addition	of	standard	dose	PD.	We	will	aim	for	a	CCCA	
reference	probability	of	50%	with	low-dose	PD	+	letrozole	(T1),	adjusting	the	PD	dose	from	
phase	I	if	needed	after	the	first	ten	patients	(Subaims	1a	and	1b).			
	
2.2.4 Phase	IIPart	2	Secondary		Objectives	and	Endpoints	
• To	determine	the	impact	of	adding	hydroxychloroquine	to	low	dose	palbociclib	and	letrozole	
on	breast	tumor	indices	of	proliferation,	autophagy,	senescence,	cell	cycle	control	and	other	
intersecting	pathways.		
• Determine	longer	term	clinical	tumor	responsiveness	and	tumor	biomarkers	indices	(for	
patients	who	have	extended	pre-operative	therapy,	maximum	24	weeks).		
• To	perform	exploratory	studies	on	blood-based	tumor	protein,	DNA	and	RNA	biomarkers.	
• Obtain	additional	safety	information	for	the	combination	of	low	dose	palbociclib,	letrozole	and	
hydroxychloroquine.		
	
	
3.0 	INVESTIGATIONAL	PLAN	
	
3.1 Overall	Design	
	
This	is	an	open	label	Phase	I/II		prospective	interventional	trial	with	a	safety	component	in	metastatic	
disease	and	a	“window”	component	in	the	neo-adjuvant	setting.	
	
	
Phase	I	Safety	Component:	
The	Phase	I	is	designed	to	evaluate	the	safety	and	tolerability	of	adding	hydroxychloroquine	to	standard	
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dose	palbociclib	and	letrozole	in	the	metastatic	setting	and	to	determine	the	recommended	phase	2	
dose	for	hydroxychloroquine.	
This	safety	component	will	be	completed	before	the	initiation	of	the	window	trial	(Phase	II)	in	the	pre-
operative	setting.	
	
	
Phase	II	Pre-operative	“Window”	Component:	
	
The	“window”	component	of	the	trial	evaluates	the	combination	of	pre-operative	palbociclib	plus	
letrozole	followed	by	the	addition	of	hydroxychloroquine	(HCQ)	for	postmenopausal	patients	with	
Stage	I-III	estrogen	receptor-positive	and	HER2-negative	breast	cancer	(	Figure	2).			
Correlative	studies	using	baseline	and	follow	up	breast	biopsies	and	blood	work	are	included	in	the	
research	plan.	The	Phase	II	portion	will	assess	the	change	in	the	percentage	of	all	patients	who	achieve	
CCCA	when	adding	HCQ	to	the	palbociclib/letrozole	combination.	
	
	
	
	
3.2 Trial	Schemata	
3.2.1 Trial	Overview	Schema	
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3.2.2 Window	Component	Schema	
	
	
	
	
	
	
	
	
	
FIGURE	2.	Schema	for	pre-operative	“window”/neoadjuvant	trial.		Part	1		dose	
responsiveness	evaluation	followed	by	Part	2	fixed	dose	cohort	using	same	design	and	biopsy	
timepoints	(T0	[baseline/pretreatment,	T1	[after	2	weeks	P+L],	T2	[after	addition	of	HCQ]),	
with	option	to	proceed	with	surgery	right	after	T2	biopsy	or	up	to	24	weeks	from	initiation	of	
therapy.		P=	continuous	low	dose	palboclib	at	75	mg	three	times	a	week	(Mon/Wed/Fri);	
L=letrozole	at	2.5	mg	daily;	HCQ=hydroxychloroquine	continuous	daily	at	assigned	dose;	
N=number	of	patients;	U/S	=	ultrasound;	DLT=dose	limiting	toxicity.
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Design	for	the	Safety	Component/Phase	I	
A	cycle	will	be	defined	as	28	days.	
	
The	dose	of	letrozole	and	palbociclib	will	be	fixed	for	the	safety	cohorts	at	
•	 Palbociclib:	125	mg	capsule	taken	orally	once	daily	for	21	consecutive	days	followed	by	7	days	
off	treatment	to	comprise	a	complete	cycle	of	28	days	
•	 Letrozole:	2.5mg/d	taken	orally	once	daily	continuously	
	
Hydroxychloroquine	Dose	Escalation	Scheme	
Dose Level (DL) Hydroxychloroquine Letrozole Palbociclib 
-1 200 mg/d 2.5 mg/d 125 mg capsule taken orally once daily for 
21 consecutive days followed by 7 days off 
treatment to comprise a complete cycle of 
28 days 
0 (Starting Dose) 400 mg/d 2.5 mg/d 125 mg capsule taken orally once daily for 
21 consecutive days followed by 7 days off 
treatment to comprise a complete cycle of 
28 days 
+1 600 mg/d 2.5 mg/d 125 mg capsule taken orally once daily for 
21 consecutive days followed by 7 days off 
treatment to comprise a complete cycle of 
28 days 
+2 800 mg/d 2.5 mg/d 125 mg capsule taken orally once daily for 
21 consecutive days followed by 7 days off 
treatment to comprise a complete cycle of 
28 days 
	
The	dose	escalation	portion	will	use	a	3+3	dose	escalation	design	to	evaluate	escalating	dose	levels	of	
hydroxychloroquine	in	combination	with	palbociclib	and	letrozole	(see	dose	level	table	below).	enroll	3	
patients	in	the	first	dose	level	of	the	triplet	combination.	At	least	3	patients	must	complete	a	treatment	
cycle	(28	days)	with	the	triple	combination	and	undergo	toxicity	assessment	before	any	additional	
patients	are	enrolled	into	higher	dosing	cohorts.	Intrapatient	dose	escalation	or	change	of	dosing	
schedule	is	not	allowed.	At	least	6	evaluable	patients	are	to	be	treated	at	a	dose	level	for	an	MTD/RP2D	
to	be	declared.	
	
• If		0	out	of	3	patients	in	a	dose	level	experience	a	DLT	in	the	defined	timeframe	another	3	
patients	will	be	enrolled	at	the	next	higher	dose	level.	
• If	no	more	than		1	patient	experienced	a	DLT	at	a	dose	level,	then	more	patients	will	be	added	
to	that	cohort	to	increase	the	cohort	up	to	six	patients	at	the	same	dose	level	
• If	no	more	than	one	of	the	first	6	patients	treated	experiences	a	DLT,	then	3	patients	will	be	
enrolled	at	the	next	higher	dose	level.	
• If	two	or	more	of	the	first	6	patients	treated	within	a	cohort	experience	DLT,	then	this	dose	
level	will	be	considered	not	tolerated	and	the	dose	escalation	will	be	halted.	If	two	DLTs	are	
seen	in	any	cohort,	no	further	patients	will	be	enrolled	at	that	level	and	next	level	lower	will	be	
declared	the	RP2D.	
The	RP2D	is	defined	as	the	highest	dose	level	at	which	6	patients	have	been	treated	with	at	most	1	
instance	of	DLT.	
	
If	dose	level	-1	is	found	to	have	unacceptable	rates	of	DLT,	accrual	will	be	discontinued.	
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If	two	DLTs	are	seen	at	the	starting	dose	(DL	0),	then	the	HCQ	dose	will	be	lowered	to	200	mg	daily	and	
six	patients	will	be	enrolled	and	if	one	or	no	DLTs	are	seen,	this	will	be	declared	the	recommended	
phase	II	dose	(RP2D).		
	
A	Safety	Monitoring	Committee	(SMC)	comprised	of	the	PI,	Co-PI,	Biostatistician	and	collaborators	will	
be	established	to	monitor	safety	throughout	the	study,	review	patient	data	and	make	decisions	prior	to	
advancing	to	the	next	dose	cohort.		
The	SMC	will	review,	at	a	minimum,	the	following	safety	data:	
•	Vital	signs	
•	Clinical	laboratory	values	
•	Physical	examination	findings	
•	Adverse	events/serious	adverse	events	
•	ECOG	performance	status	
	
The	SMC	will	meet	prior	to	dose	escalations	in	Phase	I,	prior	to	opening	the	Phase	II	Stage	1	for	
determination	of	the	RP2D	and	prior	to	opening	Phase	I	Stage	2.After	the	Phase	I	has	been	completed	
the	SMC	will	review	aggregate	safety	data	on	a	regular	basis	approximately	every	2	months	and	on	an	
ad	hoc	basis	as	needed.	The	study	SMC	will	review	all	available	safety	data	to	determine	if	this	dose	
should	be	declared	not	tolerated	or	if	any	further	dose	escalation	should	occur.	While	dose	escalation	
decisions	will	be	made	based	upon	data	from	the	first	cycle	of	treatment	for	each	patient	within	a	given	
cohort,	the	SMC	will	also	review	safety	data	from	patients	receiving	additional	treatment	cycles	of	the	
triple	combination.	
Based	on	the	review	of	the	data,	the	SMC	will	recommend	that	the	study	continue	as	planned,	
or	may	alternatively	recommend	that	the	study	be	placed	on	hold,	that	the	dose	of	study	drug	be	
de-escalated,	or	that	the	study	be	terminated.	A	recommendation	of	study	hold,	study	drug	dose	
de-escalation,	or	study	termination	would	be	made	in	the	event	of	the	discovery	of	an	
unexpected,	serious,	or	unacceptable	risk	to	the	subjects	in	the	study.	
	
For	the	purpose	of	the	SMC	review,	a	patient	will	be	considered	evaluable	if	s/he	has	received	at	least	
75%	of	the	planned	dosing	of	the	triplet	combination	during	Cycle	1.	If	the	reason	for	not	receiving	75%	
or	more	of	the	planned	doses	is	dose-limiting	toxicity	(DLT),	or	if	a	patient	has	received	a	dose	
reduction,	a	patient	will	still	be	considered	evaluable	for	this	SMC	review.	Patients	considered	non-
evaluable	will	be	replaced.	
	
3.3 Dose	Limiting	Toxicity	Definition	
	
A	DLT	will	be	defined	as	any	grade	3	toxicity	deemed	attributable	to	either	palbociclib	or	HCQ	occurring	
in	the	first	28	day	study	treatment	period,	with	the	exception	of	neutropenia,	for	which	any	of	grade	4	
or	febrile	neutropenia	event	defines	a	DLT.		All	adverse	events	will	be	classified	and	graded	using	CTCAE	
V	4.03	criteria.			
	
The	decision	to	open	the	Phase	II	window	part	of	the	trial	will	be	made	after	all	6	patients	on	the	
highest	dose	level	All	Safety	Data	will	be	reviewed	and	input	from	the	SMC	will	be	used	to	determine	
whether	the	study	proceeds	to		the	“window”	part	of	the	trial	in	the	neo-adjuvant	setting.		
	
	
3.4 Phase	II	Part	1	(neo-adjuvant	cohorts)	
Pre-operative	“Window”	Component:	
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The	“window”	component	of	the	trial	evaluates	the	combination	of	pre-operative	palbociclib	
plus	letrozole	followed	by	the	addition	of	hydroxychloroquine	(HCQ)	for	postmenopausal	
patients	with	Stage	I-III	estrogen	receptor-positive	and	HER2-negative	breast	cancer	(	Figure	2).			
Correlative	studies	using	baseline	and	follow	up	breast	biopsies	and	blood	work	are	included	in	
the	research	plan.	The	Phase	II	portion	will	assess	the	change	in	the	percentage	of	all	patients	
who	achieve	CCCA	when	adding	HCQ	to	the	palbociclib/letrozole	combination.	
	
To	determine	the	dose	responsiveness	in	the	pre-operative	setting	2	groups	of	6	patients	each	
will	be	enrolled	at	the	following	dose	levels:	
	
Dose Level (DL)  
neo- adjuvant cohorts 
 
Hydroxychloroquine Letrozole Palbociclib 
Group 1 400 mg/d 2.5 mg/d 75 mg/tiw  
Group 2 800 mg/d or RP2D 2.5 mg/d 75 mg/tiw 
Should	the	RP2D	be	<	800mg/d	the	second	group	will	be	receive	the	RP2D	of	hydroxychloroquine	in	
the	combination	as	determined	in	the	Phase	I.	
	
	
3.5 Phase	II	Part	2	Window/Neo-adjuvant	Component	
	
The	dose	defined	in	the	Phase	I	portion	as	RP2D	will	be	used	in	the	Phase	II	Stage	2	part	of	the	study.			
	
The	design	for	both	Phase	II	Stage	1	and	2	components	are	the	same	except	for	the	2	HCQ	dose	levels	in	
Stage	2	whereas	the	HCQ	dose	is	fixed	at	the	recommended	Phase	II	dose	for	the	Phase	II	portion.			
The	dose	of	palbociclib	for	both	Stage	1	and	2	is	fixed	at	a	dose	of	at	a	dose	of	75	mg	orally	three	times	
a	week	(Mon/Wed/Fri)	continuously	without	a	break.	After	4	weeks	(T2),	the	primary	endpoint	will	
have	been	obtained.	If	the	T1	and	T2	Ki67	determination	show	CCCA	(Ki67	≤	2.7%)	that	patient	may	
elect	to	stay	on	therapy	for	an	additional	3	to	5	four-week	cycles	(week	16	to	24	as	shown	on	Table	X)	
before	proceeding	with	definitive	surgery.	Details	on	dosing	and	dose	adjustments	are	shown	in	
Sections	6.14	and	6.23.Using	the	same	population,	treatment	and	biopsy	schema,	30index	patients	will	
be	enrolled	for	the	phase	II	Stage	2	portion	of	the	trial.	
	
3.6 Phase	II	Patient	Evaluability	
Patients	who	meet	the	eligibility	criteria	and	complete	a	full	4	weeks	of	therapy	(14	days	of	low-dose	
palbociclib	plus	letrozole	and	14	days	of	dose	palbociclib	plus	letrozole	with	HCQ)	will	be	considered	
evaluable	for	Phase	II.		In	addition,	the	completion	of	biopsies	at	T0,	T1	and	T2	with	interpretability	of	
Ki67	are	required	for	evaluability.	
3.7 		Replacement	of	Patients	
Patientswho	are	not	evaluable	for	dose-limiting	toxicity	in	the	Phase	I	portion	and	those	not	evaluable	
for	Ki67	at	T0,	T1	and	T2	in	the	Phase	II	portion	will	be	replaced.	
3.8 Target	Accrual	
A	total	of	60	patients	will	be	enrolled	to	the	study.	This	includes	18	patients	(6	per	dose	cohort	at	400,	
600	and	800	mg	of	HCQ	daily)	in	the	Phase	I	metastatic	portion,	12	patients	in	the	neo-adjuvant	Phase	II	
Part	1	and	30	patients	(25	needed	for	statistical	plan	and	5	expected	to	drop	out)	for	the	Phase	II	Part	2	
portion.	
	
4.0 		PATIENT	SELECTION	
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4.1 Inclusion	Criteria	
Patient	eligibility	criteria	include	all	of	the	following:	
1. Signed	written	informed	consent	
2. ECOG	performance	status	0-1	
3. Female	and	age	≥	18	years	and	postmenopausal	defined	by:	
a. Age	≥	55	years	and	1	year	or	more	of	amenorrhea	
b. Age	<	55	years	and	1	year	or	more	of	amenorrhea	with	LH	and/or	FSH	levels	in	the	
postmenopausal	range	
c. Age	<	55	with	prior	hysterectomy	but	intact	ovaries	with	LH	and/or	FSH	levels	in	the	
postmenopausal	range	
d. Status	after	bilateral	oophorectomy	(≥	28	days	prior	to	first	study	treatment)	
4. Adequate	hematological,	renal,	hepatic	function	defined	as	follows:	
a. ANC	≥	1500	cells/μl	
b. Platelet	count	≥	100,000/μl	
c. Serum	creatinine	concentration	<	1.5	x	ULN	
d. Bilirubin	level	<	1.5	x	ULN	
e. Aspartate	aminotransferase	(AST)	or	alanine	aminotransferase	(ALT)	<3	x	ULN	
f. Alkaline	phosphatase	≤	2.5	ULN	
	
5. Metastatic	cohorts	(Phase	I):	Diagnosis	of	Stage	IV	estrogen	positive	breast	cancer,	estrogen	
receptor-positive	and	HER2-negative	by	ASCO/CAP	criteria1,2	
6. Metastatic	cohorts:	Must	be	a	candidate	for	treatment	with	CDK4/6	inhibitor	as	standard	of	care	
7. Metastatic	cohorts	(Phase	I):	No	prior	exposure	to	CDK	4/6	inhibitors.	
8. Neoadjuvant	cohorts	(Phase	II):	Diagnosis	of	Stage	I-III	estrogen	positive	breast	cancer,	estrogen	
receptor-positive	and	HER2-negative	by	ASCO/CAP	criteria1,	2.	If	Stage	I,	clinical	tumor	size	must	
be	≥1.5	cm.	
9. Neo-adjuvant	cohorts(Phase	II):	Surgical	candidate	and	appropriate	for	pre-operative	endocrine	
therapy	
	
	
4.2 Exclusion	Criteria	
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Patient	exclusion	criteria	include	any	of	the	following:	
1. Neo-adjuvant	cohorts	(Phase	II):	Inoperable	or	metastatic	breast	cancer	based	on	standard	
evaluation	
2. Inflammatory	breast	cancer		
3. Neo-adjuvant	cohorts:	clinical	T4	disease	
4. History	of	retinal	disease	
5. History	of	active	visual	disturbances	(normal	baseline	study-specified	retinal	exam	required)	
6. Neo-adjuvant	cohorts:	Prior	therapy	for	breast	cancer	(medical,	surgical	or	radiation	therapy)	
7. Acute	illness,	including	infections	requiring	medical	therapy,		
8. Known	bleeding	diathesis	or	need	for	anticoagulation	
9. Neo-adjuvant cohorts: Treatment with any of the following medications within 4 weeks 
before the baseline diagnostic biopsy is taken:	
a. Oral estrogens, including hormone replacement therapy (but prior depot estrogen use not 
allowed) 
b. Investigational agents (or 5 half-lives, whichever is longer) 
10. Required	concomitant	use	of	any	drug	that	is	a	strong	CYP3A	inhibitor.	
11. Psychological, familial, sociological or geographical conditions that do not permit 
compliance with the study protocol.	
	
5.0 STUDY	PROCEDURES	AND	SCHEDULE	OF	ASSESSMENTS	
	
5.1 Patient	Identification	
	
Eligible	patients	will	be	referred	by	members	of	the	MD	Anderson	Department	of	Breast	
Medical	Oncology	or	screened	through	electronic	medical	records	and	our	Departmental	database.	
	
5.2 Schedule	of	Assessments	
Table	1	–	Study	Procedures	and	Assessments	Phase	I	
 Baseline C1W1 
C1
W2 
C1
W3 
C1
W4 
C2
W5 
C2
W6 
C2
W7 
C2
W8 
C3+ 
W1  
Off 
Study 
Day  D1 D8 D15 D22 D1 D8 D15 D22 D1   
Scheduling 
Window -14d +/- 2 
+/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 Within 
30d  
Laboratory XA  X X X X X X X X X X 
Adverse event 
assessment)   X X X X X X X X X X X 
Physical Exam/ 
Weight/Vital Signs X
A X X X X X X X X X X X 
ECOG performance 
status evaluation X            
Ophthalmologic 
Exam X
B           X 
Imaging XA        X    
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Assessments 
             
Palbociclib  X X X  X X X  X X  
HCQ     X X X X X X X X  
Letrozole  x x x x x x x x x x  
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Table	2	–	Study	Procedures	and	Assessments	Phase	II	
	 	 	 	 																										Surgery	(“window”	option)	 								Surgery	(extended	option)	
	
 Baseline W1 W2 W3 W4 W6 W8 W12 W16 W20 W24 Off Study 
Day  D1 D8 D15 D22 D36 D50 D64 D96 D124 D152  
Scheduling 
Window -14d +/- 2 
+/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 Within 
30d  
Laboratory XA  X X X X X X X X X X 
Adverse event 
assessment)   X X X X X X X X X X X 
Physical Exam/ 
Weight/Vital Signs X
A X X X X X X X X X X X 
ECOG performance 
status evaluation X            
Ophthalmologic 
Exam X
B           X 
Breast ultrasound XA    X   X   X  
Research blood XA  X  X X X X X X X X 
Research biopsy XA  X  XC      XC  
Low dose palbo + 
letrozole  X X X X X X X X X X  
HCQ    X X X X X X X X  
             
             
Abbreviations:	W=week	(week	1	is	the	same	as	day	1	prior	to	starting	palbociclib);	palbo	=	palbocilib;	HCQ	=	hydroxychloroquine	
Laboratory	assessments:	Baseline,	W2,	W4	and	every	4	weeks	thereafter	until	off	study	labs	include	CBC/differential,	electrolytes,	BUN,	creatinine,	
AST,	ALT,	Total	Bilirubin,	Alkaline		Phosphatase.	CBC/diff	done	with	every	lab	draw	at	the	timepoints	described	in	the	study	calendar.		Baseline	only:	PT,	
PTT,	urinalysis	with	microscopic	exam	
Superscripts:		
A=Phase	II:	done	within	2	weeks	prior	to	starting	therapy	(low	dose	palbociclib/letrozole);	Phase	I:	Any	imaging	assessments	already	completed	during	
the	regular	work-up	of	the	patient	within	28	days	prior	to	starting	study	treatment,	including	before	signing	the	main	study	ICF	can	be	considered	as	
the	baseline	images	for	this	study	
B=	done	within	8	weeks	of	starting	study	medication;		
C=third	biopsy	done	either	at	W4	for	patients	going	on	to	surgery	at	that	time,	for	those	waiting	until	between	week	20-24,	biopsy	done	pre-
operatively.	Patients	who	know	in	advance	that	they	will	proceed	with	surgery	at	T2	will	not	need	a	biopsy	and	biomarkers	will	be	measured	
on	the	surgical	specimen.	
	
	
	
5.2.1 Baseline	Assessments		
All	patients	will	undergo	a	baseline	standard	evaluation	for	newly	diagnosed	breast	cancer	
including	(note	that	some	baseline	tests	can	be	done	prior	to	day	1	(week	1)	as	shown	on	Table	1):		
• Review	of	systems	all	organ	systems	will	be	examined.	
• Physical	examination,	vital	signs,	weight,	height,	and	evaluation	of	ECOG	performance	status.			
• Standard	of	care	pathological	diagnosis	of	breast	cancer,	imaging	(Phase	II:breast	ultrasound;	
Phase	II:	CT,	MRI)	and	clinical	staging.			
• Laboratory	studies:	CBC/differential,	electrolytes,	BUN,	creatinine,	AST,	ALT,	Total	Bilirubin,	
Alkaline		phosphatase,	PT,	PTT	
• Urinalysis	
	 276 
• Ophthalmological	exam	per	latest	guidelines	of	the	American	Academy	of	Ophthalmology	
(AAO)	for	baseline	screening	with	HCQ	treatment.	
• Fresh	Tumor	Biopsy	(Phase	II	only)	
• Research	blood	draw	(Phase	II	only)	
	
ECOG	performance	status	
Grade	ECOG	status	
	
0 - Fully active, able to carry on all pre-disease performance without restriction 
1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary 
nature e.g., light house work, office work 
2 - Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about 
more than 50% of waking hours 
3 - Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 - Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 - Dead 
	
	
5.2.2 Evaluation	During	Study	Phase	II	
	
Patients	will	be	evaluated	with	an	organ-specific	review	of	systems	and	physical	exam	at	
weeks	2,	3,	4,	and	those	who	choose	and	are	eligible	to	go	beyond	the	“window	period”	(as	
described	in	Sections	1.3,	3.2	and	5.2.3)	and	stay	on	study	until	definitive	surgery	at	week	16	
to	24	will	undergo	additional	evaluation	at	weeks	6,	8	and	every	4	weeks	thereafter	until	the	
last	pre-operative	visit	between	week	16	and	24	at	the	discretion	of	the	medical	and	surgical	
oncologist	as	shown	on	Table	1.		
	
	
5.2.3 Treatment	Duration	
5.2.3.1 Phase	I	
Patients	will	receive	treatment	for	a	maximum	of	24	weeks	if	receiving	clinical	benefit	as	
determined	by	the	treating	physician.	
	
5.2.3.2 Phase	II	
Following	the	study	schema	(Figure	2)	patients	are	expected	to	complete	28	days	of	study	
treatment	followed	by	surgery	for	the	“window	option”,	with	an	off	study	visit	after	surgery,	
and	will	be	monitored	for	adverse	events	up	to	30	days	after	the	last	dose	of	study	drug.		
	
Patients	whose	tumors	at	T1	biopsy	show	Ki67	>	10%	will	be	required	to	come	off	study	and	per	
standard	of	care	would	typically	be	recommended	to	proceed	to	definitive	surgery	or	standard	
neoadjuvant	chemotherapy.		All	other	patients	will	continue	on	study	therapy	and	at	T2	(week	
4),	patients	and	their	physicians	can	opt	to	either	come	off	study	and	proceed	with	definitive	
surgery	or	continue	for	12	to	20	additional	weeks	(between	weeks	16	and	24	as	shown	on	Table	
1)	if	CCCA	(Ki67	≤	2.7%)	is	achieved	at	both	T1	and	T2	and	there	is	no	evidence	of	clinical	
progression	(25%	increase	in	volume	by	ultrasound)	up	until	the	time	of	definitive	surgery.	
	
5.2.4 End	of	treatment	visit	and	Follow	up	assessments		
Patients	who	discontinue	study	treatment,	will	be	followed	for	30	days	after	stopping	the	study	
drugs	for	assessment	of	safety	(i.e.,	assessment	of	AEs	and/or	serious	AEs	[SAEs]	and	
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concomitant	medications)	and	resolution	of	any	treatment	related	toxicity.	Patients	continuing	
to	experience	toxicity	at	this	point	following	discontinuation	of	treatment	will	continue	to	be	
followed	at	least	every	4	weeks	until	resolution	or	determination,	in	the	clinical	judgment	of	
the	investigator,	that	no	further	improvement	is	expected.	
	
5.2.5 Early	discontinuation	
Patients	who	come	off	trial	early	will	be	asked	to	return	for	the	off-study	assessments	as	
detailed	in	Table	XX.	In	the	event	of	a	continuing	AE,	the	patient	will	be	asked	to	return	for	
follow-up	until	resolution	or	stabilization	of	the	AE..	
	
5.2.6 Review	of	Systems	and	Physical	Exam	
A	full	review	of	systems	that	covers	all	of	the	domains	and	systems	represented	in	CTCAE	C	
4.03	toxicity	criteria	will	be	performed	at	screening/baseline.	Subsequent	physical	exams	may	
be	limited	and	should	be	focused	on	sites	of	disease	to	explore	clinical	signs	and	symptoms.	
	
5.2.7 Laboratory	Assessments	
CBC/differential,	electrolytes,	BUN,	creatinine,	AST,	ALT,	Total	Bilirubin,	Alkaline		
Phosphatase,	
	
5.2.8 Imaging	assessments	Phase	I	
Tumor	response	will	be	assessed	according	to	RECIST	Version	1.1.	Patients	should	have	at	
least	one	documented	measurable	lesion	(per	RECIST	v1.1)	or	in	the	absence	of	measurable	
disease,	have	at	least	one	lytic	or	mixed	(blastic/lytic)	bone	lesion	at	study	entry.	
	
Imaging	assessments	will	be	performed	as	per	standard	of	care	at	screening	within	28	days	
prior	to	first	dose	of	study	treatment,	at	8	weeks	(+/-	1	week)	from	day	one	of	study	
treatment	and	subsequently	every	8-12	weeks	(+/-	2	weeks)	thereafter.	
Tumor	response	should	be	assessed	using	the	same	imaging	method	throughout	the	study.	
	
5.2.9 Imaging	assessments	Phase	II	
Methods	for	ultrasound	evaluation	and	volumetric	measure	of	response		
Grayscale	and	power	Doppler	ultrasound	will	be	performed	on	the	breast	and	regional	nodal	
basins	using	a	Philips	iU22	system	or	Sonoline	Antares	systems	equipped	with	a	5-	to	13-MHz	
broadband	linear	transducer.	Ultrasound	images	of	the	index	tumors	and	index	nodes	will	be	
captured	in	the	longitudinal	and	transverse	planes	with	three	dimensions	measured.	The	size	
of	the	index	tumors	and	index	nodes	will	be	reported	in	three	dimensions	to	allow	for	
volumetric	calculation.	The	percent	change	in	volume	will	then	be	calculated	and	reported	to	
determine	response.	
	
	
5.3 Correlative	Biomarker	Studies	
	
5.3.1 Biopsies,	Tissue	Handling	and	Analysis	
All biopsies will be done under ultrasound guidance by a member of the research 
team using standard of care imaging-guided biopsy.  Local anesthesia and 
hemostasis protocols will be used as per standard protocol.  Core needles of 
18 of 16G size will be used and 3-4 core biopsies will be obtained. The first 
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core will be placed in standard 10% formalin, and all other cores will be placed 
in a cryovial and snap frozen in liquid nitrogen. 
All of the correlative studies (unless otherwise indicated) will be performed in the 
laboratory of Dr. Khandan Keyomarsi located in the Zayed building at 6565 MD 
Anderson Blvd, Houston, Texas, 77030.  For all the correlative analysis we will 
use tumor tissues collected from the biopsies and at surgical resections.  
Cyclin	E,	and	Rb	immunohistochemistry	(IHC)	assays.			FFPE	tumor	tissue	slides	will	be	
prepared	from	paraffin	imbedded	blocks	per	standard	methodologies	and	subjected	
to	IHC	analysis	with	2	different	antibodies:	cyclin	E	and	Rb:		
	
Cyclin	E:	the	anti-human	C-19	polyclonal	antibody	(Santa	Cruz	Biologicals)	at	1:2000	
dilution	will	be	used	to	stain	each	slide.	Each	slide	will	be	scored	for	percent	nuclear	
and	percent	cytoplasmic	positive	staining.	Only	tumor	cells	with	greater	than	5%	
nuclear	or	cytoplasmic	positivity	are	considered	as	cyclin	E	positive.	Nuclear	and	
cytoplasmic	staining	scores	are	assigned	according	to	the	staining	intensity	(0	=	no	
staining,	1	=	blush	staining,	2	=	weak	staining,	3	=	intermediate	staining	and	4=	strong	
staining).	The	nuclear	and	cytoplasmic	scores	are	then	combined,	and	four	
immunophenotypes	are	identified.	First,	breast	tumors	will	be	considered	to	be	
negative	for	cyclin	E	when	staining	is	not	detected	in	the	nuclei	or	cytoplasm	
(phenotype	1).	Second,	in	cases	determined	to	be	cyclin	E+,	if	the	nuclear	staining	
score	exceeded	the	cytoplasmic	score,	cyclin	E	expression	is	defined	as	predominantly	
nuclear	(phenotype	2).	Third,	when	the	nuclear	and	cytoplasmic	staining	scores	are	
equal,	cyclin	E	expression	is	considered	to	be	both	nuclear	and	cytoplasmic	
(phenotype	3).	Fourth,	if	the	cytoplasmic	staining	score	is	higher	than	the	nuclear	
score,	cyclin	E	expression	is	considered	to	be	predominantly	cytoplasmic	(phenotype	
4).		
	
Rb:	The	anti-human	Clone	4H1	mouse	monoclonal	antibody	(Cell	Signaling	
Technology,	Denvers,	MA)	at	1:100	dilution	will	be	used	to	stain	each	slide.	Each	slide	
will	be	scored	separately	for	intensity	of	staining	and	percentage	of	positive	cells.	
Staining	intensity	will	be	scored	as	follows:	0,	no	staining;	1,	weak	positive	(faint	
yellow	staining);	2,	intermediate	positive;	and	3,	strong	positive	(brown	staining).	The	
number	of	positive	cells	will	visually	be	evaluated	and	stratified	as	follows:	<1%,	0	
(negative);	1	to	<5%	positive	cells,	1	(weak);	5-50%	positive	cells,	2	(moderate);	>50%	
positive	cells,	3	(strong).	The	sum	of	the	staining	intensity	and	percentage	of	positive	
cell	scores	will	be	used	to	determine	the	staining	index	for	each	section,	with	a	
minimum	score	of	0	and	maximum	score	of	6;	scores		>1	will	be	defined	as	Rb	
positivity.		
	
5.3.2 Whole	Blood/Plasma	Biospecimens	
Blood	specimen	will	be	collected	as	shown	on	Table	1	at	baseline,	week	2	and	week	for	
patients	on	the	“window”	option	and	for	those	who	stay	on	study	until	surgery	will	be	
collected	at	weeks	6,	8	and	every	weeks	thereafter	until	surgery.	Each	blood	draw	will	be	to	
collect	2	7.5	mL	tubes	–	one	for	plasma	(green	top)	and	the	other	for	serum	(red	top).		
Blood	will	be	processed	immediately	following	collections	–	tubes	will	be	gently	inverted	
	 279 
and	kept	at	room	temperature	prior	to	centrifuging,	and	clotted	tube	(red	top)	will	have	
serum	aspirated,	while	the	green	top	tube	will	have	plasma	aspirated	–	both	being	
aliquoted	in	0.5	mL	cryovials	and	placed	in	a	-20⁰C	freezer	(and	stored	long	term	at	-80⁰C).	
	
	
5.3.3 Ki67	Tumor	Assay	and	Scoring	
	
CLIA-approved	Ki67	staining	will	be	performed	using	anti-Ki67	rabbit	monoclonal	antibody	(isotype	
IgG1κ,	clone	MIB-1,	DAKO)	in	the	diagnostic	Immunohistochemistry	Laboratory	of	Department	of	
Pathology	using	an	established	protocol.	Briefly	this	protocol	includes	de-paraffinization	(30	minutes	
at	72°C)and	rehydration	with	antigen	retrieval	performed	at	100°C	for	20	minutes	with	Tris-EDTA	
buffer,	pH	6.0.		Endogenous	peroxidase	is	blocked	with	3%	peroxide	for	5	minutes.	Primary	anti-Ki-
67	antibody	(Dako,	clone	MIB-1)	is	applied	at	1:100	dilution	for	15	minutes.	Post	primary	antibody	
detection	is	carried	out	using	a	commercial	polymer	system	(Bond	Polymer	Refine	Detection,	Leica),	
and	stain	development	is	achieved	by	incubation	with	DAB	and	DAB	Enhancer	(Leica).			
	
Ki67	staining	will	be	evaluated	in	whole	tissue	sections	without	focusing	on	the	hot	spots.	The	
staining	will	be	quantitatively	assessed	by	automated	image	analysis	using	the	Aperio	ScanScope	AT2	
scanner	(Leica	Biosystems,	Inc.,	1700	Leider	Lane,	Buffalo	Grove	IL,	60089).		All	Ki67	immunostained	
slides	will	be	scanned	at	20	X	magnification.		As	Ki67	is	a	nuclear	stain,	the	Genie	nuclear	v9.1	
algorithm	will	be	used	to	create	a	custom-made	classifier.		A	color	graphic	phase	of	image	analysis	is	
afterward	performed	using	red,	orange,	and	yellow		(high,	medium,	and	low	reaction,	respectively)	
to	represent	positive	cells,	and	blue	to	represent	negative	ones.		A	curvature	threshold	adjustment	is	
made	to	de-cluster	or	break	up	large	groups	of	closely	apposed	nuclei	when	needed.	The	original	
factory	algorithm	is	also	adjusted	to	avoid	false	positives	by	lowering	the	Cytoplasmic	Intensity	
settings.	All	algorithm	adjustments	are	tested	to	assure	accurate	detection	of	positive	and	negative	
nuclei.			
	
	
5.4 Concomitant	Medications	
In	general,	the	use	of	any	concomitant	medication	or	therapies	deemed	necessary	for	the	care	of	
the	patient	is	permitted.			
	
5.5 Banked	biospecimens	
Leftover	blood	and	tumor	samples	which	are	not	consumed	for	planned	study	testing	will	be	
retained	for	potential	additional	testing	at	a	later	date	(i.e.	if	newer	technologies	become	available)	
under	the	same	objectives.	Samples	will	be	retained	at	a	secure	storage	facility	(				)	in	case	there	is	
need	for	retesting	or	additional	testing.	Samples	will	be	stored	for	up	to	10	years	or	until	termination	
of	this	study.	
	
6.0 	INVESTIGATIONAL	AND	NON-INVESTIGATIONAL	AGENTS	
	
6.1 Palbocilib	
	
6.1.1 Description	of	palbociclib	
Palbociclib	is	an	inhibitor	of	cyclin-dependent	kinase	(CDK)	4	and	6,	which	are	downstream	of	
signaling	pathways	that	lead	to	cellular	proliferation.	In	vitro,	palbociclib	reduced	cellular	
proliferation	of	ER-positive	breast	cancer	cell	lines	by	blocking	progression	of	the	cell	from	G1	
into	S	phase	of	the	cell	cycle.	Treatment	of	breast	cancer	cell	lines	with	the	combination	of	
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palbociclib	and	antiestrogens	leads	to	decreased	retinoblastoma	protein	(Rb)	
phosphorylation	resulting	in	reduced	E2F	expression	and	signaling,	and	increased	growth	
arrest	compared	to	treatment	with	each	drug	alone.	In	vitro	treatment	of	ER-positive	breast	
cancer	cell	lines	with	the	combination	of	palbociclib	and	antiestrogens	leads	to	increased	cell	
senescence,	which	was	sustained	for	up	to	6	days	following	drug	removal.	In	vivo	studies	
using	a	patient-derived	ER-positive	breast	cancer	xenograft	model	demonstrated	that	the	
combination	of	palbociclib	and	letrozole	increased	the	inhibition	of	Rb	phosphorylation,	
downstream	signaling	and	tumor	growth	compared	to	each	drug	alone	(Pfizer	Pharma	United	
States	product	insert	(USPI),	(2015).	Highlights	of	Prescribing	Information;	IBRANCE®	
(palbociclib)	for	oral	use.	New	York:	Pfizer,	Inc).20	
Complete	information	for	Palbociclib	may	be	found	in	the	single	reference	safety	document	
(SRSD),	which	for	this	study	is	the	Pfizer	Investigator	Brochure	for	Palbociclib	(PD-0332991).	
	
6.1.2 Source	of	palbociclib	
Palbociclib	will	be	provided	by	Pfizer	Inc.	Palbociclib	commercial	supply	will	be	supplied	as	75	
mg	capsules	in	High	Density	Polyethylene	(HDPE)	bottles,	labeled	according	to	local	
regulatory	requirements.	
	
6.1.3 Preparation	and	dispensing	
Qualified	site	personnel	will	provide	adequate	palbociclib	supplies	for	patient	to	take	home	
until	next	scheduled	visit.	
Patients	will	receive	a	drug	diary	to	document	dosing.	The	completed	diary	must	be	returned	to	
the	site	at	the	next	study	visit	
	
6.1.4 Dosing	of	palbociclib	and	dose	adjustments	for	palbociclib	(holding,	discontinuation)	
Patients	should	be	instructed	to	swallow	palbociclib	capsules	whole	and	not	to	manipulate	or	
chew	them	prior	to	swallowing.	No	capsule	should	be	ingested	if	it	is	broken,	cracked,	or	
otherwise	not	intact.	Patients	should	be	encouraged	to	take	their	dose	at	approximately	the	
same	time	each	day.	Patients	should	be	instructed	to	record	daily	administration	in	the	
patient	diary.	
Patients	should	take	palbociclib	with	food.		
• Patients	who	miss	a	day’s	dose	entirely	must	be	instructed	NOT	to	“make	it	up”	the	next	
day.	
• Patients	who	vomit	any	time	after	taking	a	dose	must	be	instructed	NOT	to	“make	it	up,”	
and	to	resume	treatment	the	next	day	as	prescribed	
• Patients	who	inadvertently	take	1	extra	dose	during	a	day	must	be	instructed	to	skip	the	
next	day’s	dose.	
	
Dosing	of	palbociclib	will	follow	recommendations	listed	on	the	package	insert	based	on	
hematological	and	other	major	side	effects.	
	
For	Phase	2	palbociclib	dosing:	
• On	the	day	of	or	day	prior	to	administration	of	day	1	of	palbociclib	(Weeks	4,	8	and	every	4	
weeks	thereafter	while	on	study	drug)	for	grade	3	or	4	neutropenia,	palbociclib	will	be	
held	and	CBC/diff	will	be	checked	in	one	week	intervals,	with	treatment	resumed	at	the	
same	dose	when	neutropenia	has	recovered	to	Grade	≤2.		If	more	than	two	weeks	are	
required	for	recovery	to	Grade	≤2,	the	dose	will	be	lowered	to	75	mg	p.o.	twice	a	week.	
• On	weeks	2	and	6,	for	Grade	3	neutropenia	without	fever	≥38.5	°C,	treatment	will	
continue	and	CBC/diff	will	be	repeated	1	week	later.		At	these	timepoints	and	at	another	
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other	time,	Grade	4	neutropenia	or	Grade	3	neutropenia	with	fever	≥38.5	°C,	palbociclib	
will	be	held	until	recovery	to	Grade	≤2.	
• For	Grade	≥3	non-hematologic	toxicity	attributed	to	palbociclib,	palbociclib	will	be	held	
until	the	toxicity	in	question	resolves	to	Grade	≤1	or	Grade	≤2	if	not	considered	a	risk	to	
the	patient.	
• Once	palbociclib	dose	has	been	lowered,	it	will	not	be	re-escalated	
	
6.2 Hydroxychloroquine	
	
6.2.1 Description	of	hydroxychloroquine	(HCQ)	
Hydroxychloroquine	(HCQ)	is	a	small	molecule	drug	that	is	indicated	for	the	suppressive	
treatment	and	treatment	of	acute	attacks	of	malaria	due	to	Plasmodium	vivax,	P.	malariae,	P.	
ovale,	and	susceptible	strains	of	P.	falciparum.	It	is	also	indicated	for	the	treatment	of	discoid	
and	systemic	lupus	erythematosus,	and	rheumatoid	arthritis,	and	often	used	for	overlap	
connective	tissue	disorders.	Although	the	exact	mechanism	of	action	is	unknown,	it	may	be	
based	on	ability	of	HCQ	to	bind	to	and	alter	DNA.	HCQ	has	also	has	been	found	to	be	taken	up	
into	the	acidic	food	vacuoles	of	the	parasite	in	the	erythrocyte.	This	increases	the	pH	of	the	
acid	vesicles,	interfering	with	vesicle	functions	and	possibly	inhibiting	phospholipid	
metabolism.	In	suppressive	treatment,	HCQ	inhibits	the	erythrocytic	stage	of	development	of	
plasmodia.	In	acute	attacks	of	malaria,	it	interrupts	erythrocytic	schizogony	of	the	parasite.	
Its	ability	to	concentrate	in	parasitized	erythrocytes	may	account	for	their	selective	toxicity	
against	the	erythrocytic	stages	of	plasmodial	infection.	As	an	anti-rheumatic,	HCQ	is	thought	
to	act	as	a	mild	immunosuppressant,	inhibiting	the	production	of	rheumatoid	factor	and	
acute	phase	reactants.	It	also	accumulates	in	white	blood	cells,	stabilizing	lysosomal	
membranes	and	inhibiting	the	activity	of	many	enzymes,	including	collagenase	and	the	
proteases	that	cause	cartilage	breakdown.		
	
HCQ	is	also	known	to	inhibit	autophagy,	a	cellular	process	that	may	also	lead	to	resistance	to	
several	cancer	drugs,	and	as	such,	several	trials	have	been	conducted	and	shown	safety	of	
HCQ	combined	with	several	antineoplastic	agents.34-37	However,	no	trials	have	tested	HCQ	in	
the	setting	and	with	the	rationale	and	drug	combination	proposed	in	this	trial.	
	
6.2.2 Source	and	dispensing	of	hydroxychloroquine	
Generic	HCQ	will	be	obtained	from	a	commercial	source,	Quality	Prescription	Drugs	(Suite	
#245,	7360	137th	Street,	Surrey,	B.C.	V3W	1A3),	a	Canada-based	company	that	uses	U.S.	
sources	that	is	both	CIPA	certified	and	PharmacyChecker	approved.	The	drug	will	be	ordered	
for	direct	delivery	to	the	Investigational	Pharmacy	at	MD	Anderson	in	batches	to	maintain	at	
least	a	3	months	of	supply	on	hand	and	will	be	dispensed	as	an	investigational	drug	with	
standard	logging	of	drug	acquisition,	dispensation	and	final	accounting	for	disposition.		
Unused	or	returned	drug	will	be	destroyed.	Drug	will	be	dispensed	to	patients	with	the	name	
and	dosage	drug,	date	dispensed,	name	of	patients,	name	of	study	and	instructions	for	use.	
	
6.2.3 Dosing	of	hydroxychloroquine	and	dose	adjustments	for	hydroxychloroquine		
HCQ	will	be	given	at	the	assigned	dose	for	the	Phase	I	dose	escalation	and	Phase	II	fixed	dose	
parts	of	the	trial	The	dose	of	400	mg	daily	was	chosen	as	the	starting	dose	for	the	Phase	I	
portion	as	this	is	the	usual	dose	used	clinically	and	has	been	combined	with	hormonal	and	
other	and	cancer	therapies	at	this	does	in	prior	studies.34-37	There	will	be	no	dose	adjustments	
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for	HCQ,	and	any	grade	3	toxicity	that	is	attributed	to	HCQ	will	require	discontinuation	of	
drug	and	for	the	patient	to	come	off	study.	Subsequent	treatment	will	be	as	per	standard	of	
care.	For	patients	on	the	Phase	I	portion,	any	Grade	III	toxicity	attributed	to	HCQ	will	also	be	
counted	as	a	dose-limiting	toxicity	if	occurring	in	the	first	28	days		
	
6.3 Letrozole	
	
Letrozole	at	the	standard	approved	dose	of	2.5	mg	by	mouth	daily	continuous	dosing	will	be	prescribed	
as	standard	of	care	for	neoadjuvant	endocrine	therapy	through	MD	Anderson’s	or	the	patient’s	choice	
of	pharmacy.		There	will	be	no	dose	adjustments	for	letrozole.		If	the	patient	is	felt	to	be	having	
unacceptable	toxicities	due	to	letrozole,	then	treatment	will	be	stopped	and	the	patient	will	come	off	
study.		Subsequent	treatment	will	be	as	per	standard	of	care.	
	
7.0 		ADVERSE	EVENT	MONITORING	AND	REPORTING	
	
7.1 Definition	of	an	Adverse	Event	
An	adverse	event	is	the	appearance	or	worsening	of	any	undesirable	sign,	symptom	or	medical	
condition	occurring	after	starting	protocol	intervention,	up	to	30	days	after	the	last	dose	of	the	
study	therapy,	even	if	the	event	is	not	considered	to	be	related	to	the	study	drug.	
This	includes	the	following:	
• AEs	not	previously	observed	in	the	patient	that	emerge	during	the	protocol-specified	
AE	reporting	period,	including	signs	or	symptoms	that	were	not	present	prior	to	the	AE	
reporting	period	
• Complications	that	occur	as	a	result	of	protocol-mandated	interventions	(e.g.,	invasive	
procedures	such	as	cardiac	catheterizations)	
• If	applicable,	AEs	that	occur	prior	to	assignment	of	study	treatment	associated	with	
medication	washout,	no	treatment	run-in,	or	other	protocol-mandated	intervention	
• Pre-existing	medical	conditions	(other	than	the	condition	being	studied)	judged	by	the	
investigator	to	have	worsened	in	severity	or	frequency	or	changed	in	character	during	
the	protocol-specified	AE	reporting	period	
	
7.2 Definition	Serious	Adverse	Event	
An	adverse	event	or	suspected	adverse	reaction	is	considered	“serious”	if,	in	the	view	of	either	
the	investigator	or	the	sponsor,	it	results	in	any	of	the	following	outcomes:		
• Death		
• A	life-threatening	adverse	drug	experience	–	any	adverse	experience	that	places	the	
patient,	in	the	view	of	the	initial	reporter,	at	immediate	risk	of	death	from	the	adverse	
experience	as	it	occurred.	It	does	not	include	an	adverse	experience	that,	had	it	
occurred	in	a	more	severe	form,	might	have	caused	death.		
• Inpatient	hospitalization	or	prolongation	of	existing	hospitalization.	
• A	persistent	or	significant	incapacity	or	substantial	disruption	of	the	ability	to	conduct	
normal	life	functions.		
• A	congenital	anomaly/birth	defect.		
		
Medical	conditions/disease	present	before	starting	study	drug	are	only	considered	adverse	
events	if	they	worsen	after	starting	study	drug.		Abnormal	laboratory	values	of	test	results	
constitute	adverse	events	only	if	they	induce	clinical	signs	or	symptoms,	are	considered	
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clinically	significant	or	require	therapy.		Information	about	common	side	effects	already	known	
about	the	investigational	drug	can	be	found	in	the	Investigators’	Brochure.		
		
7.3 Adverse	Event	Reporting	Period	
The	study	period	during	which	all	AEs	and	SAEs	must	be	reported	begins	after	informed	consent	
is	obtained	and	starting	protocol	intervention	and	ends	30	days	following	the	last	administration	
of	study	treatment	or	study	discontinuation/termination,	whichever	is	earlier.		After	this	period,	
investigators	should	only	report	SAEs	that	are	attributed	to	prior	study	treatment.	
	
7.4 Recording	of	Adverse	Events	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Medical	events	that	may	not	result	in	death,	be	life-threatening,	or	require	hospitalization	may	be	
considered	a	serious	adverse	drug	experience	when,	based	upon	appropriate	medical	judgment,	
they	may	jeopardize	the	patient	or	subject	and	may	require	medical	or	surgical	intervention	to	
prevent	one	of	the	outcomes	listed	in	this	definition.	Examples	of	such	medical	events	include	
allergic	bronchospasm	requiring	intensive	treatment	in	an	emergency	room	or	at	home,	blood	
dyscrasias	or	convulsions	that	do	not	result	in	inpatient	hospitalization,	or	the	development	of	
drug	dependency	or	drug	abuse	(21	CFR	312.32).		
• Important	medical	events	as	defined	above,	may	also	be	considered	serious	adverse	events.	
Any	important	medical	event	can	and	should	be	reported	as	an	SAE	if	deemed	appropriate	by	
the	Principal	Investigator.		
• All	events	occurring	during	the	conduct	of	a	protocol	and	meeting	the	definition	of	a	SAE	must	
be	reported	to	the	IRB	in	accordance	with	the	timeframes	and	procedures	outlined	in	“The	
University	of	Texas	M.	D.	Anderson	Cancer	Center	Institutional	Review	Board	Policy	for	
Investigators	on	Reporting	Serious	Unanticipated	Adverse	Events	for	Drugs	and	Devices”.		
Unless	stated	otherwise	in	the	protocol,	all	SAEs,	expected	or	unexpected,	must	be	reported	to	
the	IND	Office,	regardless	of	attribution	(within	5	working	days	of	knowledge	of	the	event).		
• Serious	adverse	events	will	be	captured	from	the	time	of	the	first	protocol	specific	intervention,	
until	30	days	after	the	last	dose	of	drug,	unless	the	participant	withdraws	consent.	Serious	
adverse	events	must	be	followed	until	clinical	recovery	is	complete	and	laboratory	tests	have	
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returned	to	baseline,	progression	of	the	event	has	stabilized,	or	there	has	been	acceptable	
resolution	of	the	event.		
	
It	is	the	responsibility	of	the	PI	and	the	research	team	to	ensure	serious	adverse	events	are	reported	
according	to	the	Code	of	Federal	Regulations,	Good	Clinical	Practices,	the	protocol	guidelines,	the	
sponsor’s	guidelines,	and	Institutional	Review	Board	policy.	
	
7.5 Assessment	of	Adverse	Events	
	
The	PI	or	designee	will	be	responsible	for	assigning	attribution	of	adverse	events	to	the	study	agent.		As	
far	as	possible,	each	adverse	event	should	be	evaluated	to	determine:	
• The	severity	grade	(mild,	moderate,	severe)	or	grade	(1-4)	
• Its	relationship	to	the	study	drug(s)	(suspected/not	suspected)	
• Its	duration	(start	and	end	dates	or	if	continuing	at	the	final	exam)	
• Action	taken	(no	action	taken;	study	drug	dosage	adjusted/temporarily	interrupted;	study	drug	
permanently	discontinued	due	to	this	adverse	event;	concomitant	medications	taken;	non-drug	
therapy	given;	hospitalization/prolonged	hospitalization.	
• Whether	it	constitutes	a	serious	adverse	events	(SAE).	
	
All	AEs	and	SAEs,	whether	volunteered	by	the	patient,	discovered	by	study	personnel	during	
questioning,	or	detected	through	physical	examination,	laboratory	test,	or	other	means,	will	be	
reported	appropriately.			
Expected	AEs	are	those	AEs	that	are	listed	or	characterized	in	the	Package	Insert	(PI)	or	current	
Investigator’s	Brochure.	
Unexpected	AEs	are	those	not	listed	in	the	PI	or	current	Investigator’s	Brochure	or	not	
identified.	This	includes	AEs	for	which	the	specificity	or	severity	is	not	consistent	with	the	description	in	
the	PI	or	Investigator’s	Brochure.	For	example,	under	this	definition,	hepatic	necrosis	would	be	
unexpected	if	the	PI	or	Investigator’s	Brochure	only	referred	to	elevated	hepatic	enzymes	or	hepatitis.	
	
7.6 Communications	between	the	Investigator	and	Supporting	Company	Pfizer	
	
SAEs	that	occur	after	completion	of	the	reporting	time	period	as	defined	above	are	reportable	to	Pfizer	
if	the	Investigator	suspects	a	causal	relationship	between	the	Pfizer	product	and	the	SAE.	
	
	
8.0 	STATISTICAL	CONSIDERATIONS	
	
Phase	I:	
For	the	phase	I	portion,	six	patients	for	each	cohort	for	better	statistical	power	in	the	dose-
response	biomarker	analysis	and	expanded	safety	data.		
	
Phase	II:	
For	phase	II,	we	will	use	a	2-stage	Simon	optimal	design,	looking	to	increase	the	CCCA	rate	from	
50%	to	75%.	This	design	requires	11	patients	in	the	first	stage	and	14	patients	in	the	2nd	stage.	It	
would	stop	after	the	1st	stage	if	no	more	than	six	patients	with	CCCA	are	seen	and	declare	the	
treatment	promising	if	at	least	17	out	of	25	total	evaluable	patients	with	CCCA	are	seen.		
	
This	design	has	alpha	=	4%,	81%	power,	and	a	probability	of	0.73	of	terminating	after	the	1st	stage	
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if	the	true	CCCA	rate=50%.		We	therefore	plan	a	sample	size	of	30	patients	over	12-15	months,	
accounting	for	patient	dropout	(including	those	with	Ki67	>10%	at	T1).	We	have	a	large	eligible	
patient	population	and	have	led	national	accruals	in	other	multi-center	neoadjuvant	endocrine	
trials	in	post	menopausal	women	(eg.	ALTERNATE	Trial).	In	addition,	recent	local	experience	of	
conducting	window	of	opportunity	trials	in	this	setting	have	demonstrated	the	feasibility	of	accrual	
at	a	rate	of	~2	patients	per	month.	Thus,	we	expect	to	achieve	accrual	goals.	
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